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Abstract  
 
CLL T cells exhibit functional defects and alterations in gene expression that show 
similarities to exhausted T cells in chronic viral infections. It is unclear whether CLL T 
cells are truly exhausted, or whether these defects are restricted to expanded populations 
of CMV specific cells. The phenotype and function of T cells from CLL patients was 
compared to age- and CMV-serostatus-matched controls. There were an increased 
proportion of effector T cells in CLL patients and CMV-seropositive individuals. CD8
+
 
and CD4
+
 T cells from CLL patients had increased expression of exhaustion markers 
CD160 and CD244 irrespective of CMV-serostatus, whereas increased PD1 expression 
on CD8
+
 T cells was limited to CMV-seronegative patients. CLL CD8
+
 T cells also 
showed defects in proliferation and cytotoxicity irrespective of CMV-serostatus, with 
the cytolytic defect caused by impaired granzyme packaging into vesicles and non-
polarized degranulation. In contrast to virally-induced exhaustion, CLL T cells had 
increased expression of TBET and increased interferon-γ production, but normal IL-2 
production.  
 
As lenalidomide repairs the functional and phenotypic defects associated with T-cell 
exhaustion, the effect of this agent on the gene expression profiles of lymphocyte 
subsets from CLL patients and healthy controls was investigated. Lenalidomide induced 
the expression of genes involved in cytoskeletal signalling, lymphocyte activation, and 
proliferation. In particular, lenalidomide up-regulated the expression of several genes 
involved in tight junction signalling, a pathway that is potentially involved in 
lymphocyte motility, immune synapse formation, and transendothelial migration. This 
pathway was down-regulated in T cells from CLL patients, but, intriguingly, was up-
regulated in CLL cells compared with healthy B cells. This pathway is known to be 
negatively regulated by a phosphatase, PP2A. Treatment of CLL cells and T cells with 
the PP2A inhibitor okadaic acid mimicked the effect of lenalidomide. 
 
In conclusion, CLL T cells exhibit features of pseudo-exhaustion irrespective of CMV 
serostatus. Lenalidomide up-regulates tight junction signalling, which is down-regulated 
in CLL T cells. Inhibition of PP2A is implicated in the mechanism of action of 
lenalidomide on T cells.  
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BAFF   B-cell activating factor 
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MAP   Mitogen-associated protein 
MAPK   Mitogen-associated protein kinase 
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MDS   Myelodysplastic syndrome 
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MHC   Major histocompatibility complex 
MM   Multiple Myeloma 
mTOR   Mammalian target of rapamycin 
NFAT   Nuclear factor of activated T-cells 
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NLCs   Nurse-like cells 
NK   Natural killer 
NOS   Nitric oxide synthase 
ORR   Overall response rate 
OS   Overall survival 
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PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PD1   Programmed death-1 
PDL1    Programmed death ligand-1 
PDL2   Programmed death ligand-2 
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PPP2R3C  Protein phosphatase 2, regulatory subunit B, gamma 
PVDF   Polyvinylidene fluoride 
QRT-PCR  Quantitative Real Time Polymerase Chain Reaction 
Rap1   Ras-related protein 1 
RasGRP  RAS guanyl nucleotide-releasing protein 
REC   Research Ethics Committee 
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RIN   RNA integrity number 
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Tfh   Follicular helper T-cell 
TGFβ   Transforming growth factor-β 
Th1   T helper 1 cell 
Th2   T helper 2 cell 
Th9   T helper 9 cell 
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TNFα   Tumour necrosis factor α 
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XIAP   X-linked inhibitor of apoptosis protein 
ZAP70   Zeta-chain-associated protein kinase 70 
ZO2   Zona occludens 2  
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1 Chapter 1: Introduction 
 
1.1 Background 
 
It is now understood that the immune system plays a crucial role in the development of 
cancer. In addition to the importance of the innate inflammatory response in promoting 
this disease, the ability of malignant cells to evade immune destruction has been 
identified as an “emerging hallmark” of cancer in a recent prominent review (Hanahan 
and Weinberg 2011). The concept of cancer immune-surveillance appears to be 
particularly important in cancers of the immune system, due to the potential for high 
levels of interaction between the tumour cells and the non-malignant immune cells. This 
is highlighted by the clinical observation that reconstitution of an intact immune 
response, in the form of allogeneic haematopoietic stem cell transplantation, can be 
curative for a range of haematological malignancies. The fact that this graft-versus-
lymphoma/leukaemia effect appears to be primarily mediated by T cells underlies the 
concept of repairing T-cell responses as a potentially potent therapeutic modality (Kolb 
2008). 
 
B-cell chronic lymphocytic leukaemia (CLL) is a disease caused by a clonal expansion 
of small, mature B lymphocytes. The immune-surveillance hypothesis would suggest 
that in order to produce a clinically detectable tumour mass, the malignant B cells must 
have evolved strategies of evading or suppressing the immune system, especially the 
anti-cancer effects of T cells (Dunn et al. 2002). Surprisingly, it has been known for 
several decades that T cells are actually expanded in CLL, with a range of functional 
defects (Catovsky et al. 1974; Chiorazzi et al. 1979). It still remains unclear whether 
this expansion reflects a defective immune response, or whether these T cells have been 
co-opted by the tumour cells to form a vital part of the cancer microenvironment. An 
understanding of T-cell dysfunction should allow for the development of strategies that 
repair T-cell anti-tumour responses, resulting in an “autograft versus leukaemia effect”. 
Furthermore, T cells provide “help” to B cells as part of normal immune responses, by 
stimulating the B cells to proliferate, inducing B-cell antibody class switching and 
promoting plasma cell differentiation. It could be postulated that in CLL, the T cells 
have been skewed to provide “help” for the malignant B cells. Therefore in addition to a 
direct anti-tumour effect, successful immune reconstitution should also have an indirect 
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effect, by reducing the availability of T-cell derived pro-CLL factors with resultant 
“starvation” of the CLL cells. Even in the absence of any anti-tumour effects, immune 
reconstitution could be beneficial to patients by enabling them to fight infections more 
effectively, and counteract the immune suppression induced by both the disease and by 
current therapies. Strategies employing this approach should result in therapies that are 
both more tolerable to vulnerable patients, and show enhanced efficacy in the more 
challenging poor risk subgroups. This thesis will aim to characterise the nature of the T-
cell defect that is present in CLL, and investigate the potential for repairing this defect. 
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1.2 Normal T-cell function 
 
1.2.1  T-cell Development and Activation 
The life of a T cell begins as a lymphocyte progenitor derived from pluri-potent 
haematopoietic stem cells in the bone marrow. These progenitors subsequently migrate 
to the thymus, and it is there that all the important stages in their development occur: 
hence the name thymus-dependent (T) lymphocyte. After migrating to the thymus these 
lymphoid progenitors undergo expansion to generate a large population of immature T 
cells that do not express either the CD4 or CD8 co-receptor: double-negative CD4-
CD8- T cells. Approximately 98% of these immature T-cells will subsequently die 
before they leave the thymus. The fate of each individual CD4-CD8- T cell depends 
largely on the outcome of the rearrangement of its T-cell receptor (TCR) genes, with 
cells that express a TCR with either too-high or too-low an affinity for self-peptide:self-
MHC complexes undergoing cell death by apoptosis, in processes known as positive or 
negative selection. Positive selection essentially selects for T cells capable of interacting 
with self-MHC, with only those T cells that bind self-peptide:self MHC complexes with 
adequate affinity receiving the necessary signals to survive. T-cell co-receptor 
expression is also determined during this process with cells with TCRs that can 
recognise MHC class II molecules becoming CD4
+
 cells, while cells with TCRs that can 
recognise MHC class I molecules maturing into CD8
+
 cells. In contrast, negative 
selection removes T cells that bind too strongly to self-peptide:self-MHC, and is a 
critical step in preventing autoimmunity. While the thymus is the source of large 
numbers of new T cells in the foetus and juvenile, the development of new T cells in the 
thymus diminishes in adults. Here peripheral expansion plays a greater role, with T-cell 
numbers being maintained by both the presence long-lived T cells, together with the 
division of mature T cells outside the central lymphoid organs (Murphy et al. 2008). 
Once T cells have completed their development and have left the thymus, they 
continuously re-circulate between the blood, lymphatics and lymphoid tissues. This 
continuous circulation allows them maximal chance of encountering their specific 
antigen. Mature T cells that have not encountered their specific antigen are known as 
naive T cells and usually express CD45RA. Naive T cells can live for many years, 
infrequently divide or undergo apoptosis, and have a low rate of RNA/protein synthesis. 
Morphologically, they are small with condensed chromatin and scanty cytoplasm. To 
participate in an adaptive immune response, a naive T cell must meet its specific 
antigen, presented to it as a peptide:MHC complex on the surface of an antigen 
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presenting cell (APC) - typically a macrophage, B-cell or dendritic cell, in a process 
known as priming. Engagement of the T-cell receptor (TCR) by the peptide:MHC 
complex induces the T cells to proliferate and differentiate into effector cells that clear 
the antigen. APCs deliver three kinds of signal for clonal expansion and differentiation 
of naive T cells (Murphy et al. 2008): 
- Signal 1: TCR engagement + CD4/CD8 co-receptor: ACTIVATION 
- Signal 2: Co-stimulatory molecules: SURVIVAL 
- Signal 3: Cytokines: DIFFERENTIATION 
 
Once a T cell has been activated, it re-enters the cell cycle and divides rapidly to 
produce the large numbers of daughter cells that become effector T cells, in a process 
known as clonal expansion. The cytokine interleukin-2 (IL2) is critical for this 
proliferation and differentiation, and is produced by the activated T cell itself, along 
with the alpha chain of the IL2 receptor, CD25. TCR engagement by the peptide:MHC 
complex causes clustering of the TCR complex and CD4/CD8 co-receptors. The kinases 
Fyn and Lck phosphorylate tyrosine residues on the CD3ε and ITAMs, allowing zeta-
chain-associated protein kinase 70 (ZAP70) to bind. Lck activates ZAP70, which in turn 
phosphorylates the linker for the activation of T cells (LAT) and src homology 2 
domain-containing leukocyte protein of 76 kDa (SLP76). SLP76 binds and activates 
phospholipase C-γ (PLCγ) which in turn cleaves phosphatidylinositol biphosphate 
(PIP2) to yield diacylglyceral (DAG) and inositol triphosphate (IP3). DAG activates 
both protein kinase C-θ (PKCθ) and Ras guanyl nucleotide-releasing protein (RasGRP), 
which activate the transcription factors nuclear factor-κB (NFκB) and activated protein-
1 (AP1) (via a MAP kinase cascade) respectively. IP3 increases the intracellular calcium 
concentration, activating a phosphatase, calcineurin, which in turn activates nuclear 
factor of activated T cells (NFAT)(Smith-Garvin et al. 2009). 
 
It is these transcription factors, NFAT, AP1, and NFκB, which regulate cell 
differentiation and proliferation, including upregulation of IL2 production by binding to 
the promoter region of the IL2 gene. Co-stimulation through CD28 contributes to the 
production of IL2 in at least two ways. First, signals from CD28 increase the production 
of AP1 and NFκB, which increases the initiation of transcription of IL2 mRNA 
approximately threefold. The second effect of CD28 signalling is thought to be the 
stabilisation of IL2 mRNA, which increases the production of IL2 protein 20-30-fold. 
These two effects together allow co-stimulation by CD28 to increase IL2 production as 
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much as a 100-fold compared with TCR engagement alone (Appleman et al. 2000). 
When a T cell recognizes specific antigen in the absence of co-stimulation through its 
CD28 molecule, relatively small amounts of IL2 are produced and the T cell does not 
proliferate. This mechanism plays an important role in avoiding auto-immune 
responses. Although many autoreactive T cells undergo clonal deletion during their 
development in the thymus, some potentially autoreactive T cells will remain, as not all 
self-proteins are presented by the APCs in the thymus. To protect against the induction 
of T-cell responses against tissue-specific proteins, there is a relative absence of co-
stimulatory activity on tissue cells. Therefore, T-cells recognizing self-peptides on 
tissue cells are not activated, instead they are thought to become anergic, becoming 
refractory to activation by the specific antigen even when it is subsequently presented 
by an APC expressing co-stimulatory molecules. These anergic T cells may play an 
important role in preventing responses by naive, non-anergic T cells to foreign antigens 
that mimic self-peptide:self-MHC complexes. Anergic T cells could recognize and bind 
to such complexes on APCs without responding, and thus could compete with the 
potentially autoreactive naive T cells of the same specificity. Another explanation is that 
the anergic cells are in fact a form of regulatory T cell, as there are some similarities in 
the phenotype (Schwartz 2003).  
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1.2.2  T-cell Activation and the Immunological Synapse 
A key part of T-cell activation after recognition of a peptide:MHC complex is formation 
of an immunological synapse. This involves polymerisation of F-actin and polarisation 
of the cytoskeleton, resulting in the redistribution of TCRs, signalling, and adhesion 
molecules into a region beneath the T-cell:APC contact site (Huppa and Davis 2003). 
These molecules are segregated into supramolecular activation clusters (SMACs), the 
central (cSMAC), peripheral (pSMAC) and distal (dSMAC) respectively (Figure 1.1). 
The cSMAC contains a concentration of TCR:CD3:peptide:MHC complexes, 
costimulatory molecules such CD28, and signalling molecules such as PKCθ. The 
pSMAC is enriched with adhesion molecules such as lymphocyte function-associated 
antigen 1 (LFA1), and the dSMAC contains large glycoproteins such as CD45 (Grakoui 
et al. 1999). In the case of CD8
+
 cytotoxic T-lymphocytes (CTLs) there is also 
recruitment of cytotoxic granules into the central area of the synapse, allowing targeted 
release and cell death (Huppa and Davis 2003).  
 
Figure 1.1 Overview of a mature immunological synapse (Huppa and Davis 2003)  
 
The rearrangement of the actin cytoskeleton is an active process which is regulated by 
TCR-signalling. An important bridge between upstream Lck/ZAP70 signalling and 
downstream events such as calcium flux, Ras activation, and phosphatidylinositol 
cleavage is LAT. LAT is phosphorylated by ZAP70, allowing it to bind the adaptor 
protein GRb2-like adapter downstream of Shc (Gads) and recruit the scaffold protein 
SLP76 to the activation complex. After phosphorylation by ZAP70, SLP-76 binds the 
adaptor protein, Nck, and the guanine nucleotide exchange factor (GEF), Vav. Nck 
recruits the actin nucleation factor Wiskott-Aldrich Syndrome Protein (WASp) to the 
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TCR site, and Vav activates the Rho GTPases, cdc42 and Rac1 (Rossman et al. 2005). 
These RhoGTPases regulate actin filament polymerisation through three different 
classes of actin nucleation factors: the actin related proteins 2/3 (Arp2/3) complex 
(activated by WASp and WASp family-verprolin homologous protein 2 (WAVE2)), the 
formins, and the spire proteins (Reicher and Barda-Saad 2010). 
 
The polarisation of the actin cytoskeleton and formation of the immunological synapse 
plays a pivotal role in antigen recognition, signal transduction, T-cell proliferation, 
migration, adhesion, and tissue invasion. The synapse appears to act as a type of 
adaptive controller that can both amplify and attenuate T-cell receptor signalling (Lee et 
al. 2003). Endocytosis of the TCR is an important component of this control, as the 
TCR has been shown to be downregulated after formation of the cSMAC (Lee et al. 
2003). The actin cytoskeleton also regulates integrins such as LFA1 which undergoes 
clustering and conformational changes upon T-cell activation. These changes rapidly 
enhance its affinity and avidity for its ligand, intracellular adhesion molecule (ICAM), 
enabling stable T-cell:APC interactions and efficient activation. The actin cytoskeleton 
is highly involved in the signalling pathways that lead to integrin activation. In 
particular WAVE2 is thought to play a major role, both by activating the small GTPase, 
Ras-proximity-1 (Rap1) and through the recruitment of the integrin scaffolding protein 
talin, which binds integrins in a Rap1 dependent manner (Nolz et al. 2007; Smith-
Garvin et al. 2009).  
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1.2.3 T-cell Differentiation 
Our understanding of T-cell differentiation has evolved considerably over the last 
decade. The traditional paradigm developed during the 1980s hypothesised that T-cells 
could be divided into functional subsets according their co-receptor expression (CD4
+
 
versus CD8
+
) and cytokine production. CD8
+
 T-cells were all thought to differentiate 
into cytotoxic T cells that were able to kill their target cells and were important in the 
defence against intracellular pathogens such as viruses. In contrast, CD4
+
 T-cells could 
differentiate into two principle subsets that provided “help” for other immune cells. The 
basis for the concept of classifying these two subtypes had come from observations of 
the heterogeneous course of some infectious diseases such as leprosy. The healing 
(tuberculoid) form of leprosy was found to be associated with strong delayed-type 
hypersensitivity (DTH) reactions and relatively low levels of antibody, whereas 
uncontrolled (lepromatous) leprosy was associated with high antibody titres and weak 
DTH (Turk and Bryceson 1971). It was subsequently demonstrated that mouse CD4
+
 T-
cells could be classified into two distinct populations on the basis of their patterns of 
cytokine production: Th1 cells that produced IFNγ, IL2, and TGFβ and mediated DTH 
reactions, and Th2 cells that produced IL4, IL5, IL6, and IL13 and mediated humoral 
immunity (Mosmann et al. 1986; Fiorentino et al. 1989). This paradigm not only 
provided a simple explanation for the dichotomy of the clinical observations, but also 
provided other key concepts for an understanding of T-cell differentiation. Each T-cell 
subset was shown to produce cytokines that serve as their own autocrine growth factor 
and promote differentiation of naive T cells to that subset (Lichtman et al. 1987). 
Furthermore, the two subsets were shown to produce cytokines and modulate 
transcriptional activity to cross-regulate the other’s development and activity.  
 
However, while certain aspects of this paradigm have held true, it has become apparent 
that the situation is considerably more complex. A naive T cell, whether CD4
+
 or CD8
+
, 
has an increasing variety of functional fates open to it upon activation. These are 
determined by integration of a number of different signals: the strength of signalling 
from the TCR, the presence or absence of co-stimulation, the cytokine milieu in which 
the T cell finds itself, and small molecule modifiers. Both naive CD4
+
 and CD8
+
 T-cells 
can develop into effector or memory cells, with memory cells being further subdivided 
into effector-memory or central-memory. Within the effector subsets there are a range 
of phenotypes defined both by the principle cytokine produced, and whether they have 
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an immuno-regulatory function. The cytokine milieu in which a naive T-cell recognises 
antigen is particularly critical, with the resultant effector phenotype in both CD4
+
 and 
CD8
+
 T cells being determined certain cytokines: for example IL12 and IFNγ for 
Th1/Tc1, IL-4 for Th2/Tc2, and IL-6 and TGFβ for Th17/Tc17 (Mosmann et al. 1986; 
Maggi et al. 1994; Mosmann et al. 1997; Jager and Kuchroo 2010). In many of the 
CD4
+
 subtypes, the cytokines have been shown to upregulate specific transcription 
factors, which act as “master controllers” of the various differentiation pathways (Table 
1) (Zheng and Flavell 1997; Szabo et al. 2000; Hori et al. 2003; Ivanov et al. 2006; 
Nurieva et al. 2009) (Table 1.1).  There is emerging evidence that TBET, GATA3, 
RORγt, may play a similar role in regulating differentiation of CD8+ T cells resulting in 
Tc1, Tc2, and Tc17 cells respectively (Apte et al. ; Szabo et al. 2000; Curtis et al. 2009; 
Hamada et al. 2009). 
 
T-cell subtype Differentiation factor Transcription factor 
Th1/Tc1 IL12 TBET 
Th2/Tc2 IL4 GATA3 
Th9 IL4, TGF PU.1 
Th17/Tc17 IL6, TGFβ, then IL23 RORγt 
Tfh IL21 Bcl6 
Treg IL2 FoxP3 
Table 1.1: Cytokines and transcription factors regulating T-cell differentiation 
 
The mechanisms underlying the interaction between cytokines, signal-transducing 
activator of transcription (STAT) signalling and transcription factors are best 
understood in Th1/Th2 differentiation in CD4
+
 cells. This is summarised in Figure 1.2 
(Amsen et al. 2009). These two distinct pathways of helper T-cell differentiation are 
driven by the cytokines IL12 and IL4 and the transcription factors TBET and GATA3 
respectively. Engagement of the TCR by its specific peptide:MHC complex initially 
induces low grade expression of the IFNγ (IFNG) and TBET (TBX21) genes. When 
IL12 is present, STAT4 signalling increases the expression of IFNγ which bind to the 
IFNγ receptor in an auto/paracrine manner. This activates STAT1 which strongly 
promotes expression of the TBX21 gene. The resultant upregulation of the transcription 
factor TBET has a number of important effects including a further increase in IFNγ 
production, increased expression of the IL12 receptor β-chain, and also prevention of 
Th2 differentiation by directly inhibiting GATA3 (Szabo et al. 2000; Mullen et al. 
2001; Hwang et al. 2005). 
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Figure 1.2 Regulation of Th1/Th2 differentiation (Amsen et al. 2009) 
 
In contrast, Th2 development is directed by IL4. Initial activation of TCR-signalling in 
the presence of IL4 causes activation of STAT6, which promotes expression of the 
GATA3 and IL4 genes. The transcription factor GATA3 reorganises chromatin structure 
in the Th2 locus, which encompasses the IL4, IL5 and IL13 genes, increasing their 
translational competence. Increased production of IL4 further enhances Th2 
differentiation in a positive feedback loop. GATA3 prevents Th1 differentiation by 
inhibiting expression of the IL12 receptor β-chain and the STAT4 gene (Zhang et al. 
1997; Zheng and Flavell 1997; Yamashita et al. 2004; Kim et al. 2007). 
 
Similarly, there also appears to be a reciprocal relationship between Th17 cells and 
Tregs. Th17 cells, so called because of their production of the effector cytokine IL17, 
were the third class of CD4
+
 helper T cells to be described (Langrish et al. 2005). They 
are thought to be particularly important in the defence against certain extracellular 
bacteria such as Citrobacter, Klebsiella pneumoniae, and Borrelia burgdorferi, and 
fungi such as Candida albicans (Bettelli et al. 2008). IL17 also appears to play an 
important role in tissue inflammation, and thus Th17 cells heavily implicated in 
autoimmune diseases, particularly those affecting the central nervous system (Langrish 
et al. 2005; Ivanov et al. 2006). It was initially suggested that IL23 was the 
differentiation factor for Th17 cells, but subsequent work has shown that their 
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differentiation is driven by TGFβ and IL6 (Bettelli et al. 2006). IL6 signalling leads to 
the phosphorylation of STAT3, and ultimately to expression of RORγt, which is 
believed to regulate many components essential for the differentiation of Th17 cells 
including IL17A, IL17F, and the IL23 receptor (Ivanov et al. 2006; Yang et al. 2007).  
 
While Th17 cells have been found to promote tissue inflammation and autoimmunity, 
activation and expansion of self-reactive T-cells is suppressed by “naturally occurring” 
CD4
+
CD25
+
 regulatory T cells (Tregs) (Sakaguchi et al. 1995; Sakaguchi 2000). It was 
subsequently demonstrated that the transcription factor, FoxP3, plays a key role in 
regulating the development of these cells (Hori et al. 2003). In the same way that there 
is a reciprocal relationship between Th1 and Th2 cells, there appears to be a similar 
relationship between Th17 cells and Tregs. TGFβ alone is anti-inflammatory and is 
essential for the development of Tregs, but the presence of pro-inflammatory IL6 has 
been shown to inhibit the induction of FoxP3
+
 Tregs, and simultaneously promote Th17 
differentiation (Bettelli et al. 2006). It was subsequently demonstrated at the molecular 
level that RORγt and FoxP3 can bind to each other and inhibit each other’s function 
(Zhou et al. 2008). Furthermore, IL2, a growth factor for Tregs, inhibits Th17 
differentiation through activation of STAT5, whereas IL21, which promotes Th17 
differentiation, inhibits the expansion of Tregs (Laurence et al. 2007). Retinoic acid has 
also been shown to promote Treg differentiation while inhibiting Th17 cells (Mucida et 
al. 2007).  
 
The situation is further complicated by the emergence of another helper T-cell subset, 
Th9 cells. In contrast to Th17 cells and Tregs, these are induced by the combination 
TGFβ and IL4 and primarily produce IL9 and IL10 (Jager and Kuchroo 2010). The 
transcription factor PU.1,  previously shown to be essential for many aspects of 
lymphoid and myeloid cell development, has recently emerged as being required for the 
development of this subset (Chang et al. 2010). They appear to be effector rather than 
regulatory, and have been implicated in the development of allergic inflammation, 
particularly in the lungs (Carotta et al. 2010). 
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1.2.4 Transcriptional Control of Effector/Memory Development 
In addition to their role as controllers of T-cell differentiation, some of these 
transcription factors also regulate the development of effector and memory T cells. In 
contrast to the effector T cells described above, memory T cells are long-lived and 
persist after an infection has been cleared. They are so-called because of their ability to 
undergo rapid expansion to generate large numbers of effector T cells upon re-exposure 
to their specific antigen, thus providing the immune system with memory against past 
infections. Memory T cells can be divided into two main subtypes on the basis of 
distinct expression of chemokine receptors (CCRs) or homing molecules: 
CD44
+
CD62L
+
CCR7
+
 central memory T cells (TCM cells) and CD44
+
CD62L
-
CCR7
-
 
effector memory T cells (TEM cells) (Sallusto et al. 1999). TCM cells mediate what has 
been called “reactive memory”, with their constitutive expression of CCR7 and CD62L 
allowing them to home to secondary lymphoid organs. They have little or no effector 
function, but in comparison to naive T cells show greater sensitivity to antigenic 
stimulation, are less dependent on co-stimulation, and up-regulate CD40L to a greater 
extent. However, upon recognition of their cognate antigen, they have a high 
proliferative potential and can rapidly differentiate into large numbers of effector cells 
(Sallusto et al. 2004).  
 
In contrast, TEM cells mediate what has been called “protective memory”, by migrating 
to inflamed peripheral tissues and displaying immediate effector function. CD8
+
 TEM 
cells carry large amounts of perforin, and both CD4
+
 and CD8
+
 TEM cells can produce 
IFNγ, IL4 and IL5 within hours after following antigenic stimulation. Within the CD8+ 
TEM subtype, there is a subset that expresses CD45RA and contains large amounts of 
perforin, termed TEMRA cells (Sallusto et al. 2004). This subset also shows reduced 
expression of co-stimulatory molecules such as CD27 and CD28, and has been found to 
be enriched in CMV infection (Hamann et al. 1997; Champagne et al. 2001; Appay et 
al. 2002). Interestingly, while all memory T cells show a relatively low threshold for 
activation, the potential for expansion progressively decreases from TCM cells to TEM 
cells, with TEMRA cells having a particularly low capacity for proliferation and 
expansion (Geginat et al. 2003). This correlates with a decrease in telomere length and 
an increased tendency to undergo apoptosis. These constraints can be overcome by co-
stimulation, which has been shown to both induce telomerase activity, and upregulate 
anti-apoptotic Bcl-XL (Boise et al. 1995; Son et al. 2000).  
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Under normal circumstances the relative proportions of TCM and TEM cells in blood are 
associated with their co-receptor expression: TCM cells are predominant in the CD4
+
 
compartment and TEM cells in the CD8
+
 compartment. Within the tissues, TCM and TEM 
cells show characteristic patterns of distributions with TCM cells enriched in lymph 
nodes and tonsils, whereas lung, liver and gut contain greater proportions of TEM cells 
(Campbell et al. 2001). Significantly, TCM cells appear to be heterogeneous in their 
ability to differentiate into a Th1 or Th2 phenotype and this has been shown to correlate 
with expression of CXCR3 and CCR4 respectively. A proportion of circulating TCM 
cells express CXCR5, the receptor for CXCL13, which is a chemokine produced in B 
cell follicles, and hence have been called follicular helper T cells (Tfh-cells). They are 
produce IL2, IL10, and IL21 upon activation, and when present in tonsils express 
CD40L, ICOS, CD84 and CD200 providing spontaneous help to B cells (Breitfeld et al. 
2000; Schaerli et al. 2000; Chtanova et al. 2004; Vogelzang et al. 2008).  IL21 has been 
found to be the principle differentiation factor, and has been demonstrated to upregulate 
the transcription factor BCL6, which regulates Tfh-cell development (Nurieva et al. 
2008; Nurieva et al. 2009; Stewart 2009).  
 
During an immune response, naive T cells undergo a pronounced clonal expansion 
during which large numbers of antigen-specific T cells are generated. This initial phase 
of expansion and acquisition of effector functions is followed by a contraction phase 
where the majority of the reactive T cells undergo apoptosis, leaving behind a small, but 
relative stable population of memory T cells. As described above, when these cells re-
encounter their specific antigen they can efficiently proliferate and undergo rapid 
transition into effector cells. Traditionally memory T cells were considered to arise 
during the contraction phase, and were felt to directly develop from effector cells. 
However, observations that memory cells display many features that are more 
characteristic of naive T-cells, along with the discovery of the IL7 receptor α-chain 
(IL7R; CD127) expression as a hallmark for memory cells and their precursors, 
conflicts with this model. Instead, memory T cells are thought to diverge early during 
an immune response, and arise in parallel with short-lived effector cells (Kallies 2008). 
 
In line with this “fixed lineage model” of differentiation, there is evidence that the 
cytokine milieu also determines distinct transcriptional profiles of effector and memory 
T-cells, and that these are imprinted early during the immune response. A number of 
transcription factors have been implicated in this process, including TBET, 
John Riches Chapter 1: Introduction 
36 
 
Eomesodermin (EOMES), BCL6 and BLIMP1. Like TBET, EOMES is also a member 
of the T-box family, and together these transcription factors have been demonstrated to 
regulate CD8
+
 T-cell effector and memory differentiation. They have been shown to 
enhance expression of IL2Rβ, a component of the IL15 receptor, and therefore enhance 
the IL15 signalling required for the survival of memory T cells (Intlekofer et al. 2005). 
Interestingly, while deficiency of just one of these two transcription factors does not 
appear to significantly affect CD8
+
 T-cell effector/memory differentiation, absence of 
both transcription factors leads to aberrant differentiation into IL17 producing CD8
+
 T-
cells (Intlekofer et al. 2008). Evidence is emerging that differentiation of CD8
+
 T-cells 
occurs in two principle phases, and the mammalian target of rapamycin (mTOR) plays a 
key role in regulating their fate. The mTOR kinase senses environmental cues, nutrient 
availability, internal energy stores, and growth factor signalling to regulate cell growth, 
proliferation and differentiation (Powell and Delgoffe 2010). Inhibition of mTOR by 
rapamycin has been previously demonstrated to induce a state of anergy in CD4
+ 
T 
cells, and has also been shown to induce CD4
+
Foxp3
+
 Tregs (Powell et al. 1999; 
Haxhinasto et al. 2008). In naive CD8
+
 T-cells, mTOR plays an essential role in 
regulating TBET versus EOMES expression. During the early stages of infection, high 
amounts of antigen, inflammation and the presence of cytokines such as IL12 resulted 
in increased and sustained expression of TBET and mTOR activity, promoting the 
differentiation of TEM cells. As levels of antigen fall in the setting of decreased 
inflammation, decreased mTOR activity switches the transcriptional program from 
TBET to EOMES promoting the differentiation of TCM cells (Figure 1.3) (Shrikant et 
al. 2010).  
 
 
 
 
 
 
 
 
 
 
 Figure 1.3 Regulation of CD8
+
 T cell effector and memory differentiation 
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This highlights the importance of the concept of strength of TCR signalling, with strong 
signals promoting the development of an effector phenotype, while weaker signals 
promote memory cell differentiation. Of note, CD8
+
 T-cells that have been treated with 
rapamycin, with enhanced memory-like attributes, demonstrate significantly enhanced 
activity to control tumour growth, which correlates with observations that TCM cells are 
required for durable and effective anti-tumour immune responses (Shrikant et al. 2010). 
 
The expression of TBET and EOMES also correlates with the surface expression of 
IL7R. Both naive and memory T cells express high levels of IL7R, but this molecule is 
downregulated by most T cells in the early stages after antigenic stimulation. A 
subpopulation of these cells will regain expression of IL7R during the course of the 
immune response, and this population has a high capacity to become memory T cells. 
TBET has been shown to directly repress expression of the IL7R gene, thus promoting 
effector cell differentiation at the expense of memory cell formation (Joshi et al. 2007; 
Kallies 2008). In contrast, ectopic T-bet expression by OT1 CD8
+
 T cells down-
regulated CD127 and SOCS1, and upregulated CD122 and IL15Rα, switching the 
cellular survival cytokine profile from IL7 to IL15 (Yeo and Fearon 2011). 
 
The transcription factors BCL6 and BLIMP1 have also been implicated the regulation 
of memory CD8+ T-cell development. BLIMP1 was originally shown to regulate the 
terminal differentiation of B cells into antibody secreting plasma cells (Turner et al. 
1994). Bcl6 was initially cloned from patients with non-Hodgkin lymphoma, and it was 
subsequently shown to be crucial for B cell memory development in germinal centres 
(Ye et al. 1993; Fukuda et al. 1997). Overexpression of BLIMP1 has been shown to 
suppress T-cell proliferation and may be important in terminating the immune response 
by promoting activation induced cell death (AICD). BLIMP1 is expressed most strongly 
in the later stages of T-cell differentiation and its expression may block memory 
differentiation (Kallies 2008). In contrast, BCL6 has been shown to promote the 
development of TCM cells, and may work in part by antagonising the AICD promoting 
activity of BLIMP1 (Ichii et al. 2002; Kallies 2008). 
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1.2.5 Chronic Antigenic Stimulation and T-cell Exhaustion 
Significantly, there are significant differences in CD8
+
 memory T-cell differentiation in 
acute and chronic viral infections. As described above, in acute infections antigen 
stimulation results in the production of activated CD8
+
 T-cells which proliferate 
extensively and acquire effector functions such as cytokine production and cytotoxicity, 
along with chemokine production and new migratory properties. The majority of the 
effector CD8
+
 T cells then die during the contraction phase, with about 5 – 10% 
remaining as memory CD8
+
 T cells (Angelosanto and Wherry 2010). In contrast during 
chronic viral infections, the effector T cells are unable to differentiate into functional 
memory cells, and become dysfunctional as the infection progresses. Exhausted CD8
+
 T 
cells progressively lose the ability to produce IL2, have reduced capacity to proliferate, 
show reduced cytotoxicity, and have a greater propensity to undergo apoptosis (Figure 
1.4). Eventually, fully exhausted CD8
+
 T cells can even lose the ability to produce 
cytokines including IFNγ (Zajac et al. 1998; Fuller and Zajac 2003; Wherry et al. 
2003). A further characteristic is the of exhausted CD8
+
 T cells is the upregulation of 
inhibitory receptors including PD1, LAG3, CD160, and 2B4 (Barber et al. 2006; 
Blackburn et al. 2009).  
Figure 1.4 T-cell exhaustion (Wherry 2011) 
 
Some functions of these exhausted T cells can be regained by blocking inhibitory 
receptor pathways, such as PD1 and/or LAG3, but the greater the number of inhibitory 
receptors expressed by a cell, the more severe the exhaustion and the less chance of 
regaining function (Blackburn et al. 2008; Blackburn et al. 2009). Antigen independent 
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memory T-cell maintenance can also become compromised during chronic viral 
infection, with exhausted CD8
+
 T-cells responding poorly to IL7 and IL15. Instead 
virus-specific CD8
+
 T cells generated during chronic infection require antigen to 
survive, and the pattern of division for maintenance is distinct from memory CD8
+
 T 
cells generated after acute infection (Shin et al. 2007).  
 
Programmed cell death 1 (PD1) is a known T-cell inhibitory receptor, with expression 
of its ligand, PDL1, on non-haematopoietic cells, playing an important role in the 
maintenance of peripheral tolerance and preventing autoimmunity (Sharpe et al. 2007). 
Its expression on T-cells is inducible, being upregulated within 24-72 hours of 
stimulation. This axis has been exploited by a variety of infectious organisms, such as 
HIV, to attenuate antimicrobial immunity and facilitate chronic infection, and has also 
been implicated in cancer (Weber 2010). Engagement of PD1 by its ligands during TCR 
signalling can block T-cell proliferation, cytokine production and cytolytic function, 
and impair T-cell survival. The extent of PD1 inhibition depends on the strength of the 
TCR signal, with more inhibition occurring at lower levels of TCR stimulation. CD28 
co-stimulation or IL2 can override PD1 mediated inhibition (Francisco et al. 2010). 
PD1 engagement has a number of effects on TCR signalling, including inhibition of 
PI3K/Akt activity, and prevention of the induction of BclxL and transcription factors 
such as GATA-3, TBET and Eomes (Nurieva et al. 2006). The expression of the two 
ligands, PDL1 and PDL2 is regulated by inflammatory milieu, with cytokines such as 
the IFNγ and TNFα upregulating their expression on T cells, B cells, endothelial cells, 
and epithelial cells (Keir et al. 2008). 
 
The transcription factor BLIMP1 has emerged as playing a key role in CD8
+
 T-cell 
exhaustion during chronic viral infection (Shin et al. 2009). It has been shown to be 
dramatically upregulated in virus specific CD8
+
 T-cells as these cells became exhausted. 
It has also been shown to both upregulate inhibitory receptors such as PD1, and also 
repress key molecules involved in normal memory CD8
+
 T-cell differentiation, 
including IL7R and CD62L. NFAT has also been implicated, with a defect in its nuclear 
translocation having been demonstrated to be responsible for defective cytokine 
production by exhausted CD8
+
 T-cells (Agnellini et al. 2007). Under normal 
circumstances these transcription factors may act to regulate cytotoxicity in exhausted T 
cells whilst avoiding excess damage from release of pro-inflammatory cytokines 
(Angelosanto and Wherry 2010).  
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1.3 Chronic lymphocytic leukaemia  
 
1.3.1 Chronic lymphocytic leukaemia  
B-cell chronic lymphocytic leukaemia (CLL) is a disease caused by a clonal expansion 
of small, mature IgM
+
/IgD
+
 B lymphocytes. It is the commonest leukaemia in the 
western world, and is a disease of the elderly with a median age of 72 years at diagnosis 
(SEER Cancer Factsheet)(2012). CLL has characteristic immunophenotype with co-
expression of the T-cell antigen CD5 and B-cell antigens CD19, CD20, and CD23. The 
levels of surface immunoglobulin, CD20 and CD79b are generally decreased compared 
to those found on normal B cells (Table 1.2). The diagnosis of CLL is dependent on the 
presence of >5 x 10
9
/L monoclonal lymphocytes with this phenotype in the peripheral 
blood persisting for more than 3 months (Figure 1.5). The disease can also present with 
lymphadenopathy, splenomegaly, hyper-metabolic symptoms such as weight loss, 
fevers and night sweats, and evidence of bone marrow failure. The term small 
lymphocytic leukaemia (SLL) is used where there is lymphadenopathy and/or 
splenomegaly due to an infiltration of clonal B cells with the same phenotype as CLL, 
but with a circulating lymphocytosis < 5 x 10
9
/L (Hallek et al. 2008; Swerdlow 2008). 
 
Table 1.2 CLL Scoring System 
Marker  (Score)  (Score) 
SmIg Weak (1) Moderate/Strong (0) 
CD5 Positive (1) Negative (0) 
CD23 Positive (1) Negative (0) 
FMC7 Negative (1) Positive (0) 
CD79b Weak (1) Strong (0) 
Total Score for CLL: 3 – 5; scores for non-CLL cases: 0 – 2 
 
Figure 1.5 Peripheral blood smear and bone marrow aspirate in CLL  
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1.3.2 Prognostic Stratification 
CLL is a very heterogeneous disease. The clinical course can range from indolent, 
where patients may never require treatment, to aggressive, where patients have rapid 
progression of disease in the peripheral blood, bone marrow, and lymphoid organs. This 
heterogeneity is maintained after treatment, with a wide variation between patients in 
terms of depth of response to treatment and response duration.  
 
Several prognostic markers have been identified that identify patients with poorer risk 
disease. Classically, assessment of risk was based on clinical and basic laboratory 
parameters. The Rai and Binet staging systems are the most widely used, in both patient 
care and clinical trials (Rai et al. 1975; Binet et al. 1981). The original Rai classification 
had five prognostic groups before it was modified to three groups, such that both 
systems now have three major subgroups with discreet clinical outcomes (Table 1.3). 
 
Table 1.3 Rai and Binet staging systems in CLL 
Rai modified staging Binet clinical staging 
Risk Stage Clinical features Median 
survival 
Stage Clinical features Median 
survival 
Low 0 Lymphocytosis alone >12.5 
yrs  
A No anaemia or 
thrombocytopenia 
<3 lymphoid regions 
enlarged 
12 yrs 
Intermediate I Lymphocytosis & 
lymphadenopathy 
8.4 yrs B No anaemia or 
thrombocytopenia 
5 yrs 
 II Lymphocytosis & 
spleno/hepatomegaly 
5.9 yrs  3 or more lymphoid 
regions enlarged 
 
High III Lymphocytosis & 
anaemia (< 11.0 g/dL) 
1.6 yrs C Anaemia (< 10.0 
g/dL) and/or 
2 yrs 
 IV Lymphocytosis & 
thrombocytopenia  
(< 100 x 10
9
/L) 
1.6 yrs  thrombocytopenia  
(< 100 x 10
9
/L) 
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Over the last 10 – 15 years several other prognostic markers have emerged, based on the 
biological characteristics of the disease. The most extensively used and studied of these 
include IGVH gene mutation status, ZAP70 and CD38 expression, and cytogenetics 
(Chiorazzi 2012). Cytogenetic abnormalities as defined by fluorescence in situ 
hybridisation are the most frequently used and widely available biological prognostic 
markers for the clinical care of CLL patients. A landmark paper published in 2000 
documented the most frequent genetic alterations present in CLL and correlated them 
with outcome (Dohner et al. 2000). On the basis of a regression analysis of 325 patients, 
a hierarchical model of chromosomal aberrations was defined that was predictive of 
both median survival and time to first treatment. Five categories were defined: 17p 
deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole 
abnormality; the median survival times for patients in these groups were 32, 79, 114, 
111, and 133 months, respectively. Patients with deletion of either 17p or 11q were also 
noted to have the most clinically advanced disease as defined by the Rai and Binet 
criteria, as well as more extensive lymphadenopathy and splenomegaly. Ongoing work 
has identified the critical gene(s) within the affected regions in these chromosomes 
(Table 1.4).  
 
Table 1.4 Critical genes implicated within chromosomal abnormalities in CLL 
Chromosomal abnormality Critical genes within the affected region Reference 
Deletion 13q14 DLEU2: codes for miR15a and miR16-1 (Calin et al. 2002) 
Trisomy 12 NOTCH1 (Balatti et al. 2012) 
Deletion 11q22-23 RDX; ATM (Stilgenbauer et al. 2002) 
Deletion 17p TP53 (Zenz et al. 2010) 
 
IGVH gene mutation status is a second important prognostic marker in CLL. Under 
normal circumstances, naive B cells are continuously circulating through the blood and 
lymphatic system. Upon encountering their cognate antigen, the activated B cells 
migrate to lymph node primary follicles, where along with their associated T cells, they 
proliferate and form a germinal centre. As part of this “germinal centre reaction”, these 
B cells undergo somatic hypermutation of the V regions of their immunoglobulin genes, 
which in turn allows for the selection of mutated B cells with increased affinity for the 
antigen (affinity maturation).  In just over half (~55%) of CLL cases, the malignant B 
cells show evidence of having been through this process, as sequencing of their IGVH 
genes shows < 98% sequence homology to germline (“mutated”). In the other 45% of 
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cases the malignant B cells have features of naive B cells, in that their IGVH genes 
show > 98% sequence homology to germline (“unmutated”), suggesting that the cell of 
origin had not passed through the germinal centre reaction. These two categories were 
associated with radical differences in prognosis, with patients with mutated IGVH genes 
in the tumour cells having a significantly better outcome than patients with unmutated 
IGVH genes (Hamblin et al. 1999). It has been postulated that this may be due to 
differences in the affinity of the BCR for autoantigens in these two situations. Cases 
with mutated IGVH genes may have CLL cells with BCRs that have higher affinity for a 
more restricted range of antigens than unmutated cases, which may lead to either anergy 
where antigens are present, or death by neglect where antigens are absent (Chiorazzi 
2012). High expression of CD38 and ZAP70 are both correlated with unmutated IVGH 
genes, and are predictive of a poorer prognosis (Damle et al. 1999; Crespo et al. 2003).  
Both CD38
+ 
and ZAP70
+ 
cases show evidence of a higher degree of cellular activation 
of the clone, with evidence of more recent proliferation and greater responsive to 
surface immunoglobulin cross-linking in CD38
+
 cases, and prolongation of BCR-
signalling in ZAP70
+
 cases (Zupo et al. 1996; Chen et al. 2002; Damle et al. 2002; 
Lanham et al. 2003; Pepper et al. 2006; Calissano et al. 2009). Overall, a picture is 
emerging where patients with aggressive disease have “weakly anergic” tumour cells 
that have higher capacity to respond to BCR-signalling and proliferate, which 
corresponds to high expression of CD38 and ZAP70 and unmutated IVGH genes. In 
contrast, patients with more indolent disease have “strongly anergic” tumour cells, 
which are relatively quiescent, with low expression of CD38 and ZAP70, and mutated 
IGVH genes.  
  
John Riches Chapter 1: Introduction 
44 
 
1.3.3 Standard Treatments 
In standard practice, newly diagnosed patients with early stage disease (Rai 0, Binet A) 
should be monitored without therapy unless they have evidence of disease progression. 
Treatment guidelines state that therapy should be reserved for those with advanced, 
symptomatic or progressive disease, as a meta-analysis of more than 2000 patients with 
early disease showed no survival benefit with early treatment with alkylating agents 
(1999; Hallek et al. 2008). Patients with Binet stage B or C, or Rai intermediate or high 
risk disease usually benefit from treatment. The following criteria are useful in 
determining the need for treatment initiation: 
- Evidence of progressive bone marrow failure 
- Massive, progressive, or symptomatic splenomegaly 
- Massive, progressive, or symptomatic lymphadenopathy 
- Progressive lymphocytosis with an increase of more than 50% over a two-month 
period or lymphocyte doubling time of less than six months. 
- Autoimmune anaemia/thrombocytopenia unresponsive to standard therapy 
- Constitutional symptoms of weight loss, night sweats, fevers or fatigue 
 
Combination therapy with fludarabine, cyclophosphamide and rituximab (FCR) has 
emerged as the current standard of care for CLL. The German CLL Study Group 
(GCLLSG)-led CLL8 study showed that patients treated with this combination achieved 
significant improvements in progression free survival (PFS) and overall survival (OS) 
compared to patients treated with fludarabine and cyclophosphamide (FC) alone, with 
overall response rates (ORR) of 95% (Hallek et al. 2010). Despite these encouraging 
results, FCR is not curative, with complete remission (CR) rates of only 44%, and a 
median progression free survival (PFS) of 52 months. Furthermore, this regimen is also 
not suitable for all patients. FCR has a significant side effect profile, and appears too 
toxic for the elderly and those with co-morbidities. The GCLLSG also conducted a 
randomized phase III trial comparing upfront therapy with single agent fludarabine 
against chlorambucil in patients over 65 years of age. A total of 193 patients with a 
median age of 70 years were enrolled. Despite higher ORR and CR rates, this did not 
translate into improved PFS or OS (Eichhorst et al. 2009). This is highly relevant given 
that two-thirds of patients are over 65 years of age at the time of diagnosis.  Even in the 
younger age-group, high risk patients such as those with 17p deletion, or who have 
treatment-refractory or rapidly relapsed disease, represent a major challenge. Therefore 
there is an urgent need for novel agents in CLL.  
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1.3.4 Molecular Targeted Therapies 
Given the success of the tyrosine kinase inhibitors in chronic myeloid leukaemia (CML) 
there has been increasing interest in developing more targeted therapies for CLL. Many 
of the most recent therapeutic developments directed at the CLL B cells have focused 
on signalling through the B-cell receptor (BCR). BCR signalling is known to be crucial 
for B-cell proliferation and survival, and a number of major prognostic markers that are 
clinically useful in CLL are associated with aberrations in BCR signalling, as described 
above. The BCR consists of a surface immunoglobulin (Ig) molecule non-covalently 
associated with an Ig /Ig  CD79a/CD79b) heterodimer. In normal B cells, 
engagement of the BCR by antigen induces phosphorylation of the immunoreceptor 
tyrosine-based activation motifs (ITAMs) within the cytoplasmic domains of Ig  and 
Ig  This phosphorylation is primarily mediated by the Src family kinase Lyn, and 
results in the recruitment and activation of the tyrosine kinase Syk. The activated Syk 
forms a membrane associated complex with other tyrosine kinases such as Lyn and the 
Tec kinase, Bruton’s tyrosine kinase (BTK), and adapter molecules such as B-cell linker 
protein (BLNK). This complex mediates the activation of downstream signalling 
pathways, such as phosphatidyl 3-kinase (PI3K), and phospholipase C 2 (PLC 2). PI3K 
generates the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which 
recruits molecules such as the kinase Akt. PLC 2 activation leads to the release of 
intracellular calcium and subsequent activation of protein kinase C (PKC). These events 
lead in turn to activation of mitogen activated protein kinases (MAPKs) including 
extracellular signal regulated kinase (ERK), c-JUN NH2-terminal kinase (JNK) and p38 
MAPK. Activation of PKC also increases expression of the transcription factor nuclear 
factor- B (NF B), while the rise in the intracellular calcium concentration causes 
activation nuclear factor of activated T cells (NFAT). It is likely that the expression 
profile of these transcription factors is fundamental in determining B-cell fate (Niiro and 
Clark 2002).  
 
One of the most striking aspects of CLL biology is that the immunoglobulin variable 
heavy (IgVH) and light chain genes (IgVL) have a very limited repertoire, with highly 
similar gene rearrangements being demonstrated in a number of patients. This suggests 
that chronic antigenic drive plays a critical role in the pathogenesis of this disease, 
conferring a selective growth advantage to the malignant cells (Rosen et al. 2010). In 
light of the of the importance of BCR signalling in promoting CLL, there has been a 
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large amount of interest in targeting key molecules in this signalling pathway. A variety 
of molecules that inhibit the activity of downstream kinases have been developed, 
including inhibitors of Lyn, Syk, BTK and PI3K (Figure 1.6). Two of these, the BTK-
inhibitor ibrutinib (PCI-32765) and the PI3K-inhibitor idelalisib (CAL-101; GS-1101) 
look particularly exciting and are in advanced stage clinical trials with/without other 
agents.
 
Figure 1.6 BCR-signalling pathway and targets for molecular inhibitors 
 
Pre-clinical studies of the BTK inhibitor, ibrutinib, showed that it is directly cytotoxic to 
primary CLL cells, dependent on caspase activation. This agent also appears to have 
effects on the microenvironment, by blocking the protective effect of factors such as 
CD40 ligand (CD40L), TNF , IL6, and B cell activating factor (BAFF) (Herman et al. 
2010). A recently published clinical phase Ib/II study of two-dose cohorts 
(420mg/840mg) of ibrutinib in patients with relapsed or refractory CLL/SLL showed 
ORRs of 71% in both cohorts, with PFS of 75% and OS of 83% at 26 months. 
Intriguingly, one of the defining characteristics of ibrutinib treatment was rapid lymph 
node shrinkage associated with an increase in the circulating lymphocytosis, consistent 
with mobilisation of the CLL cells from the tissues to the blood. This lymphocytosis 
complicated the analysis of response by standard criteria: if an additional category of 
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response with lymphocytosis was included, a further 20% and 15% of patients in the 
two dose cohorts could be considered to respond. Ibrutinib was well tolerated with 
minimal haematological toxicity (Byrd et al. 2013).  
 
Inhibitors of PI3K are also under investigation as potential treatments for CLL. The 
PI3K pathway has been shown to play a pivotal role in CLL-cell growth, with sustained 
activation being critical for their survival (Cuni et al. 2004). Constitutive activation of 
this pathway prevented the downregulation of  Bcl-xL (B-cell lymphoma-xL) and the 
caspase inhibitor proteins FLICE-inhibitory protein ligand (FLIPL) and X-linked 
inhibitor of apoptosis protein (XIAP). Idelalisib is a small-molecule inhibitor of the 
p110  isoform of PI3K, which is generally restricted to cells of hematopoietic origin. It 
has been demonstrated to promote caspase dependent apoptosis in primary CLL cells 
independently of common prognostic markers. Idelalisib has also been shown to 
overcome the anti-apoptotic effects of CD40L, TNF-α, and fibronectin, and to also 
inhibit the protective effects of stromal cells (Herman et al. 2010). A phase I study of 
the use of single agent idelalisib in patients with relapsed or refractory CLL has shown 
it to be well tolerated, with partial remissions being observed in 33% of patients. 
Interestingly, the drug-mediated mobilisation of lymphocytes from the lymph nodes to 
the peripheral blood was also observed with this agent (Furman et al. 2010).  
 
A further area that has been the subject of recent investigation is the use of agents that 
inhibit the anti-apoptotic Bcl2 family members, Bcl2, BclxL, and Mcl1. These proteins 
prevent apoptosis by sequestering the pro-apoptotic proteins Bax and Bak. They are 
commonly over-expressed in CLL B cells, with evidence that this is due to sustained 
BCR-signalling and prolonged activation of the PI3K/Akt and MEK/ERK pathways 
(Gottardi et al. 1996; Longo et al. 2008). Several inhibitors of the Bcl2 family have 
been developed, which inhibit one or more of these molecules. The first-generation Bcl2 
inhibitor, navitoclax, achieved partial remissions (PRs) in 35% of patients with 
relapsed/refractory CLL (Roberts et al. 2009). However, this agent also inhibited BclxL 
expressed in platelets, resulting in dose-limiting thrombocytopenia. ABT-199 is a  
second generation Bcl2 inhibitor that has greater affinity for Bcl2 but 500-fold less 
affinity for Bcl-xL. Preliminary data from a phase I study of this agent in patients with 
relapsed/refractory CLL have shown impressive efficacy, with 85% ORR including 
88% responses in patients with deletion of 17p and 78% responses in fludarabine-
refractory patients (Roberts et al. 2013).   
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1.4 The Immune System in CLL 
 
Immune dysfunction is a key feature of CLL, highlighted by the 
hypogammaglobulinaemia, increased susceptibility to infections, and increased 
incidence of autoimmune cytopenias that are commonly seen in this disease. As a 
consequence, attempts to understand nature of the immune defect in CLL have been 
active areas of investigation. The immune-surveillance hypothesis would suggest that in 
order to produce a clinically detectable tumour mass, the malignant B cells must have 
evolved strategies of evading or suppressing the immune system, especially the anti-
cancer effects of T lymphocytes (Dunn et al. 2002). An understanding of these 
mechanisms and the subsequent immune cell defects, should allow the development of 
new therapeutic approaches aimed at restoring anti-tumour immune responses. 
 
1.4.1 T-cell Dysfunction in CLL: Abnormalities in T-cell Numbers 
It has been known for some time that the T-cell compartment is highly abnormal in 
CLL, with one of the earliest studies reporting an increase in absolute numbers of T 
cells in the PB (Catovsky et al. 1974). This expansion is primarily accounted for by an 
increase in CD8
+
 T cells, resulting in a fall in the CD4:CD8 ratio,(Lauria et al. 1980; 
Herrmann et al. 1982; Mills et al. 1982; Platsoucas et al. 1982) in contrast with the 
situation in the LNs and bone marrow, where increased numbers of CD4
+
 T cells have 
been reported (Pizzolo et al. 1983). The mechanism behind these changes remains 
unclear, although it has been suggested that the relative reduction in numbers of PB 
CD4
+
 T cells is due to their increased susceptibility to FasL-mediated apoptosis 
(Tinhofer et al. 1998). A number of studies have linked changes in the numbers of 
circulating T cell numbers to prognosis. Early work demonstrated that there was greater 
expansion of CD8
+
 T cells, reflected in falling CD4:CD8 ratios, with advancing Rai 
stage (Herrmann et al. 1982).  A more recent study has shown that inverted CD4:CD8 
ratios predict shorter time to first treatment and reduced progression-free survival 
(Nunes et al. 2012). Furthermore, other investigators have shown that patients with 
“pre-malignant” monoclonal B cell lymphocytosis (MBL) appear to lack any significant 
expansion in T cell numbers, in contrast to patients with CLL (Te Raa et al. 2012). 
However, there may be difficulties trying to prognosticate based on just the PB 
microenvironment, as another study found that increased numbers of circulating CD8
+
 
correlate with longer median time of survival (Gonzalez-Rodriguez et al. 2010). 
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1.4.2 T-cell Dysfunction in CLL: Abnormalities in Cytokine Secretion Profiles 
Despite their increased numbers, these T cells show profound defects in function and 
proliferative capacity, and abnormal cytokine secretion profiles (Chiorazzi et al. 1979; 
Lauria et al. 1983; Prieto et al. 1993). Early studies suggested that CLL was a Th2/Tc2 
mediated disease, with increased numbers of CD4
+
 and CD8
+
 T cells producing 
interleukin-4 (IL4).(Mu et al. 1997; Mainou-Fowler et al. 2001) Further work showed 
that these IL4-producing T cells also upregulate CD30 by an IL4 and OX40L-dependent 
mechanism (de Totero et al. 1999; Cerutti et al. 2001). Interaction of CD30 with 
CD30L expressed on the CLL cells results in increased TNFα production and CLL-cell 
proliferation. In contrast, ligation of CD30L on the surface of the non-malignant B cells 
impairs isotype class switching, and increases their sensitivity to FasL-mediated cell 
death, potentially contributing to the hypogammaglobulinaemia observed in CLL. IL4 
also appears to be able to protect the CLL cells from undergoing apoptosis, by 
increasing/maintaining bcl2 protein levels (Dancescu et al. 1992; Panayiotidis et al. 
1993). There is evidence to suggest that interleukin-6 (IL6) production by CLL cells 
drives this skew towards IL4 producing T cells. Healthy T cells stimulated in the 
presence of tumour supernatant containing high levels of IL6 have been shown to 
increase their production of IL4, findings that could be replicated using recombinant 
IL6, or reversed by removal or blockade of this cytokine (Buggins et al. 2008). 
Furthermore, IL6 has been demonstrated to be increased in the serum of patients with 
CLL, with higher levels predicting poorer survival (Kurzrock et al. 1993; Fayad et al. 
2001). 
 
This shift towards a type 2 T-cell response was an attractive hypothesis given that these 
T cells could be expected to both enhance humoral immunity and “help” the malignant 
B cells, while suppressing Th1/Tc1 mediated cellular anti-tumour immune responses. 
However, a number of other reports have described increased production of IFNγ and 
TNFα by T cells from CLL patients, showing correlation with disease stage (Zaki et al. 
2000; Bojarska-Junak et al. 2002; Gallego et al. 2003; Podhorecka et al. 2004; Kiaii et 
al. 2005) Furthermore, IFNγ and TNFα have been shown to protect CLL cells from 
apoptosis and induce their proliferation in vitro (Digel et al. 1989; Buschle et al. 1993). 
It is probable that the situation in vivo is more complicated than the traditional Th1/Th2 
paradigm, with interplay between a variety of cell types producing a mix of cytokines, 
chemokines, and cell surface molecules that protect the CLL cells from apoptosis and 
regulate their proliferation (Table 1.5). 
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Table 1.5 Cytokines implicated in the pathogenesis of CLL 
Cytokine Action Reference 
IFN-γ Protects CLL cells from apoptosis (Buschle et al. 1993) 
TNF-α Increases CLL cell proliferation (Digel et al. 1989) 
TGF-β Inhibits CLL cell proliferation (Lotz et al. 1994) 
IL-2 Increases CLL cell proliferation (Yoshizaki et al. 1982) 
IL-4 Protects CLL cells from apoptosis (Dancescu et al. 1992; Panayiotidis et al. 1993) 
IL-5 Induces CLL cell apoptosis (Mainou-Fowler et al. 1994) 
IL-6 Protects CLL cells from apoptosis; 
inhibits CLL cell proliferation 
(Aderka et al. 1993; Reittie et al. 1996) 
IL-7 Increases CLL cell proliferation; 
protects CLL cells from apoptosis 
(Yoshioka et al. 1992; Long et al. 1995) 
IL-10 Inhibits CLL cell proliferation; 
induces CLL cell apoptosis 
(Fluckiger et al. 1994; Tangye et al. 1998) 
IL-21 Induces CLL cell apoptosis (di Carlo et al. 2007) 
 
1.4.3 T-cell Dysfunction in CLL: Chronic Activation and the Role of CMV? 
Another feature of CLL T cells is that they show evidence of chronic activation, with 
upregulation of activation markers such as CD69, HLA-DR and CD57, and down-
regulation of CD28 and CD62L (Velardi et al. 1985; Rossi et al. 1996; Van den Hove et 
al. 1998; Van den Hove et al. 1998). Several reports document expansions of clonal and 
oligoclonal T cells in CLL, in both CD4
+
 and CD8
+
 populations (Wen et al. 1990; 
Farace et al. 1994; Rezvany et al. 1999; Goolsby et al. 2000). There is also evidence 
that these oligoclonal expansions are primarily restricted to populations with an 
activated CD57
+
 phenotype, suggesting a role for chronic antigen stimulation in their 
development (Serrano et al. 1997). However, it remains unclear as to whether this is 
directly related to CLL, or whether other factors such as cytomegalovirus (CMV) are 
involved. CMV is known to have a profound influence on distribution of lymphocyte 
subsets in healthy individuals, with CMV sero-positivity driving the T-cell repertoire 
towards greater clonality in the elderly (Khan et al. 2002; Chidrawar et al. 2009). 
Subsequent reports have demonstrated an expansion of CMV-specific CD4
+
 and CD8
+ 
T cells in patients with CLL, with an effector phenotype (Mackus et al. 2003; 
Pourgheysari et al. 2010; Walton et al. 2010). It is therefore possible the earlier reports 
of clonality and increased expression of activation markers merely reflect an immune 
response to CMV. 
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1.4.4 T-cell Dysfunction in CLL: cytoskeletal dysfunction and inhibitory ligands 
An important finding in the immuno-biology of CLL was the work of my group 
demonstrating profound changes in the global gene expression profiles of T cells from 
CLL patients when compared with healthy age-matched controls (Gorgun et al. 2005). 
Despite not being part of the malignant clone, alterations were found in the expression 
of genes involved in cell differentiation and cytoskeletal formation in patient CD4
+
 T 
cells, and in cytoskeletal formation, vesicle trafficking, and cytotoxicity pathways in 
patient CD8
+
 T cells. Similar defects in gene expression could be induced in healthy T 
cells by co-culturing them with CLL cells. These changes in the expression of 
cytoskeletal genes translated into a functional defect in filamentous actin (F-actin) 
polymerization, with T cells from CLL patients exhibiting defective immunological 
synapse formation with antigen presenting cells (APCs)(Ramsay et al. 2008). Again, 
this functional defect could be induced in healthy T cells by co-culturing them with 
CLL cells. In both cases the induction of the defects relied on direct contact between the 
CLL cells and the T cells, as the defects were not seen after co-culture experiments 
using the transwell system.  
 
Intriguingly, similar defects could be observed in T cells taken from the Eμ-TCL1 
mouse model of CLL. In this model, the TCL1 gene is placed under the control of a B-
cell specific IgVH promoter and IgH Eμ enhancer, resulting in mice that develop 
normally into adulthood, but then subsequently develop lymphadenopathy and 
hepatosplenomegaly, with increased numbers of circulating CD19
+
CD5
+
IgM
+
 
lymphocytes (Bichi et al. 2002). Despite this model being dependent on a single 
transgene, T cells from animals that had developed the disease showed alterations in the 
expression of cytoskeletal genes, and exhibited dysfunctional immunological synapse 
formation. Furthermore, infusion of CLL cells into young Eμ-TCL1 mice caused 
defects comparable to those seen in mice that had clinically apparent leukaemia, 
demonstrating causality of the CLL cells to induce the T cell defects (Gorgun et al. 
2009). Interestingly, another study has shown that this model also accurately mimics the 
shift towards the antigen-experienced phenotype observed in the human disease 
(Hofbauer et al. 2011). This work demonstrated both a skewing of T-cell subsets 
towards antigen-experienced memory T cells, and development of clonal T-cell 
populations, consistent with a CLL–dependent antigen-driven skewing of the T cells in 
these mice. 
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My supervisors subsequently examined the mechanism by which CLL cells induce 
these defects in the T cell populations. Using functional screening assays based on actin 
polymerization responses to APCs, the molecules CD200, CD270 (Herpes virus entry 
mediator; HVEM), CD274 (Programmed death ligand-1; PDL1), and CD276 (B7-H3) 
were found to induce impaired immunological synapse formation in both allogeneic and 
autologous T cells (Ramsay et al. 2012). Higher expression of these molecules was 
observed on CLL cells compared to healthy B cells, with increased expression of 
CD200 and CD274 correlating with poor prognosis. Notably, signalling axes involving 
these inhibitory ligands were also able to induce impaired F-actin polymerization in 
other cancers, suggesting that both hematologic and solid cancer cells use common 
immunosuppressive mechanisms to suppress T-cell mediated anti-tumour immune 
responses. Of note, there is evidence that some of the receptors for these inhibitory 
ligands are increased on CLL T cells. PD1 (CD279) is an inhibitory T-cell receptor that 
has been postulated to be important in the maintenance of peripheral tolerance. 
Engagement of PD1 by PDL1 leads to the inhibition of T-cell receptor-mediated 
lymphocyte proliferation and cytokine secretion (Freeman et al. 2000). My group has 
recently reported that PD1 expression is increased on CD3
+
 T cells from CLL patients 
and is an indicator of poor prognosis (Ramsay et al. 2012). Another group has reported 
similar findings, showing that PD1 expression is increased on CD8
+
 T cells, with its 
expression predicting a more aggressive clinical course (Nunes et al. 2012). However, 
another report has suggested that PD1 expression is decreased on effector T cells, that 
are expanded in CLL (Tonino et al. 2012).  
 
1.4.5 T-cell Dysfunction in CLL: Regulatory T cells  
In addition to increased expression of inhibitory receptors in CLL, there is also an 
increase in CD4
+
CD25
hi
 regulatory T-cells (Tregs) in CLL. Tregs have been shown to 
inhibit proliferation and cytokine release by conventional CD4
+
CD25
-
 T cells, and 
increased numbers of Tregs are associated with inhibition of anti-tumour immunity in 
solid cancers (Baecher-Allan et al. 2004; Curiel et al. 2004). The expansion of Tregs in 
CLL has been postulated to be due to two factors. Firstly, there is evidence of increased 
formation, facilitated by CD27-CD70 interactions in LN proliferation centres (Jak et al. 
2009). CD200 expression on the CLL cells may also play a role, as anti-CD200R 
antibodies promote development of Tregs, and whereas CD200 blockade significantly 
decreases Treg numbers (Gorczynski et al. 2005; Pallasch et al. 2009). Secondly, Tregs 
from patients with CLL have increased resistance to drug induced apoptosis, compared 
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to Tregs from healthy donors, as a consequence of higher expression of Bcl-2 (Jak et al. 
2009). The degree of increase correlates with disease stage, with the greatest increases 
found in patients with the most clinically advanced disease (Beyer et al. 2005; 
Giannopoulos et al. 2008; D'Arena et al. 2011; Piper et al. 2011). Treg numbers were 
also noted to be slightly increased in patients MBL, although lower than patients with 
CLL (D'Arena et al. 2011). The degree of increase in Tregs has also been found to be of 
prognostic significance, with higher numbers of Tregs predicting significantly shorter 
time to first treatment in two studies (Weiss et al. 2011; D'Arena et al. 2012).  Tregs also 
express CD39, with increased expression of this molecule showing correlation with 
disease severity and prognosis in CLL (Pulte et al. 2011; Perry et al. 2012). 
Functionally, higher frequencies of Tregs have also been shown to correlate with 
decreased T-cell responses against viral and tumour antigens (Giannopoulos et al. 
2008). A further feature of Tregs is they express another inhibitory receptor, cytotoxic T-
lymphocyte associated antigen-4 (CTLA4; CD152).  CTLA4 is a homolog of CD28 and 
acts both directly, by decreasing phosphorylation of signalling proteins proximal to the 
T-cell receptor, and indirectly, by competing with CD28 for CD80/CD86 binding (van 
der Merwe et al. 1997; Lee et al. 1998). T cells from CLL patients have been shown to 
have significantly increased expression of both surface and cytoplasmic CTLA4 when 
compared to healthy controls, with expansion of a CD4
+
CD25
+
CTLA4
+
 subset (Motta 
et al. 2005). Furthermore, although CTLA4 is normally upregulated upon T-cell 
activation, CLL T cells also showed a greater degree of upregulation of CTLA4, and 
prolonged expression (Frydecka et al. 2004). Therefore, it is likely that CTLA4 
signalling is yet another inhibitory pathway mediating T-cell dysfunction in CLL, in 
addition to the PD-1:PD-L1, CD160:HVEM and CD200:CD200R axes (Figure 1.7). 
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1.4.6 T cell Dysfunction in CLL: T cells as Part of the Pro-tumour Niche 
In addition to the role for the CD4
+
CD25
+
 subset in the pathogenesis of CLL, evidence 
is emerging that implicates CD4
+
 T cells in the development and maintenance of this 
disease. As mentioned above, in contrast to the PB where CD8
+
 T cells are increased, 
CD4
+
 T cells are primarily expanded in the LNs and BM of CLL patients (Pizzolo et al. 
1983). It has been suggested that this is due to production of the chemokine CCL22 by 
CLL cells, which has been shown to be released into culture supernatants on CLL cell 
activation. These supernatants were able to induce the migration of activated 
CD4
+
CD40L
+
 T cells expressing the CCL22 receptor, CCR4: migration which could be 
blocked by anti-CCL22 antibodies (Ghia et al. 2002). A recent paper has highlighted the 
potential importance of CD4+ T cells in providing a protective niche for engraftment of 
CLL cells (Bagnara et al. 2011). The ability of primary human CLL cells to engraft and 
proliferate in a non-obese diabetes/severe combined immunodeficiency/γcnull mouse 
model was assessed. Intriguingly, autologous CD4
+
 T cells from the CLL patients were 
found to be key mediators of CLL cell growth in these mice, despite representing only a 
minor component of the transferred lymphocyte population. There was direct 
correlation between the degree of proliferation of T cells and that of the CLL clone, 
with selective depletion of CD4
+
 T cells leading to failure of CLL cell growth. Further 
Figure 1.7 Inhibitory signalling axes in CLL. 
Upregulation of CD200, CD270, CD274 and CD276 induces impaired actin polymerization and 
immunological synapse formation in CLL T cells. CD200 also promotes the differentiation of CD4
+
 T 
cells into Tregs, which express CD152 (CTLA4). CD274 (PDL1) can interact with its ligand CD279 
(PD1) to inhibit T-cell activation and proliferation. 
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investigation is required to corroborate these findings in CLL patients, but taken 
together, these observations suggest that the expanded CD4
+
 T cells seen in BM and 
LNs are a critical part of the pro-tumour microenvironment. 
 
1.4.7 Nurselike cells and chemokines 
Nurselike cells (NLCs) are another key constituent of the immune microenvironment 
implicated in providing a protective niche for CLL cells. NLCs are a subset of 
peripheral blood mononuclear cells (PBMCs) that differentiate into large, round, or 
fibroblast-like adherent cells in the presence of CLL cells (Burger et al. 2000). 
Although they are thought to originate from CD14
+
 monocytes, their expression of 
CD68 is significantly higher than normal monocyte-macrophages, making them more 
comparable to the CD68
+
 lymphoma-associated macrophages observed in follicular 
lymphoma (Farinha et al. 2005). Further work identified these large CD14
+
CD68
HI
 cells 
in the spleens of CLL patients, suggesting that they might also function to promote 
leukaemia cell survival in vivo  (Tsukada et al. 2002). An important feature of the 
biology of CLL cells is that they undergo spontaneous apoptosis when cultured in vitro, 
in marked contrast to their apparent longevity in vivo (Collins et al. 1989). However, 
when NLCs are present in vitro, the leukemic cells attach to them and are protected 
from undergoing spontaneous apoptosis. NLCs are thought to promote CLL cell 
survival due to a combination of secretion of the chemokine CXCL12, and increased 
expression of B cell-activating factor of the tumour necrosis factor family (BAFF), and 
a proliferation inducing ligand (APRIL)(Burger et al. 2000; Nishio et al. 2005). In 
addition, differentiation of monocytes into NLCs is associated with dysregulation of 
genes involved in antigen presentation and immunity, impairing their anti-tumour 
function (Bhattacharya et al. 2011). The receptor for CXCL12, CXCR4, is expressed on 
high levels on the surface of CLL B cells, with its expression correlating with Rai stage 
(Burger et al. 1999; Ghobrial et al. 2004). Therefore secretion of CXCL12 by both 
NLCs and stromal cells induces leukaemia cell trafficking and homing to protective 
niches populated by these cells. Furthermore, co-culture of CLL cells with NLCs 
induces the leukemic cells to release two T-cell attracting chemokines, CCL3 and 
CCL4. The production of these chemokines may explain the observation of increased 
numbers of T cells in CLL pseudofollicles, where the T cells appear to have been co-
opted to “help” B-cells activation and proliferation (Burger et al. 2009). Furthermore, 
increased CCL3 levels correlate with other adverse prognostic markers such as 
advanced clinical stage and poor risk cytogenetics, and are predictive of shorter time to 
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first treatment (Sivina et al. 2011). In addition, CXCL12 acts as a co-stimulatory factor 
for CLL CD4
+
 T cells, resulting in their increased proliferation, cytokine production, 
and increased expression of activation markers. These activated T cells are then able to 
enhance the activation and proliferation of the leukemic cells (Borge et al. 2012). It is 
therefore possible that a mix of chemokines including CXCL12, CCL3 and CCL4 
results in co-localization of stromal cells, NLCs, and activated CD4
+
 T cells, that 
provide “sanctuary sites” for the tumour cells, protecting them from chemo-
immunotherapy, resulting in drug resistance and disease persistence (Burger 2010) 
(Figure 1.8).  
 
Figure 1.8 The CLL niche. 
CXCL12 produced by stromal cells and NLCs attracts CXCR4-bearing CLL cells into the protective 
niche. Interaction of CLL cells with NLCs causes: i) further differentiation of monocytes into NLCs; ii) 
protection of the CLL cells from apoptosis associated with increased expression of BAFF and APRIL; iii) 
increased production of CCL3 and CCL4 by CLL cells. CCL3 and CCL4 chemoattract CD4
+
 T cells 
which are activated by CXCL12. These activated T cells produce cytokines including IFNγ which 
regulate CLL cell proliferation and protect them from apoptosis.  
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1.4.8 Natural killer cells 
Abnormalities have also been found in other immune cells in CLL. Initial studies 
revealed that natural killer cells (NK cells) also have a functional defect in CLL, 
showing reduced ability to lyse leukaemia cell lines associated with a lack of 
cytoplasmic granules (Ziegler et al. 1981; Kay and Zarling 1984). This activity could be 
restored by the use of IL2, which also resulted in increased granularity of the large 
granular lymphocyte subset (Kay and Zarling 1987). The mechanism by which CLL 
cells downregulate NK-cell function is not known, although there is some evidence that 
it may involve soluble factors (Burton et al. 1989; Katrinakis et al. 1996).  CLL cells 
may also inhibit NK cells by direct contact, by their expression of the tolerogenic non-
classical MHC class I molecule, HLA-G, or by expression of 4-1BB ligand (Maki et al. 
2008; Buechele et al. 2012).  Of note, NK cells from CLL patients show defective actin 
polymerization and impaired immunological synapse formation, comparable to the 
cytoskeletal dysfunction seen in CLL T cells (Gaidarova et al. 2009). The NK-cell 
defect appears to be of clinical significance, as higher NK-cell numbers were observed 
in patients with early stage disease and in those with mutated IGHV genes. Furthermore, 
for patients with a given Rai stage, a higher NK:CLL cell ratio was predictive of a 
longer time to treatment, implying a protective effect of NK cells (Palmer et al. 2008). 
In support of this, NK cells from patients with MBL have a higher cytolytic capacity 
than NK cells from CLL patients. (Kimby et al. 1989) Other studies have shown that 
numbers of CD3
+
CD16
+
CD56
+
 NKT-cells are also important, as a reduction in numbers 
is associated with disease progression and a higher risk of death in CLL patients 
(Bojarska-Junak et al. 2010). An understanding of the NK-cell defect may well prove to 
be clinically useful as pre-clinical studies have shown that CLL patient NK-cells can be 
expanded and show cytotoxicity against K562 cells, highlighting their potential as a 
source of cellular immunotherapy (Guven et al. 2003). 
  
There is also evidence suggesting that monocytes and neutrophils are defective in CLL, 
with the latter having been shown to be deficient in lysozyme and myeloperoxidase, and 
to modulate CLL B-cell survival through altered secretion of TNF-superfamily proteins. 
(Zeya et al. 1979; Sawicka-Powierza et al. 2011)  
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1.5 Immunotherapy for CLL 
 
Attempting to reconstitute the immune response in CLL is attractive for three reasons. 
First, the immune surveillance hypothesis suggests that in order to produce clinically 
detectable disease, the malignant CLL B cells must have evolved strategies of evading 
or suppressing the immune system, especially the anticancer effects of T cells. 
Therefore, successful immune reconstitution should lead to repair of antitumor 
immunity and durable clinical responses. Second, T cells provide “help” to B cells as 
part of a healthy immune system, by stimulating the B cells to proliferate, inducing B-
cell antibody class switching, and promoting plasma cell differentiation. In CLL, there 
is evidence that T cells have been skewed to provide “help” for the malignant B cells, 
and therefore successful immune reconstitution should reduce the availability of T-cell–
derived pro-CLL factors, leading to “starvation” of the CLL cells. Finally, even in the 
absence of any antitumor effects, immune reconstitution would benefit patients by 
enabling them to fight infections more effectively and would counteract the immune 
suppression induced by both the disease and current therapies. Strategies employing this 
approach should result in therapies that are more tolerable to vulnerable patients and 
show enhanced efficacy in the more challenging poor-risk subgroups. 
 
 
1.5.1 Immunomodulatory aspects of cytotoxic chemotherapy 
Virtually all treatment for CLL is immunomodulatory in one sense or another. 
Treatments that are cytotoxic to the malignant B cells are invariably toxic to other 
leucocytes as well, both granulocytes and lymphocytes. One of the most important 
clinical aspects of cytotoxic chemotherapy is the degree to which it exacerbates the 
existing immunodeficiency. Indeed, the ability of a patient to tolerate the treatment is 
often an important predictor of overall prognosis. In addition to the effects of cytotoxic 
agents on the tumour cells, there is also the potential for differential toxicity to immune 
components of the pro-tumoural microenvironment. The purine analogue fludarabine is 
widely used for the treatment of CLL (Hallek et al. 2010). As T-cell depletion is a 
commonly encountered side effect of this agent, it can be hypothesized that fludarabine 
treatment will have a significant impact on the T-cell microenvironment. Analysis of the 
composition and function of the T cell pool in CLL patients after treatment with 
fludarabine and cyclophosphamide revealed a rapid and sustained reduction of 
circulating CD4
+
 and CD8
+
 T cells as expected. Surprisingly, T cells surviving this 
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combination had a more mature phenotype, and fludarabine-treated T cells were 
significantly more responsive to mitogenic stimulation than their untreated counterparts, 
and showed a shift towards Th1 cytokine secretion (Gassner et al. 2011). Furthermore, 
fludarabine therapy appears to have a particularly marked effect on Tregs, with both a 
reduction in the inhibitory function and a decrease in the frequency of this subset after 
treatment (Beyer et al. 2005). As both these studies were performed on PB samples it 
would be particularly interesting to examine the impact of fludarabine on CD4+ T cells 
in LNs and BM. 
 
1.5.2 Improved NK-cell functionality with rituximab  
Rituximab is a humanized anti-CD20 monoclonal antibody (mAb) widely used in the 
treatment of B-cell malignancies and autoimmune diseases. The mechanism of action of 
this agent is not completely clear, although it appears to be due to a combination of 
several factors including antibody dependent cellular cytotoxicity (ADCC), complement 
dependent cytotoxicity (CDC), induction of apoptosis of CD20
+
 B cells, inhibition of 
BCR-signalling, and regulation of the cell cycle (Maloney 2001). The efficacy of this 
agent in CLL is perhaps even more paradoxical, given the relatively low expression of 
its target antigen on CLL cells when compared with normal B cells and other malignant 
B cells. An important component of the mechanism of action of rituximab in CLL 
appears to be the enhancement of NK-cell functionality. Opsonisation of CLL cells by 
anti-CD20 antibodies such as rituximab, allows binding of the NK cell Fc receptor, 
FcγRIII (CD16), to the Fc region of the antibodies. Antibody binding to CD16 results in 
NK-cell activation, release of cytolytic granules, and consequent target cell apoptosis 
(Smyth et al. 2002). Rituximab has been shown to increase NK-cell degranulation as 
measured by the CD107a assay (Fischer et al. 2006). Interestingly, there is evidence 
that FcγR polymorphisms predict response to rituximab in lymphoma patients (Weng 
and Levy 2003). Third generation monoclonal anti-CD20 antibodies such as 
obinutuzumab (GA-101) and LFB-R603 that have higher binding affinities for this 
receptor have been shown to even more efficient at inducing NK cell degranulation 
(Bologna et al. 2011; Le Garff-Tavernier et al. 2011). In vitro experiments have 
demonstrated that NK-cell functionality can be further enhanced by co-culturing the NK 
cells with cytokines such as IL21 and IL15 (Eskelund et al. 2011; Moga et al. 2011). 
Opsonisation of the tumour cells by rituximab may also be important for the activity of 
other immune cells, as there is evidence that rituximab enhances macrophage killing of 
CLL cells by increasing phagocytosis mediated ADCC (Lefebvre et al. 2006).  
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1.5.3 “Eviction from the niche”: the mobilising effect of BCR-signalling inhibitors 
There has been a great deal of recent interest in inhibitors of BCR-signalling for the 
treatment of CLL. BCR signalling is known to be crucial for B-cell proliferation and 
survival, and a number of major prognostic markers that are clinically useful in CLL, 
are associated with aberrations in BCR signalling. Absence of mutations in 
immunoglobulin variable (IgV) region genes and expression of ZAP70 have been 
shown to correlate with an inferior outcome, and are both associated with increased 
signalling through the BCR (Hamblin et al. 1999; Wiestner et al. 2003) This aberrant 
BCR-signalling has been thought to be antigen-dependent, but a recent publication has 
also suggested that BCRs from CLL patients induce antigen-independent cell-
autonomous signalling, dependent on the heavy-chain complementarity-determining 
region (HCDR3) and an internal epitope of the BCR (Minden et al. 2012). A number of 
molecules that inhibit kinases downstream of the BCR have been developed, and are 
showing great promise in early phase clinical trials. An unexpected feature of some 
these agents is that there is a transient increase in the circulating lymphocytosis after 
initiation of treatment, associated with rapid reductions in LN size, consistent with 
mobilization of the tumour cells from the LNs into the blood. The PI3K inhibitor 
GS1101 (Idelalisib), the BTK inhibitor, ibrutinib (PCI-32765), and the mTOR inhibitor, 
everolimus, have all been found to induce this lymphocytosis during the first weeks of 
treatment (Burger et al. 2010; Flinn et al. 2010; Zent et al. 2010). As discussed above 
the CXCL12-CXCR4 axis is important for the homing of CLL cells to potential 
sanctuary sites in the BM and LNs. A small molecule inhibitor of CXCR4, plerixafor, 
has also shown clinical activity in CLL patients, again associated with mobilization of 
tumour cells into the circulation (Andritsos et al. 2010). It therefore appears likely that 
the some of the clinical activity of these novel therapies may be due to their ability to 
“evict” CLL cells from protective microenvironmental niches populated by NLCs, 
stromal cells and T cells (Hoellenriegel et al. 2010; Ponader et al. 2012). 
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1.5.4 CD40L based therapies 
A key feature of CLL cells is that they have impaired antigen presenting function, due 
to reduced expression of co-stimulatory molecules including CD80 and CD86.(Dazzi et 
al. 1995) CLL cell activation by ligation of CD40 can up-regulate these proteins, along 
with adhesion molecules such as ICAM1 (Ranheim and Kipps 1993; Yellin et al. 1994; 
Van den Hove et al. 1997). Under normal circumstances this activation signal is 
provided by T cells, which transiently express CD40L (CD154) after antigen 
engagement of their TCR ((Noelle et al. 1992). However, this critical axis is impaired in 
CLL, as the tumour cells appear to be able to directly down-modulate T-cell expression 
of CD40L (Cantwell et al. 1997). In light of this, a number of strategies have been 
developed to re-express CD40L in the tumour microenvironment, thereby improving 
CLL cell antigen presenting function and overcoming T-cell anergy.  
 
One such strategy has been to use adenoviral vectors to transduce CLL cells to express 
CD40L. In addition to inducing expression of co-stimulatory and adhesion molecules on 
the transduced cells, increased expression of CD40L in the CLL microenvironment can 
activate other “bystander” CLL cells, even if they were not transfected. Further pre-
clinical work showed that the transfected CLL cells become highly effective stimulators 
of mixed lymphocyte reactions, and induce generation of cytotoxic T cells specific for 
autologous unmodified CLL cells (Kato et al. 1998; Takahashi et al. 2001). Similar 
findings have been reported by culturing CLL cells on CD40L expressing feeder cells in 
place of transfection (Buhmann et al. 1999). Use of fibroblasts over-expressing CD40L 
and OX40L to transfer both these ligands to CLL cells, also resulted in the generation of 
tumour-reactive cytotoxic T lymphocytes (Biagi et al. 2005). There were some initial 
concerns that CD40-stimulated CLL cells may become more resistant to apoptosis 
induced by fludarabine, due to upregulation of the NFκB/Rel transcription 
factors.(Romano et al. 1998) Gene expression profiling performed on CD40-stimulated 
CLL cells also identified up-regulation of several genes involved in the suppression of 
apoptosis mediated by the TNF family of receptors and NFκB (Gricks et al. 2004). 
However further investigation showed that while CD40 stimulation enhanced the 
constitutive anti-apoptotic profile of the CLL cells, and these cells were not sensitive to 
CD95L, they remained good targets for cytotoxic T cells (Chu et al. 2000; Kater et al. 
2004).  
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An early clinical trial infected the effects of infusions of autologous tumour cells that 
had been transduced ex vivo with murine CD40L, which was found to be more 
efficiently expressed than human CD40L. This treatment was well tolerated and the 
patients did show some PB and LN responses. However, some of the patients developed 
antibodies against the murine CD40L (Wierda et al. 2000). In light of this, a 
recombinant humanized CD40 binding protein, ISF35, was developed, and tested in a 
more recent phase I study. The infusions of transduced autologous tumour cells were 
again well tolerated, and were consistently followed by reductions in circulating 
lymphocyte counts and lymphadenopathy. The increased levels of this humanized 
CD40L was associated with induction of a pro-apoptotic state in the circulating CLL 
cells, with increased expression of pro-apoptotic molecules CD95, DR5, p73 and BCL-
2 interacting domain (BID), and reduced levels of the anti-apoptotic molecule, MCL1. 
Significantly, these findings were also observed in patients with deletion of 
chromosome 17p (Wierda et al. 2010). There is a rationale for combining this approach 
with rituximab, as stimulation of CLL B cells by CD40L sensitizes them to rituximab-
induced cell death (Jak et al. 2011). However of interest, evidence has emerged that 
there is significant heterogeneity in the responses of CLL B cells to CD40L stimulation. 
Patients with CLL B cells that were relatively unresponsive to CD40L showed a poor 
clinical outcome and shorter time to progression, which was felt to reflect less 
dependency on the microenvironment and higher autonomous proliferative and survival 
potential (Scielzo et al. 2011).  
 
Other work has investigated whether there is a role for anti-CD40 mAbs in the 
treatment of CLL. Two therapeutic antibodies that target the CD40 antigen are in 
development, dacetuzumab (SGN-40) which acts as a partial agonist, and lucatumumab 
(HCD122) which blocks CD40 mediated signalling (Law et al. 2005; Luqman et al. 
2008). Unfortunately, phase I trials using these agents have shown minimal single agent 
activity, but they warrant further investigation as part of combination therapies.(Furman 
et al. 2010; Byrd et al. 2012). Pre-clinical experiments have suggested that 
dacetuzumab treatment in combination with the immunomodulatory agent lenalidomide 
enhanced direct apoptosis and ADCC against primary CLL cells (Lapalombella et al. 
2009). However, it is possible that this activity represents tumour cell opsonisation and 
the induction of NK-cell responses, as much as a direct biological effect of CD40 
binding. 
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1.5.5 Vaccine therapy for CLL 
The observation that CLL cells maintain some residual B-cell function, which can be 
enhanced by appropriate stimulation, has led to attempts to induce an effective 
autologous immune response by vaccine therapy. A vital component of this approach is 
identifying a suitable tumour associated antigen (TAA), to which to induce an immune 
response. An ideal TAA should be only expressed on the tumour cells to avoid 
induction of auto-immunity, should be expressed on all of the tumour cells, and should 
be essential for tumour cell survival to prevent the emergence of antigen-negative 
variants and immune escape. The obvious major challenge to cancer vaccines is that the 
tumour cells are derived from “self”, with the consequence that few TAAs have these 
characteristics. In light of this, the search for possible TAAs has focused on proteins 
that are either commonly mutated in the malignant cells or are aberrantly expressed. 
Serological identification by recombinant expression cloning (SEREX) has been used to 
detect such mutated proteins, and cytotoxic T-cell responses could be generated against 
these antigens (Krackhardt et al. 2002). A number of other TAAs have been identified 
in CLL, including survivin, fibromodulin, RHAMM (CD168), FMNL1, MDM2 and 
CD23 (Table 1.6) (Favaro et al. 2003; Schmidt et al. 2003; Mayr et al. 2005; 
Giannopoulos et al. 2006; Mayr et al. 2006; Bund et al. 2007). Of particular interest is 
the oncofetal surface antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1), 
which has the advantage that it is selected expressed by malignant B cells, although it is 
also expressed by undifferentiated embryonic stem cells, and at low levels in adipose 
tissue (Hudecek et al. 2010). When 6 patients with CLL were infused with autologous 
CLL cells that had undergone adenoviral transfection with CD154, 3 of them (50%) 
subsequently generated antibodies against ROR1 (Fukuda et al. 2008). Furthermore, 
upregulation of CD154 by lenalidomide has also recently been shown to induce 
production of ROR1 tumour-specific antibodies, notably in a patient that had not 
received prior therapy with rituximab (Lapalombella et al. 2010). 
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Table 1.6 Tumour-associated antigens in CLL 
Type Antigen Expression patterns – potential for “on target, off 
organ” effects 
Reference 
Normal/ 
malignant 
B-cell 
antigens 
Ig idiotype Unique to an individual B-cell clone (Janeway et 
al. 1975) 
CD19 Expressed on follicular dendritic cells and normal B-
cells 
(Pesando et 
al. 1989) 
CD20 Expressed on normal B-cells (Cragg et al. 
2005) 
CD23 Expressed on mature B-cells, monocytes, follicular 
dendritic cells, and at low levels on T-cells, 
Langerhans cells, eosinophils and platelets 
(Fournier et 
al. 1991) 
ROR1 Expressed by malignant B-cells and undifferentiated 
embryonic stem cells, and at low levels in adipose 
tissue 
(Baskar et 
al. 2008) 
Human Ly9 Expressed on thymocytes and on mature T and B-
cells 
(Bund et al. 
2006) 
Onco-fetal/ 
cancer-
testis 
antigens 
RHAMM Expressed in the thymus and testis; not expressed on 
healthy B-cells 
(Giannopoul
os et al. 
2006) 
OFA-iLRP Expressed in foetal tissues but not detectable on 
normal differentiated adult cells 
 
(Siegel et al. 
2003) 
SLLP1 Expressed on spermatozoa; only expressed in the 
testis 
(Wang et al. 
2004) 
Survivin Expressed during normal foetal development and in 
the adult thymus, testis, placenta, and growth 
hormone-stimulated hematopoietic stem and 
endothelial cells. 
(Schmidt et 
al. 2003) 
Differential 
expression 
hTERT  Widely expressed, expression increased in 75% of 
CLL patients 
(Kokhaei et 
al. 2007) 
Fibromodulin Widely expressed, with the highest levels in articular 
cartilage, tendon, and ligaments 
(Mayr et al. 
2005) 
FMNL1 Expressed in normal thymus, spleen and peripheral 
blood leucocytes; overexpressed in CLL 
(Favaro et 
al. 2003) 
MDM2 Widely expressed, over expressed in many 
malignancies 
(Mayr et al. 
2006) 
BAX  Widely expressed, enhanced proteasomal degradation 
in CLL generates expression of degradation peptides 
(Nunes et al. 
2011) 
 
A particular feature of B-cell malignancies is that there is a further type of TAA in the 
form of the immunoglobulin idiotype (Janeway et al. 1975). The surface 
immunoglobulin expressed by the malignant B-cells is unique to each clone, and thus 
represents an attractive target for vaccine strategies. Using a bioinformatics approach, a 
number of human immunoglobulin derived peptides were identified that were capable 
of inducing cytotoxic T-cells. Furthermore, autologous cytotoxic T cells specific for 
these peptides were able to kill primary malignant CLL cells. One of the problems with 
this method is that the very uniqueness of the idiotype means that any potential vaccine 
would be have to individualized to each patient. However, peptides generated from the 
framework regions of the immunoglobulin molecule, regions that show less variability 
between patients, were immunogenic, allowing for a single such peptide to be used in a 
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number of patients (Trojan et al. 2000). A second problem with idiotype vaccination 
strategies is that the immunoglobulin idiotype is only weakly immunogenic and often 
only generating humoral responses (Kwak et al. 1992; Hsu et al. 1997). A solution to 
this is the use of heteroclitic peptides, where MHC-binding amino acid residues are 
modified to bind MHC more tightly, while leaving the T-cell recognition residues 
intact, inducing more potent immune responses (Harig et al. 2001).   
 
In the normal immune system, the most potent antigen presenting cells are dendritic 
cells (DCs). This property can be exploited by manipulating DCs to take up antigen in 
vitro, before presenting it to T cells causing their activation and proliferation. There 
have been a number of clinical studies that have investigated the use of DCs in CLL. In 
one such study, DCs were generated from unrelated donors, before being pulsed ex vivo 
with patient CLL cell lysate or apoptotic bodies. They were subsequently administered 
to patients with early-stage CLL, a subset of whom showed clinical responses. These 
investigators then looked at autologous DCs pulsed with CLL cell lysates, and again a 
subset of patients showed responses, that were associated with an increase in T cells 
specific for RHAMM/CD168 and fibromodulin (Hus et al. 2005; Hus et al. 2008). A 
further study used oxidizing radiation to augment the immunogenicity of the CLL cells 
by improving their antigen presenting function, resulting in enhanced T-cell anti-tumour 
activity and clinical responses. (Spaner et al. 2005). 
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1.5.6 Immune checkpoint blockade in CLL 
Suppression of anti-tumour immunity by inhibitory pathways appears to be an important 
mechanism underlying the failure of immune responses in CLL. The tumour cells have 
been demonstrated to express high levels of inhibitory ligands, which inactivate 
immune cells in the microenvironment via their increased expression of receptors for 
these ligands. An example of one such set of interactions is the PD1:PDL1 axis, which 
has been shown to be functionally important in suppressing immunological synapse 
formation between CLL cells and autologous T cells (Ramsay et al. 2012; Brusa et al. 
2013). This axis had previously been demonstrated to suppress T-cell function in 
chronic viral infections in both mice and humans (Barber et al. 2006; Day et al. 2006). 
These same studies also showed that blocking PD1:PDL1 interactions could restore T-
cell effector function, which could be further enhanced by simultaneous blockade of 
other inhibitory receptors such as CTLA4, LAG3 and TIM3 (Blackburn et al. 2009; 
Nakamoto et al. 2009; Jin et al. 2010). These findings have led to considerable interest 
in the potential for blockade of these “immune checkpoints” to enhance anti-viral and 
anti-tumour immunity in chronic viral infections and cancers (Pardoll 2012). Initial 
work highlighted the potential for blockade of CTLA4 to induce clinical responses in 
patients with advanced melanoma (Hodi et al. 2010).  Subsequent studies have also 
investigated the effect of blocking the PD1:PDL1 axis. A recent phase 1 study of an 
anti-PD1 monoclonal antibody (Nivolumab; BMS-936558) in patients with non-small 
cell lung cancer, melanoma, or renal cell cancer, showed ORRs of 18-28% dependent 
on the cancer type (Topalian et al. 2012). These response rates are very encouraging 
given the 10-15% “ceiling” of durable tumour response rates seen with trials of other 
immunotherapeutic approaches in solid cancers over the last 30 years (Ribas 2012). A 
further phase 1 trial of an anti-PDL1 antibody (BMS-936559) in a variety of advanced 
solid cancers also showed efficacy, with response rates of 6-17%, again dependent on 
the cancer type (Brahmer et al. 2012). Clinical trials of these agents in haematological 
malignancies have been notably absent, despite the fact that these cancers are generally 
more “immunosensitive” with the potential for higher response rates. A single published 
phase 1 dose-escalation study of another anti-PD1 antibody (CT-011; Pidilizumab) 
showed evidence of response in 6 out 18 patients. Of the three CLL patients that were 
enrolled, two showed evidence of stable disease, on the second and third dose levels 
(Berger et al. 2008). Given the pre-clinical data highlighting the significance of the 
PD1:PDL1 axis in suppressing T-cell function in CLL, there is a strong rationale for 
clinical assessment of immune checkpoint blockade in this disease.  
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1.5.7 Adoptive T cell therapies 
Currently, allogeneic haematopoietic stem cell transplantation remains the only curative 
option for CLL. Critical to its activity is the graft-versus-leukaemia (GVL) effect, where 
the transplanted haematopoietic stem cells differentiate into effector cells that mount an 
anti-tumour immune response. This effect is known to be primarily T-cell mediated, and 
is probably due to a combination of improved T-cell function and the presence of 
allogeneic major histocompatibility complex (MHC) molecules (Kolb 2008). The major 
drawback of myeloablative allogeneic transplantation is that it is associated with 
unacceptably high rates of non-relapse mortality, that can approach 50% even in 
younger patients (Michallet et al. 1996). This is due to combination of toxicity from the 
conditioning regimens, the prolonged period of immune-suppression during 
engraftment, and graft-versus-host disease (GVHD). One way of attempting to reduce 
non-relapse mortality is to use reduced intensity conditioning (RIC) to exploit the GVL 
effect while avoiding the significant morbidity and mortality associated with 
myeloablative conditioning. RIC regimens are associated with decreased mortality rates, 
but GVHD remains a significant problem (Dreger et al. 2003; Schetelig et al. 2003; 
Sorror et al. 2005). Therefore for the majority of patients, who are above the age of 65 
years, allogeneic hematopoietic stem cell transplantation is not a reasonable option.  
 
One approach to circumventing the problem of GVHD is the adoptive transfer of T cells 
with specificity for tumour antigens. By choosing T cells with specificity for only 
tumour cells, it should be possible to produce immune mediated anti-tumour responses 
without the corresponding GVHD. There are two main strategies for generating tumour 
specific T cells. The first involves the gene transfer of T-cell receptors (TCRs) with 
known specificity into autologous or allogeneic T cells which are then expanded in vitro 
and infused into patients. This approach has had some successes, most notably in 
melanoma and the use of Epstein-Barr virus specific T-cells to treat post-transplant 
lymphoproliferative disorders (Rooney et al. 1998; Morgan et al. 2006; Rosenberg et al. 
2011). However a potential risk of this approach is that the α or β subunit of the 
transgenic TCR could misassociate with the α or β subunit of the endogenous TCR, 
resulting in an autoreactive T-cell. Furthermore, a particular drawback to widespread 
clinical use is that the recognition of the tumour antigens is MHC-restricted, and 
therefore the use of these T cells needs to be individualized on a patient-by-patient basis 
according to their MHC type. A second strategy involves the use of the single chain 
variable fragment from an antibody molecule fused with an internal signalling domain 
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such as CD3δ, to form a chimeric antigen receptor (CAR)(June et al. 2009).  There are 
two important advantages to this approach. Firstly, it eliminates MHC restriction 
enabling the same CAR to be used for several different patients. Secondly, the use of an 
antibody receptor means that potential targets can be increased to include a wide range 
of surface proteins, sugars and lipids (Cartellieri et al. 2010)(Figure 1.9).   
 
Figure 1.9 Adoptive T cell therapies in CLL 
T-cell mediated therapies include the adoptive transfer of allogeneic T cells as part of haematopoietic 
stem cell transplantation, the transfer of allogeneic or autologous T cells with a transgenic T-cell receptor, 
and the transfer of T cells with chimeric antigen receptors (CARs). Early studies used CAR T cells 
without a co-stimulatory domain (1st generation). Current trials are using 2nd-generation CAR T cells, 
with either a CD28 or CD137 (4-1BB) co-stimulatory domain. Preclinical studies are investigating the 
combination of co-stimulatory domains (3rd generation). 
 
The target of these CARs must be carefully selected to avoid “on-target, off-organ” 
effects, which potentially can occur when the antigen is also expressed on non-
malignant tissues. In the context of CLL, particularly attractive targets are CD19, CD20, 
CD23, and ROR1. CLL B cells express high levels of CD19, in contrast to the relatively 
reduced expression of CD20. A disadvantage of targeting these molecules is that they 
are also expressed by normal B cells, so CAR T cells targeting them will also eliminate 
normal B cells, causing persistently impaired humoral immunity and exacerbating the 
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immunodeficiency already present in CLL (Koehler et al. 2012). Anti-ROR1 CAR 
CD8
+
 T cells that recognize autologous CLL B cells have been successfully generated 
from patients with CLL. ROR1 has the advantage of being selectively expressed by 
malignant B cells, although it is also expressed by undifferentiated embryonic stem cells 
and (at low levels) in adipose tissue (Hudecek et al. 2010). Similarly, anti-CD23 CAR 
T cells generated from CLL patients have shown cytotoxicity against autologous and 
allogeneic CLL cells and also have shown an in vivo antitumor effect in a xenograft 
murine model (Giordano Attianese et al. 2011). 
 
A number of phase I/II clinical trials are underway using anti-CD19 CAR T cells for the 
treatment of B cell malignancies (Koehler et al. 2012). One group has treated 8 patients 
with CLL in 2 cohorts. The first cohort of 3 patients did not receive any conditioning, 
and did not show any objective responses. They went on to give the next patient 
lymphodepleting conditioning with cyclophosphamide as part of the trial design. 
Unfortunately this patient rapidly developed hypotension, respiratory distress and renal 
failure, and died within 48 hours of infusion of the T-cells, highlighting the risks 
associated with this therapy (Brentjens et al. 2010). They have gone on to treat a further 
4 patients with cyclophosphamide conditioning and a reduced dose of T cells, with 3 out 
of 4 of the patients showing disease stabilization or LN responses (Brentjens et al. 
2011). A second group has investigated the use of anti-CD19 CAR T cells in 8 patients 
with progressive B-cell malignancies, including 4 patients with CLL. These patients 
received conditioning with cyclophosphamide and fludarabine, followed by infusion of 
anti-CD19 CAR T cells. They also received a post infusion course of interleukin-2 to 
enhance in vivo T-cell expansion. Six of the 8 patients obtained objective remissions: of 
the 4 CLL patients 1 had a complete response, 2 had partial responses, with 1 having 
stable disease. This trial also investigated some of the potential adverse effects 
associated with the use of CAR T cells. Four out of the 8 patients had increased serum 
levels of IFNγ and TNFα, which correlated with the severity of acute toxicities. It is 
likely that the CAR T cells were a source of these inflammatory cytokines because T 
cells isolated from the patients after treatment produced IFNγ and TNFα ex vivo in a 
CD19-specific manner. These trials have underscored the importance of the 
conditioning regimen in promoting T-cell engraftment and activation. As discussed 
above, it may be vital to use conditioning regimens that deplete the microenvironment 
of pro-tumoural cell types such as regulatory T cells or immature dendritic cells. One 
important aspect of forthcoming clinical trials in this area will be the determination of 
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which agents to use in the conditioning regimen, analogous to the impact of 
conditioning in allogeneic transplantation.  
 
A key finding in pre-clinical studies of CAR T cells was that their efficacy could be 
significantly improved by the addition of a co-stimulatory domain such as CD28 
(Maher et al. 2002). It is becoming apparent that the choice of co-stimulation can have 
significant impact on the clinical success of CAR T cell-based therapies.  Many of the 
CAR T cells currently under investigation in clinical trials have incorporated the use of 
the CD28 co-stimulatory domain, including the two trials discussed above (Koehler et 
al. 2012). However, in a murine model of primary human pre-B-cell acute 
lymphoblastic leukaemia, human T cells expressing anti-CD19 CARs containing the co-
stimulatory domain CD137 (4-1BB) were significantly more effective and showed 
longer survival than cells expressing CARs containing the CD28 domain (Milone et al. 
2009). Furthermore, pre-clinical data suggests that CD137 is less likely to trigger IL-2 
and TNF-α secretion, and hence induction of a “cytokine storm” and differentiation of 
regulatory T-cells. In light of this, other investigators have trialled the use of anti-CD19 
CAR T-cells incorporating a CD137 co-stimulatory domain. A recent report 
documented a case of a heavily pre-treated patient with refractory CLL who entered a 
complete remission after the adoptive transfer of anti-CD19 CAR T-cells. A significant 
feature of this case was that these cells were still detectable at 6 months post infusion, 
and had started to express molecules associated with a central memory phenotype, 
which is known to be important in maintaining robust and persistent anti-tumour 
immune responses (Porter et al. 2011). A further 2 cases have been reported one of 
whom also achieved complete remission after being heavy pre-treated. While this is 
encouraging, there remain many unresolved questions. 169 days after infusion the CAR 
T cells had high expression of CD45RA, PD1 and CD57, which may reflect the 
extensive replication history of these cells leading to T-cell exhaustion and incipient 
loss of function (Kalos et al. 2011; Wherry 2011). This could lead to treatment failure in 
the longer term, and necessitate further infusions of these T cells to maintain clinical 
responses. Furthermore, the risk associated with profound long-term B-cell 
lymphopoenia and hypogammaglobulinaemia is still unknown, and could result in 
increased susceptibility to infections analogous to Bruton’s X-linked 
agammaglobulaemia.  
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As discussed above, other issues remain, such as the best time to use these cells, the 
type of conditioning and costimulatory domain, and which antigen is best to target. The 
malignant cells may develop the ability to downregulate CD19, necessitating the use of 
CAR T cells targeting alterative tumour antigens such as CD23 and ROR1, or the use of 
combinations of CAR T cells specific for a range of antigens.(Hudecek et al. 2010; 
Giordano Attianese et al. 2011) However, the potential of CAR T cells, and indeed the 
possibility of engineering other cell types with CARs such as NK and NKT cells, means 
this remains an exciting area of research (Boissel et al. 2009). 
 
Table 1.7 Summary of Immunotherapeutic approaches in CLL 
Mechanism 
 
Examples 
CLL cell mobilization from sanctuary 
sites/ CXCR4-CXCL12 blockade 
- Plerixafor 
- CAL-101 
- PCI-32765 
- Everolimus 
 
Repair of CLL B-cell antigen 
presenting function 
- CD40L gene therapy 
- Lenalidomide 
 
Upregulation of CD40L - CD40L gene therapy 
- Lenalidomide 
 
T-cell activation and repair - Lenalidomide 
- Interleukin-2 
- Immune checkpoint blockade 
 
Enhanced T-cell co-stimulation 
 
- Lenalidomide 
- Immune checkpoint blockade 
- 2nd/3rd generation chimeric antigen receptor T-cells 
 
Targeting tumour-associated antigens - Peptide vaccines 
- Dendritic cell vaccines 
- Transgenic TCR T-cells 
- Chimeric antigen receptor T-cells 
 
Adoptive T-cell therapy - Allogeneic hematopoietic stem cell 
transplantation/donor lymphocyte infusions 
- Transgenic TCR T-cells 
- Chimeric antigen receptor T-cells 
 
 
  
John Riches Chapter 1: Introduction 
72 
 
1.6 Lenalidomide 
 
1.6.1 History and Development: Immunomodulatory aspects   
Lenalidomide (Revlimid, CC-5013) is a second-generation derivative of thalidomide 
with anti-tumour, anti-angiogeneic and immunomodulatory activity. Its parent 
compound, thalidomide, was developed in 1954 by CIBA, and was initially used as a 
sedative, tranquiliser, and anti-emetic for the treatment of morning sickness (D'Amato et 
al. 1994). Unfortunately, thalidomide was found to have potent and tragic teratogenic 
effects, and was withdrawn from the market (Lenz 1988). Despite this, it was noted to 
be an effective treatment for erythema nodosum leprosum (ENL), an acute 
inflammatory manifestation of lepromatous leprosy, and remained in use for this 
indication (Sheskin 1965). In the 1980s it became apparent that thalidomide was useful 
in the treatment of other inflammatory diseases, including rheumatoid arthritis, Behcet’s 
disease, systemic lupus erythematosus, and even GVHD (Gutierrez-Rodriguez 1984; 
Hamza 1986; Lim et al. 1988; Atra and Sato 1993). This anti-inflammatory activity was 
subsequently linked to inhibition of TNFα production, as patients with ENL who 
responded to thalidomide were noted to have rapid reductions in serum concentrations 
of TNFα, and thalidomide was observed to suppress production of TNFα by 
lipopolysaccharide (LPS)-stimulated monocytes in vitro (Sampaio et al. 1991; Sampaio 
et al. 1993).  
 
As a result of these findings, investigators at Celgene proceeded to synthesise several 
analogues of thalidomide which were optimised for their ability to control TNFα 
production (Corral et al. 1996; Muller et al. 1996). Second generation 
immunomodulatory drugs (IMiD) including lenalidomide and pomalidomide were 
found to be up to 50,000-fold more potent than thalidomide at inhibiting TNFα 
production by PBMC in vitro. Interestingly, the effect of these agents was dependent on 
the type of stimulation applied to the PBMCs, as while they inhibited IL1β, IL12, and 
IL6 production/increased IL10 production from LPS-stimulated PBMCs, they increased 
TNF and IL12 production/decreased IL10 production by anti-CD3 stimulated PBMCs. 
Furthermore, these agents were noted to have marked co-stimulatory effects on anti-
CD3 stimulated T cells, increasing T-cell proliferation and production of IL2 and IFNγ 
(Haslett et al. 1998; Corral et al. 1999).   
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The exact mechanism by which IMiDs such as lenalidomide and pomalidomide exert 
these effects is unclear. Enhanced activity of the transcription factor AP1 has been 
shown to play a role, as increased IL2 production by Jurkat T cells correlated with an 
increase in IL2 promoter activity and IL2 mRNA levels that could be eliminated by 
targeted mutations of the proximal AP1 binding site (Schafer et al. 2003). Further work 
demonstrated that pomalidomide treatment could enhance the DNA-binding activity of 
AP1, suggesting that the co-stimulatory effect of pomalidomide on T cells was due to 
enhanced binding of AP1 to its binding site in the proximal region of the IL2 promoter 
(Payvandi et al. 2005). Interestingly, the DNA-binding-enhancing effect of 
pomalidomide was not observed with other transcription factors such as NFκB, NFAT 
or OCT1. Furthermore, the increased activity of AP1 was not associated with many of 
the upstream signalling events that are classically involved in T cell activation, such as 
calcium flux, and NFAT, ERK, JNK, Jun or p38 MAPK phosphorylation. Subsequent 
work instead suggested that activation of PKCθ was important, as the co-stimulatory 
effect of pomalidomide could be blocked by two inhibitors of PKCθ, Rottlerin and 
G06976, and pomalidomide was observed to directly enhance the activity of PKCθ in 
stimulated T cells in an in vitro kinase assay. In contrast, other investigators have 
suggested that the co-stimulatory effect of IMiDs is mediated by the B7-CD28 pathway. 
In this study, lenalidomide was able to partially overcome the inhibitory effect of 
CTLA4 by triggering tyrosine phosphorylation of the intracellular domain of CD28 in T 
cells, with downstream activation of the NFκB pathway (LeBlanc et al. 2004). This 
conflicting data could be attributed to the different methods used for T-cell stimulation, 
with calcium channel activation by PMA/Ionomycin being used in the initial reports 
highlighting the importance of AP1 activation, and TCR-stimulation by anti-CD3 being 
used in the report suggesting involvement of the B7-CD28 pathway (Schafer et al. 
2003; LeBlanc et al. 2004; Payvandi et al. 2005). However, this does highlight the 
controversy that still surrounds the exact mechanism of action of lenalidomide’s effect 
on T cells (McDaniel et al. 2012). Indeed, another report has suggested that the co-
stimulatory effect of IMiDs relies on an entirely different mechanism. A recent 
investigation into the effects of IMiDs reduced on immune cells in myeloma patients, 
suggested that these agents were able to downregulate both T- and NK-cell expression 
of Suppressor of Cytokine Signalling-1 (SOCS1), an important negative regulator of 
cytokine signalling, thereby leading to enhanced cytokine production (Gorgun et al. 
2010).  
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In addition to their co-stimulatory effects, IMiDs have also been demonstrated to 
enhance T-cell cytotoxic function. Initial work demonstrated the ability of thalidomide 
to enhance the capacity of purified CD8
+
 cells to lyse allogeneic monocytes after 
priming by HLA-mismatched dendritic cells (Haslett et al. 1998). Further work by the 
same group showed that thalidomide and lenalidomide were able to enhance virus 
specific CD8+ T-cell cytokine production and cytotoxic activity in both healthy donors 
and patients chronically co-infected with HIV and CMV. The mechanistic explanation 
for the ability of IMiDs to enhance cytotoxic function appears to lie in their capacity for 
cytoskeletal activation, which is a critical regulator of T-cell function. This area has 
been of particular interest to my group after they showed that the functional defect of T 
cells in CLL was associated with alterations in the expression of cytoskeletal genes and 
defective immunological synapse formation. My supervisors subsequently demonstrated 
that treatment of both autologous T cells and CLL cells with lenalidomide resulted in 
repair of immunological synapse formation and improvement in CD8
+
 T-cell cytotoxic 
responses suggesting that this may be a key component of this agent’s activity in CLL 
(Ramsay et al. 2008). Further work by my group has demonstrated that lenalidomide 
was able to block CLL-cell induced inhibition of the RhoGTPases, RhoA, Cdc42, and 
Rac1, in healthy T cells (Ramsay et al. 2012). This effect appears to be due to a 
combination of an activatory effect of lenalidomide on these RhoGTPases, and to down-
regulation of inhibitory signalling axes between CLL cells and T cells (Ramsay et al. 
2013). Other investigators have noticed similar effects: in particular, it has been shown 
that both lenalidomide and pomalidomide can activate the cytoskeletal regulators Rac1 
and RhoA in T cells and CLL cells (Xu et al. 2009; Troeger et al. 2012). Further work 
implicated these RhoGTPases in the regulation of IL2 production, as RhoA was 
essential for pomalidomide-induced IL2 expression in T cells, which could be blocked 
by treatment with a ROCK1 inhibitor. Interestingly, otherwise unrelated work has 
provided evidence that RhoA is able to stimulate expression of members of the AP1 
family of transcription factors, providing further evidence that could potentially link the 
cytoskeletal and co-stimulatory effects of IMiDs (Marinissen et al. 2004). 
 
Lenalidomide also has effects on other non-malignant lymphocyte subsets. It has been 
shown to significantly inhibit the suppressor function and generation of Tregs in vitro, 
and was found to reduce numbers of Tregs in PB of CLL patients.(Galustian et al. 2009; 
Idler et al. 2009) There is also evidence to suggest that lenalidomide is able to alter the 
homeostatic regulation of T-cell subsets. Correlative immune studies performed on 
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patients undergoing treatment for MDS showed that patients with an erythroid response 
to lenalidomide had a greater increase in naive and central memory T-cell subsets 
compared to non-responders, with a concurrent decrease in effector memory subsets 
(McDaniel et al. 2012). A similar increase central memory T cells was observed in a 
study of myeloma patients that had received lenalidomide in combination with a 
pneumococcal vaccine (Noonan et al. 2012). Lenalidomide has also been shown to have 
comparable effects on NK cells, enhancing their proliferative and cytotoxic capacity. 
IL2 again appears to be critical, as increased NK-cell production of IFNγ, increased 
expression of CD69, and enhanced cytolytic activity, were all dependent on 
pomalidomide-induced production of this cytokine (Payvandi et al. 2005). Again, as in 
T cells, lenalidomide has been shown to immunological synapse formation between NK 
cells and target cells (Gaidarova et al. 2009). Lenalidomide has also been shown to 
downregulate the expression of inhibitory receptors on NK cells, and to enhance antigen 
specific expansion of NK T cells (Chang et al. 2006; Dauguet et al. 2010). 
 
A recent paper has identified cereblon (CRBN) as a primary target of thalidomide 
teratogenicity. Thalidomide binds to CRBN inhibiting the activity of a E3 ubiquitin 
ligase complex compromised of CRBN, DNA damage binding protein-1 (DDB1), cullin 
4A, and ring-box protein-1 (RBX1, also known as Roc1). This was shown to lead to the 
down-regulation of fibroblast growth factor genes and teratogenic effects in zebrafish 
and chick models (Ito et al. 2010). CRBN is also implicated in other pathways, as it 
binds to a calcium-activated potassium channel in the brain, a chloride channel in the 
retina, and to AMP kinase, a master sensor of energy balance in eukaryotic cells (Jo et 
al. 2005; Hohberger and Enz 2009; Lee et al. 2011). In addition, a nonsense R419X 
mutation of CRBN is associated with autosomal recessive non-syndromic mental 
retardation (Higgins et al. 2008). 
 
Further work has shown that CRBN-binding is also a critical component of the activity 
of lenalidomide and pomalidomide, as its expression was required for the anti-myeloma 
effect of these agents (Zhu et al. 2011). Although CRBN depletion was initially 
cytotoxic to human myeloma, surviving cells with stable CRBN depletion became 
resistant to IMiDs, but not to other agents such as dexamethasone, bortezomib, or 
melphalan. Gene expression changes induced by lenalidomide where suppressed by 
CRBN knockdown, demonstrating that CRBN is required for the downstream activity 
of this agent. Interestingly, these investigators noted that CRBN was required for 
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lenalidomide-induced down-regulation of interferon regulatory factor 4 (IRF4), a 
transcription factor that is known to be critical for myeloma cell survival (Shaffer et al. 
2008). Subsequent work has focused on the ability of IMiDs to modulate the activity of 
the CRBN-DDB1-Cul4A-Roc1 E3 ubiquitin ligase complex. Under normal 
circumstances this complex adds ubiquitin either to CRBN itself (auto-ubiquitination) 
or to a variety of substrate proteins. The IMiDs are all able to inhibit the auto-
ubiquitination of CRBN, but are also thought to be able to modulate the specificity of 
this ubiquitin ligase complex for other substrate proteins, inhibiting ubiquitination of 
some proteins and increasing ubiquitination of others. Importantly, evidence is 
emerging that CRBN is critical for the effect of lenalidomide and pomalidomide on T 
cell activation, as siRNA knockdown of T-cell CRBN blocked the increase in 
production of IL-2 and TNF-α induced by these agents (Lopez-Girona et al. 2012) 
Furthermore, recent work has suggested that this is specifically due to an effect on the 
CRBN-DDB1-Cul4A-Roc1 E3 ubiquitin ligase complex, rather than another of the 
potential pathways (Kronke et al. 2012). The current understanding of the mechanism 
of action of lenalidomide on T cells is summarised in Figure 1.10. 
 
Figure 1.10 The effect of lenalidomide on T cells 
Lenalidomide binds CRBN, which results in several potential effects, including modulation of the E3 
ubiquitin ligase activity of a complex of CRBN with DDB1, CUL4A, and ROC1. The subsequent 
downstream events remain unclear, but emerging evidence suggests that this ubiquitin ligase activity is 
important for the co-stimulatory effects. Lenalidomide activates PKCθ and RhoGTPases such as RhoA, 
which result in enhanced co-stimulation, cytoskeletal activation and restoration of T cell homeostasis. 
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1.6.2 The mechanism of action of lenalidomide in CLL 
Lenalidomide has been tested in several phase I and phase II clinical trials in CLL. A 
particularly interesting aspect of the clinical activity of lenalidomide in CLL is the 
tumour flare (TF) reaction. This is manifested by acute and painful swelling of involved 
lymph nodes, hepatosplenomegaly, rash, and fever, which usually occurs 8 – 72 hours 
after initial drug administration (Andritsos et al. 2008; Chanan-Khan and Cheson 2008; 
Aue et al. 2009) It can be effectively treated with both steroids and non-steroidal anti-
inflammatories: in later trials these agents were used prophylactically, which led to 
reports of a delayed TF reaction developing at the time of steroid taper (Andritsos et al. 
2008). Repeat TF symptoms were also reported to develop in subsequent cycles on 
resuming lenalidomide after the week off therapy where the drug was given for 21 days 
out of a 28 day cycle (Chen et al. 2010). The clinical manifestations are associated with 
features of immune activation, with upregulation of CD40, CD80, and CD86 on CLL 
cells, upregulation of CD69 on T cells, and elevated serum levels of cytokines and 
chemokines including IL6, IL8, TNFα, CCL2, CCL3, CCL4,  and the soluble receptor 
IL1Rα (Andritsos et al. 2008; Aue et al. 2009). There has been some suggestion that the 
presence of a tumour flare reaction correlates with clinical outcome, highlighting the 
fact that the mechanisms underlying this phenomenon may also account for 
lenalidomide’s anti-tumour effect (Chanan-Khan et al. 2010; Badoux et al. 2011). 
However this correlation has not been observed in all studies (Table 1.8). This could be 
due to the early experience with lenalidomide, that suggested that TF reactions could be 
potentially dose limiting. As a consequence of this, subsequent clinical trials sought to 
minimise the risk of TF by adjustments to lenalidomide dosing and scheduling, and by 
the use of prophylaxis. There also appears to be a confounding effect of previous 
therapy, given the observation of a higher incidence of TF in treatment naive patients, 
who potentially have more robust immune systems that are more sensitive to the 
immunostimulatory effects of lenalidomide.  
 
Therefore, the clinical activity of lenalidomide in CLL appears to be due to combination 
of activation of the CLL cells themselves, in combination with activation of components 
of the immune microenvironment, particularly T and NK cells.  The importance of 
lenalidomide-induced immune cell activation is highlighted by observations that 
lenalidomide is not directly toxic to CLL cells in vitro (Chanan-Khan and Porter 2006; 
Chanan-Khan et al. 2011). This is in contrast to the situation in myeloma, where 
lenalidomide has a direct toxic effect ((Chang and Stewart 2011)). Notably, the toxic  
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Table 1.8 The tumour flare reaction in clinical studies of lenalidomide in CLL 
Clinical trial  Lenalidomide dose  Tumour flare  Predicts better 
response?  
(Chanan-Khan et al. 
2006) 
25mg/day, then 5 mg, with 5mg 
escalations to 25mg/day (21/28 
days) 
 
58% of patients 
(8% grade III/IV)  
Yes 
(Ferrajoli et al. 2008) 10mg/day, with 5mg escalations to 
25mg/day (continuous)  
12% of courses 
(2% grade III/IV)  
30% of patients  
 
No  
(Aue et al. 2009) 20mg/day for first 10 patients 
10mg/day for next 8 patients 
83% of patients In vitro response of 
CLL cells predicts 
clearance from PB 
 
(Andritsos et al. 2008) 25mg/day (21/28 days) 
 
 
75%  Not analysed  
(Chen et al. 2010) 2.5mg/day, 5mg, 10mg  
(21/28 days) 
(21/28 days)  
88% of patients 
(0% grade III/IV)  
No  
(Badoux et al. 2011) 5mg/day, with 5mg escalations to 
25mg/day (continuous)  
52% of patients 
(0% grade III/IV)  
No (but p = 0.058) 
BUT: TFR predicts 
for longer PFS  
 
(Badoux et al. 2013) 10mg/day (continuous) 
 
 27% of patients 
(0% grade III/IV) 
Not analysed 
 
 
effect in myeloma is mediated by binding of lenalidomide to CRBN, and clinical 
responses in myeloma do correlate with CRBN levels, with levels falling in resistant 
disease (Zhu et al. 2011). This is not the case in CLL, where baseline expression of 
CRBN in the tumour cells does not appear to predict for response (Chen et al. 2012). 
Instead the immune activating effects of lenalidomide are more important in CLL, with 
CLL-cell and T/NK-cell activation resulting in increased tumour-immune cell 
interactions and enhanced anti-tumour immune responses. Indeed, NK-cell activation 
appears to be a predictor for clinical response to lenalidomide in CLL. The presence of 
higher numbers of NK-cells pre-treatment, a greater capacity for NK-cell proliferation 
in vitro, and higher baseline expression of NK-cell activating ligands MIC-A/B on CLL 
cells, all predicted for better outcome in a clinical trial (Chanan-Khan et al. 2011; 
Chanan-Khan et al. 2011).  
 
A number of studies have investigated the effect of lenalidomide on CLL cells, aiming 
to account for its ability to increase expression of co-stimulatory and activation markers 
such as CD40, CD80, CD83 and CD86. One group reported that in vitro treatment of 
CLL cells with lenalidomide was able to trigger MAPK/ERK signalling, increasing 
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levels of p-ERK (Chanan-Khan et al. 2011). Interestingly, this conflicts with previous 
reports in T cells, where lenalidomide/pomalidomide treatment was not found to have 
any effect on ERK signalling (Schafer et al. 2003; Payvandi et al. 2005). However, 
these agents were initially reported to have paradoxical effects dependent on the type of 
cell being stimulated, and the nature of stimulation (Corral et al. 1999), so it is possible 
that the mechanism of action of IMiDs varies with the target cell. Other studies have 
implicated a role for the PI3-kinase pathway in lenalidomide-induced CLL-cell 
activation (Herman et al. 2011). The combination of PI3-kinase activation and induction 
of NFκB and NFAT signalling has been showed to result in enhanced transcription and 
stabilisation of CD154 mRNA. The leads to expression of CD154 (CD40L) on CLL 
cells, which upregulate BID, DR5 and p73, and become sensitised to tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. The upregulation 
of CD40L also promotes co-stimulatory activation of normal B cells, resulting in the 
development of polyclonal antibodies, including antibodies directed at known tumour-
associated antigens such as ROR1 (Lapalombella et al. 2010). This data highlights the 
complex interplay of nature of cellular interactions that are induced by lenalidomide 
treatment in CLL.  
 
 
 
  
John Riches Chapter 1: Introduction 
80 
 
1.6.3 Clinical experience with lenalidomide in CLL 
At the time of writing, there have been eight major published clinical studies of 
lenalidomide in CLL (summarised in Table 1.9). Initial findings in pre-treated patients 
were encouraging, with an ORR of 58%, but this efficacy was not reproduced in two 
further studies in relapsed/refractory patients (Chanan-Khan et al. 2006; Ferrajoli et al. 
2008; Wendtner et al. 2012). This may be due to the dose of lenalidomide used. The 
initial study used a starting dose of 25mg/day in the majority of patients, which is the 
standard target dose used in the treatment of multiple myeloma (where it is relatively 
well tolerated). However, as discussed above, one of the clinical features of the use of 
lenalidomide in CLL is a tumour flare reaction, and concerns about this phenomenon 
led to a reduction in the doses used in subsequent studies. Further trials using single-
agent lenalidomide in previously untreated patients have been more successful. Indeed, 
lenalidomide has been demonstrated to have significant clinical activity, with an ORR 
of 72%, which compares well to single-agent response rates seen with other commonly 
used therapies such as fludarabine, alemtuzumab, bendamustine, and chlorambucil 
(Chen et al. 2010). Importantly, a recent phase II trial has demonstrated similar activity 
in elderly (> 65 years) patients, with lenalidomide being well tolerated when used at a 
lower starting dose (Badoux et al. 2011). 
 
A further key feature of the clinical experience with lenalidomide is that it has efficacy 
in patients with “poor risk” disease. This was initially noted in a subgroup analysis of 
the first published trial in relapsed/refractory patients, which showed an ORR of 38% in 
patients with deletion of 17p or 11q (Sher et al. 2010). In an upfront study of 
lenalidomide in CLL, none of the established prognostic markers correlated with 
response, with patients who had adverse risk factors (including cytogenetics, CD38 and 
ZAP70) showing comparable responses to patients without these risk factors (Chen et 
al. 2010). However, there have been other conflicting reports about the efficacy of 
lenalidomide in patients with 17p deletion. This abnormality was associated with 
significantly impaired prognosis in two studies, with ORRs of 13% and 0% in 
relapse/refractory and treatment naïve patients respectively (Ferrajoli et al. 2008; 
Badoux et al. 2011). However, in a more recent study of lenalidomide in combination 
with rituximab conducted by the same group, the ORR for the 15 patients with 17p 
deletion was 53%, which was not significantly different from the ORR for patients 
without 17p deletion (70%; P = 0.35). Once again, other established prognostic  
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Table 1.9 Summary of published clinical trials using lenalidomide in CLL 
Relapsed/Refractory 
Reference Patients Treatment Type Response Rates 
(Chanan-Khan 
et al. 2006) 
45 patients;  
Relapsed/refractory 
Median of 3 prior Rx 
Median age = 64 years 
 
Lenalidomide 25mg, 
then 5 mg, with 5mg 
escalations to 25mg 
(21/28 days) 
Phase II ORR 58% 
(18% CR + 40% PR) 
(Data from 2007 
update) 
(Ferrajoli et al. 
2008) 
44 patients; 
Relapsed/refractory 
Median of 5 prior R
x
  
Median age = 64 years 
 
Lenalidomide 10mg, 
with 5mg escalations to 
25mg 
(continuous)  
Phase II OOR 32 % 
(7% CR + 25% PR) 
25% SD 
(Wendtner et al. 
2012) 
52 patients 
Relapsed/refractory 
Median of 4 prior R
x
  
Median age = 66 years 
 
Lenalidomide 2.5mg, 
with escalations to 
20mg (continuous)  
Phase 
II/III  
ORR 12% 
(0% CR + 12% PR) 
SD 58%  
Previously untreated 
Reference Patients Treatment Type Response Rates 
(Chen et al. 
2010) 
25 patients 
Untreated 
Median age = 60 years  
Lenalidomide 2.5mg, 
5mg, 10mg (21/28 
days) 
(21/28 days)  
Phase II  ORR 72% 
20% CR + 52% PR 
40% SD  
(Data from ASH 
2012 update) 
 
(Badoux et al. 
2011) 
60 patients 
Untreated 
Median age = 71 years  
Lenalidomide 5mg, 
with 5mg escalations to 
25mg (continuous)  
Phase II ORR 65% 
(15% CR + 50% PR) 
40% SD 
 
Lenalidomide based combinations 
Reference Patients Treatment Type Response Rates 
(Brown et al. 
2010) 
9 patients 
Untreated 
Median age = 59 years 
Fludarabine 25mg/m
2
 
for 3 – 5 days 
Rituximab 375mg/m
2
 
on day 1  
Lenalidomide 2.5mg 
(21/28 days) 
 
Phase I ORR 56% 
(11% CR + 44% PR) 
11% SD 
(Badoux et al. 
2013) 
59 patients 
Relapsed/refractory 
Median of 2 prior R
x
  
Median age = 62 years  
Rituximab 375mg/m
2
 
on days 1, 8. 15, and 22 
in cycle 1; subsequent 
cycles day 1 
Lenalidomide 10mg 
(continuous) 
 
Phase II ORR 66% 
(12% CR + 54% PR) 
 
(Shanafelt et al. 
2013) 
44 patients (34 patients 
received lenalidomide) 
 
Pentostatin 2mg/m
2
 on 
day 1 
Cyclophosphamide 
600mg/m
2
 on day 1 
Rituximab 375mg/m
2
 
on day 1 (100mg/m
2
 
first dose in cycle 1) 
Lenalidomide 
consolidation (after 
completing PCR) 5mg, 
escalation up to 10mg 
 
Phase II Induction (PCR) 
ORR 93% 
(32% CR + 61% PR) 
 
Lenalidomide 
consolidation 
24% improved depth 
of response (overall 
CR rate improved to 
53% in lenalidomide 
patients) 
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markers such as CD38 and IGVH mutation status did not correlate with ORR. Whether 
these observations translate into improved overall survival for poor risk patients remains 
to be determined. 
 
Combinations of lenalidomide with other agents are now being tested in clinical trials. 
The addition of rituximab appears particularly attractive, given pre-clinical observations 
demonstrating enhanced NK cell responses after in vitro treatment with this agent (Wu 
et al. 2008). The ORR of the combination of lenalidomide and rituximab in 
relapsed/refractory patients was 66%, which compares very favourably to the ORRs of 
other salvage regimens such as FCR and BR. In contrast, the addition of fludarabine to 
lenalidomide and rituximab was not well tolerated, due to a combination of 
idiosyncratic drug reactions, tumour flare and myelosuppression (Brown et al. 2010). 
These problems made it difficult to deliver adequate amounts of fludarabine and/or 
lenalidomide to the patients, contributing to the poorer than expected ORR. Given that 
T-cell activation appears to be a crucial component of lenalidomide mechanism of 
action in CLL, it can be postulated that combinations with T-cell depleting agents such 
as fludarabine or alemtuzumab may be counterproductive. However the situation may 
be more complex, as there is some evidence that lenalidomide can still be effective after 
T-cell depletion by alemtuzumab and high-dose glucocorticoids (Arumainathan et al. 
2011). 
 
Following the example set in myeloma treatment, it is possible that lenalidomide may 
be useful as a consolidation or maintenance treatment. A recently published clinical trial 
examined the effect of induction therapy with pentostatin, cyclophosphamide and 
rituximab (PCR), followed by lenalidomide consolidation. In this context, lenalidomide 
consolidation improved the depth of response in 24% of eligible patients, with evidence 
suggesting that lenalidomide will extend time to retreatment (Shanafelt et al. 2013). 
Interestingly, correlative studies performed alongside this clinical trial contributed to by 
my group showed that anti-tumour T-cell immunological synapse activity was enhanced 
after PCR alone, and improved further with lenalidomide consolidation. Trials to 
investigate the combinations of lenalidomide with ofatumumab and dexamethasone, and 
as a maintenance treatment after FR/BR are ongoing (Ferrajoli et al. 2011; Chang et al. 
2012; Chen et al. 2012; Ujjani et al. 2012).  
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Given the emergence and success of BCR-signalling inhibitors such as ibrutinib the 
future use of lenalidomide in CLL is unclear. It may well prove useful in combinations 
with these newer agents, or with more established chemotherapy drugs or monoclonal 
antibodies. As in myeloma, it may have a role to play as a consolidation or maintenance 
treatment, or as second line treatment in patients failing to respond. It may also be 
useful in enhancing T-cell and NK-cell responses post allogeneic stem cell 
transplantation or in combination with CAR T cells. Understanding the mechanism of 
action of lenalidomide in CLL will be key to developing rational novel drug 
combinations in the fight against this disease.  
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1.6.4 Lenalidomide in other haematological malignancies 
Lenalidomide was first widely used in the treatment of multiple myeloma where it has 
been shown to have potent anti-tumour properties (Richardson et al. 2002). 
Lenalidomide has a dual mechanism of action in MM, involving direct tumouricidal 
activity that leads to MM cell death, and an immunomodulatory effect that keeps the 
tumour in remission and improves immune function (Davies and Baz 2010). The 
tumouricidal activity of lenalidomide is thought to be mediated by a combination of a 
direct cytotoxic effect, and by removal of bone marrow stromal cell (BMSC) support. 
BMSCs are thought to play an important role in the maintenance of myeloma cells in 
vivo, due to their ability to secrete factors such as IL6 and VEGF and to induce VEGF 
secretion by MM cells (Gupta et al. 2001). IL6 and VEGF are known to be important 
mediating MM cell growth and survival, and lenalidomide-induced downregulation of 
the production of these factors is thought to be an important part of the mechanism of 
action of this agent in MM (Lichtenstein et al. 1995; Breitkreutz et al. 2008) In 
addition, lenalidomide has a direct cytotoxic effect on MM cells, which is in contrast to 
CLL. This is thought to be a result of caspase activation, NFκB inhibition, and cell 
cycle arrest via upregulation of tumour suppressor genes including the cyclin-dependent 
kinase inhibitor p21 (Mitsiades et al. 2002; Davies and Baz 2010; Gandhi et al. 2010). 
However, as in CLL the immunomodulatory effect of lenalidomide is also important. 
Increased levels of IL2 in the MM microenvironment can potentiate T- and NK-cell 
proliferation, while an increase in their cytotoxic activity appears to be due to a 
combination of enhanced phagocytic function and antibody dependent cellular 
cytotoxicity (Hayashi et al. 2005). The activating effect of IMiDs on NK-cells appears 
to be particularly important in myeloma, where IMiDs have been shown to enhance 
NK-cell lytic activity against myeloma cell lines and autologous patient myeloma cells 
(Davies et al. 2001).   
 
In addition, lenalidomide has also been found to have significant clinical activity in 
patients in MDS. Intriguingly, an early clinical study found that patients with 5q deleted 
MDS responded especially well to lenalidomide with an ORR of 83%, compared with 
ORRs of 57% for those with a normal karyotype and 12% for those with other 
karyotypic abnormalities (List et al. 2005). This observation sparked a great deal of 
interest in whether the genes that were normally encoded in the deleted part of 
chromosome 5q were important in the mechanism of action of lenalidomide. As a result 
of this several candidate genes were identified as being potentially important in 
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lenalidomide sensitivity, including PP2A, ERG1, CDC25C, and CTNNA1 (Padron et al. 
2011). Subsequent work showed that two dual specific phosphatases, Cdc25C and 
PP2Aα, which are co-regulators of the G2-M cycle checkpoint, were inhibited by 
lenalidomide (Wei et al. 2009). The 5q deleted MDS progenitors were already 
haplodeficient for PP2A and Cdc25, making them especially sensitive to cell arrest 
induced by further inhibition of phosphatase activity by lenalidomide. Further 
investigation revealed that secondary resistance to lenalidomide in 5q deleted patients 
was associated with upregulation of PP2Acα with consequent restoration of p53 
activation and hypo-proliferative anaemia (Wei et al. 2012). Similar reasoning provided 
the rationale for investigation of the tumour expression gene SPARC, which is also 
encoded on the region that is commonly affected in 5q deleted MDS patients (Pellagatti 
et al. 2007). Incubation with lenalidomide was found to up-regulate expression of this 
gene back to normal levels, potentially restoring its anti-proliferative, anti-adhesive, and 
anti-angiogenic functions. 
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1.7 Aims and objectives 
This project has two principle aims. The first is to characterise the nature of the T-cell 
defect in CLL, focusing on the expansion of CD8
+
 T cells in the peripheral blood of 
CLL patients. Given that an expansion of CD8
+
 T cells in the peripheral blood is usually 
seen as part of the normal immune response to acute viral infections, a critical 
component of this will be to test the hypothesis that CLL peripheral blood T cells are 
phenotypically and functionally exhausted, analogous to observations in chronic viral 
infections. As part of this investigation there will be particular emphasis on assessing 
the differentiation state of CLL T cells, both in terms of cytokine secretion profiles and 
transcription factor expression. 
 
The second aim is to investigate the potential of reversing these T-cell defects. The 
immunomodulatory drug lenalidomide is known to be clinically efficacious in CLL, an 
effect which relies on induction of an anti-tumour immune response rather than a direct 
cytotoxic effect. This project will investigate the mechanism of action of lenalidomide 
in CLL, with the hope that an increased understanding of this area will allow for further 
characterisation of the nature of the immune defect in this disease, and the development 
of novel immunotherapeutic approaches.  
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2 Chapter 2: Materials and Methods 
 
2.1 Ethical considerations 
Ethical approval for a study entitled “The impact of the tissue microenvironment and 
immune system on haematological malignancies” was confirmed by the East London & 
The City Health Authority Local Research Ethics Committee 3. The research ethics 
committee (REC) reference number was 05/Q0605/140. This allowed for the use of 
stored samples of human biological material (e.g. blood, lymph nodes, bone marrow) 
and also covered the use of new samples of human biological material, from both 
patients with haematological malignancies, and healthy donors. 
 
2.2 Patient samples 
Samples of peripheral blood from patients with CLL were obtained from the tissue bank 
maintained by the Centre for Haemato-Oncology at Barts Cancer Institute. This tissue 
bank is maintained according to the Human Tissue Act 2004 (license no. 12199). All 
patients had signed consent forms to allow storage of specimens for research purposes 
after appropriate counselling in accordance with the Declaration of Helsinki. Further 
peripheral blood samples were also obtained from the tissue core maintained by the 
CLL Research Consortium (CRC), a United States-based multi-institutional programme 
project, funded by the National Institute of Health. The CRC tissue core is maintained 
according to the guidelines established by the Health Insurance Probability and 
Accountability Act (HIPAA). Similarly, all patients had been consented for sample 
storage in accordance with the Declaration of Helsinki, and any studies had to have 
been approved by the Institutional Review Board (IRB) of the relevant CRC site(s), of 
which Barts is the only non-USA based site. 
 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were separated from 
buffy coats or buffy cones supplied by the National Blood Service, which were 
specifically designated for research use. Where additional clinical data was required 
(e.g. for purposes of age-matching) PBMCs were separated from peripheral blood 
samples kindly donated by known donors who were all were appropriately counselled 
and consented. Where required, the CMV serostatus of patients and healthy donors was 
determined by the Virology Department at the Royal London Hospital. 
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2.3 Cell thawing and freezing 
Up to 10
8
 human cells were suspended in a solution of 90% foetal calf serum 
(FCS)(PAA Laboratories Ltd.) + 10% dimethylsulphoxide (DMSO)(Fisher Scientific). 
Up to 1.5ml cell suspension was then transferred to 2ml cryovials (Nunc), which were 
placed in freezing containers (Nalgene) at -80
o
C overnight to allow gradual cooling at a 
rate of approximately 1
o
C/minute. They were subsequently transferred to liquid nitrogen 
for long term storage. 
 
On removal from liquid nitrogen the cells were rapidly thawed at 37
o
C. The contents of 
the cryovial were then transferred to 10 – 20mls of full medium (RPMI 1640 + 10% 
FCS (both PAA Laboratories Ltd.) with 25mg gentamicin (Gibco)). The cell suspension 
was then rapidly washed to minimise toxicity from the DMSO. 
 
2.4 Separation of PBMCs from whole blood/buffy coats/cones 
Venous blood from patients with CLL was drawn into standard 6 – 10ml vacutainer 
tubes spray coated with ethylenediaminetetraacetic acid (EDTA) anticoagulant (BD). 
The anticoagulated blood was subsequently diluted in an equal volume of phosphate-
buffered saline (PBS). Buffy cones from the National Blood Service were diluted 5-fold 
with 4 volumes of PBS due to the higher concentration of mononuclear cells. Up to 
35ml of cell suspension was then layered on to 15ml Lymphoprep (Axis Shield) in 50ml 
Falcon tubes. These were then centrifuged at 1500rpm for 25 minutes at room 
temperature with the brake off. Lymphoprep has a specific gravity of 1.077 and thus 
mononuclear cells are found at the 1.077/plasma interface after centrifugation. This 
interface was carefully removed with a pastette and washed twice in full medium or 
MACS buffer (PBS, pH 7.2, 0.5% bovine serum albumin, and 2mM EDTA) (Miltenyi 
Biotec) prior to cell counting. Cell counting was performed on the Vi-cell XR, an 
automated cell counter (Beckman Coulter). 
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2.5 Cell Separation Protocols 
2.5.1 Negative selection using magnetic microbeads 
Negative selection was performed by use of a magnetic cell sorting protocol developed 
by Miltenyi Biotec (Figure 2.1). MACS® LS columns, QuadroMACS® magnet, 
reagents and cell isolation kits were used as part of this protocol (Miltenyi Biotec). 
MACS buffer (PBS, pH 7.2, 0.5% bovine serum albumin, and 2mM EDTA) was 
prepared diluting MACS BSA Stock Solution 1:20 with autoMACS™ Rinsing Solution. 
The cells and buffer were kept cold (2-8
o
C) throughout the isolation procedure to 
prevent capping of antibodies on the cell surface and non-specific cell labelling. PBMCs 
were isolated by density gradient centrifugation as described above. After washing and 
cell counting, the cells were resuspended in 40μl buffer per 107 total cells. 10μl of biotin 
antibody cocktail per 10
7
 total cells was then added, and the cell suspension was then 
incubated for 10 minutes at 4
o
C. Subsequently a further 30μl of buffer and 20μl of anti-
biotin microbeads per 10
7
 total cells were added. The cell suspension was mixed and 
then incubated for an additional 15 minutes at 4
o
C. The cells were then washed by 
adding 10-20x labelling volume of buffer and then resuspended at a concentration of up 
to 1 x 10
8
 cells in 500μl of buffer. The LS columns were prepared by rinsing with 3ml 
MACS buffer during the wash step. The cell suspension was applied to the column and 
washed through with 3 x 3ml of buffer. The entire effluent was collected, which was 
enriched for the unlabelled cells. Post separation the fractions were counted and aliquots 
removed for analysis of cell purity by flow cytometry. The remaining cells were used 
for downstream applications, or frozen as described above.  
 
https://www.miltenyibiotec.com/Products-and-Services/MACS-Cell-Separation/MACS-
Technology/Separation-strategies.aspx 
  
 Figure 2.1 Negative selection using immunomagnetic cell sorting  
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2.5.2 Positive selection using magnetic microbeads 
Positive selection was also performed by use of a magnetic cell sorting protocol 
developed by Miltenyi Biotec (Figure 2.2). MACS® LS columns, MACSbuffer, 
QuadroMACS® magnet, reagents and cell isolation kits were similarly used as part of 
this protocol (Miltenyi Biotec). PBMCs were isolated by density gradient centrifugation 
as described above. After washing and cell counting, the cells were resuspended in 80μl 
buffer per 10
7
 total cells and 20μl of antibody conjugated microbeads per 107 total cells 
were added. The cell suspension was mixed and then incubated for 15 minutes at 4-8
o
C. 
The cells were then washed by adding 10-20x labelling volume of buffer and 
subsequently resuspended at a concentration of up to 1 x 10
8
 cells in 500μl of buffer. 
The LS columns were prepared by rinsing with 3ml MACS buffer during the wash step. 
The cell suspension was applied to the column and washed through with 3 x 3ml of 
buffer. The LS column was removed from the magnetic field and flushed through with 
5ml MACS buffer by firmly pushing the plunger into the column. This labelled cell 
fraction was counted and aliquots taken for analysis of cell purity by flow cytometry. 
The remaining cells were used for downstream applications such as bioassays or RNA 
extraction, or frozen as described above. 
https://www.miltenyibiotec.com/Products-and-Services/MACS-Cell-Separation/MACS-
Technology/Separation-strategies.aspx 
  
Figure 2.2 Positive selection using immunomagnetic cell sorting 
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2.5.3 Immunomagnetic cell sorting using the AutoMACS™ Pro Separator 
Immunomagnetic cell sorting was also performed using the AutoMACS™ Pro 
Separator (Miltenyi Biotec). This automated approach has two main advantages. Firstly, 
the ability to use variable flow rates through the magnet and single/double column 
separations allowed for greater flexibility when selecting for different frequencies of 
target cells with different levels of target antigen expression. Secondly, the automated 
labelling and separation reduced the potential for human error, particularly when 
separating multiple samples. After density gradient centrifugation or cell culture, 
PBMCs were washed in autoMACS running buffer (Miltenyi Biotec) and counted. The 
cells were then resuspended in 80μl autoMACS running buffer per 107 total cells for 
positive selection programs, and 40μl buffer per 107 total cells for negative selection 
programs. The total volume of the cell suspensions were then programmed into the 
separator, along with the appropriate reagents for the target cell type, and the optimised 
cell separation strategy. The following cell separation programs were available (Table 
2.1): 
Positive selection programs: 
POSSEL Positive selection in standard mode: isolation of cells with normal antigen expression 
and frequencies higher than 5%; use if purity is the highest priority 
POSSEL_S Positive selection in sensitive mode: isolation of cells with low antigen expression and 
frequencies higher than 5%; use if yield is the highest priority 
POSSELD Positive selection in standard mode I, double column program: for isolation of rare cells 
in low elution volume 
POSSELDS Positive selection in sensitive mode, double column program: for isolation of rare cells 
with low antigen expression 
POSSELD2 Positive selection in standard mode II, double column program: for isolation of rare cells 
if purity is the highest priority 
POSSELWB Special positive selection in special mode, double column program: for isolation of cell 
subsets from whole blood 
Negative selection programs: 
DEPLETE Depletion in standard mode: for removal of cells with normal to high antigen expression 
and results in better target cell yield 
DEPLETES Depletion in sensitive mode I: removal of cells with low antigen expression and results 
in better target cell purity 
DEPL05 Depletion in sensitive mode II: removal of cells with low antigen expression and results 
in stringent depletion of cells 
DEPL025 Depletion in sensitive mode III: removal of cells with low antigen expression and results 
in stringent depletion of cells 
Table 2.1 autoMACS® Pro Cell Separation programs  
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2.5.4 Separation of T and NK cells from CLL PBMCs using the autoMACS Pro 
The low frequencies of T and NK cells in the peripheral blood of patients with CLL 
meant that selection of these subsets at a high purity was particularly challenging. The 
following strategy was used to isolate CD3
+
, CD4
+
 and CD8
+
 T cells, and CD56
+
 NK 
cells using the autoMACS Pro system (Table 2.2): 
Step Reagent Cell separation Program  
Pre-depletion of CLL cells 
If white blood count > 15 
If white blood count < 15 
 
CD19 microbeads 
CD19 microbeads 
 
possel_s 
possel 
Negative selection of: 
CD3
+
 T cells 
CD4
+
 T cells 
CD8
+
 T cells 
NK cells 
 
Pan T cell Isolation Kit II 
CD4
+
 T cell Isolation Kit II 
CD8
+
 T cell Isolation Kit  
NK isolation kit  
 
deplete 
deplete 
depletes 
depletes 
Table 2.2 Strategy for the separation of T and NK cells from CLL PBMCs 
 
This approach generally resulted in CD4
+
 T cells with a purity of >95%, CD8
+
 T cells 
with a purity of >90%, and NK cells with a purity of >85% by flow cytometry. 
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2.6 T-cell stimulation in vitro 
 
For most assays, T cells were stimulated by using anti-CD3 antibodies, with or without 
co-stimulation using anti-CD28 antibodies. The HIT3a anti-CD3 antibody (BD) was 
optimised for use in solution at concentration of 1µg/ml with 5µg/ml soluble anti-CD28 
(clone CD28.2, eBioscience) where required. This combination induced a strong 
proliferative response in healthy T cells. Where immobilized anti-CD3 antibodies were 
required for stimulation, 100μl – 1ml of a 10μg/ml solution of mouse anti-human CD3 
(clone: OKT3 - eBioscience) was used to coat the bottom of flat bottom 6-, 12-, 24-, or 
96-well plates (Corning). The plates were incubated at 4
o
C overnight, washed twice 
with full medium, before the relevant cell suspension was added. T cells were also 
stimulated using magnetic beads coated with mouse anti-human anti-CD3 and anti-
CD28 (Dynabeads® Human T cell expander; Invitrogen). These were prepared by 
washing three times in PBS with the aid of a magnet to separate the beads from the 
supernatant. The beads were resuspended at a concentration of 1 x 10
8
 beads/ml and 
then added to the T-cell suspension at a starting ratio of 3:1 beads:T cells and mixed 
thoroughly. 
 
For the analysis of intracellular cytokine production, phorbol 12-myristate 13-acetate 
(PMA) and ionomycin are widely used for T-cell stimulation. Cells were initially 
stimulated for 1 hour with 50 ng/ml PMA (Sigma Aldrich) and 1μg/ml ionomycin 
(Sigma Aldrich) and incubated at 37
o
C; 5% CO2. 0.066% monensin (Golgistop BD) 
was then added and the cultures were then incubated for a further 4 hours (5 hours PMA 
and ionomycin stimulation in total). Monensin is a protein transport inhibitor, and has 
been demonstrated to significantly increase the ability to detect cytokine-producing cells 
by immunofluorescent staining (Jung et al. 1993).  
 
A similar protocol was used for assessment of degranulation, although cells were 
stimulated with 1µg/ml staphylococcal enterotoxin B (SEB, Sigma) with the addition of 
10µl/ml anti-CD107a-AlexaFluor647, instead of PMA and ionomycin. The 
fluorochrome was added during the incubation period as the CD107a protein gets 
internalised after translocation to the surface of the cell (Betts et al. 2003). As above, 
the cell cultures were incubated for 1 hour with SEB and anti-CD107a-AlexaFluor647, 
prior to addition of 0.066% monensin for 4 hours further incubation at 37
o
C; 5% CO2.  
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2.7 Flow cytometry 
 
This has been used for several purposes during this project including: purity of cell 
fractions after isolation procedures; lymphocyte phenotyping; intracellular cytokine 
expression; intranuclear transcription factor expression; assessment of lymphocyte 
proliferation and degranulation. A list of fluorochrome conjugated antibodies is given in 
the appendix. In general, a minimum of 10,000 - 20,000 events were used for each 
analysis and so 2 x 10
5
 cells were used at the start of these staining protocols. Where the 
cells of interest were a relatively rare subset (e.g. T cells in PBMCs from CLL patients), 
the starting number of cells was increased proportionally to account for this. The 
centrifugation steps were all performed at 1200 rpm for 5 minutes at 4
o
C or room 
temperature, dependent on whether the cells were live or fixed respectively. 
 
2.7.1 Surface staining 
PBMCs or pre-isolated lymphocytes were used after the thawing, cell separation, or 
culture procedures described above. All staining procedures on live cells were 
performed at 2 - 8
o
C to avoid antibody capping and internalisation. The cells were 
transferred to 5ml polystyrene round-bottom tubes (BD), washed twice with 2ml 
PBS+2% FCS, prior to centrifugation at 1200 rpm for 5 minutes at 4
o
C. They were then 
resuspended in 100μl PBS+2% FCS prior to addition of the fluorochrome conjugated 
antibody. Each antibody was optimised to determine the volume used for surface 
staining – this ranged from 1 – 20 μl. Where multiple colours were being analysed a 
master mix was prepared to ensure consistency of staining. The samples were then 
incubated for 30 minutes at 4
o
C in the dark. The cells were then rewashed in 2ml 
PBS+2% FCS, centrifuged, and then resuspended in 400μl PBS+2% FCS. 4’6-
diamidino-2-phenylindole (DAPI) was added to this final cell suspension at a 
concentration of 250ng/ml to allow for live/dead discrimination. The cells were kept on 
ice in the dark until flow cytometry was performed.  
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2.7.2 Intracytoplasmic staining (cytokines) 
DAPI cannot be used for live-dead discrimination with intracellular staining. DAPI 
stains dead cells because their cell membranes are more permeable, allowing the dye 
into the nucleus where it binds A-T rich regions of DNA. All intracellular staining 
protocols include a permeabilisation step, which will be mean that all cells will 
subsequently stain with DAPI. Therefore, live-dead discrimination was performed using 
a fixable viability dye (eBioscience) before performing surface staining. PBMCs or 
lymphocytes were washed twice with 2ml PBS and subsequently resuspended in 1ml 
PBS with fixable viability dye at a concentration of 1μl/ml. The cells were then washed 
in 2ml PBS+2% FCS, centrifuged, and then resuspended in 100μl PBS+2% FCS for 
surface staining as above. After surface staining the cells were washed with 2ml 
PBS+2% FCS, centrifuged and then resuspended in 200μl cold IC fixation buffer 
(eBioscience). The samples were then incubated at room temperature for 20 minutes in 
the dark. Without washing 2ml of 1x permeabilisation buffer (eBioscience) was added 
and the samples re-centrifuged. A further wash was performed in 1x permeabilisation 
buffer before the cells were centrifuged and resuspended in ~100μl 1x permeabilisation 
buffer for intracytoplasmic staining. A relevant volume (typically 1 - 2μl) of anti-
cytokine antibody was then added at this stage and incubated for 30 minutes in the dark 
at room temperature. The samples were then washed in 1ml of 1x permeabilisation 
buffer, centrifuged, and resuspended in 400μl for PBS+2% FCS for flow cytometric 
analysis. 
 
2.7.3 Intranuclear staining (transcription factors)  
Fixable viability dye and surface staining were performed in the same manner as for 
intracytoplasmic staining. After surface staining the cells were washed with 2ml 
PBS+2% FCS, centrifuged and then resuspended in 1ml of a formaldehyde based 
fixation/permeabilisation buffer (Fixation/Permeabilization Concentrate and Diluent, 
eBioscience). The samples were then incubated at room temperature for 30 - 60 minutes 
in the dark. Washing and permeabilisation was performed as above. The cells were then 
centrifuged and resuspended in 100μl 1x permeabilisation buffer for intranuclear 
staining. A relevant volume (typically 1 - 2μl) of anti-transcription factor antibody was 
then added at this stage and incubated for 30 minutes in the dark at room temperature. 
The samples were then washed in 2ml of the permeabilisation buffer, centrifuged, and 
resuspended in 400μl for PBS+2% FCS for flow cytometric analysis. 
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2.7.4 Carboxyfluorescein Succinimidyl Ester (CFSE) staining for proliferation  
For assessment of proliferation, cells were stained prior to cell culture with CFSE. 
Thawed cells were washed twice in pre-warmed (37
o
C) serum free media (RPMI 1640 
(PAA Laboratories Ltd.) + 25mg gentamicin (Gibco)) and counted. Cells were 
resuspended at a concentration of 2 x 10
7
/ml in serum free media. CFSE was diluted to 
make a 10μM working stock in pre-warmed serum free media. The cell suspension and 
CFSE working solution were mixed in equals volumes to achieve a final cell 
concentration of 1 x 10
7
/ml, and a final concentration of CFSE of 5μM. This resulting 
mixture was rapidly vortexed to ensure full distribution of CFSE, and incubated at 37
o
C 
5% CO2 for 10 minutes. The cell suspension/CFSE staining reaction was then quenched 
by adding 10 – 20mls of cold (4oC) full medium and then left to stand for five minutes. 
The cells were then washed three times in full medium prior to re-suspension for cell 
culture. Extra cells were stained purposes of CFSE compensation.  
 
2.7.5 Typical multicolour flow panel design 
Combinations of fluorochromes were optimised to allow for performing multicolour 
flow cytometry. This had the dual advantages of enabling greater characterisation of 
cells with respect to both phenotype and function, and higher throughput and data 
gathering. Up to 8 colours were commonly used: some example “fluorochrome panels” 
as used on the Fortessa flow cytometer (BD) are shown (Table 2.3): 
Laser Violet Blue Blue Red Red Red 
Yellow/ 
Green 
Yellow/ 
Green 
Filter 450nm 530nm 695nm 670nm 730nm 780nm 585nm 780nm 
Fluorochrome 
DAPI/ 
Pacific 
Blue 
FITC 
PerCP/ 
PerCP-
Cy5.5 
APC/ 
AF647 
AF700 
APC-
Cy7/ 
AF780 
PE PE-Cy7 
Surface 
Staining 
DAPI PD1 CD8 CD160 CD19 CD4 CD244 CD3 
Intracellular 
Staining  
CD3 IFNγ CD8 CD45RA CD19 
Fix-Via 
Dye 
CCR7 CD4 
Table 2.3 Examples of multicolour flow panels used 
Up to 8 colours were used for flow cytometry. DAPI was used as the live/dead discriminator for live 
cells, whereas fixable-viability dye eFluor780 (eBioscience) was used as the live/dead discriminator for 
permeabilised cells. For common used antigens (e.g. CD19, CD3, CD4, CD8) a wide range of directly 
conjugated antibodies were commercially available, whereas antibodies to less commonly used antigens 
(e.g. CD160, CD244) were often only available conjugated to FITC, PE, or APC. Therefore these colours 
were reserved for “target antigens”.  
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2.7.6 Controls 
Unstained controls were used in all experiments to set the voltages on the flow 
cytometer. Fixation and permeabilisation of cells alters their forward and side scatter 
characteristics and so controls for these experiments were prepared in the same way as 
the sample tubes. Isotype controls were used for surface staining experiments where 
there was not expected to be a significant population of target antigen negative cells. 
Isotype controls were not used for intracellular staining, because most antibodies exhibit 
some non-specific binding which is a particular problem when intracellular epitopes and 
binding sites are available after permeabilisation. Therefore for anti-cytokine staining 
the anti-cytokine antibody was used its own control with the cells in the unstimulated 
state (Ormerod 2000). This was complemented by the use of internal controls within the 
experimental design. Flourescence minus one (FMO) controls were also used for certain 
experimental conditions, although as with isotype controls their reliability was reduced 
in the context of intracellular staining.  
 
Compensation was performed using single stained controls when the cells were known 
to express the target antigen, or with compensation beads when the target antigen was 
under investigation. Anti-mouse immunoglobulin compensation beads (CompBeads, 
BD) were prepared by adding a drop each of negative control beads and anti-mouse 
compensation beads to a 5ml polystyrene round-bottom tube. A separate tube was 
prepared for each fluorochrome. A relevant volume of Igκ mouse anti-human 
flourochrome conjugated antibody was added to each tube, and incubated at 4
o
C for 30 
minutes in the dark. The beads were then washed with 2ml PBS+2% FCS and 
resuspended in 400μl for PBS+2% FCS for flow cytometric analysis. Cells were used to 
prepare a single stained sample for compensating the live-dead discrimination dye, and 
to provide an unstained control for settings voltages on the cytometer.  
 
Figure 2.3 An example of compensation beads for a single stained control (PE) 
  
FSC 
SSC SSC 
YG-585: PE 
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2.7.7 Flow cytometric acquisition and analysis 
Initially a Cyan (Dako) and FacsCalibur (BD) and subsequently LSRFortessa (BD) 
were used for data acquisition. FlowJo (Tree Star Inc) software was used for analysis. 
The unstained control tube was primarily used to set voltages, although the single 
stained cell or compensation beads controls were also run prior to data recording. 
Analysis proceeded by defining the fluorochrome negative and positive populations on 
the single stained controls to allow for spectral compensation. For cells, these 
populations were defined on singlet-cells, and for beads, these were defined on the 
beads themselves, gating out any debris. These populations were then used to define a 
compensation matrix, which was subsequently applied to the test samples. After 
compensation, the following gating strategy was applied to the test samples. First, a gate 
was applied on the basis of DAPI/fixable viability dye and side scatter (SSC) to exclude 
dead cells from the analysis (A). A second gate was applied to the live cells to exclude 
doublets from the analysis, on the basis of SSC-area (SSC-A) and SSC-width (SSC-
W)/pulse width (B). A third gate was then applied to the live-singlets to exclude debris 
from the analysis, on the basis of forward scatter (FSC) and SSC characteristics (C). For 
purity checks this would select all live-singlet-cells, for other analyses this gate could be 
adjusted to select a subpopulation (e.g. lymphocytes) based on FSC/SSC characteristics. 
Therefore all subsequent analysis of fluorochrome intensity was performed on 
compensated live-singlet-cells. A minimum of 10,000 events of the cells of interest 
were acquired when running samples on the cytometer. 
 
 
Figure 2.4 Gating Strategy for Flow Cytometry 
(A) Events that have not stained for DAPI are gated on to exclude dead cells. (B) Single events (singlets) 
are gated on to exclude cell clumps (doublets/triplets etc). (C) Events with the forward and side scatter 
characteristics of cells are gated on to exclude debris and any contaminating red blood cells. 
  
A B C 
DAPI 
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2.8 RNA extraction 
 
RNA extraction was initially performed using the RNAeasy Mini Kit (Qiagen). 
However, there were consistent problems with genomic DNA contamination, so a 
switch was made to the RNAeasy Plus Mini Kit (Qiagen), which includes a step for the 
elimination of genomic DNA. The Qiagen kit contained all reagents apart from the 
QIAshredder (also Qiagen), 70% ethanol (VWR), and β-mercaptoethanol (Sigma 
Aldrich). 
 
2.8.1 RNA extraction 
A total of 7 x 10
6
 isolated lymphocytes were used for RNA extraction. This provided 
satisfactory quantities of RNA without overloading the column and reducing purity. The 
cells were centrifuged for 1200 rpm x 5 minutes at room temperature to obtain a cell 
pellet. The supernatant was completed removed before the addition of 600μl Buffer 
RLT Plus with 1% β-mercaptoethanol. The lysate was pipetted directly into a 
QIAshredder spin column placed in a 2ml collection tube, and centrifuged for 2 minutes 
at 14,000 rpm. The homogenized lysate was transferred to a gDNA Eliminator spin 
column placed in a 2 ml collection tube and centrifuged for 30 seconds at 14,000 rpm. 
600μl of 70% ethanol was added to the homogenized lysate, which was thoroughly 
mixed by pipetting. 600μl of the sample was transferred to an RNeasy spin column 
placed in a 2 ml collection tube and pulsed for 15 seconds at 14,000 rpm. The flow-
through was discarded and this step was repeated with any further sample. The RNeasy 
spin column was then washed with 700μl of Buffer RW1 and pulsed for 15 seconds at 
14,000 rpm to wash the spin column membrane. The flow-through was discarded prior 
to the addition of 500 μl Buffer RPE to the column. The samples were then pulsed for 
another 15 seconds at 14,000 rpm to wash the spin column membrane, and the flow-
through was discarded. A further 500 μl Buffer RPE was added to the RNeasy spin 
column, but this time the centrifugation was performed for 2 minutes at 14,000 rpm to 
dry the spin column membrane. The RNeasy spin column was placed in a fresh 2 ml 
collection tube and centrifuged for a further 60 seconds to ensure that no ethanol was 
carried over during RNA elution. The RNeasy spin column was then placed in a 1.5 ml 
collection tube, and 30μl of RNase-free water was added directly to the spin column 
membrane. A 4μl aliquot was taken for determination of RNA purity and integrity, and 
both the extracted RNA and test aliquot were rapidly frozen at -80
o
C for long term 
storage.  
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2.8.2 RNA spectrometry to determine quantity and quality of RNA 
RNA spectrometry was performed to assess RNA quantity and quality on a Nanodrop 
spectrophotometer using 1.5μl of the RNA solution. The absorbance was measured at 
230, 260, and 280 nm wavelengths. The ratio of absorbance at 260nm:280nm indicates 
purity and should be approximately 2.0 for good quality RNA. A reduction in the ratio 
indicates greater absorbance at 280nm which implies protein contamination. Similarly 
absorbance at 230nm indicates phenol contamination which is reflected in a fall in the 
ratio of absorbance at 260nm:230 nm to < 1.8. The RNA extracted using the Qiagen kits 
was usually of very high purity and no further precipitation steps were needed. 
Figure 2.5 RNA Spectrometry to determine quantity and quality of RNA 
Shows high quality RNA at a concentration of 199.4 ng/μl 
 
 
2.8.3 RNA electrophoresis to determine integrity 
Due to the omnipresence of RNases, and the instability of RNA, a check of RNA 
integrity was performed on all RNA samples using the Agilent 2100 Bioanalyzer. This 
uses electrophoretic separation of nucleic acid fragments through an interconnected set 
of micro channels to produce information about the amount and integrity of total RNA. 
Gel-dye mix is loaded onto a chip using a priming device. Up to 12 samples of 1μl RNA 
solution at a concentration of 50 – 500ng/μl are then loaded with a standard RNA 
ladder. The samples are then driven through the gel-dye mix by electrophoresis, 
generating an electropherogram of fluorescence against time. Intact RNA should show 
to sharp peaks corresponding to the 28S and 18S subunits of ribosomal RNA. Agilent 
have developed a RNA integrity number (RIN) as a measure of integrity ranging from 1 
representing most degraded, 10 most intact. A RIN above 6 is sufficient for most 
downstream applications, but virtually all samples had RINs greater than 8.  
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2.9 Gene expression microarrays (Affymetrix) 
 
The protocol documented in the Affymetrix GeneChip® 3’ IVT Express Kit User 
Manual was used to synthesis fragmented and purified aRNA for hybridisation to the 
microarrays. The quantity and purity of the starting RNA was assessed by spectrometry, 
and the integrity confirmed by RNA electrophoresis as above. The protocol 
recommended between 50 – 500ng starting RNA: due to cell numbers 250ng was used 
for both CLL and healthy B and CD4
+
 T cells, and 125ng for both CLL and healthy 
CD8
+
 T cells and NK cells. The quantity and integrity of RNA was retested after in 
vitro transcription and fragmentation (Figure 2.6) 
   
Figure 2.6 Overview of the GeneChip® 3’ IVT Express Kit Labelling Assay 
(A) Summary of the GeneChip® 3’ IVT Express Kit Labelling Assay workflow. Electropherograms of 
intact starting RNA with clear ribosomal peaks (B), aRNA post in vitro transcription (C), and after 
fragmentation (D).    
A 
D 
C 
B 
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2.9.1 Reverse transcription to synthesise first-strand cDNA 
All reagents were included in the GeneChip® 3’ IVT Express Kit. Samples were 
prepared on ice in 200μl PCR tubes. Reactions were assembled using “master mixes” to 
ensure consistency of reagent concentrations between samples. 
Assembly of First Strand Master Mix (per sample): 
 First-Strand Buffer Mix      4μl 
 First-Strand Enzyme Mix      1μl 
 Total volume        5μl  
 
5μl of the First-Strand Master Mix was then added to 5μl of Total RNA/poly-A control 
mixture which was prepared as follows: 
 Total RNA sample        variable 
 Nuclease-free water       variable 
 Diluted Poly-A Controls*      2μl 
 Total volume        5μl  
*A set of Poly-A controls were supplied with the GeneChip® 3’ IVT Express Kit – 
these were designed to provide exogenous positive controls to monitor the labelling 
process. For 250ng of RNA, the control stock was diluted 1:200000 in four sequential 
dilutions (1:20; 1:50; 1:50; 1:4). For reactions using RNA extracted from low numbers 
of CD8
+
 T cells and NK cells the Poly-A controls were omitted to allow for the use of a 
greater volume of target total RNA (5μl instead of 3 μl). 
After mixing and brief centrifugation, the samples were incubated for 2 hours at 42
o
C, 
before being placed on ice and immediately prepared for second strand cDNA synthesis. 
 
2.9.2 Second Strand cDNA synthesis 
Assembly of Second Strand Master Mix (per sample): 
 Second-Strand Buffer Mix      5μl 
 Second-Strand Enzyme Mix      2μl 
 Nuclease-free water       13μl  
 Total volume        20μl 
20μl of the Second-Strand Master Mix was then transferred to each 10μl cDNA sample. 
After mixing and brief centrifugation, the samples were incubated for 1 hour at 16
o
C, 
followed by 10 minutes at 65
o
C, before being placed on ice and immediately prepared 
for in vitro transcription.  
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2.9.3 In Vitro Transcription (IVT) to synthesise labelled aRNA 
Assembly of IVT Master Mix (per sample): 
 IVT Biotin Label       4μl 
 IVT Labelling Buffer       20μl 
 IVT Enzyme Mix       6μl  
 Total volume        30μl 
30μl of the Second-Strand Master Mix was then transferred to each 30μl double 
stranded cDNA sample. After mixing and brief centrifugation, the samples were 
incubated for 16 hours at 40
o
C, before being placed on ice and immediately prepared 
aRNA purification. 
 
2.9.4 aRNA purification 
The aRNA elution solution was pre-heated to 55
o
C for at least 10 minutes. While this 
was heating the aRNA Binding Mix was assembled (per sample): 
 RNA Binding Beads       10μl 
 aRNA Binding Buffer Concentrate     50μl 
 Total volume        60μl 
60μl of aRNA Binding Mix was then added to each sample, and the resultant mixture 
transferred to a U-Bottomed 96-well plate. 120μl of 100% ethanol were then added to 
each sample to enable aRNA binding, and the plate was then shaken for 3 minutes at 
400rpm on a MixMate Shaker (Eppendorf). The RNA bound beads were then captured 
by leaving to stand on a magnet for 5 minutes. The supernatant was then aspirated 
without disturbing the magnetic beads. After removal of the plate from the magnet, 
100μl of aRNA Wash Solution was then added and then the plate was shaken for 1 
minute at 800rpm on the MixMate shaker. The plate was then transferred to the magnet 
and the beads re-captured as previously. The supernatant was then aspirated without 
disturbing the magnetic beads, and the beads were then rewashed with a further 100μl 
of aRNA Wash Solution. After magnetic bead capture, the plate was dried by shaking 
for 2 minutes at 1200rpm on the MixMate shaker. The RNA was then eluted by adding 
50μl of the pre-heated aRNA elution solution. The plate was then shaken for 3 minutes 
at 1200rpm on the MixMate shaker, and the aRNA binding beads were recaptured on 
the magnetic stand. The supernatant, containing the eluted RNA was then transferred to 
a nuclease-free PCR tube, quantified by spectroscopy and the quality check by 
electrophoresis before freezing at -20
o
C.  
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2.9.5 Fragmentation of labelled aRNA 
Fragmentation of the aRNA target before hybridisation onto the GeneChip probe array 
is critical in obtaining assay sensitivity. Therefore 15μg of purified aRNA was prepared 
for fragmentation by assembling the aRNA fragmentation mixture (49/64 Format – 
per sample): 
 aRNA (15μg)        variable 
 5x Array Fragmentation Buffer      8μl 
 Nuclease-free Water       variable 
 Total volume        40μl 
After mixing and brief centrifugation, the samples were incubated for 35 minutes at 
94
o
C, before being placed on ice and immediately prepared for hybridisation. 
 
2.9.6 Target hybridisation for Affymetrix U133Plus2.0 Microarrays 
Reagents for this step were contained in the GeneChip® Hybridisation, Wash and Stain 
kit. The hybridisation cocktail was prepared (per sample - the 20x Hybridisation 
Controls were heated to 65
o
C for 5 minutes to completely resuspend the aRNA before 
aliquoting) : 
 Fragmented and labelled aRNA (12.5μg)    33.3μl 
 Control Oligonucleotide B2 (3nM)     4.2μl 
 20x Hybridisation Controls (bioB, bioC, bioD, cre)   12.5μl  
 2x Hybridisation Mix       125μl 
 DMSO          25μl 
 Nuclease-free Water       50μl 
 Total volume        250μl 
The hybridisation cocktail was then heated for 5 minutes at 99
o
C. During this time the 
array (Affymetrix Human Genome U133Plus2.0) was wetted with 200μl of Pre-
hybridisation mix and incubated for 10 minutes at 45
o
C with rotation. The heated 
hybridisation cocktail was then transferred to a 45
o
C heat block for 5 minutes and then 
centrifuged to collect any insoluble material from the hybrisation mixture. The pre-
heated array was removed from the hybridisation oven and the pre-hybridisation mix 
was replaced by the clarified hybridisation cocktail. The probe array was then 
hybridised for 16 hours at 45
o
C rotating at 60rpm. The hybridised arrays were then 
analysed using the GeneChip Fluidics station 450. The approach used to analyse the 
data will be discussed in chapter 4. 
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2.10 Quantitative real-time polymerase chain reaction (QRT-PCR) 
2.10.1 High Capacity cDNA reverse transcription  
Total RNA was reverse transcribed to produce cDNA for QRT-PCR using the high 
capacity cDNA reverse transcription kit (Applied Biosystems). The workflow for this 
procedure is illustrated in Figure 2.7. The total RNA was thawed on ice and re-
quantified by RNA spectroscopy. 500-2000ng RNA was then diluted in an appropriate 
volume of RNAase free water to make up the total volume to 10μl.  A Reverse 
Transcription Master Mix was assembled (per sample): 
 10x RT Buffer        2μl 
 25x dNTP Mix (100 mM)      0.8μl 
 10x RT Random Primers      2μl 
 Multiscribe Reverse Transcriptase      1μl 
 Nuclease-free Water        4.2μl 
 Total Volume        10μl 
10μl of the Reverse Transcription Master Mix was then transferred to each 10μl total 
RNA sample. After mixing and brief centrifugation, the samples were incubated for 10 
minutes at 25
o
C, 120 minutes at 37
o
C, and then 5 minutes at 85
o
C. The cDNA placed on 
ice and then either frozen at -20
o
C or immediately used for gene expression assays. 
 
  
Figure 2.7 Overview high capacity cDNA reverse transcription kit workflow 
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2.10.2 Taqman® gene expression assays 
Applied Biosystems Taqman® Gene Expression assays were used to validate the 
changes in gene expression observed using the Affymetrix Genechip® arrays. Assays 
were chosen on the basis of whether they spanned an exon-exon junction of the 
associated genes and therefore would not detect genomic DNA (_m suffix: 
http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/PCR/ 
real-time-pcr/real-time-pcr-assays.html).  
A Taqman® Gene Expression Assay Master Mix was assembled to ensure 
consistency between samples (per sample): 
 2x Taqman® Universal PCR Master Mix (Applied Biosystems) 10μl 
 20x Taqman® Gene Expression Assay    1μl 
 RNA-ase Free Water       7-8 μl 
 Total Volume        18-19μl 
The total volume of 18-19μl was then added to each well of a MicroAmp Fast Optical 
96-well plate (Applied Biosystems) in a dedicated hood that was cleaned and UV 
decontaminated between uses. 1-2μl of cDNA template produced by the reverse 
transcription reaction was then added to make the final volume up to 20μl. Typically 
50ng of cDNA in 1μl (50ng/μl) was used. Samples were loaded in duplicate with 
GAPDH (Applied Biosystems) as an endogenous control. An example of a plate design 
used is shown in Table 2.4. 
 
R127 R127 R127 R127 R127 R127 R127 R127 R127 R127 R127 R127 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R131 R131 R131 R131 R131 R131 R131 R131 R131 R131 R131 R131 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R139 R139 R139 R139 R139 R139 R139 R139 R139 R139 R139 R139 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R144 R144 R144 R144 R144 R144 R144 R144 R144 R144 R144 R144 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R150 R150 R150 R150 R150 R150 R150 R150 R150 R150 R150 R150 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R155 R155 R155 R155 R155 R155 R155 R155 R155 R155 R155 R155 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R174 R174 R174 R174 R174 R174 R174 R174 R174 R174 R174 R174 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
R179 R179 R179 R179 R179 R179 R179 R179 R179 R179 R179 R179 
CLDN12 CLDN12 F11R F11R CTNNA CTNNA TJP2 TJP2 RND1 RND1 GAPDH GAPDH 
Table 2.4 Example of a QRT-PCR 96-well plate design with samples in duplicate 
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Plates were sealed with MicroAmp Optical Adhesive Film (Applied Biosystems) and 
pulsed to 1500rpm. Reactions were performed on an Applied Biosystems 7900HT Fast 
Real Time PCR System using the standard thermal cycler protocol (50
o
C for 2 minutes, 
95
o
C for 10 minutes, then 50 cycles of 95
o
C for 15 seconds and 60
o
C for 1 minute).  
 
2.10.3 Principle of QRT-PCR: 5’ nuclease assay 
QRT-PCR enables quantification of amplified DNA in real time. The Taqman® gene 
expression assays use sequence-specific oligonucleotide DNA probes labelled with a 
fluorescent reporter linked to the 5’ end of the probe, (typically FAM™: 6-
carboxyfluorescein) along with a minor groove binder (MGB) and non-fluorescent 
quencher (NFQ) at the 3’end of the probe. This system permits detection only after 
hybridisation of the probe with its complementary DNA target, resulting in significantly 
increased specificity. An exponential increase in the product targeted by the reporter 
probe at each PCR cycle causes a proportional increase in fluorescence due to the 
breakdown of the probe and release of the reporter (Figure 2.8).  
 
Figure 2.8 Taqman® Chemistry: Principle of the 5’ nuclease assay 
 (A) During PCR, the Taqman MGB probe anneals specifically to a complementary sequence between the 
forward and reverse primer sites. (A) and (B) When the probe is intact, the proximity of the reporter dye 
to the quencher dye results in suppression of the reporter fluorescence, primarily by Förster type energy 
transfer. (C) The DNA polymerase cleaves only probes that are hybridised to the target. Cleavage 
separates the reporter dye from the quencher dye resulting in increased fluorescence by the reporter. (D) 
Polymerisation of the strand continues, but because the 3’ end of the probe is blocked, no extension of the 
probe occurs during PCR. Adapted from Taqman® Gene Expression Assays Protocol (Applied 
Biosystems). 
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2.10.4 QRT-PCR analysis 
Initial analysis was performed using the SDS2.3 and RQ Manager1.2 software for the 
7900HT Fast Real Time PCR System (Applied Biosystems). Using this software a cycle 
threshold value (CT) was automatically calculated for each sample. This value is the 
fractional cycle number at which fluorescence from that sample exceeds background 
levels. As fluorescence reflects the relative amount of DNA present in the reaction, the 
CT value is reached more quickly (i.e. in fewer cycles) when there is a greater amount of 
target DNA in the sample. As each sample was run in duplicate, the average of the 
duplicate was taken where the standard deviation was <0.25. Where this was exceeded, 
the data was visualised. Where there was a clear outlier, this was excluded, and the CT 
value calculated from the remaining value. When it was unclear as to the true value, the 
sample was excluded for downstream analysis. The expression of each target was then 
normalised to GAPDH expression to give a ΔCT value. This was calculated by 
subtracting the mean CT value for reference gene (GAPDH) from the mean CT value of 
the target gene. Where there were paired samples (e.g. with/without drug treatment), the 
ΔCT value for the control sample was subtracted from the ΔCT value for the treated 
sample to give a ΔΔCT value. As the fluorescence doubles with each cycle during the 
exponential phase of the reaction, log base 2 of the -ΔΔCT value (2
-ΔΔCT
) gives a measure 
of the absolute differences in cDNA between reactions. Where gene expression between 
unpaired samples was being compared (e.g. healthy versus CLL), the expression of the 
target gene relative to GAPDH (2
-ΔCT
) was used. 
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2.11 Western blotting 
2.11.1 Extraction of total cell lysate 
For each protein sample at least 1 x 10
6 
of cells (5 x 10
6
 primary cells) was required to 
harvest enough total protein lysate for western blotting analysis. For western blotting 
analysis where the target protein had low expression, or for enzyme activity assays, 
significantly more primary cells (ideally 20-50 x 10
6
 primary lymphocytes) were 
required to give good results. Isolated or thawed cells were washed twice in cold (4
o
C) 
serum-free buffer. PBS was used to prepare cells for lysing for western blotting. 
However a phosphate-free buffer such as Tris-buffered saline (TBS) was used to 
prepare cells for lysing for phosphatase assays. The cell suspensions (in 1ml of buffer) 
were then transferred to a pre-cooled 1.5ml Eppendorf, and centrifuged in a pre-cooled 
centrifuge for 5 mins at 2000rpm at 4
o
C. During the centrifugation step the lysis buffer 
mixture was assembled: 
             Western Blotting   PP2A assay 
 CelLytic Cell Lysis Reagent (Sigma)    980μl  970μl 
 Protease Inhibitor Cocktail (Sigma)      10μl    10μl 
 Phosphatase Inhibitor Cocktail Set 2 (Sigma)    10μl      0μl 
 PMSF (Phenylmethylsulfonyl fluoride; Sigma)      0μl    10μl 
 DTT (Dithiothreitol; Sigma)         0μl    10μl 
Total Volume                1000μl           1000μl   
 
After centrifugation, the supernatant was removed and 30 – 120 µl lysis buffer mixture 
added (volume dependent on size of cell pellet). The cell pellet was resuspended by 
pipetting and vortexed for 10 seconds. The lysis reaction was then incubated on ice for 
15 minutes, with repeated vortexing every 5 minutes. After incubation, the extracts were 
re-vortexed before centrifuging for 10 minutes at 14000rpm at 4
o
C. The supernatant 
containing the total protein extract was then transferred into fresh pre-cooled 1.5ml 
Eppendorfs and immediately analysed for protein concentration or frozen at -80
o
C. 
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2.11.2  Determination of protein concentration (Bradford Assay) 
The Bradford Assay uses the dye Coomassie® (Brilliant Blue) G-250 to determine 
protein concentration. Coomassie® G-250 (Bio-Rad Protein Assay Dye Reagent 
Concentrate; BioRad) binds to protein forming a protein-dye complex which induces a 
change in the colour of the dye from reddish to blue, shifting the absorbance maximum 
of the dye from 465nm to 595nm. The absorption increase at 595nm is proportional to 
the protein concentration and is measured using a spectrophotometer (Bradford 1976). 
This assay uses defined BSA concentrations to produce a standard curve from which 
unknown protein concentrations can be calculated by linear regression. 100µl of 1× 
Bio-Rad reagent working solution was added to the wells of a flat bottomed 96-well 
plate using a multichannel pipette. A 0.5mg/ml BSA working solution was prepared and 
increasing volumes were added to the Bio-Rad reagent to produce a standard curve. 1µl 
of a 1:10 dilution of the sample protein lysates was then added to the Bio-Rad reagent in 
the test wells and mixed thoroughly. The protein concentration was then determined at 
595nm using an Opsy MR 96-well plate reader 
 
Example 96-well plate (triplicates): 
S1 S1 S1 X X X X X X X X X 
S2 S2 S2 X X X X X X X X X 
S3 S3 S3 X X X X X X X X X 
S4 S4 S4 X X X X X X X X X 
S5 S5 S5 X X X X X X X X X 
T1 T1 T1 X X X X X X X X X 
T2 T2 T2 X X X X X X X X X 
B1 B1 B1 X X X X X X X X X 
Standard1 = 100µl Biorad + 0µl BSA  Test1 = 100µl Biorad + 1µl Sample  
Standard2 = 100µl Biorad + 0.5µl BSA  Test2 = 100µl Biorad + 1µl Sample  
Standard3 = 100µl Biorad + 1µl BSA  Blank1 = 100µl Biorad  
Standard4 = 100µl Biorad + 2µl BSA  X = no sample 
Standard5 = 100µl Biorad + 4µl BSA 
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2.11.3 Western blotting 
Western blotting is a widely accepted technique used to detect specific proteins in cell 
lysates. It uses gel electrophoresis to separate denatured proteins by molecular weight. 
The proteins are then transferred to a polyvinylidene fluoride (PVDF) membrane, where 
they are stained with antibodies specific to the target protein. The following solutions 
were prepared: 
 
10x Tris Buffered Saline (TBS): 
 Distilled Water        1 litre 
 TRIS-HCl (Sigma)       24.2g 
 Sodium Chloride (Sigma)      80g 
 Adjust pH to 7.6        
 
1x Tris Buffered Saline-Tween (TBS-T) 
 Distilled Water       900ml 
 10x TBS        100ml 
 Tween20 (Sigma)       1ml 
 
Running buffer:  
 NUPAGE SOS running buffer (Invitrogen)    50ml 
 (MOPS for proteins > 40KDa, MES for proteins < 40KDa)   
 Distilled Water        950ml 
 
5% Milk Blocking buffer 
 TBS-T         20ml 
 Dried Milk Powder (Marvel)      1g 
 
5% BSA Blocking buffer 
 TBS-T         20ml 
 BSA (Sigma)        1g 
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The volume of cell lysate required for a constant amount of total protein (10-100µg) per 
sample was calculated and lysis buffer mixture was added to produce a fixed 
concentration/volume of protein. The samples (with equivalent amounts of total protein) 
were mixed with LDS sample buffer in a 3:1 (Sample:LDS Sample buffer) ratio. The 
samples were then denatured at 70
o
C for 10 minutes in a hot block. During this period 
the gel chamber was prepared for electrophoresis. A Nupage 4-12% Bis-Tris 10-well 
gel was used for most experiments. The white tape was stripped off from the lower end 
and top insert removed without disrupting wells. The gel was placed in the gel chamber, 
which was then filled with MOPS/MES running buffer. To visualize the molecular 
weight of the proteins, a standard containing 9 recombinant proteins ranging in size 
from 20-220 kDa was prepared (MagicMark; Invitrogen). 3μl Magic mark was added to 
22μl loading buffer, with 10μl of the resultant solution being added to the first gel 
pocket. Up to 25μl of the denatured protein samples were added to the remaining gel 
pockets. The lid of the gel cell was replaced, the electrodes were aligned and leads 
attached to the power unit. 200V of current was then applied for 40-50 minutes to allow 
the samples to run to the bottom of the gel. After the electrophoresis the gel was 
removed from the chamber and prepared for blotting. The iBlot device (Invitrogen) was 
used for this (Figure 2.9). The cassette was opened and the gel was placed on top of the 
anode, removing any excess parts of the gel. Pre-soaked filter paper was placed directly 
on top of the gel and any air bubbles removed. The cathode stack and disposable sponge 
were then applied and blotting was performed using programme P3 for 7 minutes. After 
Figure 2.9 Blotting using the iBlot Device 
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the programme had run the membrane was removed and immediately transferred to the 
blocking solution. The subsequent protocol was optimised for each antibody used. 
Typically, the membrane was then blocked for 1 hour in 5% milk blocking buffer at 
room temperature on a rocker. The membrane was then incubated overnight at 4
o
C on a 
rocker with an appropriate dilution of primary antibody (e.g. 1:1000). The membrane 
was then washed twice for 10 minutes in TBS-T. It was subsequently incubated with 
and appropriate dilution of secondary antibody (e.g. 1:2000 for Polyclonal goat anti-
rabbit; Dako) for 1 hour at room temperature on a rocker. The membrane was then 
washed three times in TBS-T for 10 minutes before preparation for chemiluminescence. 
 
The membrane was then read on a Fuji-film image reader LAS-4000 machine which 
had been pre-cooled to -30
o
C. Following washing the membrane was soaked in 1ml of 
Novex® ECL Chemiluminescence Substrate Reagent Kit (Invitrogen). This was prepared by 
mixing reagent A (luminol) and reagent B (an enhancer) in equal volumes. The 
membrane was then incubated for 2-5 minutes in the dark at room temperature, before being 
transferred to the image reader. The images were then acquired: “super binning” was used first 
to determine the quality of the membrane and to check position; the final images were 
acquired using the “high resolution” setting. After image acquisition the membrane was 
washed three times with TBS-T and could be re-probed or stored as required. For short 
term (< 1 week) storage the membrane was stored in TBS-T at 4
o
C, for longer term 
storage the membrane was dried between two sheets of Whatman paper, wrapped in 
cling film and stored at -20
o
C. 
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2.12 Phosphatase assay 
The activity of protein phosphatase 2A (PP2A) was determined using the PP2A 
Immunoprecipitation Phosphatase Assay Kit (Millipore). The kit was used according to 
the manufacturer’s instructions with a few modifications. Cell lysates were prepared as 
described above.  
 
2.12.1 Binding of anti-PP2A to beads  
An anti-PP2A monoclonal antibody (clone 1D6) was bound to beads as follows. A 
Bead Binding Mixture was assembled in a 1.5ml Eppendorf (per sample): 
 pNPP Ser/Thr Assay Buffer      300µl 
 Protein A agarose slurry           40µl 
 anti-PP2A C (200µg/200µl solution)       4µl 
 Total volume        344µl 
The resultant mixture was then incubated for 1 hour on a rotor at 4
o
C. During this time 
the sample lysates were thawed and their protein concentration determined using the 
Bradford assay as above.  
 
2.12.2 Enzyme assay 
After bead binding 100μg of total protein was added to the Bead Binding Mixture. The 
total volume was made up to 500µl using pNPP Ser/Thr Assay Buffer. The resultant 
solution was then incubated for 2 hours on rotor at 4
o
C. After incubating the beads were 
washed 3 times with 700µl TBS, followed by one wash with 500µl Ser/Thr Assay 
buffer. A 1mM solution of Threonine Phosphopeptide was prepared by adding 1.1ml 
distilled water to the 1mg peptide supplied. 60µl of this diluted phosphopeptide was 
then added to each sample along with 20µl Ser/Thr Assay buffer. The reaction was then 
incubated for 10 minutes at 30
o
C in a waterbath with continuous agitation before being 
placed back on ice. The Malachite Green Phosphate Detection Solution was prepared by 
adding 10µl of Solution B to each 1ml of Solution A provided in the kit. 100µl of this 
solution was then added to the wells of flat-bottomed 96-well plate. A phosphate 
standard was prepared by diluting 125µl of phosphate standard solution C with 1125µl 
of distilled water to make a 0.1mM working solution. This was used to prepare a 
phosphate standard curve as shown in Table 2.5. 25μl of the standards and samples 
were added to each of the wells (samples prepared in triplicate) which were then read at 
630nm using an Opsy MR 96-well plate reader to determine phosphate concentration. 
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Volume of diluted 
stock (0.1mM) 
200µl 160µl 120µl 80µl 40µl 0µl 
Volume of 
distilled water 
50µl 90µl 130µl 170µl 210µl 250µl 
Picomoles of 
phosphate/ 25µl 
2000 1600 1200 800 400 0 
Table 2.5 Preparation of phosphate standard curve for phosphatase assay 
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2.13 Cell conjugation assays and confocal microscopy 
Confocal microscopy was used to assess the cellular localisation of target proteins, and 
to evaluate immunological synapse formation.  
 
2.13.1 Cell conjugation assays 
T and B cells were isolated as previously described. Where thawed cells were used, 
these were “rested” in full medium for 1-2 hours or overnight as required. Healthy B 
cells or CLL cells (1.5 × 10
6
 cells) were washed in serum-free medium and then stained 
with 7-amino-4-chloromethylcoumarin CellTracker Blue for 30 minutes at 37°C. They 
were subsequently incubated in full medium for a further 30 minutes at 37°C, with or 
without 2μg/ml of staphylococcal superantigen cocktail (Sigma).  After washing the 
cells were then centrifuged with an equal number of T cells at 1500rpm for 5 minutes to 
allow a cell pellet to form. The resultant cell conjugates were then incubated at 37°C for 
10-15 minutes, gently resuspended, and then transferred onto and Poly-l-lysine coated 
glass slides using a cytofuge (Statspin).  
 
2.13.2 Staining for confocal microscopy 
After transfer to the slides the cells were fixed in 3% methanol-free formaldehyde in 
PBS (TAAB Laboratories Equipment Ltd) for 15 minutes. The cells were then washed 3 
times in PBS, and then permeabilised in 0.3% tritonx100 (Sigma) in PBS for 5 minutes. 
The cells were then washed a further 3 times in PBS, before being blocked with 0.1% 
BSA (Miltenyi Biotec)/PBS blocking solution for 10 minutes. If primary antibodies 
were being used, the cells were incubated with the relevant antibody diluted in goat 
serum buffer (Sigma) for 45 minutes at 4
o
C. The cells were then rewashed 3 times in 
PBS. A secondary staining solution was prepared with a 1:40 dilution of rhodamine 
phalloidin (Invitrogen) in goat serum buffer and appropriate secondary antibody if 
required (e.g. Alexa 488 anti-mouse IgG 1:500 dilution; Invitrogen). The cells were 
then incubated for a further 20 minutes at 4
o
C in the dark. The cytofuge unit was then 
disassembled and the slides mounted with coverslips with fluorescent mounting 
medium (DAKO). Confocal microscopy was performed using a Zeiss LSM510 confocal 
laser-scanning microscope using a 63x objective. Images were acquired from the slides 
in a consistent manner: a minimum of 10 images /50 cell conjugates were acquired per 
condition.  
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2.14 Mass spectrometry 
As several pharmacological agents used during the course of this project, mass 
spectrometric analysis was frequently performed to confirm drug stability and quantity. 
The stock solution of the agent under investigation was diluted as required (usually 1 in 
1000) in 30% acetonitrile solution containing 0.1% formic acid in LC-MS grade water 
(all from Fisher Scientific). The diluted solution was infused into the mass spectrometer 
directly using 500µl Hamilton Syringe (Sigma-Aldrich, UK) at flow rate of 5µl/min into 
the triple stage quadrupole (TSQ) Vantage mass spectrometry system (Thermo 
Scientific, UK) equipped with a heated electrospray ion source. All experiments were 
carried out in positive ionization mode. Spray voltage was set at 3500 volts; sheath gas 
(nitrogen) flow rate was 20 arbitrary units. Argon was used as collision gas with 
pressure of 1.5 mTorr. The predicted molecular weight of the compound under 
investigation was used to find candidate molecules. These were then fragmented to 
establish a breakdown curve: the mass transitions could be used to confirm the identity 
of the parent compound. The ion count of the parent compound or principle fragment 
was compared with a freshly reconstituted standard for assessing drug stability. Data 
were acquired using Thermo Xcalibur software (version 2.1). 
  
 
(A) Mass spectrogram showing the presence of a parent compound with a mass of 260 with a high ion 
count of 1.5 x 10
7
. (B) When fragmented, this compound had a principle fragment with a mass of 149.1 
consistent with the principle transition of lenalidomide (Liu et al. 2008). 
Figure 2.10 Mass spectrogram of 10μM lenalidomide in DMSO 
A B 
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3 Chapter 3: Characterisation of T cells from CLL patients 
 
3.1 Introduction 
CLL is associated with profound defects in T-cell function, resulting in failure of anti-
tumour immunity and increased susceptibility to infections. Despite this, it has been 
known for some time that there is actually an increase in absolute numbers of T cells in 
the peripheral blood in CLL, which is primarily accounted for by an increase in CD8
+
 T 
cells, resulting in a fall in the CD4:CD8 ratio (Catovsky et al. 1974; Lauria et al. 1980; 
Herrmann et al. 1982; Mills et al. 1982; Platsoucas et al. 1982). A number of studies 
have linked these changes to prognosis, with early work demonstrating that there was 
greater expansion of CD8
+
 T cells with advancing Rai stage (Herrmann et al. 1982), 
with a more recent study showing that inverted CD4:CD8 ratios predict shorter time to 
first treatment and reduced progression-free survival (Nunes et al. 2012). Another 
important feature of these T cells is that they show evidence of chronic activation, with 
upregulation of markers of activation such as CD69, HLA-DR and CD57, and down-
regulation of CD28 and CD62L (Velardi et al. 1985; Rossi et al. 1996; Van den Hove et 
al. 1998; Van den Hove et al. 1998). This expansion of activated T cells has also been 
observed in the Eμ-Tcl1 mouse model of CLL, where a skewing of T-cell subsets 
towards antigen-experienced memory T cells, and development of clonal T-cell 
populations have been reported (Hofbauer et al. 2011).  
 
An expansion of activated CD8
+
 T cells in the peripheral blood is seen as part of the 
normal immune response to acute viral infections. During a primary immune response 
to viruses, naïve CD8
+
 T cells expressing TCRs specific for viral peptides clonally 
expand and differentiate into effector CD8
+
 T cells that control the primary infection. 
These effector T cells are then able to destroy any virally infected cells through the 
targeted secretion of perforin and granzyme from lytic vesicles. After the primary 
infection is cleared there is a contraction phase when most of these effector CD8
+
 T 
cells die by apoptosis. However an effective immune response also produces a stable 
population of long lived memory CD8
+ 
T cells that can respond rapidly to clear 
secondary infections. These memory CD8
+ 
T cells are maintained in the absence of 
antigen by interactions with homeostatic cytokines such as IL7 and IL15, that mediate 
survival and self-renewal signals (Cui and Kaech 2010). 
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However some viruses, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and 
human immunodeficiency virus (HIV) in humans, and lymphocytic choriomeningitis 
virus (LCMV) in mice, have evolved mechanisms enabling them to evade effector 
immune responses. This leads to failure of immune responses to clear these viral 
infections, and persistence of viral antigens beyond the effector phase. This continued 
presence of antigen drives ongoing replication of effector T cells, leading to a number 
of phenotypic and functional changes that have been termed T-cell “exhaustion”. In 
particular, there is a hierarchical loss of effector CD8
+
 T-cell function, resulting in loss 
of proliferative capacity, impaired cytotoxicity, and reduced cytokine production. This 
is associated with increased expression of inhibitory receptors such as PD1, CD160 and 
CD244, and increased expression of transcription factors implicated in promoting 
exhaustion such as BLIMP1 and eomesodermin (Wherry 2011). Notably, gene 
expression profiling of exhausted CD8
+
 T cells reveals a distinct transcriptional state 
with down-regulation of cytoskeletal genes leading to impaired immunological synapse 
formation and vesicle trafficking (Thoulouze et al. 2006; Wherry et al. 2007). We noted 
similarities in these changes to the alterations in gene expression that my group has 
previously observed in CD8
+ 
T cells in CLL patients (Gorgun et al. 2005). 
 
One of the concepts in CLL that has emerged over the last few years is that chronic 
antigenic drive plays a key role in the pathogenesis of this disease. Observations such as 
the presence of stereotyped B-cell receptors, the importance of prognostic markers 
associated with BCR-signalling, and the success of therapies targeting BCR-signalling 
have highlighted the importance of chronic antigenic stimulation in driving the disease 
(Hamblin et al. 1999; Rosen et al. 2010). Therefore it would be reasonable to speculate 
that this continued antigenic drive could also result in persistent T-cell stimulation and 
activation. In light of this, it was hypothesized that the presence of an expanded 
population of activated CD8
+
 T cells in the peripheral blood of CLL patients is a 
consequence of chronic antigenic stimulation of the T-cells compartment. Furthermore, 
it was also hypothesized that the functional defects represent a state analogous to the T-
cell exhaustion that has observed in the context of chronic viral infections. Importantly, 
T-cell exhaustion has recently been reported in haematological malignancies, including 
adult T-cell leukaemia/lymphoma, chronic myeloid leukeamia, and acute myeloid 
leukaemia (Kozako et al. 2009; Mumprecht et al. 2009; Zhou et al. 2011). 
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However, a major potential confounding factor is previous cytomegalovirus (CMV) 
infection. CMV is known to have a profound influence on distribution of lymphocyte 
subsets in healthy individuals, with CMV seropositivity associated with driving the T-
cell repertoire towards greater clonality in the elderly (Khan et al. 2002; Chidrawar et 
al. 2009). Subsequent reports have demonstrated an expansion of CMV-specific CD4+ 
and CD8+ T cells in patients with CLL, that have an effector phenotype (Mackus et al. 
2003; Pourgheysari et al. 2010; Walton et al. 2010).  It is therefore possible that the 
expansion of activated CD8+ T cells in the peripheral blood of CLL patients merely 
represents an immune response to CMV. As CMV is a chronic viral infection, it was 
crucial to control for this factor when testing the hypothesis that CLL T cells are 
“exhausted”. 
 
 
3.2 Aims and objectives 
The primary aim of this work was to characterise T cells from patients with CLL and 
test the hypothesis that they are phenotypically and functionally “exhausted”. The 
secondary aim was to assess the impact of CMV-serostatus on the function of T cells 
from CLL patients. 
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3.3 Materials and Methods 
 
3.3.1 Patients and Samples 
Peripheral blood samples were obtained from 39 CLL patients from the tissue bank 
maintained by the Department of Haemato-Oncology of St. Bartholomew’s Hospital, 
London, United Kingdom. Ethical approval was confirmed by the East London & The 
City Health Authority Local Research Ethics Committee, and written informed consent 
was obtained in accordance with the Declaration of Helsinki. All of the patients were 
untreated at time of blood withdrawal, and had a median age of 59 years (range 43 – 
86). The patients had predominantly early stage CLL with 31/39 (79.5%) classed as 
having Binet stage A disease. Peripheral blood samples were also obtained from a 
control group of 20 healthy volunteers, who were age-matched with a median age of 61 
years (range 49–72). The CMV serostatus of patients and healthy donors was 
determined by the Virology Department at the Royal London Hospital. 22/39 (56%) of 
patients and 13/20 (65%) of healthy donors were found to be CMV+.  
 
3.3.2 Monoclonal antibodies 
The following directly conjugated monoclonal antibodies were used in this study: CD3-
Pacific Blue, CD3-PECy7, CD4-PECy7, CD4-eFluor780, CD8-PerCPCy5.5, CD107a-
AlexaFluor647, CD127-FITC, CD160-AlexaFluor647, CD197-PE, CD197-APC, 
CD244-PE, CD244-APC, TBET-PE, IFNγ-FITC, CTLA4-PE, TIM3-APC were all 
obtained from eBioscience. CD19-AlexaFluor700, CD45RA-FITC, CD122-PE, PD1-
FITC, PD1-APC, IL2-PE, IL4-PE, TNFα-FITC were all obtained from BD Biosciences; 
Blimp1-PE was obtained from Santa-Cruz Biotec; LAG3-APC was obtained from R&D 
Systems. For confocal microscopy, unconjugated primary antibodies specific for 
CD107a and Granzyme B were from Abcam, and Alexa Fluor 488 and 647-labeled goat 
anti-mouse IgG were from Life Technologies. 
  
3.3.3 Isolation of PBMCs and lymphocyte subsets 
Peripheral blood samples were diluted 1:1 with PBS prior to separation of PBMCs by 
density gradient centrifugation as described in section 2.4. CD8
+
 T cells were negatively 
selected using the CD8
+
 T cell Isolation Kit (Miltenyi Biotec) using the AutoMACS Pro 
as described in section 2.5.3. 
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3.3.4 Immunofluorescence staining and flow cytometric analysis  
Surface and intracellular staining for flow cytometric analysis was performed as 
described in section 2.7. Flow cytometry was performed on a BD Fortessa flow 
cytometer with subsequent analysis using FlowJo software (Tree Star). Analysis was 
performed on a minimum of 10,000 T-cell events after gating on live singlet cells.  
 
3.3.5 T-cell stimulation  
For assessment of cytokine production, cells were stimulated with 50ng/ml phorbol 
myristate acetate (PMA) and 1µM ionomycin (Sigma). For assessment of degranulation, 
cells were stimulated with 1µg/ml staphylococcal enterotoxin B (SEB)(Sigma) with the 
addition of 10µl/ml anti-CD107a-AlexaFluor647.(Betts et al. 2003) For both 
experiments the cell cultures were incubated for 1 hour prior to addition of 0.66 µl/ml 
Golgistop (BD), before 4 hours further incubation at 37
o
C; 5% CO2. For assessment of 
proliferation, 1x10
7
cells/ml were washed and stained with 5µM carboxyfluorescein 
succinimidyl ester (CFSE, eBioscience) for 10 minutes at 37
o
C. After quenching and 
further washing, the cells were stimulated with 1µg/ml soluble anti-CD3 (clone HIT3a, 
BD) and 5µg/ml soluble anti-CD28 (clone CD28.2, eBioscience) for 72 hours.  
 
3.3.6 Cytotoxicity assay 
Cytotoxicity assays were performed with Dr Alan Ramsay and Mrs Rewas Fatah. HLA-
A*0201–expressing CD8+ cells were stimulated in vitro with dendritic cells pulsed with 
a CLL IgVH-derived peptide TLYLQMNSL weekly for 4 weeks, and killing of peptide-
pulsed H2 cells was assessed. Target cells were labelled with 100μCi 51Cr (3.7MBq; 
NEN) and seeded in 96-well U-bottom microtiter plates at a concentration of 2.5 × 
10
3
/ml in triplicates. Effector cells were added in a ratio of 1:3, 1:10, and 1:30 and co-
cultured for 4 hours at 37°C; 5% CO2. After 4 hours the supernatants were harvested 
and the released 
51Cr was measured in a γ-Counter (Wallac). Spontaneous release was 
determined by incubation of treated target cells in medium alone and maximum release 
was determined by resuspending the wells with 2% Triton X-100. Specific lysis was 
determined as previously described (Ramsay et al. 2008). 
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3.3.7 Cell conjugation assays and confocal microscopy 
Cell conjugation assays and confocal microscopy were performed with Dr Alan Ramsay 
and Mrs Rewas Fatah. Healthy B cells or CLL cells (1 × 10
6
 cells) were stained with 7-
amino-4-chloromethylcoumarin CellTracker Blue and pulsed with 2μg/ml of 
staphylococcal superantigen cocktail (Sigma) for 30 minutes at 37°C. B cells were 
centrifuged with an equal number of CD8
+
 T cells and incubated at 37°C for 10 
minutes, plated onto poly-L-lysine–coated slides, and fixed for 15 minutes at room 
temperature with 3% formaldehyde. After fixation, the cells were permeabilised in 0.3% 
Triton (Sigma) for 5 min and blocked with 0.1% Bovine serum albumin (Miltenyi 
Biotec) in PBS for 10 minutes. Primary and secondary antibodies were applied 
sequentially for 30 minutes at 4°C in 5% goat serum (Sigma). Filamentous actin (F-
actin) was stained with rhodamine phalloidin (Invitrogen). Confocal microscopy was 
performed using a Zeiss LSM510 confocal laser-scanning microscope using a 63x 
objective.  
 
3.3.8 Statistical analysis 
All data sets were subject to normality testing using the Shapiro-Wilk normality test. 
Where all data sets could be accurately modelled by a Gaussian distribution an unpaired 
t test was used for analysis of differences between groups; where this was not the case 
the 2-sided Mann Witney U test was used. For comparison of 4 groups the Kruskal-
Wallis test was used with Dunn’s post test for multiple comparisons. P values of less 
than 0.05 were considered statistically significant. 
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3.4 Results 
 
3.4.1 Increased numbers of CD3+CD8+ and CD3+CD4+ T cells in the peripheral 
blood of patients with CLL 
Initial immunophenotyping showed an increase in absolute numbers of CD3
+
CD8
+
 (and 
CD3
+
CD4
+ 
T cells circulating in the peripheral blood of patients with CLL compared to 
age-matched healthy controls. The expansion of CD3
+
CD8
+ 
T cells (P = 0.0004) was 
greater than the expansion of CD3
+
CD4+ T cells (P = 0.0036), resulting a fall in the 
CD4:CD8 ratio consistent with previous reports (P = 0.021)(Catovsky et al. 1974; 
Lauria et al. 1980; Herrmann et al. 1982; Mills et al. 1982; Platsoucas et al. 
1982)(Figure 3.1).  
 
Figure 3.1 Increased numbers of CD8
+
 and CD4
+ 
T cells in the peripheral blood of 
patients with CLL 
Absolute numbers of CD3
+
CD8
+
 and CD3
+
CD4
+
 T cells were measured in the peripheral blood of 
patients with CLL. CLL patients had increased absolute numbers of both CD3
+
CD8
+
 T cells (A) and 
CD3
+
CD4
+
 T cells (B) compared to health controls. (C) The expansion of CD3
+
CD8
+
 T cells was greater, 
resulting in a fall in the CD4:CD8 ratio. 
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3.4.2 Increased expression of PD1, CD160 and CD244 on T cells from CLL patients  
Increased expression of CD160, CD244 and PD1 are key features of T-cell exhaustion 
(Wherry 2011). These molecules can act as negative regulators of lymphocyte activation 
when bound by their respective ligands, herpes virus entry mediator (HVEM), CD48, 
and programmed death ligand-1 (PDL1)(Freeman et al. 2000; Cai et al. 2008; 
Blackburn et al. 2009). Immunophenotyping of peripheral blood CD3
+
 T cells from 
patients with CLL was compared with healthy controls, to determine whether they 
expressed these exhaustion markers. Compared with controls, there was a significant 
increase in both the percentage and absolute numbers of both CD4
+
 and CD8
+
T cells 
from CLL patients expressing CD244, CD160 and PD1 (Figures 3.2 and 3.3).  
 
Figure 3.2 Increased expression of PD1, CD160 and CD244 on CD3
+
CD8
+
 T cells 
from patients with CLL 
The expression of (A) CD244, (B) CD160 and (C) PD1 were assessed on CD8
+
 T cells from patients with 
CLL and healthy age-matched controls. Significant increases in both the proportion, and the absolute 
number, of T cells expressing these molecules were observed. 
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Figure 3.3 Increased expression of PD1, CD160 and CD244 on CD3
+
CD4
+
 T cells 
from patients with CLL 
The expression PD1, CD160, and CD244 on CD4
+
 T cells from patients with CLL and healthy age-
matched controls was measured by flow cytometry . There was a significant increase in numbers of PD1+ 
(A) and CD160+ (B) and CD244+ (C) CD3
+
CD4
+
 T cells in CLL patients compared to healthy controls. 
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3.4.3 Expansion of PD1+BLIMP1HI T cells in the peripheral blood of CLL patients 
B-lymphocyte induced maturation protein 1 (BLIMP1) has been shown to be important 
in driving CD8
+
 T cell exhaustion in chronic viral infections (Shin et al. 2009). 
Expression of PD1 identified a subset of T cells with high expression of BLIMP1 
(PD1
+
BLIMP1
HI
), that were expanded in both the CD3
+
CD8
+
 (P < 0.0001) and 
CD3
+
CD4
+
 (P < 0.0001) compartments in CLL (Figure 3.4). In contrast, expression of 
CD160 and CD244 did not identify subsets of T cells with upregulation of BLIMP1. 
(A) Flow cytometric dot plots showing the presence of PD1
+
BLIMP1
HI 
T cells in CLL patients.  
(B) CD3
+
CD8
+
PD1
+
BLIMP1
HI
 and (C) CD3
+
CD4
+
PD1
+
BLIMP1
HI
 cells are expanded in CLL patients. 
 
 
 
 
 
 
  
Figure 3.4 Expansion of PD1
+
BLIMP1
HI
 T cells in the peripheral blood of CLL 
patients 
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3.4.4 Expression of CD127 (IL-7R) on T cells from CLL patients 
A further feature of exhausted T cells in many chronic viral infections is down-
regulation of CD127 (IL-7R), as the T cells lose responsiveness to homeostatic 
cytokines and become dependent on antigen for continued survival (Paiardini et al. 
2005; Radziewicz et al. 2007). There was a not statistically significant trend to 
decreased expression of CD127 on CLL CD8
+
 T cells compared to healthy controls (P = 
0.079). However, there was a significant decrease in the expression of CD127 on CLL 
CD4
+
 T cells (P = 0.012)(Figure 3.5). 
Expression of CD127 (IL-7R) on CD3
+
CD8
+
 T cells (A) and CD3
+
CD4
+
 T cells (B). 
 
 
 
 
 
 
 
  
Figure 3.5 Expression of CD127 on T cells from CLL patients 
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3.4.5 CD8+ T cells from patients with CLL show functional defects in proliferation  
T cell exhaustion also results in progressive loss of T-cell function, including loss of 
proliferative and cytotoxic capacity (Wherry 2011). Therefore, the ability of T cells 
from CLL patients and controls to proliferate in response to 72 hours of anti-CD3/anti-
CD28 stimulation was assessed using a CFSE based assay (Lyons and Parish 1994). 
The proliferation index of both CD3
+
CD8
+
 and CD3
+
CD4
+
 T cells from CLL patients 
was significantly lower than healthy controls (both: P < 0.0001)(Figure 3.6). There was 
also a reduction in the proportion of CD3
+
CD8
+
 T cells that had entered cell division, 
but no significant difference when comparing healthy and CLL CD3
+
CD4
+
 T cells. This 
suggests that the proliferative defect seen in CLL T cells is due to a combination of a 
reduction in the proportion of cells able to divide upon polyclonal activation, and 
prolongation of the division time of the proliferating cells. 
 
Figure 3.6 T cells from CLL patients show functional defects in proliferation 
The proliferative potential of T cells from CLL patients and healthy controls was assessed using a CFSE 
based assay. Representative histograms are shown of (A) a healthy donor and (B) a CLL patient. (C) The 
proliferation index was significantly lower for CD3
+
CD8
+
 T cells from CLL patients when compared with 
healthy controls. (D) There was also a reduction in the proliferation index for CD3
+
CD4
+
 T cells from 
CLL patients when compared with healthy controls.  
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3.4.6 CD8+ T cells from patients with CLL show functional defects in cytotoxicity  
Another feature of functional T-cell exhaustion is impairment of ex vivo target cell 
killing (Wherry et al. 2003). Therefore, the ability of CD8
+
 T cells from CLL patients 
and healthy donors to lyse idiotype-pulsed target cells was assessed by a 
51
chromium 
release assay. In keeping with previous observations by my group, there was impaired 
ability to induce idiotype-specific CD8
+
 T cells capable of killing idiotype-pulsed target 
cells compared to healthy donors (Krackhardt et al. 2002; Ramsay et al. 2008). This 
defect in target cell lysis was observed at all effector:target cell ratios. (P < 0.0001 at 
effector:target ratio of 30:1)(Figure 3.7).  
 
Figure 3.7 CD8
+ 
T cells from CLL patients show functional defects in cytotoxicity 
The cytotoxic activity of CD8
+
 T cells from patients and controls was assessed. CD8
+
 T cells from CLL 
patients fail to lyse idiotype pulsed target cells in contrast to CD8
+
 T cells from healthy controls: % 
specific lysis at all effector target ratios (A), and at a effector-target ratio of 30:1 (B). Data generated in 
conjunction with Professor John Gribben and Dr Alan Ramsay. 
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3.4.7 T cells from CLL patients retain the capacity for cytokine secretion 
A further feature of functional T-cell exhaustion during chronic viral infections is 
failure to produce effector cytokines. This happens in a hierarchical manner, with the 
ability to produce IL2 being lost at early stages of exhaustion, followed by loss of TNFα 
production and finally IFNγ (Shin and Wherry 2007). Therefore cytokine production 
after stimulation with PMA and ionomycin was analysed. In contrast to the pattern 
observed in chronic viral infections, CD3
+
CD8
+
 T cells from CLL patients had 
increased production of IFNγ (P < 0.0001) and TNFα (P = 0.033) without any reduction 
in IL2 production (P = 0.29) when compared with healthy controls. CD3
+
CD4
+
 T cells 
from CLL patients also showed increased production of IFNγ (P = 0.0089), along with 
increased IL2 (P = 0.015), and no reduction in TNFα production (P = 0.20)(Figure 3.8). 
Figure 3.8 Comparison of cytokine production by CD8
+
 and CD4
+ 
T cells 
from CLL patients and healthy controls 
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3.4.8 T cells from CLL patients have increased expression of TBET 
The transcription factor TBET plays a crucial role in T-cell development, acting as a 
master controller of Th1/Tc1 differentiation (Szabo et al. 2000). Given the higher 
production of IFNγ by both CD8+ and CD4+ T cells from CLL patients, it was 
postulated that they would have increased expression of TBET consistent being 
Th1/Tc1 differentiated. When TBET expression was assessed, both CD3
+
CD8
+
 T cells 
(P = 0.0002) and CD3
+
CD4
+
 T cells (P < 0.0001) had significantly higher expression 
than healthy T cells, providing support for this hypothesis. 
 
 
  
Figure 3.9 T cells from CLL patients have increased expression of TBET 
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3.4.9 CCR7- effector T cells are increased in CLL 
Previous studies have shown skewing of the T-cell compartment towards activated T-
cell subsets, in both CLL patients and in the Eµ-TCL1 mouse model.(Van den Hove et 
al. 1998; Hofbauer et al. 2011) Expression of C-C chemokine receptor type 7 (CCR7), a 
chemokine receptor that controls homing to secondary lymphoid organs, divides human 
memory T cells into two functionally distinct subsets. CCR7
-
 cells express receptors for 
migration to inflamed tissues and display immediate effector function, whereas CCR7
+
 
cells express lymph-node homing receptors and lack immediate effector function, but 
efficiently stimulate dendritic cells and differentiate into CCR7
-
 effector cells upon 
secondary stimulation (Sallusto et al. 1999). In light of this the balance between the 
CCR7
+
 and CCR7
-
 subtypes was investigated. When compared with healthy controls, 
there was both a greater proportion and increased numbers of CD3
+
CD8
+
CCR7
-
 (P = 
0.0043) and CD3
+
CD4
+
CCR7
-
 (P < 0.0001) T cells in CLL patients (Figure 3.10). 
 
Figure 3.10 CCR7
-
 effector T cells are increased in CLL patients 
The expression of the chemokine receptor CCR7 was assessed. (A) & (B) CLL patients had an increased 
proportion and increased numbers of CD3
+
CD8
+
CCR7
-
 T cells. (C) & (D) Similarly, CLL patients had an 
increased proportion and increased numbers of CD3
+
CD4
+
CCR7
-
 T cells. 
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3.4.10 The observed phenotypic and functional changes in T cells from CLL patients 
reflect the skew towards CCR7
-
 effector subsets 
T cells can be further subdivided based on their expression of CD45RA, and defined as 
naïve (CCR7
+
CD45RA
+
), central memory (TCM: CCR7
+
CD45RA
-
), and effector 
memory (TEM: CCR7
-
CD45RA
-
). Within the CD3
+
CD8
+
 TEM subtype, there is also a 
subset that re-expresses CD45RA, termed TEMRA-cells; this subset is rare within the 
CD3
+
CD4
+
 compartment (Sallusto et al. 2004). TEMRA cells have many similarities to 
exhausted T cells, in that they show reduced expression of co-stimulatory molecules 
such as CD28, reduced proliferative capacity, and an increased tendency to undergo 
apoptosis (Geginat et al. 2003). Therefore the phenotypic and functional parameters 
described above were correlated with the different CD3
+
CD8
+
T cell subsets as defined 
by their expression of CCR7 and CD45RA (Figure 3.11; summarised in Table 3.2). 
TEMRA cells showed many features consistent with exhaustion, with the highest 
expression of CD160, CD244 and TBET, the lowest expression of CD28, the lowest 
proliferative capacity, and loss of IL2 production. Notably however, CCR7
-
CD45RA
-
 
TEM cells had the highest expression of PD1. These results indicate that the phenotypic 
and functional changes in T cells from CLL patients reflect the skew towards CCR7
-
 
antigen experienced effector subsets.  
 
Table 3.1 Summary of phenotypic and function parameters by CD3
+
CD8
+ 
T subset 
Subset Naïve 
CCR7
+
CD45RA
+
 
Central Memory 
CCR7
+
CD45RA
-
 
Effector Memory 
CCR7
-
CD45RA
-
 
TEMRA  
CCR7
-
CD45RA
+
 
PD1  
expression 
Low Low High Moderate 
CD160 
expression 
Low Low Moderate High 
CD244 
expression 
Low Low Moderate High 
CD28  
expression 
High High Moderate Low 
TBET  
expression 
Low Low Moderate High 
EOMES  
expression 
Low Low High High 
IFNγ  
production 
Low Moderate High High 
IL2  
production 
Low High Moderate-High Moderate 
TNFα 
production 
Low High High Moderate-High 
Proliferative 
capacity 
High High Moderate Low 
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 (A) Within the CD3
+
CD8
+
 compartment all 4 subsets were observed. (B) In comparison CCR7
-
CD45RA
+
 cells were rarely seen in the CD3
+
CD4
+
 compartment. (C) Expression of PD1 was highest on 
TEM cells. (D)&(E) In contrast, expression of CD160 and CD244 was increased on TEM cells, but was 
highest on TEMRA cells. (F) Expression of CD28 was decreased on TEM cells, but was lowest on TEMRA 
cells. (G) The proliferative capacity of TEM cells was reduced, but TEMRA cells had the lowest capacity to 
proliferate. (H) Flow cytometric dot plot showing the relative reduction in proliferative capacity (CFSE 
dye dilution) of CD3
+
CD8
+
CCR7
-
 T cells compared to CD3
+
CD8
+
CCR7
+
 T cells. 
Figure 3.11 Phenotypic and functional parameters by CD3
+
CD8
+
 subsets 
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Figure 3.11 (continued) 
The expression of TBET and the production of IFNγ, TNFα, and IL2 by CD3+CD8+ T-cell subsets from 
CLL patients was analysed. (I) The expression of TBET was increased in TEM cells, with the highest 
expression levels in the TEMRA subset. (J) – (L) TEMRA cells had high production of IFNγ, slightly reduced 
production of TNFα, and substantially reduced production of IL2.  
  
John Riches Chapter 3: Characterisation of T cells from CLL patients 
137 
 
3.4.11 CD8+ T cells from CLL patients have increased expression of eomesodermin 
Eomesodermin (Eomes) is a second transcription factor implicated in both effector 
differentiation and T-cell exhaustion. Eomes has been shown to be upregulated in 
exhausted CD8
+ 
T cells, with Eomes-expressing cells having higher expression of 
Blimp-1 and several inhibitory receptors including PD1 (Paley et al. 2012). Therefore, 
the expression of Eomes in T cells from healthy donors and CLL patients was assessed. 
CD3
+
CD8
+
 T cells from CLL patients had significantly higher expression of Eomes 
than healthy CD3
+
CD8
+
 T cells (P = 0.0061), whereas there was no difference in the 
CD3
+
CD4
+
 compartment. The expression of Eomes was also assessed in the various 
CD3
+
CD8
+
T cell subsets as defined by expression of CCR7 and CD45RA. Expression 
of Eomes was confined to the CCR7
-
 subsets, TEM and TEMRA (Figure 3.12).  
 
Figure 3.12 CD8
+ 
T cells from CLL patients have increased expression of Eomes 
The expression of Eomes was compared in healthy and CLL T cells. (A CD3
+
CD8
+
 T cells from CLL 
patients had significantly higher expression of Eomes than healthy T cells. (B) No difference was 
observed when comparing healthy and CLL CD3
+
CD4
+
 T cells. (C) & (D) Expression of Eomes was 
largely confined to CCR7
-
 effector subsets.  
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3.4.12 The impact of CMV serostatus on expression of CD244, CD160, and PD1 
CMV seropositivity is known to have a profound influence on the major lymphoid 
subsets in healthy individuals, with expanded populations of CMV specific CD4
+
 and 
CD8
+
 T cells reported in CMV+ CLL patients (Khan et al. 2002; Mackus et al. 2003; 
Chidrawar et al. 2009; Pourgheysari et al. 2010). Since T-cell exhaustion has been 
extensively described in chronic viral infections, it was important to assess the effect of 
this in CLL. Expression of CD244 and CD160 was increased on CD3
+
CD8
+
 T cells 
from CLL patients compared to healthy controls irrespective of CMV-serostatus. In 
contrast, PD1 expression was increased on CLL CD3
+
CD8
+
 T cells only when 
comparing CMV- individuals (P = 0.002). The increased expression of CD244, CD160, 
and PD1 seen in CLL patients again reflected the skew towards CD3
+
CD8
+
CCR7
-
 
effector cells, which were expanded in CLL patients irrespective of CMV-serostatus. 
Qualitatively similar findings were observed in the CD3
+
CD4
+
 compartment, although 
the expression of CD244, CD160, and PD1 was considerably lower CD3
+
CD4
+
 T cells, 
and the differences were not always statistically significant. One important area where 
the expression of these molecules did differ when comparing CD3
+
CD8
+
 and 
CD3
+
CD4
+
 T cells, was that expression of PD1 was increased on CD3
+
CD4
+
 T cells 
from CLL patients irrespective of CMV serostatus (Figure 3.13). 
 
To examine these findings in more detail, the proportion of naïve, TCM, TEM and TEMRA 
cells was compared in CLL patients and controls separately for CMV+ and CMV- 
individuals. Importantly, CMV serostatus affected the balance of the TEM/TEMRA 
subsets, with CMV seropositivity skewing CD8
+
 T-cell differentiation from a naïve to a 
TEMRA phenotype in both patients and healthy controls. In contrast, in CMV- CLL 
patients, the increased proportion of CD8
+
CCR7
-
 effector cells primarily reflected an 
expansion of TEM cells. These alterations in the distribution of lymphocyte subsets 
account for the observation that PD1 expression was only significantly increased in 
CMV- CLL patients, as the expanded TEM cells seen in these patients had increased 
expression of PD1. In contrast, in CMV+ CLL patients there was no global increase in 
PD1 expression, since there was expansion of TEMRA cells that have lower expression of 
PD1. Expression of PD1 was increased on CD3
+
CD4
+
 T cells from CLL patients 
irrespective of CMV serostatus, as the equivalent TEMRA subset is not present in the 
CD3
+
CD4
+
 compartment as described above (Figure 3.14). 
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Figure 3.13 The impact of CMV serostatus on T-cell phenotype 
Significant increases in the expression of CD244 (A) and CD160 (B) on CLL CD3
+
CD8
+
 T cells were 
observed independently of CMV serostatus. (C) In contrast, expression of PD1 was only increased when 
comparing CMV- patients and controls. (D) CD3
+
CD8
+
CCR7
-
 cells are expanded in CLL irrespective of 
CMV serostatus. (E) & (F) Similar differences in the expression of CD244 and CD160 were noted on 
CD3
+
CD4
+
 T cells although the level of expression was considerably lower. (G) In contrast, expression of 
PD1 CD3
+
CD4
+
 T cells was increased in CLL patients irrespective of CMV- serostatus. (H) 
CD3
+
CD4
+
CCR7
-
 cells are expanded when comparing CMV- patients and controls. 
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Figure 3.14 CLL skews the CD3
+
CD8
+
 T cell repertoire towards a CCR7
-
CD45RA
-
 
effector memory phenotype, whereas the presence of CMV leads to an expansion 
of CCR7
-
CD45RA
+
 TEMRA subtype 
CLL patients and healthy CMV+ individuals had a reduction in CCR7
+
CD45RA
+
 naive (A) and 
CCR7
+
CD45RA
-
 central memory T-cell (B) numbers when compared with healthy CMV- controls. (C) 
CCR7
-
CD45RA
-
 effector memory T cells were only significantly expanded when comparing CMV- 
patients and controls. (D) In contrast CCR7
-
CD45RA
+
 TEMRA cells were only significantly expanded in 
CMV+ patients and controls.  
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3.4.13 The defects in CLL T-cell function are present irrespective of CMV  
The description of expanded populations of CMV-specific T cells in CLL also raised 
the question as to whether the observed defects in T-cell function are due to CMV 
(Akbar 2011). Therefore the impact of CMV serostatus on proliferation, cytolytic 
activity, and cytokine production of T cells from CLL patients was examined. The 
proportion of CD3
+
CD8
+
 T cells that were positive for IFNγ was increased in CLL 
patients irrespective of CMV serostatus, correlating with the expression of TBET. A 
similar pattern was observed in the CD3
+
CD4
+
 compartment. Both CD3
+
CD8
+
 and 
CD3
+
CD4
+
 T cells from CLL patients also exhibited a decreased capacity to proliferate 
irrespective of CMV serostatus. The ability of CD8
+
 T cells from CLL patients to lyse 
idiotype pulsed target cells was assessed. There was a reduction in the cytolytic function 
of CD3
+
CD8
+
 T cells from CLL patients in all cases, regardless of CMV serostatus. 
These findings exclude CMV seropositivity as the sole cause of functional defects in 
CLL T cells.  
 
 
 
 
 
 
 
 
 
Figure 3.15 (overleaf) The defects in T-cell function observed in CLL are present 
irrespective of CMV serostatus 
The function of CLL T cells was compared with T cells from healthy controls matched for CMV 
serostatus. (A) Increased production of IFNγ by CLL CD3+CD8+ T cells was observed irrespective of 
CMV serostatus. (B) Increased production of IFNγ by CLL CD3+CD4+ T cells was observed when 
comparing CMV- individuals; there was a trend to increased production when comparing CMV+ 
individuals but this was not statistically significant. (C) & (D) There was increased expression of TBET 
in CD3
+
CD8
+
CCR7
-
 and CD3
+
CD4
+
CCR7
-
 T cells from CLL patients irrespective of CMV serostatus. 
(E) & (F) CD3
+
CD8
+
 and CD3
+
CD4
+
 T cells from CLL patients showed decreased proliferative capacity 
irrespective of CMV serostatus. (G) A reduction in the cytolytic capacity of CD3
+
CD8
+
 T cells was also 
observed in all CLL patients. Pulsed target cells (closed symbols); unpulsed control target cells (open 
symbols). The graph representing % specific lysis shows the mean and standard error of results obtained 
from 13 CLL patients, (5 CMV- and 8 CMV+), and 12 healthy controls (5 CMV- and 7 CMV+). 
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Figure 3.15 The defects in T-cell function observed in CLL are present irrespective 
of CMV serostatus  
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3.4.14 CD8+ T cells from CLL patients show defective cytotoxicity due to failure of 
granzyme localization to the immunological synapse 
My group has previously demonstrated that CLL T cells exhibit impaired actin 
polymerization and defective immunological synapse formation with APCs. Therefore, 
the impact of dysfunctional immunological synapse formation on the observed cytolytic 
defects was examined. The ability of the CD8
+
 T cells to degranulate in response to 
SEB was assessed by analysis of CD107a (LAMP1) transfer to the cell surface (Betts et 
al. 2003). CD8
+
 T cells from CLL patients retained the ability to degranulate, and 
actually showed enhanced transfer of CD107a to the cell surface, again irrespective of 
CMV serostatus. Confocal microscopic analysis revealed that while normal T cells were 
able to localize F-actin, CD107a and granzyme B to the immunological synapse, there 
was failure of transport of these molecules within CLL T cells, irrespective of their level 
of expression. This suggests that the cytotoxic defect seen in CLL T cells is due to a 
combination of disordered, non-polarized degranulation, and failure of effective 
granzyme B packaging into the cytolytic vesicles (Figure 3.16). 
 
Figure 3.16 CD8
+
 T cells from CLL patients show defective cytotoxicity due to 
failure of granzyme localization to the immunological synapse 
The cytotoxic activity of CD8
+
 T cells from CLL patients was assessed further. (A) CD8
+
 T cells from 
CLL patients retain the ability to degranulate in response to SEB, as shown by their increased ability to 
transfer CD107a to the cell surface. (B) Healthy CD8
+
 T cells showed effective F-actin (red, rhodamine 
phalloidin) immunological synapse formation with co-localization of CD107a (yellow, Alexa Fluor 647) 
and granzyme B (green, Alexa Fluor 488) at the synapse contact site with healthy B cells (+sAg). (C) In 
contrast, CD8
+
 T cells from CLL patients fail to form effective F-actin immune synapses with autologous 
CLL cells (+sAg) that is associated with strong, non-polarized expression of CD107a and a lack of 
granzyme B polarization to the contact site.  
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3.5 Discussion 
This study demonstrates that T cells from CLL patients exhibit features of T-cell 
exhaustion, an acquired state of T-cell dysfunction that was first described in the context 
of chronic viral infections (Shin and Wherry 2007). Both CD4
+
 and CD8
+
 T cells are 
expanded in the peripheral blood of CLL patients, with the degree of expansion being 
greater in the CD8
+
 compartment, consistent with previous reports (Lauria et al. 1980; 
Herrmann et al. 1982; Platsoucas et al. 1982). CLL T cells have increased expression of 
the exhaustion markers, CD244, CD160, and PD1, and show functional evidence of 
exhaustion with an impaired capacity to proliferate. CD8
+
 T cells also have a cytotoxic 
defect, having a reduced ability to lyse target cells. These phenotypic and functional 
defects are more apparent in CCR7
-
 effector cells, and the global defects described here 
correlate with a skewing of T-cell subsets in the peripheral blood of CLL patients 
towards effector differentiation.  
 
These results also provide evidence that the transcriptional control of T-cell 
differentiation is also abnormal in CLL, with increased expression of BLIMP1, TBET, 
and Eomes. Our understanding of the role of these transcription factors in regulating 
both normal T-cell differentiation and T-cell exhaustion is still evolving. A role for both 
TBET and Eomes in promoting the normal differentiation of effector memory cells is 
well established, and it perhaps of no surprise that the expression of these transcription 
factors is increased in T cells from CLL patients, where there is skew towards effector 
differentiation (Sullivan et al. 2003; Intlekofer et al. 2005). However, the interplay of 
these molecules with other transcription factors such as BLIMP1, NFAT2, and BATF in 
the regulation of T-cell exhaustion is complex (Wherry 2011). It has recently emerged 
that BLIMP1 and Eomes are both implicated in promoting high expression of PD1, but 
TBET can actually suppress expression of this inhibitory receptor and sustain CD8
+
 T-
cell responses (Kao et al. 2011; Paley et al. 2012). These findings may explain the 
observations reported here that TEM cells have a higher expression of PD1 than TEMRA 
cells, which otherwise more classically phenotypically and functionally “exhausted”. 
These results are consistent with descriptions of exhausted T cells in HIV infection, 
where HIV tetramer positive PD1-expressing cells had low expression of both CCR7 
and CD45RA, consistent with a TEM phenotype (Day et al. 2006). The high expression 
of PD1 in TEM cells may be due to the activity of Eomes and BLIMP1 on a background 
moderate TBET expression. In contrast the relatively lower expression of PD1 on 
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TEMRA cells may be due to the very high expression of TBET, suppressing the 
expression of this inhibitory ligand.  
 
The principal way in which CLL T cells differ from exhausted T-cells described in 
chronic viral infections is that they retain the capacity to produce cytokines such as 
IFNγ and TNFα. It is possible that the use of PMA and ionomycin to stimulate cytokine 
production could potentially overcome any subtle defects in cytokine production. 
However, a greater proportion of CLL T cells were positive for the Th1 cytokines IFNγ 
and TNFα, and this data correlated well with the expression of TBET, the prototypical 
Th1 transcription factor, that was analysed in resting cells (Szabo et al. 2000). 
Furthermore, there was relatively less production of IL2 in TEMRA cells, which had the 
highest expression of CD244 and CD160, and the lowest proliferative capacity. The 
observation of a relative preservation of cytokine production may reflect differences in 
antigen affinity, with chronic stimulation by high affinity viral antigens leading to a 
spectrum of functional disturbances distinct to that seen after chronic stimulation by low 
affinity self-antigens. It is also possible that the exhaustion pathways are co-opted by 
CLL cells to inhibit immune responses, but to maintain production of cytokines such as 
IFNγ and TNFα which have been shown to be pro-tumoural (Digel et al. 1989; Buschle 
et al. 1993). This finding may also be of immunotherapeutic importance, signifying a 
less exhausted state that could potentially be reversed with appropriate intervention. 
 
Interestingly, the phenotypic and functional profile reported here mirrors that of 
“senescent” T cells induced by regulatory T cells (Ye et al. 2012). Regulatory T cells 
are expanded in CLL, with numbers correlating with disease stage and prognosis, so it 
is probable that this T-cell subgroup regulates anti-tumour immune responses in CLL 
(Beyer et al. 2005; Giannopoulos et al. 2008; D'Arena et al. 2012). Regulatory T cells 
are one of the three main pathways implicated in promoting the development of T-cell 
exhaustion in combination with chronic antigenic drive (Wherry 2011). The other two 
major pathways involve inhibitory cytokines such as IL10, and inhibitory signalling 
axes such as PD1:PDL1 interactions. Serum levels of IL10 are known to be increased in 
patients with CLL, with higher levels associated with impaired prognosis (Fayad et al. 
2001). The role of inhibitory axes in CLL has been a target of recent research by my 
group. T cells from CLL patients exhibit impaired ability to form immunological 
synapses with antigen presenting cells, and this defect can be induced in healthy 
allogeneic T cells by co-culturing them with CLL cells (Ramsay et al. 2008). 
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Subsequent work demonstrated that this inducible defect was dependent on the 
expression of four inhibitory ligands expressed by CLL cells: CD200, CD270 (HVEM), 
CD274 (PDL1), and CD276 (Ramsay et al. 2012). Two of these molecules, PDL1 and 
HVEM are ligands for inhibitory receptors (PD1 and CD160) expressed by exhausted T 
cells, suggesting that PD1:PDL1 and CD160:HVEM interactions are crucial in 
promoting exhaustion and suppression of T-cell function in CLL. This may well be of 
importance in other cancers given recent reports documenting mutations/gene fusions of 
PDL1 and HVEM in other B-cell malignancies.(Cheung et al. 2010; Steidl et al. 2011)  
 
Ever since the description of expanded populations of CMV specific T cells in CLL, it 
has been unclear as to the contribution of these populations to the T-cell defects 
observed in this disease (Mackus et al. 2003; Pourgheysari et al. 2010). It has been 
suggested that these CMV specific T cells inhibit the function of other antigen-specific 
T cell populations, either by a direct effect, or by constriction of the total T-cell 
repertoire (Akbar 2011). These results show that while CMV positivity modulated the 
distribution of lymphocyte subsets, the functional defects were present irrespective of 
CMV serostatus, thereby excluding CMV as the sole cause of T-cell defects in CLL. 
The modulation of lymphocyte subset distribution accounts for some previously 
reported differences regarding the expression of PD1 on CLL T cells (Nunes et al. 
2012; Tonino et al. 2012). Use of both CMV serostatus and expression of 
CCR7/CD45RA allowed the impact of CLL and CMV on the distribution of CD8
+
 T 
cell subsets to be disentangled. In agreement with previous studies, TEMRA cells were 
only significantly expanded in CMV+ patients and controls (Mackus et al. 2003; Tonino 
et al. 2012). However it was also observed that the presence of CLL alone skews the T 
cell repertoire towards a TEM phenotype. Interestingly, as described above, TEMRA cells 
are “classically exhausted”, with the highest expression of CD244 and CD160, the 
lowest proliferative capacity, and loss of IL2 production. Both CLL and CMV exposure 
lead to a reduction in naive and TCM cell numbers compared with healthy CMV- 
controls.  
 
Given the importance of BCR-signalling in CLL, there has been a great deal of 
speculation as to the identity of other antigens that may drive this disease (Rosen et al. 
2010). A recent landmark paper has provided evidence that a particular feature of CLL 
BCRs is that they are able to induce autonomous signalling independent of antigen, in a 
manner dependent on the heavy-chain complementarity-determining region (HCDR3) 
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and an internal epitope of the BCR.(Minden et al. 2012) A further finding was that 
BCRs derived from leukemic cells in the TCL1 mouse model of CLL were also 
autonomously active. As described above, the development of leukaemia in this mouse 
model is also associated with an expansion of CD8
+
 effector T cells, despite being 
dependent on the single TCL1 transgene. It is therefore possible that the 
“pseudoexhausted” state of CLL T cells described here is due to their chronic 
stimulation by autonomously active CLL cells. However, several other reports have 
implicated a role for a wide variety of specific antigens in CLL, so this remains a 
controversial area. 
 
In conclusion, this work has identified a novel phenotypic and functional profile of 
terminally differentiated CD8
+
 T cells in patients with CLL. These “pseudo-exhausted” 
T cells may be a result of chronic stimulation by low affinity self-antigens, producing a 
state that is distinct to the exhaustion seen after chronic stimulation by high affinity 
viral antigens. They retain some functions, such as the ability to produce pro-tumoural 
cytokines and the ability to degranulate, but their effector cytotoxic function is blocked 
by cytoskeletal defects. These are likely to be due to a combination of their pseudo-
exhausted state, and increased interaction with inhibitory ligands expressed on the 
surface of the CLL cells (Wherry et al. 2007; Ramsay et al. 2012). Furthermore, 
although CMV seropositivity has profound effects on the T-cell repertoire of both 
healthy individuals and CLL patients, these alterations in T-cell phenotype and function 
are also apparent in CMV- patients.  
 
There do remain some answered questions. Much of the groundwork in understanding 
T-cell exhaustion has been undertaken in CD8
+
 T cells, with this phenomenon being 
less well characterised in CD4
+
 T cells. Therefore it remains unclear as to what the 
implications of this area are for the lymph node microenvironment in CLL, where CD4
+
 
T cells appear to be particularly important in promoting tumour cell survival (Pizzolo et 
al. 1983; Bagnara et al. 2011). Furthermore, T-cell exhaustion is thought to be chronic 
process that occurs over weeks/months, yet functional defects can be induced in healthy 
T cells after only 24 hours in co-culture with CLL cells. However, these results do have 
potential implications for immunotherapy, as molecules such as CD244, CD160 and 
PD1 may be useful biomarkers of immune reconstitution, and be potential targets for 
therapeutic strategies aimed at improving T-cell immunity. Interestingly, the 
immunomodulatory drug lenalidomide is able to repair many of the functional defects 
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associated with T-cell exhaustion. Data from pre-clinical models and clinical trials has 
shown that lenalidomide treatment is able to enhance cytokine production, improve 
proliferative capacity, and repair immunological synapse formation and cytotoxic 
function of CLL T cells (Corral et al. 1999; Ramsay et al. 2008; Shanafelt et al. 2013). 
Furthermore, lenalidomide is able to modulate “exhausting promoting pathways”, by 
down-regulating the expression of inhibitory receptors and ligands, and by inhibiting 
the differentiation of regulatory T cells (Galustian et al. 2009; Idler et al. 2009; Ramsay 
et al. 2012). Investigation into how lenalidomide exerts these effects will be the focus of 
the next two chapters. 
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4 Chapter 4: The Impact of L enalidomide on Gene Expression 
Profiling of Healthy and CLL lymphocytes 
 
4.1  Introduction 
Lenalidomide has recently been demonstrated to have significant activity in CLL. As it 
is not directly toxic to tumour cells in vitro, this clinical effect appears to be mediated 
by improvement of anti-tumour immune responses and reduction of pro-tumoural 
factors in the CLL microenvironment. An interesting feature of its clinical use is a 
“tumour flare reaction” which is associated with features of both CLL-cell and T-cell 
activation (Aue et al. 2009). There is some evidence that the presence of a tumour flare 
reaction correlates with improved outcome, but this is controversial and confounded by 
the use of prophylactic anti-inflammatory agents and by the use of highly immuno-
suppressive drugs as part of previous treatments. An effect on NK cells also appears to 
contribute to the clinical efficacy of this agent, as the presence of higher numbers of 
NK-cells pre-treatment and better NK-cell function, predicted for better outcome in a 
clinical trial (Chanan-Khan et al. 2011; Chanan-Khan et al. 2011). However, the exact 
mechanism of action of this agent in CLL in particular how it repairs anti-tumour 
immune responses, remains unclear. An improved understanding of lenalidomide’s 
mechanism of action in CLL could provide novel insights into the nature of the immune 
defect in this disease. 
 
My group previously demonstrated profound changes in the global gene expression 
profiles of T cells from CLL patients when compared with healthy age-matched controls 
(Gorgun et al. 2005). Despite not being part of the malignant clone, alterations were 
found in the expression of genes involved in cell differentiation and cytoskeletal 
formation in patient CD4
+
 T cells, and in cytoskeletal formation, vesicle trafficking, and 
cytotoxicity pathways in patient CD8
+
 T cells. They subsequently showed that these 
changes in gene expression translate into a deficit in T-cell function, due to impaired 
actin polymerization resulting in defective immunological synapse formation. 
Treatment of both autologous T-cells and CLL cells with lenalidomide was able to 
repair this defect, suggesting that this may be a key component of this agent’s activity in 
CLL (Ramsay et al. 2008).  
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4.2 Aims and objectives 
In light of the fact that the cytoskeletal defect was initially observed as a consequence of 
comparing the gene expression profiles of T cells from CLL patients and healthy 
donors, we hypothesised that investigation of the impact of lenalidomide on the 
transcriptome of T cells would lead to novel mechanistic insights. Given that CLL-cell 
and NK-cell activation has also been implicated in the clinical efficacy of lenalidomide, 
we also aimed to investigate the impact of this agent on the transcriptome of CLL cells 
and NK cells. As my group and others have previously reported the alterations in the 
gene expression profiles of CLL B and T cells when compared with healthy 
lymphocytes, we also aimed to examine the effect of lenalidomide on these subsets 
from healthy donors to investigate whether there was a differential effect. And finally, a 
comparison of the gene expression profiles of NK cells from CLL patients and healthy 
controls has never been reported: a further aim was to investigate this.  
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4.3 Materials and Methods 
 
4.3.1 Patients and Samples 
For the gene expressing profiling, peripheral blood samples were obtained from 22 CLL 
patients from the tissue bank maintained by the Department of Haemato-Oncology of 
St. Bartholomew’s Hospital, London. Ethical approval was confirmed by the East 
London & The City Health Authority Local Research Ethics Committee, and written 
informed consent was obtained in accordance with the Declaration of Helsinki. All of 
the patients were untreated at time of blood withdrawal, and had a median age of 60 
years (range 43 – 84). The patients had predominantly early stage CLL with 18/22 
(81.8%) classed as having Binet stage A disease. Healthy PBMCs were obtained from 
16 buffy coats/cones supplied by the National Blood Service. For the validation 
experiments, a second cohort of patient samples was obtained from a combination of 
Bart’s Haemato-Oncology tissue bank and the CLL Research Consortium tissue core.  
 
4.3.2 Preparation for Cell Culture and Lenalidomide Treatment 
Peripheral blood samples were diluted 1:1 with PBS prior to separation of PBMCs by 
density gradient centrifugation as described in section 2.4. Buffy coats/cones were 
diluted 4:1 with PBS due to the higher concentration of mononuclear cells. After 
density gradient centrifugation up to 1 x 10
9
 PBMCs were split into two fractions for 
cell culture. CLL or healthy PBMCs were then cultured at a concentration of 5 x 10
6
/ml 
for 24-48 hours with either 1μM lenalidomide or vehicle control. As the lenalidomide 
has been reconstituted in DMSO, 0.01% DMSO (Fisher Scientific) was added as the 
vehicle control.  
 
4.3.3 Isolation of lymphocyte subsets 
After 48 hours the healthy or malignant B and T cells were separated using the 
AutoMACS Pro (Miltenyi Biotec) as described in section 2.5.3. B cells were positively 
selected using CD19 microbeads, whereas CD4
+
 or CD8
+ 
T cells were negatively 
selected using the relevant isolation kits (Miltenyi Biotec). Due to the excess numbers 
of B cells in CLL PBMCs, the malignant B cells were pre-depleted prior to negative 
isolation of T or NK cells as described in section 2.5.4. Initial experiments showed that 
quantity and viability of NK cells decreased rapidly during the in vitro culture. In light 
of this, NK cells were isolated after 24 hours culture.  
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4.3.4 Determination of the purity of the isolated lymphocyte subsets 
After cell isolation a sample of the isolates was taken for determination of purity by 
flow cytometry. The purity of CD4
+
 and CD8
+ 
T cells from both healthy and CLL 
patients was determined using antibodies to detect CD3, and CD4 and CD8 
respectively. The purity of NK cells from both healthy and CLL patients was 
determined using antibodies to detect CD3 and CD56, where NK cells were defined as 
CD3
-
CD56
+
. The purity of healthy B cells was defined by their expression of CD20. 
The purity of the CLL cells was more challenging. Firstly, the relatively low expression 
of CD20 in CLL, and the variable expression of molecules such as CD23, made these 
molecules unsuitable targets for routine flow cytometry. Secondly, CD19 could not be 
used after positive isolation using CD19-microbeads due to either epitope occupation or 
CD19 internalisation after microbead binding. Instead CLL-cell purity was determined 
using antibodies to CD3 and CD5, where the CLL cells were defined as CD3
-
CD5
+
. The 
following purities were considered acceptable for downstream analysis: 
 CLL B cells      > 95% 
 Healthy B cells     > 90% 
 Healthy/CLL CD4
+ 
T cells    > 95% 
 Healthy/CLL CD8
+ 
T cells    > 90% 
 Healthy/CLL NK cells    > 85% 
 
4.3.5 RNA extraction and quality control 
RNA was then immediately extracted from the isolated lymphocyte subsets using the 
RNAeasy Plus Mini Kit (Qiagen) as described in section 2.8. Quality control of the 
RNA samples was performed by spectrophotometric analysis (Nanodrop) to confirm the 
concentration and to detect contaminating proteins and other molecules, and RNA 
electrophoresis (Agilent) was used to determine the RNA integrity. The following 
values were considered acceptable for downstream analysis 
 RNA concentration     > 25ng/μl 
 260/230      > 2.0 
 260/280      > 2.0 
 RNA Integrity Number     > 8.0 
 
250ng RNA was used for the GeneChip arrays for CLL/healthy B cells and CD4
+
 T 
cells; 125ng RNA was used for CD8
+
 T cells and NK cells. 
 
John Riches Chapter 4: The impact of lenalidomide on gene expression 
153 
 
4.3.6 Affymetrix Human Genome U133Plus2.0 gene arrays 
RNA conversion to cDNA, in vitro transcription and subsequent hybridization to gene 
arrays using the GeneChip® 3’ IVT Express Kit was performed according to the 
manufacturer’s instructions (Affymetrix) as described in section 2.9. Briefly, RNA was 
reverse transcribed to synthesise first-strand cDNA using a T7 oligo(dT) primer to 
synthesize cDNA containing a T7 promoter sequence. The single-stranded cDNA was 
then converted into dsDNA using DNA polymerase and RNase H. The double-stranded 
cDNA was used as the template in an in vitro transcription (IVT) reaction catalysed by 
T7 polymerase and containing biotinylated CTP and UTP in addition to the 4 
unmodified ribonucleoside triphosphates. The aRNA was then purified to remove 
unincorporated NTPs, salts, enzymes, and inorganic phosphate to improve the stability 
of the biotin-modified aRNA, before fragmented and prepared for hybridisation. The 
hybridisation to an Affymetrix HGU133Plus2.0 GeneChip and subsequent analysis 
using the GeneChip Fludics station 450 was performed by Tracy Chaplin in the 
Affymetrix core facility at Barts Cancer Institute. An initial quality control check was 
performed to exclude significant degradation in the sample aRNA. A number of 
control/housekeeping genes (e.g. actin, GAPDH) were included on the arrays with 
sequences covering the complete transcript. As RNA is usually degraded from the 5’ to 
the 3’ end loss of signal from probes for the transcripts towards the 5’ end of the 
transcribed genes was a marker of any degradation of the RNA. 3’:5’ signal ratios of < 3 
were used for downstream analysis. 
 
4.3.7 Initial Biostatistical analysis  
To assess the impact of lenalidomide on gene expression profiling 8 paired 
(lenalidomide/DMSO control) samples were prepared for both healthy and CLL B cells, 
CD4
+
 and CD8
+
 T cells. 6 paired samples were used for healthy and CLL NK cells. The 
raw data was analysed by a dedicated biostatistician, Ajanthah Sangaralingham, at Barts 
Cancer Institute. Data was analysed within the R statistical environment using 
Bioconductor packages (http://www.bioconductor.org). Stringent quality control criteria 
were applied to the data, with probes that did not pass the quality control being 
removed. To detect differentially expressed genes between the subgroups, limma was 
used to fit a linear model to normalized expression data for each probe. False discovery 
rates (FDRs) were estimated using the Benjamini-Hochberg method (Benjamini and 
Hochberg 1995). An FDR cutoff of 0.05 and an absolute fold change cutoffs of 2-3 
were applied to filter the list of differentially expressed genes. Initial unsupervised 
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analysis showed clustering of the paired samples from each CLL patient/healthy 
control. Therefore gene lists were generated by supervised analysis; heatmaps were 
subsequently generated by using unsupervised hierarchical clustering using the gene 
lists. Pathways were analysed using Ingenuity Pathway Analysis software 
(www.ingenuity.com). 
 
4.3.8 QRT-PCR 
The expression of twelve genes found to be differentially expressed after lenalidomide 
treatment was validated by QRT-PCR (Table 4.1). These were chosen to include those 
genes with the greatest fold-change in expression, and also to include gene of potential 
biological interest in the mechanism of action of lenalidomide. QRT-PCR was 
performed using the same RNA samples as were used for the gene microarrays. The 
method used was as described in section 2.10. 400 – 2000ng of RNA was used for 
cDNA synthesis, with 50ng of RNA being used for each Taqman® assay reaction. 
 
Table 4.1 Genes validated by QRT-PCR 
Gene Name Description Taqman® Gene 
Expression Array 
CLDN12 claudin 12 Hs01082669_m1 
F11R F11 receptor Hs00170991_m1 
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa Hs00944794_m1   
TJP2 tight junction protein 2 (zona occludens 2) Hs00910543_m1 
PPP2R3C protein phosphatase 2, regulatory subunit B'', gamma Hs00215595_m1 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 Hs00388776_m1 
RHOC ras homolog gene family, member C Hs00237129_m1 
RND1 Rho family GTPase 1 Hs00205507_m1 
ARL11 ADP-ribosylation factor-like 11 Hs00544739_m1 
WASF1 WAS protein family, member 1 Hs01591751_m1 
TPM2 tropomyosin 2 (beta) Hs00268540_m1 
CYFIP1 cytoplasmic FMR1 interacting protein 1 Hs00383168_m1 
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4.3.9 Monoclonal antibodies 
The following directly conjugated monoclonal antibodies were used in this study: 
CD40-PECy7, CD58-FITC, CD80-PECy7, CD86-FITC, CD95-APC, CD279-APC and 
F11R-PE were all obtained from BD Biosciences; CD5-PerCPCy5.5, CD19-APCCy7, 
CD54-APC, CD59-FITC, CD134-FITC, CD154-PE and CD262-PE were all obtained 
from eBioscience; CD223-ATTO647 was obtained from Enzo Life Sciences. 
 
4.3.10 Immunofluorescence staining and flow cytometric analysis  
Surface and intracellular staining for flow cytometric analysis was performed as 
described in section 2.7. Flow cytometry was performed on a BD Fortessa flow 
cytometer with subsequent analysis using FlowJo software (Tree Star). Analysis was 
performed on a minimum of 10,000 events after gating on live singlet cells. A 
fluorescent bead immunoassay for detection of levels of CCL4 in culture supernatants 
was performed using the Flowcytomix system from eBioscience according to the 
manufacturer’s protocol: http://ebioscience.instant.at/bm_products/MAN/8420FF.pdf 
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4.4 Results 
 
Gene expression profiling was performed after CLL or healthy PBMCs had been in 
cultured with lenalidomide or vehicle control for 24 – 48 hours. This in vitro model 
system had major advantages in terms of simplicity and experimental ease of use, but 
the period in culture meant that it was important to validate the system by comparing 
the results to data from in vivo analyses. This was done in several ways: 
i) Comparison of the gene expression signature of untreated CLL cells in this 
dataset with previously published datasets in the literature.  
ii) Comparison of the gene expression signature of untreated T cells from CLL 
patients in this dataset with previous work done by my group. 
iii) Comparison of the effect of in vitro exposure to lenalidomide on the gene 
expression profiles of CLL cells in this dataset, with published data 
generated from in vivo exposure to lenalidomide in a clinical trial. 
 
4.4.1 Comparison of the gene expression profiles of CLL cells with healthy B cells 
There have been several published analyses comparing the gene expression profiles of 
the malignant CLL B cells to healthy B cell subsets. The first two major analyses both 
concluded that CLL cells have a characteristic gene expression signature that was 
largely independent of their IGVH mutation status (Klein et al. 2001; Rosenwald et al. 
2001). These observations are in contrast to the situation in diffuse large B-cell 
lymphoma, where the disease can be divided into two molecularly distinct forms based 
on gene expression profiling: “germinal centre B-like” and “activated B-like” (Alizadeh 
et al. 2000). The data from these first analyses was subsequently incorporated into a 
meta-analysis which also included a further cohort of samples where the gene 
expression profiling had been performed using nylon membrane arrays (Wang et al. 
2004). This meta-analysis identified a number of genes that were consistently 
differentially expressed between CLL cells and healthy B cells. This dataset was used as 
a reference against which to compare differences in gene expression between CLL cells 
and healthy B cells in the control (i.e. lenalidomide untreated) condition. 
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Table 4.2 Genes over-expressed in CLL cells 
Symbol Description  Abs. Fold Change 
TNFRSF7 Tumour necrosis factor receptor superfamily, member 7 (CD27) 2.38 
MOX2 Antigen identified by monoclonal antibody MRC OX-2 (CD200) 3.14 
BCL2 B-cell CLL/lymphoma 2 2.60 
TRA T-cell receptor alpha locus (TRAC) 6.28 
DSIPI Delta sleep inducing peptide, immunoreactor (TSC22D3) 1.97 
IL10RA Interleukin 10 receptor, alpha 2.22 
CDC25B Cell division cycle 25B 2.99 
FCGRT Fc fragment of IgG, receptor, transporter, alpha Not present 
AIM2 Absent in melanoma 2 Not present 
MXI1 MAX interacting protein 1 2.22 
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 2.68 
FGR Gardner–Rasheed feline sarcoma viral (v-fgr) oncogene homolog 4.69 
IL4R IL4R Interleukin 4 receptor 1.56 
PECAM1 Platelet/endothelial cell adhesion molecule (CD31 antigen) Not present 
TTN TTN Titin 12.13 
PTPN12 Protein tyrosine phosphatase, non-receptor type 12 4.32 
IL24 IL24 Interleukin 24 1.66 
FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23A) 5.31 
PPP2R5C Protein phosphatase 2, regulatory subunit B (B56), gamma isoform 2.55 
PNOC Prepronociceptin Not present 
TNFSF1B Tumour necrosis factor receptor superfamily, member 1B (LTA) Downregulated 
MHC2TA MHC class II transactivator (CIITA) Not present 
PIM1 pim-1 oncogene 4.14 
CD5 CD5 antigen (p56-62) 11.71 
COPEB Core promoter element binding protein (KLF6) 1.54 
ALOX Arachidonate 5-lipoxygenase Not present 
PLCL2 Phospholipase C-like 2 2.57 
TOSO Regulator of Fas-induced apoptosis (FAIM3) 1.99 
C6orf32 Chromosome 6 open reading frame 32 Not present 
NIFU Nitrogen fixation cluster-like Not present 
ITGAX ITGAX Integrin, alpha X (antigen CD11C, alpha polypeptide) Not present 
COL9A2 Collagen, type IX, alpha 2 3.84 
CCND3 Cyclin D3 Not present 
CG018 CG018: NEDD4 binding protein 2-like 1 (N4BP2L1) 1.92 
CD6 CD6 antigen 2.69 
FCGR2B Fc fragment of IgG, low affinity IIb, receptor for (CD32) Not present 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 4.38 
LCK Lymphocyte-specific protein tyrosine kinase 2.95 
PPP3CC Protein phosphatase 3, catalytic subunit, gamma isoform Not present 
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As shown in table 4.2, 67% of the genes that were over-expressed in the reference 
dataset were also found to be significantly unregulated when comparing the gene 
expression profiles of the in vitro cultured cells. These included genes encoding proteins 
of known importance in CLL, such as CD5, CD23, CD200, LCK, IL4R and BCL2. The 
expression of a select group of other genes that were highlighted in the first two 
analyses and of known importance in CLL, but were not identified in the meta-analysis, 
were also investigated (Table 4.3). Again the data from the cultured cells was consistent 
with previous findings, with FMOD (Fibromodulin), CTLA4 (Cytotoxic T-lymphocyte-
associated protein 4), and ROR1 (Receptor tyrosine kinase-like orphan receptor 1) being 
amongst the most upregulated genes in the new dataset. 
  
Table 4.3 Other over-expressed genes in CLL cells 
Symbol Description  
Reference Abs. Fold 
Change 
FMOD Fibromodulin Klein et al. 390.72 
WNT3 Wingless-type MMTV integration site family 3 Rosenwald et al.  198.09 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 Rosenwald et al.  144.01 
LEF1 Lymphoid enhancer-binding factor 1 Klein et al. 30.91 
FILIP1L Filamin A interacting protein 1-like Klein et al. 27.28 
RAPGEF3 Rap guanine nucleotide exchange factor (GEF) 3 Klein et al. 23.92 
TGFBR3 Transforming growth factor, beta receptor III Klein et al. 20.53 
ROR1 Receptor tyrosine kinase-like orphan receptor 1 Klein et al. 17.51 
IGFBP4 Insulin-like growth factor binding protein 4 Klein et al. 9.58 
ATXN1 Ataxin 1 Klein et al. 9.38 
SELP P-selectin (CD62) Klein et al. 8.34 
IGSF3 Immunoglobulin superfamily, member 3 Klein et al. 6.11 
IL2RA Interleukin 2 receptor, alpha Rosenwald et al.  3.16 
DGKA Diacylglycerol kinase, alpha 80kDa Rosenwald et al.  3.07 
GCLC Glutamate-cysteine ligase, catalytic subunit Klein et al. 2.71 
TBXA2R Thromboxane A2 receptor Klein et al. 2.48 
KLF11 Kruppel-like factor 11 (TIEG2) Klein et al. 2.16 
PRKCB Protein kinase C, beta Rosenwald et al.  2.07 
MAP3K1  Mitogen-activated protein KKK 5 (MEKK1) Rosenwald et al.  2.06 
SELPLG Selectin P ligand (CD162) Klein et al. 1.80 
TXNIP Thioredoxin interacting protein (HHCPA78) Rosenwald et al.  1.79 
Absolute fold change (Abs. Fold Change) refers to the absolute fold change in gene expression observed 
from the new in vitro dataset, and does not refer to values published in the literature. 
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Similarly, 72% of the genes that were under-expressed in the reference dataset were also 
found to be significantly down-regulated in the new dataset. These included genes such 
as CD83, MYC, CCL4, CD10, CD38 and ADA (Table 4.4). Once again, the expression 
of a select group of other genes that were highlighted in the first two analyses and of 
known importance in CLL, but were not identified in the meta-analysis, was also 
investigated (Table 4.5). The data from the cultured cells was again consistent with 
previous findings, with CCL22, BID (BH3 interacting domain death agonist), and 
CDKN3 (Cyclin dependent kinase inhibitor 3) being amongst the most downregulated 
genes in the cultured dataset.  
 
Therefore CLL cells retain remarkably consistent changes in the gene expression profile 
when compared with healthy B cells, even after 48 hours of culture. This also validates 
the gene expression datasets of the B cells cultured under control conditions. A list of 
the most highly (> 8 fold absolute change in expression; log2 fold change > 3) up-
regulated and down-regulated genes in CLL cells compared with healthy CD19
+
 B cells 
is included in Appendix C. 
 
Table 4.4 Genes underexpressed in CLL cells 
Symbol Description  Exp. Fold Change 
SLU7 Step II splicing factor SLU7 Not present 
CD83 CD83 antigen  3.32 
LMO2 LIM domain only 2 (TTG2) 22.47 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 7.62 
CYBB Cytochrome b-245, beta polypeptide  15.03 
GS3955 GS3955 protein (TRIB2) 23.43 
CD1C CD1C antigen, c polypeptide 96.34 
SORL1 Homo sapiens cDNA: FLJ21930 fis, clone HEP04301 27.10 
NME1 Non-metastatic cells 1, protein (NM23A) 6.11 
IGL@ IGL@ Immunoglobulin lambda locus 19.97 
SLC2A5 SLC2A5 Solute carrier family 2, member 5 15.45 
SLC2A3 SLC2A3 Solute carrier family 2 , member 3 3.81 
SLAM SLAM Signaling lymphocytic activation molecule (SLAM7) 20.53 
SORL1 SORL1 Sortilin-related receptor, L, A repeats-containing 27.10 
CREM cAMP responsive element modulator 2.45 
RGS16 Regulator of G-protein signaling 16 Not present 
KIAA0084 KIAA0084 protein (RPTN1) 3.25 
NP Nucleoside phosphorylase (PNP) 4.66 
BCL2A1 BCL2-related protein A1 13.09 
CD22 CD22 antigen 3.27 
KIAA0870 KIAA0870 protein (DENND3) 25.11 
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Symbol Description  Exp. Fold Change 
STK17A Serine/threonine kinase 17a (DRAK1) 1.56 
SATB1 Special AT-rich sequence binding protein 1 3.16 
NFKB1 Nuclear factor of kappa light gene enhancer in B-cells 1  1.80 
TNF Tumour necrosis factor (TNF superfamily, member 2) 3.73 
PRKACB Protein kinase, cAMP-dependent, catalytic, beta 16.80 
ID2 Inhibitor of DNA binding 2 16.91 
PAICS Phosphoribosylaminoimidazole carboxylase 5.31 
IGHM Immunoglobulin heavy constant mu 61.39 
SCYA4 Small inducible cytokine A4 (CCL4) 10.93 
BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog  17.15 
STK15 Serine/threonine kinase 15 Not present 
IFI30 Interferon, gamma-inducible protein 30 4.66 
PSCDBP Pleckstrin homology, Sec7 and coiled/coil domains, BP Not present 
? H.sapiens, clone MGC:3963 IMAGE:3621362 Not present 
MS4A1 Membrane-spanning 4-domains, subfamily A, member 2  4.63 
BASP1 Brain abundant, membrane attached signal protein 1 6.77 
BIN1 Bridging integrator 1 1.96 
SSI1 JAK binding protein (SOCS1) 5.74 
CD38 CD38 antigen (p45) 9.51 
MADH7 MAD, mothers against decapentaplegic homolog 7 (SMAD7) 7.78 
LCP1 Lymphocyte cytosolic protein 1 (L-plastin) 3.07 
SCYB10 Small inducible cytokine subfamily B, member 10 (CXCL10) 23.92 
EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 Not present 
GBP1 Guanylate binding protein 1, interferon-inducible, 67 kDa 51.63 
TRIO Triple functional domain (PTPRF interacting) 3.14 
ADA Adenosine deaminase 11.63 
GLRX Glutaredoxin (thioltransferase) 7.11 
HSPCA Heat-shock 90 kDa protein 1, alpha (HSP90AA1) Not present 
CTPS CTP synthase 3.61 
EGR3 Early growth response 3 8.69 
RGS1 Regulator of G-protein signaling 1 Not present 
CSE1L CSE1 chromosome segregation 1-like (yeast) Not present 
LBR LBR Lamin B receptor Not present 
RBMS1 RNA-binding motif, single-stranded interacting protein 1 2.20 
LDHA Lactate dehydrogenase A 3.14 
MME Membrane metallo-endopeptidase (CD10) Not present 
TNFRSF5 Tumour necrosis factor receptor superfamily, member 5 Not present 
ADSL Adenylosuccinate lyase 2.16 
JUP Junction plakoglobin 7.78 
NUP153 Nucleoporin 153 kDa 2.10 
IL7R Interleukin 7 receptor 5.78 
NOL1 Nucleolar protein 1 (NSUN5) Not present 
GPRK5 G-protein-coupled receptor kinase 5 Not present 
CDC20 CDC20 cell-division cycle 20 homolog  18.25 
BLMH Bleomycin hydrolase 2.51 
SKIL SKI-like 1.87 
BCL2L1 BCL2-like 1 2.19 
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Symbol Description  Exp. Fold Change 
CR2 Complement component (3d/Epstein–Barr virus) receptor 2 Not present 
IFITM1 Interferon-induced transmembrane protein 1 (9–27) 3.34 
DUSP2 Dual specificity phosphatase 2 Not present 
HIF1A Hypoxia-inducible factor 1, alpha subunit Not present 
PEA15 Phosphoprotein enriched in astrocytes 15 2.30 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 4.23 
DAPK1 Death-associated protein kinase 1 11.39 
VDR Vitamin D (1,25-dihydroxyvitamin D3) receptor Not present 
CRIP2 Cysteine-rich protein 2 Not present 
BLR1 Burkitt lymphoma receptor 1, GTP-binding protein Not present 
CDC2 Cell-division cycle 2, G1 to S and G2 to M 30.48 
PPP1R16B Protein phosphatase 1, regulatory (inhibitor) subunit 16B Not present 
CENPF Centromere protein F (350/400 kDa, mitosin) 4.47 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 6.59 
EGFL5 EGF-like-domain, multiple 5 Not present 
PLCG2 Phospholipase C, gamma 2 (phosphatidylinositol-specific) Not present 
RGS13 Regulator of G-protein signaling 13 Upregulated 
 
 
Table 4.5 Other genes underexpressed in CLL cells 
Symbol Description  Reference Exp. FC 
CCL22 Macrophage derived chemokine Klein et al. 178.53 
BID BH3 interacting domain death agonist Klein et al. 17.88 
CIP2 PTP Cyclin-dependent kinase inhibitor 3 (CDKN3) Klein et al. 16.34 
EC-2 Ubiquitin-conjugating enzyme E2C (UBE2C) Klein et al. 12.91 
CCR6 Chemokine (C-C motif) receptor 6 Klein et al. 9.32 
CD18 Integrin, beta 2 (ITGB2) Klein et al. 8.28 
P1CDC21 Minichr. maintenance complex component 4 (MCM4) Klein et al. 6.73 
Cyclin B Cyclin B1 (CCNB1) Klein et al. 5.90 
fls353 TPX2, microtubule-associated, homolog (TPX2) Klein et al. 4.82 
Zyxin Zyxin (ZYX) Klein et al. 4.00 
ICAM1 Intercellular adhesion molecule 1 Klein et al. 4.00 
LFA-1α Integrin, alpha L (antigen CD11A, ITGAL) Klein et al. 3.46 
DRAK2 Serine/threonine kinase 17b (STK17B) Klein et al. 2.95 
DP1 E2F  Transcription factor Dp-1 (TFDP1) Klein et al. 2.68 
TNFSF11 TNF (ligand) superfamily, 11 (Osteoprotein ligand) Klein et al. 2.27 
Fascin FSCN1 Klein et al. 1.65 
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4.4.2 Comparison of the gene expression profiles of CD3+CD4+ T cells from CLL 
patients with healthy CD3
+
CD4
+
 T cells 
My group has previously compared the gene expression profiles of peripheral blood T 
cells from previously untreated patients with CLL with those from age-matched healthy 
donors (Gorgun et al. 2005). Despite the cells not being part of the malignant clone, 
analysis revealed significant alterations in gene expression. Furthermore, these changes 
could be induced in healthy T cells by co-culturing them with the malignant CLL cells. 
In CD4
+
 T cells, the majority of the differentially expressed genes were involved in cell 
differentiation and proliferation, survival, cytoskeleton formation, and vesicle 
trafficking. In particular, there was decreased expression in a number of genes in the 
Ras-dependent JNK and p38 MAPK pathways, including MINK (MAP4K6), GDI1, and 
NFRKB. Genes involved in regulating cell growth (e.g. PIK3CB) and in cytoskeleton 
formation and vesicle trafficking were also prominently dysregulated (e.g. AAK1, 
AP3M2, SPTBN1, ARPC1, and ADIR).  
 
As a part of the validation of the gene expression profiling performed here, the genes 
that were differentially expressed between healthy and CLL CD4
+
 T cells in the control 
condition were compared with the published dataset (Gorgun et al. 2005). The 
alterations in gene expression were modest with only 8 probes that were significantly 
up-regulated and 14 probes that were significantly down-regulated (> 1.5 absolute fold 
change; P < 0.05). None of the same genes that had been identified as dysregulated n 
the published dataset recurred in the new dataset. Despite this, dysregulation of the JNK 
and p38 MAPK pathways was still apparent, with decreased expression of both ATF2 
(activating transcription factor 2), and RPS6KA5 (ribosomal protein S6 kinase, 
polypeptide 5). Indeed this pathway was highlighted in an ingenuity analysis of this 
dataset (Figure 4.1). The complete list of dysregulated probes is in Appendix D.  
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Figure 4.1 Ingenuity pathways analysis of dysregulated genes in CLL CD4
+
 T cells 
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4.4.3 Comparison of the gene expression profiles of CD3+CD8+ T cells from CLL 
patients with healthy CD3
+
CD8
+
 T cells 
Previous work by my group had identified a greater degree of dysregulation in the gene 
expression profiles of circulating CD8
+ 
T cells (Gorgun et al. 2005). These observations 
highlighted defects in several cellular pathways, including cytoskeleton formation, 
intracellular transportation, vesicle trafficking, and cytotoxicity. In particularly there 
was dysregulation of a number of cytoskeletal genes including down-regulation of 
ARAP3; myosin IXB; AP3M2; VAMP2; GPR57; and AKAP9, and up-regulation of 
CDC42; PIK4CB; RAB35; FLNA; FMNL; ARPC1B; SPEC1; NCK2; RAB22A; 
RALGDS; and RASGRP2.  
 
As above, these previously published observations were compared with the genes 
differentially expressed in CLL CD8
+
 T cells in the new dataset. Of the 36 genes 
highlighted as being dysregulated in the original publication, only 2 (6%) recurred in 
the new dataset. These were SPTB (sprectrin beta) and RALGDS (ral guanine nucleotide 
dissociation stimulator): both of which are implicated in cytoskeletal regulation. 
However there was down-regulation of several other important cytoskeletal genes in 
CLL CD8
+
 T cells including WASF1, RAB13, RHOH, ACTN1 and CAMSAP1L1, with 
“leucocyte extravasation signalling” being highlighted by Ingenuity pathways analysis 
as the most the dysregulated pathway (Figure 4.2). A list of the most dysregulated 
genes (> 3 fold change dysregulated) is given in Appendix E. 
 
Figure 4.2 Ingenuity pathways analysis of dysregulated genes in CLL CD8
+
 T cells  
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4.4.4 CD3+CD8+ T cells from CLL patients have altered expression of genes 
implicated in T-cell exhaustion 
 
Given the findings described in chapter 3, the new dataset was also examined for 
alterations in gene expression consistent with T-cell exhaustion. Importantly, there was 
dysregulation of several genes implicated in this process, including up-regulation of 
LAG3, KLRG1, and PRDM1 (BLIMP1), and down-regulation of IL7R (Table 4.6). This 
confirms that the observed changes in protein expression and cytokine production are 
also present at the mRNA level.  
 
Table 4.6 The expression of “Exhaustion” genes in CD8+ T cells from CLL patients 
Upregulated 
Symbol Description 
Absolute  
Fold change 
Adjusted  
P value 
IFNG Interferon, gamma 5.8 0.004 
LAG3 Lymphocyte-activation gene 3 2.7 0.009 
KLRG1 Killer cell lectin-like receptor subfamily G, member 1 2.6 0.001 
FASLG Fas ligand (TNF superfamily, member 6) 2.4 0.026 
PRDM1 PR domain containing 1, with ZNF domain (BLIMP1) 2.1 0.014 
TBX21 T-box 21 (TBET) 2.0 0.047 
EOMES Eomesodermin  1.9 0.014 
    Downregulated 
Symbol Description 
Absolute  
Fold change 
Adjusted  
P value 
IL7R Interleukin 7 receptor 1.5 0.040 
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4.4.5 Comparison of the gene expression profiles of CD3-CD56+ NK cells from CLL 
patients with healthy CD3
-
CD56
+
 NK cells 
While my group has compared the gene expression profiles of T cells from CLL 
patients with healthy controls, a comparison of the transcriptome of NK cells from CLL 
patients and controls has not previously been investigated. In light of this, a comparison 
was made of the gene expression profiles of NK cells from the control (i.e. lenalidomide 
untreated) condition, after 24 hours in culture. 18 probes were showed a >2-fold 
increase in expression, and 117 probes showed a >2-fold decrease in expression after 
filtering for probes with an adjusted p-value < 0.05.  
 
A particularly striking feature of the genes which were down-regulated in CLL NK cells 
was that they were enriched for interferon-inducible genes. 52 out of the 117 probes 
(44.4%) that were significantly down-regulated > 2-fold were for interferon inducible 
genes, including STAT1, SOCS1, and IRF9 (Figure 4.3/Table 4.7). These were 
regulated by type 1 interferons (e.g. IFNα and IFNβ) and type 2 interferons (e.g. IFNγ), 
with the majority of these genes being inducible by both types. Many of these genes 
have been implicated in host immunity to viral infections, and so it is possible that 
decreased NK-cell responsiveness to interferon contributes to the increased 
susceptibility of CLL patients to viruses. There was also altered expression of the same 
pathways that were dysregulated in CLL T cells. JUN was significantly down-regulated 
in NK cells from CLL patients, which would correspond to the down-regulation in 
JNK-signalling in CD4
+
 T cells. Dysregulation of a number of cytoskeleton genes was 
also observed including RAB3GAP1, RAB38, and EPHA1. These changes were not due 
to differences in the relative frequencies of CD56
DIM
 and CD56
BRIGHT
 NK cells. A list 
of the most dysregulated genes (> 3 fold change dysregulated) is given in Appendix F. 
 
Figure 4.3 Ingenuity pathways analysis of dysregulated genes in CLL NK cells 
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Table 4.7 Down-regulation of IFN-inducible genes in CLL CD3
-
CD56
+
 NK cells  
Symbol Description 
Log2  
Fold change 
Adjusted  
P value 
IFI44L Interferon-induced protein 44-like 6.529 6.0E-05 
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 4.212 4.7E-05 
RSAD2 Radical S-adenosyl methionine domain containing 2 4.018 6.0E-05 
IFI44 Interferon-induced protein 44 3.237 3.5E-04 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 3.201 4.2E-04 
OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 3.108 1.1E-03 
MX1 Myxovirus resistance 1, interferon-inducible protein p78  3.061 3.6E-03 
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 2.996 4.8E-04 
IFI6 Interferon, alpha-inducible protein 6 2.540 7.1E-04 
EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 2.354 1.4E-03 
JUN Jun proto-oncogene 2.119 7.4E-05 
SOCS1 Suppressor of cytokine signaling 1 2.086 1.2E-03 
USP18 Ubiquitin specific peptidase 18 2.048 2.1E-03 
EPSTI1 Epithelial stromal interaction 1 (breast) 1.978 4.7E-05 
CCRL2 Chemokine (C-C motif) receptor-like 2 1.880 3.0E-02 
MX2 Myxovirus resistance 2  1.873 1.2E-02 
OASL 2'-5'-oligoadenylate synthetase-like 1.870 4.8E-04 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 1.858 1.8E-02 
ISG15 ISG15 ubiquitin-like modifier 1.724 1.9E-02 
HERC6 HECT & RLD domain containing E3 ubiquitin protein ligase 6 1.718 5.2E-04 
IRF7 Interferon regulatory factor 7 1.556 7.9E-04 
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 1.542 2.8E-02 
HERC5 HECT & RLD domain containing E3 ubiquitin protein ligase 5 1.514 4.6E-03 
XAF1 XIAP associated factor 1 1.511 7.0E-03 
BTG1 B-cell translocation gene 1, anti-proliferative 1.387 1.7E-03 
STAT1 Signal transducer and activator of transcription 1, 91kDa 1.363 2.2E-03 
DUSP10 Dual specificity phosphatase 10 1.335 3.9E-03 
PLSCR1 Phospholipid scramblase 1 1.203 2.4E-03 
CXCR4 Chemokine (C-X-C motif) receptor 4 1.132 1.0E-02 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.091 1.0E-02 
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2  1.091 1.8E-03 
IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 1.091 1.4E-03 
IRF9 Interferon regulatory factor 9 1.091 3.1E-03 
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4.4.6 The impact of lenalidomide on the gene expression profiles of CLL cells 
In order to investigate the effect of lenalidomide on the gene expression profiles of CLL 
cells, PBMCs from CLL patients were cultured in the presence of 1μM lenalidomide or 
vehicle control for 48 hours, followed by RNA extraction and gene expression profiling. 
Lenalidomide was primarily an activator of gene expression with 357 probes being 
significantly (adjusted P-value < 0.05) up-regulated with >2-fold increase in expression 
and 173 probes being significantly down-regulated with >2-fold decrease in expression. 
Lenalidomide had significant effects on genes implicated in a variety of different 
pathways (Figure 4.4): 
- TNF family: TNF, TNFRSF4 (OX40), TNFSF4 (OX40L), TNFRSF13B (TACI), 
TNFSF13 (APRIL), TNFRSF10B (DR5), TNFRSF10D (DCR2) 
- Adhesion molecules: ICAM1, CLDN12, JAM2, CD58 (LFA1), ITGAX (CD11c) 
- Cytoskeletal pathways: COL9A, TPM2, RND1, RIN2, SNX8, MAP2, WASF1, 
RAPGEF5, RAB13, EMILIN2, FMNL3, FILIP1L, RAB20, ARHGAP31, 
RASGRP2, COL18A1, COL9A3, ANK1, FLNA, RAB37, ARHGEF10L 
- Cell cycle: CDKN1C, CDKN1A, CCND2, CCND1 
- Apoptosis pathways: BID, BIK, FAS, HRK 
- Chemokines, chemokines receptors and B cell activation markers: CCL4, CCL2, 
CCR2, CCR6, LAG3, CD70, CD83, CD274, CD72, CD200 
- Genes associated with chromosome 5q: SPARC, PPP2R3C 
Overall, lenalidomide treatment led to CLL-cell activation in this assay, with increased 
expression of several activation markers and chemokines/chemokine-receptors, 
increased adhesion molecule expression, and up-regulation of pro-proliferative genes. 
There was up-regulation of several genes involved in cytoskeletal pathways, which is 
also likely to reflect CLL cell activation, and is consistent with my group’s previous 
observations regarding improved CLL-cell antigen presenting function and 
immunological synapse formation after lenalidomide treatment (Ramsay et al. 2008). A 
list of the genes that were most affected by lenalidomide treatment (> 3 fold change) is 
given in Appendix G. 
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Figure 4.4 Heatmap showing genes with > 3-fold change in expression after 
lenalidomide treatment in CLL cells 
Red = upregulated; Blue = downregulated 
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4.4.7 Comparison of the in vitro findings with in vivo results from a clinical study 
Lenalidomide has been shown to have efficacy in previously untreated CLL  patients, 
with overall response rates of 72% in a recent clinical trial (Chen et al. 2012). 
Correlative studies were performed as part of this trial to assess the impact of 
lenalidomide treatment on the gene expression profiles of PBMCs enriched for CLL 
cells (purity > 85%) (Chen et al. 2010). Gene expression profiling was performed on 
enriched PBMCs taken on day 1 (pre-dosing) and on day 8 from 24 patients. Affymetrix 
Genechip U133 Plus2.0 microarrays were used for this analysis, the same arrays as used 
for the in vitro studies described in this thesis. A lenalidomide-induced signature 
representing 42 differentially expressed gene with at least a 2-fold difference in 
expressed was identified, with 26 genes up-regulated, and 16 genes down-regulated. 
The altered genes were enriched for immune-associated genes including TNF and 
LAG3, and IFN-induced genes such as OAS3 (2,5-oligoadenylate synthetase). Notably, 
the most up-regulated gene in this analysis was TPM2 (tropomyosin 2), a cytoskeletal 
regulatory protein. 
 
A part of the validation of the in vitro dataset, this data and the lenalidomide-induced 
gene expression signature from the clinical trial were directly compared (Figure 4.5). 
27 of the 46 (59%) differentially expressed probes detected in the clinical trial also 
showed statistically significant changes in expression in the in vitro dataset. This 
included 21 out of the 29 (72%) upregulated probes, and 6 out of the 17 (35%) 
downregulated genes. These included the genes highlighted in the clinical trial report: 
TNF, LAG3, OAS3 and TPM2. This data provides further validation of the in vitro 
PBMC model system. 
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Figure 4.5 Comparison of the in vitro dataset with published data from a clinical 
trial (Chen et al. 2010) 
Published data from a clinical trial was compared with the in vitro dataset in order to assess which genes 
were dysregulated in both analyses. The overlapping genes are highlighted in colour in the left hand 
column (blue = downregulated; red = upregulated). The fold change in expression in the in vitro dataset 
was highlighted in brackets. 
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4.4.8 The impact of lenalidomide on the gene expression profiles of healthy B cells 
The effect of lenalidomide on the transcriptome of healthy B cells was also analysed. 
Interestingly, lenalidomide had less of an effect here, with only 130 probes being 
significantly up-regulated with >2-fold increase in expression and 107 probes being 
significantly down-regulated with >2-fold decrease in expression. When analysing the 
most highly altered probes (>3-fold changes), only 30 probes were significantly up-
regulated in healthy B cells, compared to 98 in CLL cells, and only 17 probes were 
significantly down-regulated, compared to 29 in CLL cells.  
 
Lenalidomide had effects on genes in some of the same pathways as observed in CLL 
cells (Figure 4.6): 
- TNF family: TNFSF4 (OX40L), TNFRSF11B, TNFSF11, TNFRSF10D (DCR2) 
- Adhesion molecules: CLDN12, JAM2 
- Cytoskeletal pathways: RND1, WASF1, FMNL3, RAB37, ARHGEF5, RHOQ, 
MYO1B, ARHGAP20, CAMSAP2, COL1A1 
- Genes associated with chromosome 5q: SPARC 
Interestingly, there were no significant changes in the expression of genes implicated in 
the cell cycle, apoptosis, and B-cell activation/chemokine signalling pathways that were 
observed in CLL cells with lenalidomide treatment. This would suggest that 
lenalidomide activates the cytoskeleton and up-regulates the expression of TNF family 
members and adhesion molecules directly, but has a co-stimulatory effect with regard to 
B-cell activation and proliferation, augmenting events induced by BCR-signalling. This 
would also suggest that there is ongoing tonic BCR-signalling in CLL cells, which is 
not present in healthy B cells in this PBMC culture system. A list of the genes that were 
most affected by lenalidomide treatment (> 3 fold change) is given in Appendix H. 
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Figure 4.6 Heatmap showing genes with > 3-fold change in expression after 
lenalidomide treatment in healthy CD19
+ 
B cells 
Red = upregulated; Blue = downregulated  
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4.4.9 Validation of Affymetrix array observations: upregulation of surface proteins 
on CLL cells with lenalidomide treatment 
The gene expression profiling data from the Affymetrix HGU133Plus2.0 microarrays 
was validated at the protein level. As several of the up-regulated genes coded for B-cell 
activation markers that were surface molecules, the expression of these proteins was 
determined by flow cytometry. PBMCs from an independent cohort of 40 CLL patients 
were cultured in vitro for 48 hours with 1μM lenalidomide or vehicle control, using the 
same culture conditions as used for gene expression profiling. A panel of 12 surface 
markers were selected including: 
- CD134 (TNFRSF4; OX40), CD54 (ICAM1), CD59, CD223 (LAG3), CD279 
(PD1), CD58 (LFA3) , CD95 (FAS), and CD262 (TNFRSF10B; DR5) on the 
basis of being significantly up-regulated > 2-fold in the array dataset 
- CD40, CD80, CD86, and CD154 (CD40L), on the basis of having been 
previously described as up-regulated by lenalidomide treatment (Andritsos et al. 
2008; Aue et al. 2009; Lapalombella et al. 2010) 
 
Figure 4.7 Validation of the changes in expression of genes encoding CLL cell 
surface proteins  
The % change with lenalidomide treatment of surface protein expression as measured by MFI is shown 
normalised to the untreated condition. The fold-changes from the array dataset are highlighted in red.  
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Figure 4.7 summarises the findings. All of the data points shown were generated by 
normalising the median fluorescence intensity (MFI) in the treated condition to the 
paired control sample. This approach was most appropriate for proteins that were 
constitutively expressed by CLL cells, such as CD40, CD58, CD59, and CD54. 
However proteins marked by a red asterisk are inducibly expressed by CLL cells. In 
particular, CD223 and CD134 were not expressed on CLL cells in the control condition, 
but were significantly up-regulated by a subset of CLL cells with lenalidomide 
treatment (Figure 4.8). This change is best described by an increase in the percentage of 
cells positive for a given antigen, but MFI was used here to allow comparison between 
all of the surface markers.  
 
 
Figure 4.8 Increased expression of CD134 (OX40) on a subset of CLL cells with 
lenalidomide treatment 
Flow cytometric plot showing an large expansion of CD134
+
 CLL cells with lenalidomide treatment. 
 
Taking this into account, there was a qualitative correlation between the fold-change in 
gene expression in the array data, and the degree of up-regulation of the surface protein 
with lenalidomide treatment. CD223, CD59, CD54 and CD134 showed the greatest 
changes in mRNA levels with lenalidomide treatment in the array dataset, and also 
showed the biggest changes in surface molecule expression by flow cytometry.  
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4.4.10 Validation of Affymetrix array observations: Lenalidomide treatment 
increases production of CCL4 by CLL cells. 
The chemokine gene CCL4 was one of the genes that was most up-regulated by 
lenalidomide treatment, with >7-fold increase in mRNA expression. The chemokines 
CCL3 and CCL4 have implicated in the pathogenesis of CLL in several recent 
publications.  Co-culture of CLL cells with nurse-like cells (NLCs) induces high-level 
expression of these chemokines by the tumour cells, with the degree of induction 
correlating with ZAP70 expression. NLC-induced production of CCL3/CCL4 could be 
inhibited by a Syk inhibitor; conversely BCR-triggering was noted to cause robust 
CCL3/CCL4 protein secretion by CLL cells (Burger et al. 2009). There is also evidence 
to suggest that serum levels of these chemokines have prognostic significance in CLL 
and DLBCL (Sivina et al. 2011; Takahashi et al. 2012). Interestingly, serum CCL3 and 
CCL4 levels were also shown to correlate with response in elderly patients treated with 
lenalidomide in a clinical trial, with responders having lower levels than non-responders 
(Badoux et al. 2011). In light of this the ability of lenalidomide to induce CLL-cell 
secretion of CCL4 was assessed. Lenalidomide treatment induced a dose- and time-
dependent increase in CCL4 production by CLL cells (Figure 4.9).  
 
Figure 4.9 Lenalidomide induces the secretion of CCL4 by CLL cells 
The ability of lenalidomide to induce CLL-cell secretion of CCL4 was assessed. Purified CLL cells were 
cultured in the presence of various concentrations of lenalidomide for up to 72 hours. Culture supernatant 
CCL4 levels were measured using a cytokine bead assay.   
John Riches Chapter 4: The impact of lenalidomide on gene expression 
177 
 
4.4.11 The impact of lenalidomide on the gene expression profiles of CD3+CD4+ and 
CD3
+
CD8
+
 T cells from CLL patients 
The impact of lenalidomide on the gene expression profiles of CD3
+
CD4
+
 and 
CD3
+
CD8
+
 T cells from CLL patients was also investigated. As before PBMCs from 
CLL patients were cultured in the presence of 1μM lenalidomide or vehicle control for 
48 hours, followed by RNA extraction and gene expression profiling using the 
Affymetrix U133 Plus 2.0 arrays. Once again, lenalidomide was primarily an activator 
of gene expression with 231/188 probes being significantly up-regulated with >2-fold 
increase in expression in CD3
+
CD4
+
/CD3
+
CD8
+
 T cells and 47/65 probes being 
significantly down-regulated with >2-fold decrease in expression in 
CD3
+
CD4
+
/CD3
+
CD8
+
 T cells respectively.  
 
Lenalidomide treatment affected the same pathways in both CD3
+
CD4
+
 and CD3
+
CD8
+
 
T cells demonstrated by alterations in the expression of common genes (Figures 4.10): 
- Cytoskeletal activation: WASF1, TPM2, RAB13, ARHGEF7, ARHGEF5, 
CAMSAP2, CYFIP, RAB20, RAB37, CORO1B, ARL11 
- T-cell activation: LAG3, TNF, TNFSF4, IL15 
- Interferon-inducible genes: OAS3, IRF4, IFIT3 
A list of the genes that were most affected by lenalidomide treatment (> 3 fold change) 
is given in Appendices I and J. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Heatmaps showing genes with > 3-fold change in expression after 
lenalidomide treatment in CD3
+
CD4
+
 and CD3
+
CD8
+
 T cells from CLL patients 
Next page: Red = upregulated; Blue = downregulated 
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4.4.12 Analysis of recurrently altered genes demonstrates that lenalidomide up-
regulates “tight junction signalling” pathways in healthy and malignant 
lymphocytes 
The main aim of the gene expression profiling experiment was to give greater insight 
into lenalidomide’s mechanism of action in CLL, which by extension, should allow for 
a greater understanding of the nature of the immune defect in this disease. Analysis of 
the 8 datasets showed that lenalidomide treatment altered the expression of large 
numbers of genes in each lymphocyte subset, in both patients and controls (Table 4.8). 
 
Table 4.8 Number of probes significantly dysregulated (>2-fold) by lenalidomide  
No. 
probes 
CLL 
CD4
+
 T 
Healthy 
CD4
+
 T 
CLL 
CD8
+
 T 
Healthy 
CD8
+
 T 
CLL 
CD19
+
 B 
Healthy 
CD19
+
 B 
CLL 
NK 
Healthy 
NK 
UP 231 196 188 173 357 130 209 181 
DOWN 47 38 65 35 173 107 62 54 
 
However, what was immediately apparent was that the same genes kept recurring as 
being affected by lenalidomide treatment, whether it was in B cells, T cells, or NK cells, 
or from CLL patients or controls.  
 
Table 4.9 Top 20 genes up-regulated by lenalidomide by donor/subset 
CLL 
CD19
+
 B 
Healthy 
CD19
+
 B 
CLL  
CD4
+
 T 
Healthy 
CD4
+
 T 
CLL 
CD8
+
 T 
Healthy 
CD8
+
 T 
CLL 
NK 
Healthy  
NK 
PRELP CD1E WASF1 WASF1 CLDN12 NA NA NA 
BTBD19 RGS16 CLDN12 IKZF1 NA CLDN12 LOC644135 SOX4 
CD1C SPARC NA CLDN12 LOC644135 WASF1 RNASE6 LOC644135 
NA RGS16 IKZF1 NA GNB4 LOC644135 QPCT LOC100996539 
TNFRSF4 NOD2 LOC644135 LOC644135 WASF1 NA GNB4 SNCA 
IL4I1 KCNS3 LOC100996457 ATP10D IFIT3 IKZF1 NUDT12 SOX4 
SUSD1 CTSK NA RNASE6 SLAMF8 SLAMF8 OAS3 ZNF704 
LOC158402 RND1 LOC100996457 NA NA RAB13 NA EPHA1-AS1 
C1orf228 C1orf228 ATP10D TPBG NA QPCT EMILIN2 SOX4 
CCL4 TMEM200A RNASE6 NA RNASE6 CAMSAP2 IFIT1 SOX4 
ICAM1 NA TPBG NA SLAMF8 TNFSF4 NLRP3 QPCT 
C1orf228 TNFSF4 NA TNF TPM2 SIAH3 SLAMF8 NA 
PLA2G4C IDO1 UNC13B TPM2 QPCT CAMSAP2 KIAA1211L ZNF704 
CLDN12 CLDN12 NA ARL11 IKZF1 PLXNB2 C5orf54 MFSD4 
SPRED2 GPR133 DACT1 DACT1 GBP4 DACT1 IFI44L ERBB3 
MYCN GNG8 TANC1 CRISPLD2 SLC43A3 C5orf54 NA GNB4 
RND1 C1orf228 ARHGEF7 QPCT OAS3 ZNF704 SNCA KIAA1211L 
NA CD1E TNF LAG3 GRN COL6A3 CYFIP1 EPHA1 
IFIT3 TJP2 C5orf54 C5orf54 CYFIP1 SLC43A3 F2RL2 ICA1 
C1orf95 TNFRSF11B CD14 BATF3 BATF3 PLLP C15orf48 LTF 
Top 20 genes up-regulated by lenalidomide by donor/subset. Genes that are recurrently up-regulated in 2 
or more datasets are highlighted in red. 
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Given that this data was generated over 2½ years using several different patients and 
controls, and multiple batches of lenalidomide, it was felt to be likely that these 
recurrently dysregulated genes were of importance. As highlighted in the table, there 
was the greatest degree of overlap between CD3
+
CD4
+
 and CD3
+
CD8
+
 T cells, from 
both CLL patients and healthy controls. Therefore it was hypothesised that lenalidomide 
affected a common pathway in these cells, and that focusing on genes that had altered 
expression in 2 or more of the T–cell datasets would aid identification of this pathway. 
204 probes were significantly up-regulated (> 2-fold; adjusted P-value < 0.05) in 2 or 
more of the T-cell datasets, and 39 probes were significantly down-regulated in 2 or 
more of the T-cell datasets. When pathways analysis was performed on this dataset, the 
most differentially affected pathway was the “tight junction signalling” pathway 
(Figure 4.11). 
Figure 4.11: Ingenuity analysis of recurrently altered genes identifies tight junction 
signalling pathway as most differentially affected by lenalidomide treatment 
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Figure 4.12 KEGG version of tight junction signalling pathway 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway of tight junction signalling. The genes 
recurrently altered by lenalidomide are highlighted (red = up-regulated; blue = down-regulated) 
 
Figure 4.12 highlights the genes that were altered by lenalidomide treatment in the 
KEGG pathway. Genes were altered all along this pathway, from the cell membrane 
(e.g. CLDN12; Claudin12), through adaptor proteins (e.g. TJP2, ZO2, Tight junction 
protein 2) and RhoGTPases (e.g. RAB13, Ras-related protein Rab-13), to proteins that 
directly regulate the cytoskeleton (e.g. WASF1, Wiskott-Aldrich syndrome protein 
family member 1). RAB13 is known to be particularly important in tight junction 
signalling, and was also highlighted in the clinical study (Kohler et al. 2004; Chen et al. 
2010)(see Figure 4.4). Intriguingly, a gene encoding the regulatory B subunit, γ 
(PPP2R3C) of the phosphatase PP2A, which is known to be a negative regulator of 
tight junction signalling, was downregulated in this analysis. Figure 4.13 shows the 
lenalidomide-induced changes in gene expression by donor subset. Importantly, genes 
for core tight junction (TJ) proteins, claudin12 (CLDN12), junctional adhesion molecule 
1 (JAM1, JAM-A: F11R), α-catenin (CTNNA1), and protein 4.1 (EPB41), were altered 
across all the donor subsets. This also highlights the fact that this pathway appears to be 
more differentially up-regulated in T cells. A list of the genes that were recurrently 
affected by lenalidomide in T cells is given in Appendices K and L. 
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Figure 4.13 Heatmap showing altered expression of TJ signalling genes by donor 
subset 
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4.4.13 QRT-PCR validation of changes in mRNA levels of TJS genes 
The gene expression profiling data was validated at the mRNA level using QRT-PCR. 
As the tight junction signalling pathway was of particular interest, the genes chosen for 
validation purposes were related to this pathway (see Table 4.1; Material and Methods). 
The lenalidomide-induced changes in gene expression observed in the array data were 
all seen by PCR (Figure 4.14).  
 
Figure 4.14 Validation of TJ signalling gene expression changes by QRT-PCR  
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4.4.14 Flow cytometric validation 
Further validation was performed at the protein level using flow cytometry to 
investigate for lenalidomide-induced upregulation of junctional adhesion molecule-A 
(F11R), which is expressed on the surface of lymphocytes. In vitro treatment with 1μM 
lenalidomide resulted in a significant increase in the MFI of F11R on CD3+CD8+ T 
cells from both CLL patients and healthy donors (Figure 4.15).  
 
Figure 4.15 Upregulation of F11R (JAM-A/JAM-2) on CD3+CD8+ T cells by 
lenalidomide 
PBMCs were treated with 1μM lenalidomide or DMSO vehicle control for 48 hours and the expression of 
F11R (JAM-A/JAM-2) was assessed by flow cytometry. (A) Histogram demonstrating that F11R is 
highly expressed by lymphocytes, and is further increased by lenalidomide treatment. (B) Lenalidomide-
induced upregulation of F11R was observed on CD8+ T cells from both CLL patients (n = 6) and healthy 
donors (n = 6).  
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4.4.15 The impact of lenalidomide on the gene expression profiles of NK cells from 
CLL patients and healthy controls 
The impact of lenalidomide on the gene expression profiles of NK cells from CLL 
patients and healthy controls was also investigated. As before, PBMCs from CLL 
patients or healthy controls were cultured in the presence of 1μM lenalidomide or 
vehicle control for 48 hours, followed by RNA extraction and gene expression profiling. 
Once again, lenalidomide was an activator of gene expression with over 3 times as 
many probes being significantly up-regulated as down-regulated (Table 4.8). Some of 
the genes implicated in TJ signalling were also altered in NK cells, with CLDN12, 
RAB13, and CYFIP up-regulated in CLL NK cells with lenalidomide treatment, and 
CLDN12, TJP2, TPM2, ARHGEF5, CORO1B, ARL11, and CYFIP up-regulated in 
healthy NK cells.  
 
However, there were also some striking differences in the effect of lenalidomide on NK 
cells from CLL patients when compared with healthy NK cells. In CLL NK cells, 
lenalidomide repaired the down-regulation of interferon-inducible genes, by increasing 
the expression of several of these genes including OAS3, IFIT1, IFI44L, IFIT3, OAS1, 
F2RL, PDK4, and ACTN1. Pathways analysis using ingenuity highlighted the effect of 
lenalidomide on inducing interferon signalling, and also showed significant activation 
of interferons α, γ, and λ as upstream regulators (Figure 4.16). It also highlighted the 
importance of upregulation of related pathways that are important in pattern recognition 
of bacteria and viruses, which are a crucial component of the function of NK cells in the 
healthy immune system. 
 
Figure 4.16 Top 5 canonical pathways altered by lenalidomide treatment in NK 
cells using Ingenuity pathways analysis software 
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While many of the interferon-inducible genes were up-regulated >3-fold in CLL NK 
cells, only OAS3 was significantly up-regulated in healthy NK cells. Furthermore, the 
gene for IFNγ, IFNG, was actually significantly down-regulated in healthy NK cells by 
lenalidomide treatment. Furthermore, this agent also significantly down-regulated the 
expression of 5 genes encoding killer-cell immunoglobulin-like receptors (KIRs): 
KIR2DL1, KIR2DL2, KIR2DS3, KIR2DS4, and KIR3DL2, consistent with previous 
reports (Dauguet et al. 2010). No significant downregulation of KIR genes was 
observed in the CLL NK-cell dataset. Therefore, the gene expression profiling data 
would suggest that lenalidomide has a differential effect on CLL and healthy NK cells: 
in CLL NK cells it repairs defective interferon responsiveness, whereas in healthy NK 
cells it down-regulates inhibitory pathways. A list of the genes that were most affected 
by lenalidomide treatment (> 3 fold change) is given in Appendices M and N. 
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4.5 Discussion 
 
These results demonstrate that lenalidomide has significant effects on the gene 
expression profiles of lymphocytes from CLL patients and healthy controls. It has a 
wide variety of effects, including upregulation of cytoskeletal and interferon-inducible 
genes, and genes involved in B- and T-cell activation. This latter phenomenon is of 
particular interest in light of the fact that no cell stimulants such as anti-CD3 or BCR-
cross-linking, calcium ionophores, or plant lectins, were used in the PBMC culture 
system, providing further evidence for a co-stimulatory effect of lenalidomide. 
Combined analysis of all the datasets led to the novel finding that lenalidomide activates 
the “tight junction signalling” pathway, with upregulation in the expression of genes 
throughout this pathway. This was most marked in T cells, but comparable changes 
were also observed in B and NK cells. Intriguingly, while there was significant overlap 
in the pathways affected by lenalidomide in the various lymphocyte subsets, there was 
also a differential effect, particularly with respect to B and NK cells, depending on 
whether they were from patients or controls. This may well reflect differences in the 
baseline state of these subsets. For example, increased of tonic BCR-signalling in CLL 
cells could account for some of the observed differences seen when compared with 
healthy B cells. 
 
Initial concerns about the validity of using an in vitro culture approach were not born 
out. Differences in the gene expression profiles of B and T cells from CLL patients were 
still present after 48 hours of culture, and CLL cells treated with lenalidomide in vitro 
showed remarkably comparable changes in gene expression to those treated in vivo as 
part of a clinical trial. Furthermore, while it would have been relatively straightforward 
to isolate enough CLL cells for microarray analysis from CLL patients having 
lenalidomide treatment, it would have been extremely difficult to extract enough T or 
NK cells from these patients for gene expression profiling using the same method. 
Another advantage of this approach was that it allowed comparison of the effects of 
lenalidomide on lymphocytes from CLL patients and healthy individuals, as treating 
healthy subjects with this agent would not have been ethical.  
 
However, there were some notable differences. In particular CD4
+
 T cells from CLL 
patients showed significantly fewer dysregulated genes after 48 hours of culture than in 
my group’s previous analysis of freshly isolated cells, whereas CLL CD8+ T cells 
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retained their altered transcriptional state. This could be due to the fact that changes in 
the gene expression profiles of CD4+ T cells are induced in the lymph nodes of patients, 
and get normalised after 48 hours culture in PBMCs. In contrast, the changes in CD8
+
 T 
cells may reflect both exhaustion, which is less readily reversible, and the fact that the 
PBMC culture system better reflects their “niche” in the peripheral blood of CLL 
patients. 
 
Lenalidomide had profound effects on the gene expression profiles of CLL cells, with 
alterations in the expression of genes implicated in several pathways. Of particular 
interest was the finding that lenalidomide induces CLL-activation, with upregulation of 
genes such as CCL4, LAG3, CD83, TNF, TNFRSF4 (OX40; CD134) and TNFRSF13B 
(TACI). This is potentially paradoxical given the recent reports of significant clinical 
efficacy of inhibitors of BCR-signalling such as ibrutinib and idelalisib. This 
observation might be explained by the fact that lenalidomide also has an activating 
effect on T-cells, and repairs immunological synapse formation and cytotoxicity. 
Activation of CLL cells may also lead to repair of their antigen presenting function 
rendering them more susceptible to the anti-tumour effects of the now activated and 
functional autologous T and NK cells. This process may be further enhanced by 
lenalidomide-induced secretion of the T-cell chemokine CCL4 by CLL cells, which 
would attract the T cells to their target. 
 
The observations regarding the baseline differences in the transcriptome of CLL NK 
cells and the differential effects of lenalidomide are novel and of significant interest. 
NK cells from CLL patients have widespread down-regulation of interferon-inducible 
genes, many of which are implicated in host immunity to viral infections. It is therefore 
possible that decreased NK-cell responsiveness to interferon contributes to the increased 
susceptibility of CLL patients to intracellular pathogens such as viruses. This finding 
requires further investigation, in particular, whether these changes in gene expression 
translate into functionally defective NK-cell responses to interferon and other 
macrophage-derived cytokines. The differential effect of lenalidomide on NK cells from 
CLL patients compared to healthy controls is also intriguing. While lenalidomide up-
regulates interferon inducible genes and could be postulated to restore NK-cell 
functionality in CLL, it has more complex effects on NK cells from healthy individuals, 
down-regulating both IFNγ and the expression of inhibitory KIR molecules.  
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The finding that lenalidomide activates tight junction (TJ) signalling in lymphocytes, 
particularly in T cells, was unexpected. Tight junctions are closely associated areas of 
two epithelial or endothelial cells whose membranes join together forming a barrier to 
fluid (Figure 4.17). Their principle functions are to hold cells together, joining the 
cytoskeletons of adjacent cells maintaining apical-basal cell polarity, and to prevent the 
passage of molecules and ions through the intercellular space. This latter function is 
particularly important for epithelial layers, for example in the gut, where trans-cellular 
route exchange allows for control of ion and molecular gradients (Matter and Balda 
2003). 
 
Figure 4.17 Epithelial intercellular junctions 
A schematic representation of a polarised absorptive epithelial cell. The different types of intercellular 
junction, as well as hemi-desmosomes, a type of cell-extracellular matrix adhesion a shown. It should be 
noted that TJs and adherens junctions (AJs) are linked to the actin cytoskeleton, whereas desmosomes and 
hemidesmosomes are linked to intermediate filaments (Matter and Balda 2003). 
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TJs were long regarded as simple barriers that separated compartments of different 
composition, but more recent research has also implicated them in the regulation of cell 
signalling. Evidence suggests that these structures are involved in receiving and 
converting signals from the cell interior that regulate their assembly and function 
(“inside-out”), as well as transmitting signals to the cell interior to modulate gene 
expression and cell proliferation (“outside-in”). This is an emerging area, but several 
pathways of significant interest in haematological malignancies have been implicated, 
including cyclin D1, myc, HDAC and AP1 (Figure 4.18). 
 
 
Figure 4.18 TJ proteins in the control of gene expression (Balda and Matter 2009)  
 
In light of lenalidomide’s known effects on actin polymerisation and RhoGTPase 
activation, the close association of TJ signalling to the cytoskeleton is of obvious 
interest (Ramsay et al. 2008; Xu et al. 2009). RhoGTPases such as Rac, RhoA and 
cdc42 are important components of TJs, and are known to be activated by lenalidomide. 
The link between ZO2 (TJP2; tight junction protein 2) and the AP1 transcription factors 
c-fos and c-jun is also of interest, given reports that co-stimulatory activity of IMiDs is 
associated with increased AP1 activity (Schafer et al. 2003). The next chapter will 
investigate TJ signalling in lymphocytes, and also examine whether an understanding of 
the regulation of TJ signalling illuminates the mechanism of action of lenalidomide.
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5 Chapter 5: The mechanism of action of lenalidomide 
 
5.1 Introduction 
 
5.1.1 Tight junction signalling in lymphocytes 
Investigation of the impact of lenalidomide on the gene expression profiles of healthy 
and malignant lymphocytes demonstrated that it activates the tight junction (TJ) 
signalling pathway, particularly in T cells. Very little is known about the role of this 
pathway in lymphocytes, although downstream molecules such as the RhoGTPases 
Rac1, RhoA, and cdc42 are known to be crucial, both in assembly/disassembly of TJs 
and in lymphocyte function. The junctional adhesion molecules JAMA, JAMB, and 
JAMC are known to be highly expressed by various lymphocyte subsets, and there are 
reports linking expression of these molecules to lymphocyte function and 
differentiation. JAMC has been demonstrated to be up-regulated in activated T cells via 
a transcriptional mechanism, suggesting a potential role for this molecule in T cell 
function (Immenschuh et al. 2009). JAMC has also been implicated in B-cell 
differentiation as its expression on CD27
+
 B cells has been shown to delineate B cells 
that have not undergone a germinal centre reaction (Ody et al. 2007). Occludin has also 
been shown to be up-regulated on activated lymphocytes, whereas it is virtually absent 
on resting T cells (Alexander et al. 1998). Interestingly, expression of claudin 1 and 
claudin 5 are elevated on peripheral blood leucocytes in multiple sclerosis patients at 
relapse, with claudin 5 and JAMC mRNA levels falling after glucocorticoid treatment 
(Mandel et al. 2012).  There is plenty of evidence implicating these molecules in the 
transendothelial migration of leucocytes, but nearly all of it has focused on the 
expression of these molecules by the endothelial cells rather than the leucocytes 
(Ostermann et al. 2002). However, other investigators have highlighted the high 
expression of junctional adhesion molecules by lymphocytes, and have suggested that 
there expression on leucocytes may play a role in transendothelial migration, potentially 
via homophilic interactions (Muller 2003). Interestingly, components of the tight 
junction pathway are known to be important for platelet aggregation; indeed JAMA was 
first described as an activating platelet receptor (F11R)(Gupta et al. 2000).Therefore, it 
is possible that activation of this pathway underlies the increased risk of thrombosis 
seen with the clinical use of IMiDs.  
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It light of this, it was hypothesised that components of this pathway may play an 
important role in lymphocyte function, with aspects of TJ signalling being involved in 
cell motility and immunological synapse formation, accounting for the functional 
effects that my group has previously described. Therefore, the aim of the first part of 
this chapter was to assess whether there is any evidence of defective TJ signalling in 
lymphocytes from CLL patients. 
 
5.1.2 The regulation of tight junction signalling 
The second aim of this chapter was to examine whether an understanding of the 
regulation of TJ signalling illuminates the mechanism of action of lenalidomide. TJs are 
a very active part of epithelial/endothelial cell layers, with high plasticity. Assembly 
and disassembly of TJs is a continuous process, and can occur by endocytotic 
internalization of TJ proteins or by supply of new TJ proteins from the Golgi apparatus. 
Occludin was the first integral TJ protein identified, and a consequence its regulation 
has been the most extensively studied. It localisation within the cell depends on its 
phosphorylation status, which is tightly regulated. Several kinases have been implicated 
in this process, including aPKC, PKA, MAPK, PI3K, CK1, CK2 and RhoK (Schulzke 
et al. 2012). Phosphatases are understandably also implicated, with PP2A of particular 
importance as a negative regulator. PP2A over-expression severely prevents TJ 
assembly, whereas inhibition of PP2A by okadaic acid promotes the phosphorylation 
and recruitment of ZO1 (zona occludens 1; tight junction protein 1), occludin and 
claudin1 to the TJ during functional biogenesis. The inhibitory effect of PP2A is 
mediated by its ability to dephosphorylate aPKCδ at the regulatory Thr410 residue, 
blocking the activation of this kinase (Nunbhakdi-Craig et al. 2002). PP2A also inhibits 
TJ signalling by directly dephosphorylating JAMA at Ser285, blocking JAMA adhesion 
and the development of a functional epithelial barrier (Iden et al. 2012). 
 
PP2A is one of the four major serine/threonine phosphatases. Like most phosphatases 
its broad substrate specificity means that it is implicated in many cellular processes, in 
particular as a regulator of cell growth and division. It is a heteromeric core enzyme 
composed of a structural A subunit, a regulatory B subunit, and a catalytic C subunit.  
 
Notably, there is evidence linking PP2A to the activity of lenalidomide in MDS. An 
early clinical study found that patients with 5q deleted MDS responded especially well 
to lenalidomide compared to patients with a normal karyotype or other karyotypic 
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abnormalities (List et al. 2005). This observation sparked a great deal of interest in 
whether the genes that were normally encoded in the deleted part of chromosome 5q 
were important in the mechanism of action of lenalidomide. As a result, several 
candidate genes were identified as being potentially important in lenalidomide 
sensitivity, which included PP2A, which has two subunits encoded on chromosome 5q, 
and a gene encoding another component of the TJ signalling pathway, α-catenin (Padron 
et al. 2011). Subsequent work showed that PP2A was inhibited by lenalidomide. This 
provided an explanation for the clinical efficacy of this drug, as further inhibition of 
PP2A in 5q deleted MDS progenitors that were already haplo-deficient for this 
phosphatase, made them especially susceptible to cell arrest (Wei et al. 2009). 
 
Other investigators have also noted a link between PP2A inhibition and lenalidomide. 
Lenalidomide has been shown to promote expression of CD154 on CLL cells through a 
PI3K-dependent mechanism (Lapalombella et al. 2010). Further work demonstrated that 
this effect is mediated by PP2A inhibition, which results in PI3K activation and 
increased AKT phosphorylation. This is supported by observations that the PP2A 
activating agent 1,9-di-deoxyforskolin, when co-incubated with lenalidomide, 
antagonises lenalidomide induced CD154 mRNA and protein, whereas treatment with 
the PP2A inhibitor okadaic acid mimics the effects of lenalidomide on CD154 and AKT 
phosphorylation. Therefore assessment of the effect of lenalidomide on the activity of 
PP2A in CLL cells and T cells was the second aim of this chapter. 
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5.2 Materials and Methods 
5.2.1 Patients and Samples 
Peripheral blood samples were obtained from CLL patients from the tissue bank 
maintained by the Department of Haemato-Oncology of St. Bartholomew’s Hospital, 
London. Ethical approval was confirmed by the East London & The City Health 
Authority Local Research Ethics Committee, and written informed consent was 
obtained in accordance with the Declaration of Helsinki. Healthy PBMCs were obtained 
from buffy coats/cones supplied by the National Blood Service. The same RNA samples 
that were used for the vehicle control condition for the gene expression profiling were 
also used for QRT-PCR. A different cohort of samples was used for the flow cytometric 
analyses. 
 
5.2.2 Cell Culture and isolation of lymphocyte subsets 
Peripheral blood samples were cultured as described in section 4.3.2. The lymphocyte 
subsets were isolated and their purity determined as described in sections 4.3.3 and 
4.3.4. 
 
5.2.3 QRT-PCR 
The expression of six genes involved in TJ signalling was compared between CLL cells 
and healthy B cells, and between T cells from CLL patients and controls (Table 5.1). 
RNA extracted from the vehicle control samples (i.e. lenalidomide untreated) was re-
used for the analysis. 8 patients and controls were used for CD8
+
 T cells and B cells, 
and 7 patients and controls were used for CD4
+
 T cells. In all cases the expression of 
each target was normalised to the expression of GAPDH (Human GAPDH endogenous 
control; Invitrogen/Applied Biosystems) to give a ΔCT value. This was calculated by 
subtracting the mean CT value for reference gene (GAPDH) from the mean CT value of 
the target gene. As the fluorescence doubles with each cycle during the exponential 
phase of the reaction, log base 2 of the -ΔCT value (2
-ΔCT
) gives a measure of the 
absolute relative expression of each gene compared to GAPDH in each sample. This 
value was then multiplied by 100 (100 x 2
-ΔCT
) to give % expression of each target gene 
relative to GAPDH. 
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Table 5.1 Taqman primers used for QRT-PCR 
Gene Name Description Taqman® Gene 
Expression Array 
CLDN12 claudin 12 Hs01082669_m1 
F11R F11 receptor Hs00170991_m1 
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa Hs00944794_m1   
TJP2 tight junction protein 2 (zona occludens 2) Hs00910543_m1 
RND1 Rho family GTPase 1 Hs00205507_m1 
WASF1 WAS protein family, member 1 Hs01591751_m1 
 
5.2.4 Monoclonal antibodies 
The following directly conjugated monoclonal antibodies were used in this study: 
CD40-PECy7, CD80-PECy7, CD83-PE and CD321-PE were all obtained from BD 
Biosciences; CD5-PerCPCy5.5, CD19-APCCy7, CD3-Pacific-Blue, CD8-PerCpCy5.5, 
and IFNγ-FITC were all obtained from eBioscience. 
 
5.2.5 Immunofluorescence staining and flow cytometric analysis  
Surface and intracellular staining for flow cytometric analysis was performed as 
described in section 2.7. Flow cytometry was performed on a BD Fortessa flow 
cytometer with subsequent analysis using FlowJo software (Tree Star). Analysis was 
performed on a minimum of 10,000 events after gating on live singlet cells.  
 
5.2.6 Cell stimulation and lenalidomide/okadaic acid treatment 
For assessing the impact of lenalidomide or okadaic acid on cell surface molecule 
expression, PBMCs were cultured for 48 hours in the presence of 1μM lenalidomide, 
10nM okadaic acid or 0.01% DMSO vehicle control. For assessment of IFNγ 
production PBMCs or purified CD3
+
CD8
+
 T cells were stimulated with 1µg/ml soluble 
anti-CD3 (clone HIT3a, BD) and 5µg/ml soluble anti-CD28 (clone CD28.2, 
eBioscience) for 72 hours and incubated at 37
o
C; 5% CO2.  4 hours before analysis 0.66 
µl/ml Golgistop (BD) was added to inhibit cytokine secretion. 
 
5.2.7 Western blotting 
Western blotting was performed as described in section 2.11.3. Polyclonal primary 
rabbit antibodies to human ZO2 (TJP2) and α-catenin were from Cell signaling (New 
England Biolabs); rabbit polyclonal antibody to human claudin12 was from invitrogen. 
The goat anti-rabbit-HRP secondary antibody was from Dako. 
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5.2.8 Statistical analysis 
All data sets were subject to normality testing using the Shapiro-Wilk normality test. 
Where all data sets could be accurately modelled by a Gaussian distribution an unpaired 
t test was used for analysis of differences between groups; where this was not the case 
the 2-sided Mann Witney U test was used. For comparison of more than two groups the 
Kruskal-Wallis test was used with Dunn’s post test for multiple comparisons. P values 
of less than 0.05 were considered statistically significant. 
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5.3 Results 
5.3.1 Junctional adhesion molecule-A (JAMA) is down-regulated on CD8+ T cells 
from CLL patients 
In light of the observations regarding up-regulation of TJ signalling by lenalidomide, it 
was hypothesised that some of the clinical efficacy of this agent in CLL might be due to 
repair of this pathway which is in turn defective in patient T cells. Junctional adhesion 
molecule-A (JAMA; JAM1; F11R) is 32-35kDa protein that is expressed on platelets, 
leukocytes, red blood cells, endothelial cells, epithelial cells, and various cell lines. It is 
known to be important in platelet function and is expression on endothelial cells is has 
been demonstrated to be crucial for leucocyte transendothelial migration (Ostermann et 
al. 2002). Despite the fact that JAMA is known to be highly expressed by lymphocytes, 
relatively little is known about its function on these cells. The levels of JAMA mRNA 
and protein were compared between CD8
+
 T cells from CLL patients and healthy 
controls. CLL CD8
+ 
T cells were observed to have decreased levels of JAMA mRNA by 
QRT-PCR (P < 0.0001). Patient CD8
+ 
T cells were also noted to have reduced 
expression of JAMA protein on their surface (P < 0.0001), which this defect becoming 
more pronounced with disease progression (Figure 5.1). 
 
Figure 5.1 JAMA (F11R) is downregulated on CD8
+
 T cells from CLL patients 
(A) Levels of JAMA mRNA are significantly reduced in CLL CD8+ T cells. (B)&(C) The expression of 
JAMA protein is reduced on CLL CD8
+
 T cells and falls further with disease progression (Binet B/C)  
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5.3.2 Levels of JAMA mRNA are reduced in CD4+ T cells from CLL patients but 
this does not translate into significantly reduced protein expression 
The expression of JAMA was also compared on CD4
+
 T cells from CLL patients and 
healthy controls. As with CD8
+
 T cells there was a significant reduction in the levels of 
JAMA mRNA by QRT-PCR (P = 0.0006). However this did not translate in to 
significant reduction in protein expression on the cell surface as measured by flow 
cytometry (P = 0.15)(Figure 5.2). 
 
Figure 5.2 JAMA mRNA is down-regulated in CD4
+
 T cells from CLL patients 
(A) Levels of JAMA mRNA are significantly reduced in CLL CD4
+
 T cells. (B)&(C) The expression of 
JAMA protein is not significantly reduced on CLL CD4
+
 T cells 
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5.3.3 The expression of proximal TJ signalling genes are downregulated in CD8+ T 
cells  
The expression of the proximal TJ signalling genes CLDN12 and TJP2, and the 
cytoskeletal gene WASF1 was compared between CD8
+
 T cells from CLL patients and 
healthy donors. There was a significant decrease in the expression of these genes in 
CD8+ T cells from CLL patients (Figure 5.3). 
 
Figure 5.3 The expression of proximal TJ genes is down-regulated in CD8
+
 T cells 
from CLL patients  
The expression of CLDN12, TJP2, WASF1 was compared by QRT-PCR. There was decreased expression 
of CLDN12 (A), TJP2 (B), and WASF1 (C) in CD8+ T cells from CLL patients. 
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5.3.4 The expression of proximal TJ signalling genes in CD4+ T cells  
The expression of the proximal TJ signalling genes CLDN12 and TJP2, and the 
cytoskeletal gene WASF1 was also compared between CD4
+
 T cells from CLL patients 
and healthy donors. While there was a significant decrease in the expression TJP2 (P = 
0.039) there was no change in the expression of CLDN12 or WASF1 (Figure 5.4). 
Overall, while there is some evidence consistent with a defect in this pathway in CD4
+
 
T cells from CLL patients, this is not a marked as in CD8
+
 T cells 
 
Figure 5.4 The expression of proximal TJ signalling genes in CD4+ T cells 
The expression of CLDN12, TJP2, WASF1 was compared by QRT-PCR. There was decreased expression 
of CLDN12 (A), TJP2 (B), and WASF1 (C) in CD8+ T cells from CLL patients. 
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5.3.5 JAMA is up-regulated on CLL cells  
Previous work by my group demonstrated that treatment of both CLL cells and 
autologous T cells with lenalidomide was required to repair dysfunctional 
immunological synapse formation (Ramsay et al. 2008). This suggested that a 
cytoskeletal defect was also present in CLL cells, which can be repaired by 
lenalidomide. In light of this the expression of components of TJ signalling were also 
compared between CLL cells and healthy B cells. Surprisingly, there were increased 
levels of JAMA mRNA in CLL cells, which correlated with increased expression of 
JAMA protein on the cell surface (Figure 5.5). These findings also validated data from 
the Affymetrix array comparison between healthy and CLL B cells, which also found 
increased expression of the genes that encodes JAMA, F11R.  
 
Figure 5.5 JAMA is up-regulated on CLL cells 
(A) Increased expression of JAMA mRNA in CLL cells by QRT-PCR and from the Affymetrix 
microarray dataset. (B) Increased expression of JAMA by flow cytometry  
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5.3.6 Increased expression of proximal TJ signalling genes in CLL cells  
The expression of the proximal TJ signalling genes, CLDN12 and CTNNA1, and the 
RhoGTPase, RND1, were compared between CLL B cells and healthy B cells. There 
was a significant increase in the expression of all three of these genes in CLL cells 
(Figure 5.6).  
 
Figure 5.6 Increased expression of proximal TJ signalling genes, and the 
RhoGTPase RND1 in CLL cells 
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5.3.7 Claudin 12, tight junction protein 2, and α-catenin are only very weakly 
expressed/not expressed in healthy T cells 
Attempts were made to validate alterations in expression of CLDN12, TJP2, and 
CTNNA1 at the protein level using western blotting in healthy T cells. The human 
embryonic kidney (HEK) cell line, which is known to express these molecules, was 
used as a positive control. Human T cells did show very low but detectable levels of 
Claudin-12 protein, but no detectable expression of tight junction protein 2 or α-catenin 
(Figure 5.7). No bands were detectable even after lenalidomide treatment. 
 
  
Figure 5.7 Claudin-12, tight junction protein 2 and α-catenin are only very 
weakly/not expressed in healthy T cells 
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5.3.8 Okadaic acid mimics the effect of lenalidomide on T cells 
It was hypothesised that investigation of how the TJ signalling pathway is regulated, 
would provide novel insights into the underlying mechanism of action of lenalidomide. 
As discussed, protein phosphatase 2A (PP2A) is a known to be a negative regulator of 
tight junction signalling and has been implicated in the mechanism of action of 
lenalidomide in MDS with deletions of 5q. Okadaic acid, a marine toxin that is 
responsible for the diarrhoeal illness associated with some cases of shellfish poisoning, 
is a known inhibitor of PP2A. The diarrhoea is thought to be caused by modulation of 
epithelial tight junctions in the gut, resulting in increased para-cellular permeability, and 
loss of fluid into the gut lumen. Okadaic is also known to have immunodulatory effects 
on T cells. It has been shown to enhance the cytotoxicity of CD8
+
 T cells, to activate co-
stimulatory pathways, and to activate AP-1, NF-κB, and TNFα in lymphocytes (Taffs et 
al. 1991; Chuang et al. 2000; Kray et al. 2005). Therefore the ability of okadaic acid to 
mimic lenalidomide-enhanced production of IFNγ by anti-CD3 stimulated CD3+CD8+ T 
cells was assessed. As shown in Figure 5.8, treatment with 10nM okadaic acid was able 
to mimic the effect of lenalidomide on healthy CD8+ T cells in terms of IFNγ 
production.  
 
Figure 5.8 Okadaic acid mimics the ability of lenalidomide to enhanced production 
of IFNγ by anti-CD3 stimulated CD3+CD8+ T cells 
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5.3.9 Okadaic acid mimics the effect of lenalidomide on CLL cells 
The effect of okadaic acid on CLL cells was also assessed. PBMCs from CLL patients 
were treated with either 10nM okadaic acid or 1μM lenalidomide or vehicle control for 
48 hours, before the expression of CD40, CD80, and CD83 was assessed by flow 
cytometry. Okadaic acid qualitatively mimicked the effect of lenalidomide treatment on 
CLL cells, with respect to expression of these surface molecules (Figure 5.9). 
 
Figure 5.9 Okadaic acid mimics the upregulation of CD40, CD80 and CD83 
induced by lenalidomide treatment of CLL cells.  
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5.4 Discussion 
These results provide evidence that TJ signalling is down-regulated in T cells from CLL 
patients, particularly in CD8
+
 T cells and that lenalidomide treatment repairs a defect in 
this pathway, which results in functional improvements in T-cell activation, 
immunological synapse formation and cytotoxicity. However, very little is known about 
the role of TJ signalling in lymphocytes. The junctional adhesion molecules, occludin, 
and some of the claudins are known to be highly expressed on lymphocyte subsets, but 
their functional significance remains unclear. Furthermore, investigation of expression 
of claudin12, α-catenin and TJP2 proteins showed negligible levels of these molecules 
in healthy primary T cells compared to the HEK293 cell line. It quite possible that 
upregulation of the TJ pathway by lenalidomide is an epi-phenomenon and little 
functional significance. However, other molecules downstream in this pathway are 
known to be crucial in T-cell function, including cdc42, RhoA, Rac1, and TIAM1 
(Figure 5.10). An activating effect of lenalidomide on RhoA, Rac1, and Cdc42 has 
been previously demonstrated by our group (Ramsay et al. 2012; Ramsay et al. 2013). 
Furthermore, it is reasonable to speculate that components of cell adhesion and motility 
are widely used and evolutionarily conserved between cell types. 
 
Figure 5.10 Tight junction signalling pathway (Sabio Biosciences) 
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Even if upregulation of components in this pathway do represent an epi-phenomenon in 
T cells, an understanding of the regulation of TJ signalling should shed new light on the 
underlying immunomodulatory mechanism of action of lenalidomide. It is reasonable to 
test the hypothesis that pathways involved in the regulation of TJ signalling may also be 
implicated in the mechanism of action lenalidomide. One such molecule is the protein 
phosphatase PP2A, which is known to be a negative regulator of TJ signalling. It could 
be expected that lenalidomide inhibits PP2A, and indeed evidence from the literature 
supports this hypothesis. Inhibition of PP2A has been demonstrated to underlie the 
efficacy of lenalidomide in 5q deleted MDS and to account for the up-regulated of 
CD154 induced by lenalidomide treatment of CLL (Wei et al. 2009; Lapalombella et al. 
2010).  Further support for this has been provided in by the data presented here, which 
shows that the treatment of CLL cells and T cells with the PP2A inhibitor okadaic acid 
is able to mimic lenalidomide treatment. While pharmacological manipulation provides 
some evidence, further work needs to be done. Okadaic acid has several off-target 
effects, including an ability to inhibit other phosphatases including PP1 and PP2B. A 
significant amount of effort was directed at optimising a PP2A activity assay (described 
in section 2.12). Unfortunately due to time constraints this was not completed by the 
time of thesis submission but will be re-attempted in a period of post-doctoral work. It 
would also be useful to investigate whether siRNA knockdown of PP2A is able to 
simulate the effect of lenalidomide and whether the lenalidomide effects in gene 
expression are antagonised by PP2A activators such as 1,9-di-deoxyforskolin and 
fingolimod (FTY720). 
 
An aspect of the biology of PP2A that is particularly relevant to T cells is that it 
mediates the inhibitory effects of CTLA4. CTLA4 is an inhibitory receptor that acts 
both directly, by decreasing phosphorylation of signalling proteins proximal to the T-
cell receptor, and indirectly, by competing with CD28 for CD80/CD86 binding (van der 
Merwe et al. 1997; Lee et al. 1998). The cytoplasmic domain of CTLA4 has been 
shown to associate with PP2A, and CTLA4-mediated inhibition of PI3K/AKT 
activation has been demonstrated to be sensitive to PP2A inhibition by okadaic acid 
(Chuang et al. 2000; Teft et al. 2009). In addition to PD1, CD160, and CD244, many 
other inhibitory receptors have been implicated in T-cell exhaustion, including CTLA4 
(Wherry 2011). While the function of exhausted T-cells can be improved by PD1 
blockade alone, the recovery of function is considerably enhanced by simultaneous 
blockade of PD1 and CTLA4 (Nakamoto et al. 2009). This area has considerable 
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implications for the field of cancer immunotherapy, given the successes reported with 
CTLA4 blockade in malignant melanoma, both with and without simultaneous blockade 
of PD1 (Hodi et al. 2010; Wolchok et al. 2013). It remains unclear whether the CTLA4-
PP2A axis plays a role in the immune defect in CLL. An early report showed no 
demonstrable increase in the expression of CTLA4 on T cells from CLL patients 
(Scrivener et al. 2001). However, other investigators have reported an increase in 
CTLA4 expression on CLL T cells, along with an expansion of the 
CD4
+
CD25
+
CTLA4
+
 Treg subset (Beyer et al. 2005; Motta et al. 2005). However, 
dynamic changes in expression of CTLA4 may be more important, as CLL T cells also 
show a greater degree of upregulation and prolonged expression of CTLA4 upon T-cell 
activation, (Frydecka et al. 2004). Therefore, it is possible that lenalidomide-induced 
inhibition of PP2A may “release” T cells from the inhibitory effect of this receptor. 
 
An unexpected finding was that CLL cells showed up-regulation of TJ signalling when 
compared with healthy CD19
+
 B cells. Previous observations by my group had shown 
that lenalidomide treatment of both CLL cells and autologous T cells was required to 
repair immunological synapse formation. It may be possible that lenalidomide has 
differential effects on the CLL cells as compared to T cells. One interpretation is that 
the primary effect of lenalidomide is to repair a cytoskeletal defect in the T cells, but to 
down-regulate the expression of inhibitory receptors/up-regulate the expression of co-
stimulatory ligands on the CLL cells. The activation of TJ signalling in untreated CLL 
cells may actually allow for increased tissue-homing of the circulating tumour cells, 
increasing their contact with survival and proliferation signals within lymph nodes. 
Intriguingly, this upregulation of TJ signalling in CLL cells is consistent with a report 
showing decreased activity of PP2A in these malignant cells compared to healthy B 
cells (Yamamoto et al. 1999). Indeed inhibition of PP2A is a common event in 
leukaemia, having also been observed in AML, ALL, and blast crisis CML (Yamamoto 
et al. 1999; Neviani et al. 2005; Cristobal et al. 2011). Furthermore the activators of 
PP2A, 1,9-di-deoxyforskolin and fingolimod (FTY720) have shown promising pre-
clinical activity for CLL and AML (Liu et al. 2008; Cristobal et al. 2011). However, it 
could be speculated that these agents could have potential immuno-suppressive side 
effects: indeed fingolimod has been used in the treatment of relapsing forms of multiple 
sclerosis, where it sequester lymphocytes in lymph nodes, preventing them from 
moving to the central nervous system to induce auto-immunity (Kappos et al. 2006).  
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A second molecule of significant interest in the regulation of TJ signalling is 5' 
adenosine monophosphate-activated protein kinase (AMPK). AMPK acts as a metabolic 
master switch regulating several intracellular systems including the cellular uptake of 
glucose, the β-oxidation of fatty acids and the biogenesis of glucose transporter 4 
(GLUT4) and mitochondria. In general, activation of AMPK switches on ATP-
generating pathways, while switching off ATP-consuming processes. The activity of 
AMPK is modulated both by the intracellular AMP:ATP ratio and by upstream kinases 
including AMPK kinase (AMPKK). AMPKK is a complex of three proteins, STE-
related adaptor (STRAD), mouse protein 25 (MO25), and liver kinase B1 (LKB1). 
Interestingly, LKB1 is a serine-threonine kinase and activates AMPK by 
phosphorylating it at the threonine-172 residue – a process which is known to be 
directly antagonised by the serine-threonine phosphatase activity of PP2A (Wu et al. 
2007). AMPK has been shown to be important in the regulation of epithelial tight 
junctions. AMPK is activated during calcium-induced TJ assembly and this increase 
depends on the kinase activity of LKB1 (Zheng and Cantley 2007). Furthermore, 
activation of AMPK by 5-aminoimidazole-4-carboxamide ribonucleoside facilitates TJ 
assembly under conditions of normal extracellular calcium concentrations and also 
initiates TJ formation in the absence of calcium (Zhang et al. 2006). Intriguingly, the α1 
subunit of AMPK has also been shown to interact directly with cereblon (CRBN), 
which has recently emerged as the target of IMiDs including lenalidomide (Chang and 
Stewart 2011; Lee et al. 2011). AMPK comprises a heterotrimer of a catalytic α subunit, 
and two regulatory subunits, β and γ. CRBN binding to the AMPK α1 subunit competes 
with AMPK γ1 for AMPK complex formation, with this competition resulting in 
decreased activation of AMPK. Therefore, under normal circumstances, CRBN 
functions as a negative regulator of AMPK. It is therefore possible that binding of IMiD 
drugs to CRBN reduces its affinity for the AMPK α1 subunit, leading to enhanced 
AMPK activation.  
 
AMPK is also known to be important for T-cell function. Quiescent naive and memory 
T cells have a different metabolic profile to effector cells, as the quiescent T cells only 
require enough energy to prevent cell atrophy and for survival and migration, whereas 
effector T cells need to proliferate and to release cytolytic molecules and/or effector 
cytokines. One model that has been proposed is that effector and memory T-cell 
metabolism is dominated by  two opposing metabolic pathways – PI3K/Akt/mTOR-
mediated cellular growth and AMPK/Fatty acid oxidation-mediated cellular 
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homeostasis (Cui and Kaech 2010)(Figure 5.11). It is therefore possible that 
lenalidomide treatment of T cells results in a complete metabolic re-programming that 
may have implications for exhausted T cells.  
 
 
Figure 5.11 Effector versus memory T cells and their generation 
(Cui and Kaech 2010) 
 
However, this is an emerging area and many aspects remain unclear. Firstly central 
memory cells are able to generate a strong response to antigen re-encounter, which 
involves extensive cell proliferation and production of IL2. Furthermore, while LKB1 
phosphorylates and activates AMPK in response to increases in cellular AMP:ATP 
ratios, AMPK can also be activated through a calcium-calmodulin dependent protein 
kinase pathway in response to TCR triggering, and plays a role in T-cell activation. 
Indeed it has therefore been proposed that AMPK is important for promoting the 
conservation and accelerated production of ATP during T-cell activation to regulate 
energy supplies and stop them becoming depleted (Finlay and Cantrell 2011). 
Intriguingly, the AMPK activating kinase LKB1 has also been shown to localise to the 
immunological synapse (Wildenberg et al. 2012). In light of these observations, the 
potential role of AMPK activation in the mechanism of action of lenalidomide will be a 
topic for further investigation. 
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6 Chapter 6: Discussion 
 
Over the past decade there have been major advances in our understanding of the patho-
physiology of CLL, and in the identification of biomarkers that predict the clinical 
course for individual patients. Over the same period of time, the available therapeutic 
options have developed dramatically, exemplified by the introduction of combination 
therapy with purine analogues and monoclonal antibodies, resulting in significant 
opportunities to induce complete remission (Hallek et al. 2010). B-cell receptor 
signalling inhibitors are showing great promise, but patients are starting to relapse and 
poor risk subgroups (e.g. deletions or 11q or 17p-) are already showing inferior 
response rates (Byrd et al. 2013). Therefore it does not appear that these agents are a 
true “cure” for CLL, although their clinical efficacy and better tolerability profile 
represent a major breakthrough. 
 
Currently, allogeneic HSCT remains the only curative option for CLL. The key to its 
activity is the graft-versus-leukaemia (GVL) effect, whereby the transplanted 
haematopoietic stem cells differentiate into effector cells capable of mounting an anti-
tumour immune response, which is likely directed at minor host antigenic variations. 
This effect is known to be primarily T-cell mediated, although it remains unclear 
whether it is due to improved T-cell function, the presence of allogeneic MHC 
molecules, or a combination of both (Kolb 2008).  One of the major obstacles to the 
treatment of CLL (in common with other malignancies) is that the tumour cells show a 
capacity to undergo clonal evolution and develop resistance to any single 
pharmaceutical treatment. A potential advantage of immunotherapies is that the cellular 
nature of the anti-cancer effect allows for evolution of the anti-tumour immune response 
in parallel to the changes in the genetic landscape of the tumour itself. The aim of this 
thesis was to characterise the nature of the T-cell defect in CLL, and to investigate the 
mechanism of action of lenalidomide. Lenalidomide is clinically efficacious in CLL, but 
unlike other agents is not directly toxic to the tumour cells in vitro. Instead its efficacy 
appears to be mediated by immune activation resulting in induction of anti-tumour 
immune responses, and blockade of pro-tumour factors in the CLL microenvironment. 
In light of this, it was hypothesised that a deeper understanding of exactly what 
lenalidomide is “repairing” would lead to further characterisation of the nature of the 
immune defects. This could then allow for the development of immunomodulatory 
drugs and therapies that do not have the problematic side effect profile of this agent.  
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Chronic stimulation is increasingly recognised as being important in the pathogenesis of 
CLL. Observations regarding the presence of over-represented “stereotyped” BCRs, the 
importance of prognostic markers associated with BCR-signalling, and the success of 
inhibitors of BCR-signalling have all indicated that CLL cells derive important survival 
and proliferation signals from the BCR. It is possible that this represents a property of 
the BCR itself, leading to antigen-independent cell autonomous signalling, but a wealth 
of evidence remains supporting a role for antigenic drive (Lanemo Myhrinder et al. 
2008; Minden et al. 2012). In light of this, it was hypothesised that this chronic 
antigenic drive also affects the T-cell compartment, leading to a state of T-cell 
exhaustion analogous to that observed in the context of chronic viral infections. This 
was particularly attractive given the expansion of circulating CD8
+
 T cells in the 
peripheral blood of CLL patients, a state which is normally seen in the context of viral 
infections. Investigation of this did indeed show that circulating T cells from CLL 
patients exhibited features of T-cell exhaustion, with increased expression of exhaustion 
markers, a skew towards antigen experienced subsets, an altered transcription factor 
profile, and functional defects in proliferation and cytotoxicity. The main way in which 
CLL T cells differed from classically virally exhausted T cells, what that there was no 
global defect in cytokine production. Exhausted T cells generally lose the ability to 
produce IL2 initially, with loss of TNFα and IFNγ production at more severe stages of 
dysfunction. Importantly, these observations have been made in antigen-specific cells in 
the virally-induced exhaustion, with T-cell function being studied by use of viral 
peptides. However, it was not possible to do the same investigations in CLL due to the 
elusive nature of the antigen, necessitating the use of polyclonal stimulation. 
 
There are three main pathways that have been shown to be important in the 
regulation/promotion of exhausted T cells in addition to chronic antigenic drive.  These 
include inhibitory signalling axis such as the PD1:PDL1 axis, inhibitory T cells subsets 
such as Tregs and inhibitory cytokines such as IL10 (Wherry 2011). My group has 
focused on the role of inhibitory ligand interactions in CLL. In particular, they have 
demonstrated that T cells from CLL patients exhibit impaired immunological synapse 
formation with APCs, and that this defect could be induced in healthy T cells by co-
culturing them with CLL cells (Ramsay et al. 2008; Ramsay et al. 2012). Importantly, 
subsequent work showed that this effect was mediated by 4 inhibitory ligands that 
included PDL1 and HVEM, ligands for receptors that are up-regulated on exhausted T 
cells. Furthermore, Tregs are expanded in CLL, are functionally able to suppress 
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autologous T-cell proliferation, and higher numbers are associated with an impaired 
prognosis (Beyer et al. 2005; Weiss et al. 2011). IL10 is also implicated in the 
pathogenesis of CLL, as patients have higher serum levels of this cytokine compared to 
controls with higher levels correlating with impaired outcome (Fayad et al. 2001). So 
not only are T cells in CLL phenotypically and functionally exhausted: there is 
upregulation of these pro-exhaustion pathways as well. However, there are several 
unanswered questions. The understanding of T-cell exhaustion is incomplete and 
observations have been primarily made in CD8
+
 T cells: it remains unclear what the 
implications are for CD4
+
 T cells, which are of particular importance in the lymph node 
microenvironment in CLL. As discussed above, it is also not clear what is driving this 
chronic stimulation, whether this is antigen, representing infection or autoimmunity or 
both (molecular mimicry), or whether this due to TAAs on the CLL cells themselves. 
The significance of the relative preservation of cytokine production is also unclear. It is 
possible that this is representative of a state distinct from that seen in viral infections, 
which is a result of chronic stimulation with low affinity self-antigens in contrast to 
higher affinity viral antigens. It is also possible that this state is induced by the tumour 
cells as IL2, IFNγ and TNFα have all been shown to be pro-tumour in vitro (Yoshizaki 
et al. 1982; Digel et al. 1989; Buschle et al. 1993). The relative preservation of cytokine 
production could also be indicative of less exhausted cells, which show a higher 
capacity for functional restoration. A final question is that T-cell exhaustion is thought 
to be a chronic process that develops over weeks/months.  However, functional defects 
are inducible in healthy T cells after co-culturing them with CLL cells within 24 hours. 
My group has demonstrated that inhibitory ligand expression by CLL cells is important 
for inducing T-cell defects, but it is also likely that other inhibitory factors such as IL10 
and Tregs play a role in exacerbating any defects caused by chronic antigenic drive. 
 
A major question is whether the “pseudo-exhausted” state of CLL T cells is reversible 
and whether this represents a potential target for immunotherapeutic manipulation. 
Much of the pre-clinical work in the context of chronic viral infection has focused on 
antagonising inhibitory pathways. The PD1/PDL1 axis is a major inhibitory pathway 
involved in T-cell exhaustion, and has been implicated in the context of several 
infections including chronic lymphocytic choriomeningitis virus (LCMV) infection in 
mice, and chronic HIV infection in humans (Barber et al. 2006; Day et al. 2006). 
Importantly, these same studies also showed that blocking PD1/PDL1 interactions could 
restore T-cell effector function, highlighting the functional importance of this axis. 
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Further work has shown that simultaneous blockade of other inhibitory axes can further 
enhance T-cell function, such as PD1 blockade in combination with blockade of LAG3, 
CTLA4 and TIM3 (Blackburn et al. 2009; Nakamoto et al. 2009; Jin et al. 2010). This 
has led to the concept that partial exhaustion can be reversed relatively easily, but even 
severely exhausted T cells may respond to combination of modalities aimed at 
antagonising inhibitory axes, and neutralising the inhibitory effects of Tregs and IL10 
(Wherry 2011).  
 
Several clinical trials have now shown that anti-PD1 antibodies are effective in chronic 
viral infections and cancer. In a recently reported clinical trial of PD1 blockade by 
BMS-936558 in solid cancers, objective responses were seen in 18% of patients with 
non-small-cell lung cancer, 28% of patients with melanoma, and 27% of patients with 
renal-cell cancer. Importantly, these responses were also durable with 65% of responses 
lasting more than a year (Topalian et al. 2012). These response rates are very 
encouraging given the 10-15% “ceiling” of durable tumour response rates seen with 
trials of other immunotherapeutic approaches in solid cancers over the last 30 years 
(Ribas 2012). The pre-clinical experience has also led to clinical trials of combination 
immune checkpoint blockade. Much of the work has been done in melanoma, which 
appears to be one of the most immuno-sensitive solid cancers. After initial successes 
with the anti-CTLA4 antibody ipilimumab as a single agent, a recent study has shown 
improved responses with the combination of ipilimumab in combination with the anti-
PD1 antibody nivolumab (Weber et al. 2008; Wolchok et al. 2013) Furthermore, it has 
also proven efficacious to target the ligand as well. A phase 1 trial of an anti-PDL1 
antibody (BMS-936559) in a variety of advanced solid cancers also showed efficacy, 
with response rates of 6-17%, again dependent on the cancer type (Brahmer et al. 2012). 
With several inhibitory and activating T-cell receptors available for modulation this area 
is ripe for investigation (Figure 6.1). It may well be the case that not all approaches are 
equal, with blockade of different axes being associated with different clinical efficacies 
and adverse effect profiles. In particular it appears to be safer to block inhibitory 
pathways rather than target activatory ones, as suggested by the experience with anti-
CD28 antibody TGN1412 (Suntharalingam et al. 2006). Clinical trials of these agents in 
haematological malignancies have been notably absent, despite the fact that these 
cancers are generally more “immunosensitive” with the potential for higher response 
rates. A single published phase 1 dose-escalation study of the anti-PD1 antibody 
pidilizumab (CT-011) showed evidence of response in 6 out 18 patients. Of the three 
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CLL patients that were enrolled, two showed evidence of stable disease, on the second 
and third dose levels (Berger et al. 2008). In light of the pre-clinical data highlighting 
the significance of the PD1:PDL1 axis in suppressing T-cell function in CLL and the 
emerging clinical experience in solid cancers, there is strong rationale for clinical 
assessment of immune checkpoint blockade in this disease.  
Figure 6.1 Potential axes for immune checkpoint modulation (Pardoll 2012) 
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Given the expression of inhibitory ligands by CLL cells, another way of repairing T cell 
function may simply be by reducing tumour burden. This is consistent with the 
experience in allogeneic bone marrow transplantation where patients a have 
significantly better outcome if transplanted in remission. The immuno-modulatory 
effect of a reduction in tumour load has previously been difficult to assess, due to the 
immunosuppressive effect of many standard therapies for CLL, such as chlorambucil, 
cyclophosphamide and fludarabine. With the development of less immunosuppressive 
treatments such as the BCR-signalling inhibitors, it will be an important component of 
future research to establish whether the clinical efficacy of these agents is associated 
with immune reconstitution. However, it may not be so simple, as these agents could 
have off-target effects, such as the recently reported inhibitory effect of ibrutinib on 
IL2-inducible kinase (ITK) (Dubovsky et al. 2013). Interestingly, a recent clinical trial 
that my group was involved with has shown enhanced immune synapse formation after 
induction therapy with pentostatin, cyclophosphamide, and rituximab, which was 
further improved by lenalidomide consolidation (Shanafelt et al. 2013).  
 
The clinical effectiveness of lenalidomide is of significant interest to the CLL 
immunotherapy field. As discussed above, it is not directly toxic to CLL cells in vitro, 
but is thought to mediate its effects in vivo by immune cell activation and modulation of 
the microenvironment. It has been shown to have a variety of effects on both T and NK 
cells including enhanced production of IL2 and IFNγ, enhanced proliferation, and repair 
of defective immune synapse formation resulting in improved cytotoxicity. Intriguingly, 
evidence is emerging that lenalidomide also modulates pro-exhaustion pathways. Work 
by my group has demonstrated that lenalidomide down-regulates both CLL-cell 
inhibitory ligand expression, and the expression of their receptors on T cells (Ramsay et 
al. 2012). Furthermore, other investigators have observed an effect of lenalidomide on 
T-cell differentiation, where it is able to inhibit Treg generation instead promoting Th17 
differentiation (Idler et al. 2009). Therefore, lenalidomide could have a dual effect on 
exhausted T cells by improving their function directly, but also by inhibiting their 
formation. The work described in this thesis documents some novel insights into the 
mechanism of action of lenalidomide, particularly its effect on tight junction signalling, 
which is potentially involved in lymphocyte motility, transendothelial migration and 
immunological synapse formation. It has also yielded some further insights in to the 
molecular pathways targeted by this agent. Inhibition of PP2A is of particular interest 
given its role in negative co-stimulatory pathways in T cells.  
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In many respects, T-cell exhaustion is a form of “acquired anergy”, with the defects in 
proliferation and IL2 production representing a failure of co-stimulatory responses. 
Therefore, lenalidomide treatment may simply repair these defects by providing an 
over-riding co-stimulatory signal. This also has implications for the CAR T cell field. In 
a paper that accompanied the publication of a report of the utility of CD19 CAR T cells, 
phenotyping of the CAR T cells several months post infusion showed them to consist 
primarily of CCR7
-
CD45RA
+
 TEMRA cells, with low expression of CD27, CD28 and 
CD127 and high expression of PD1: an “exhausted” phenotype (Kalos et al. 2011). 
Therefore it is quite possible that the use of the autologous T cells which have been 
extensively expanded both in vitro and in vivo, results in cells that are replicatively 
senescent with incipient loss of function which may result in treatment failure and 
disease relapse. A particularly interesting part of the most recent developments with 
CAR T cells is the significance of the co-stimulatory domain used in the CAR construct. 
It remains unclear as to how domains such as CD28 and CD137 interact with 
endogenous co-stimulatory elements, and it may be possible that introduction of these 
elements overcomes defective co-stimulatory pathways in patient T cells and is 
“protective” against exhaustion. 
 
The recent successes of CAR T cells and lenalidomide have highlighted the “coming of 
age” of immunotherapy for CLL. These approaches offer the opportunity to provide 
patients with therapies that reduce rather than exacerbate the immune suppression 
associated with this disease, allowing for treatment strategies that are viable for all 
patients, including the elderly and those with co-morbidities. Furthermore, a particularly 
exciting aspect of these treatments is that they appear to be effective in subgroups of 
patients who have posed a particular challenge to standard therapy.  Recent 
developments in the fields of immune checkpoint blockade, immunomodulatory drugs, 
vaccination, and genetically modified T/NK/NKT cells open up the potential for 
combinations of immunotherapies to finally offer a “cure” for patients with CLL. 
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7 Further work 
 
There were many aspects of this work that require further investigation, but 
unfortunately time constraints were a major limiting factor. The data described in this 
thesis does include several novel findings regarding the mechanism of action of 
lenalidomide that require further work. In particular: 
  
It would be interesting and functionally important to study the effect of lenalidomide on 
the MDCK cell line, which is a widely used model system to study mammalian tight 
junction assembly and epithelial polarity regulation. 
 
It would also be important to investigate the role of inhibition of PP2A in 
lenalidomide’s mechanism of action. This could include: further optimisation of a PP2A 
activity assay to establish whether lenalidomide inhibits this enzyme in T cells; siRNA 
knockdown of PP2A and pharmacological inhibition of PP2A to investigate whether 
this mimics lenalidomide’s effects on T-cell function and the expression of TJ 
signalling genes, experimentation with the PP2A agonists 1,9 dideoxyforskolin and 
fingolimod to analyse whether these agents antagonise the effects of lenalidomide on T-
cell function and gene expression. 
 
It would also be logical to investigate the role of AMPK activation in lenalidomide’s 
mechanism of action. This could be directed at assessment of AMPK phosphorylation 
and also the phosphorylation status of molecules downstream of AMPK such as acetyl-
CoA carboxylase. It would also be important to establish whether the effects of 
lenalidomide described here are mediated by binding to cereblon; this could be tested by 
seeing if siRNA knockdown of cereblon attenuated these effects. 
 
And finally, it would important to establish if the PP2A-AMPK axis is disturbed in CLL 
T cells. It could be hypothesised that exhausted T cells and T cells from CLL patients 
have higher activity of PP2A and lower activity of AMPK consistent with their shift to 
terminally differentiated subsets.  
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Appendices 
 
Appendix A: Conjugated antibodies for flow cytometry 
 
Antibody Clone Isotype Company Catalog Number 
CD3 FITC UCHT1 Mouse IgG1, κ BD Biosciences 555332 
CD3 PE UCHT1 Mouse IgG1, κ BD Biosciences 555333 
CD3 APC UCHT1 Mouse IgG1, κ BD Biosciences 555335 
CD3 eFluor450 UCHT1 Mouse IgG1, κ eBioscience 48-0038 
CD3 PE-Cy7 UCHT1 Mouse IgG1 κ eBioscience  25-0038 
CD4 FITC M-T466 Mouse IgG1, κ Miltenyi Biotec 130-080-501 
CD4 PE RPA-T4 Mouse IgG1, κ BD Biosciences 555347 
CD4 APC-Cy7 SK3 Mouse IgG1, κ BD Biosciences 341115 
CD4 PerCP SK3 Mouse IgG1, κ BD Biosciences 345770 
CD4 PE-Cy7 SK3 Mouse IgG1, κ eBioscience  25-0047 
CD4 APC-Cy7 RPA-T4 Mouse IgG1, κ eBioscience  47-0049 
CD5 FITC BL1a Mouse IgG2a, κ Beckman Coulter IM0468U 
CD5 PerCp-Cy5.5 L17F12 Mouse IgG2a, κ eBioscience 45-0058-42 
CD8 FITC SK1 Mouse IgG1, κ BD Biosciences 345772 
CD8 PE SK1 Mouse IgG1, κ BD Biosciences 345773 
CD8 PerCP SK1 Mouse IgG1, κ BD Biosciences 345774 
CD8 PerCP-Cy5.5 RPA-T8 Mouse IgG1, κ eBioscience  45-0088 
CD19 FITC 4G7 Mouse IgG1, κ BD Biosciences 345776 
CD19 PE J3-119 Mouse IgG1, κ Beckman Coulter IM1285 
CD19 AF700 HIB19 Mouse IgG1, κ BD Biosciences  557921 
CD19 APC-Cy7 HIB19 Mouse IgG1, κ eBioscience 47-0199-42 
CD20 FITC 2H7 Mouse IgG2b, κ BD Biosciences 555622 
CD23 PE M-L233 Mouse IgG1, κ BD Biosciences 555711 
CD28 PE CD28.2 Mouse IgG1, κ Beckman Coulter IM2071U 
CD28 FITC CD28.2 Mouse IgG1, κ eBioscience  11-0289 
CD40 FITC 5C3 Mouse IgG1, κ BD Biosciences 555588 
CD40 PE-Cy7 5C3 Mouse IgG1, κ BD Biosciences 561215 
CD45RA FITC HI100 Mouse IgG1, κ BD Biosciences  555488 
CD45RA PE HI100 Mouse IgG1, κ eBioscience 12-0458 
CD54 APC HA58 Mouse IgG1, κ eBioscience 17-0549-42 
CD56 PE B159 Mouse IgG1, κ BD Biosciences 555516 
CD56 APC B159 Mouse IgG1, κ BD Biosciences 555518 
CD58 FITC 1C3 Mouse IgG2a, κ BD Biosciences 555920 
CD59 FITC OV9A2 Mouse IgG1, κ eBioscience 11-0596-42 
CD62L FITC DREG-56 Mouse IgG1, κ eBioscience  11-0629 
CD80 FITC L307.4 Mouse IgG1, κ BD Biosciences 557226 
CD80 PE-Cy7 L307.4 Mouse IgG1, κ BD Biosciences 561135 
CD83 PE HB15e Mouse IgG1, κ BD Biosciences 556855 
CD86 FITC 2331(FUN-1) Mouse IgG1, κ BD Biosciences 555657 
CD86-FITC 2331(FUN-1) Mouse IgG1, κ BD Biosciences 555657 
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Antibody Clone Isotype Company Catalog Number 
CD95 APC DX2 Mouse IgG1, κ BD Biosciences 558814 
CD107a AF647 eBioH4A3 Mouse IgG1, κ eBioscience 51-1079 
CD122 PE Mik-b2 Mouse IgG2a, κ BD Biosciences  554522 
CD127 FITC eBioRDR5 Mouse IgG1, κ eBioscience  11-1278 
CD134 FITC ACT-35 Mouse IgG1, κ eBioscience 11-1374 
CD152 PE eBio20A Mouse IgG2a, κ eBioscience  12-1528 
CD160 AF647 BY55 Mouse IgM eBioscience  51-1609 
CD197 PE 3D12 Rat IgG2a, κ eBioscience  12-1979 
CD197 APC 3D12 Rat IgG2a, κ eBioscience  17-1979 
CD223 APC Not given Goat IgG R&D Systems FAB2319A 
CD223 ATTO647N 17B4 Mouse IgG1, κ ENZO Life Sciences ALX-804-806TS 
CD244 PE C1.7 Mouse IgG1, κ eBioscience  12-5838-73 
CD252 PE IK-1 Mouse IgG1, κ BD Biosciences 558164 
CD256 PE T3-6 Mouse IgG2a, κ Biolegend 318506 
CD262 PE DJR2-4 Mouse IgG1, κ eBioscience 12-9908-xx 
CD264 PE TRAIL-R4-01 Mouse IgG1, κ ExBio 1P-519-C100 
CD274 PE-Cy7 MIH1 Mouse IgG1, κ BD Biosciences 558017 
CD279 FITC MIH4 Mouse IgG1, κ BD Biosciences  557860 
CD279 PE MIH5 Mouse IgG1, κ BD Biosciences  557946 
CD279 APC MIH4 Mouse IgG1, κ BD Biosciences 558694 
TIM3 APC F38-2E2 Mouse IgG1, κ eBioscience  17-3109-42 
     
Transcription factors     
BLIMP1 PE C-21 Goat IgG Santa Cruz  13206  
EOMES AF647 WD1928 Mouse IgG1, κ eBioscience  51-4877-41 
TBET PE eBio4B10 Mouse IgG2, κ eBioscience  12-5825 
     
Cytokines     
IFNγ FITC 4S.B3 Mouse IgG1, κ eBioscience 11-7319 
TNFα FITC MAb11 Mouse IgG1, κ BD Biosciences 554512 
IL2 PE MQ1-17H12 Rat IgG2a, κ BD Biosciences 554566 
IL4 PE 8D4-8 Mouse IgG1, κ BD Biosciences 554516 
IL4 APC 8D4-8 Mouse IgG1, κ eBioscience 17-7049 
     
Isotype controls     
IgG1, κ FITC MOPC-21 Mouse IgG1, κ BD Biosciences 555909 
IgG1, κ PE MOPC-21 Mouse IgG1, κ BD Biosciences 559320 
IgG1, κ APC MOPC-21 Mouse IgG1, κ BD Biosciences 555751 
IgG1, κ PE-Cy7 MOPC-21 Mouse IgG1, κ BD Biosciences 557646 
IgG2a, κ FITC G155-178 Mouse IgG2a, κ BD Biosciences 555573 
IgG2a, κ PE G155-178 Mouse IgG2a, κ BD Biosciences 559319 
IgG2b, κ FITC 27-35 Mouse IgG2b, κ BD Biosciences 555742 
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Appendix B: Genes dysregulated in CLL cells 
Genes > 8 fold up-regulated in CLL cells compared with healthy CD19
+ 
B cells 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
202709_at FMOD fibromodulin 8.61 1.01E-14 
229103_at WNT3 wingless-type MMTV integration site family, member 3 7.63 3.37E-14 
236341_at CTLA4 cytotoxic T-lymphocyte-associated protein 4 7.17 1.55E-08 
1562587_at CLNK cytokine-dependent hematopoietic cell linker 6.90 7.87E-15 
231743_at WNT3 wingless-type MMTV integration site family, member 3 6.80 3.46E-11 
204072_s_at FRY furry homolog (Drosophila) 6.28 4.64E-11 
219304_s_at PDGFD platelet derived growth factor D 5.88 2.07E-14 
217504_at ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 5.80 4.66E-07 
226408_at TEAD2 TEA domain family member 2 5.66 1.41E-15 
205414_s_at RICH2 Rho-type GTPase-activating protein RICH2 5.61 4.18E-08 
226147_s_at PIGR polymeric immunoglobulin receptor 5.45 6.02E-13 
209598_at PNMA2 paraneoplastic antigen MA2 5.43 2.93E-04 
215100_at C6orf105 chromosome 6 open reading frame 105 5.27 6.41E-11 
221455_s_at WNT3 wingless-type MMTV integration site family, member 3 5.06 1.93E-09 
221558_s_at LEF1 lymphoid enhancer-binding factor 1 4.95 5.88E-13 
1570239_a_at CLNK cytokine-dependent hematopoietic cell linker 4.90 2.05E-14 
229070_at C6orf105 chromosome 6 open reading frame 105 4.88 4.80E-11 
1554966_a_at FILIP1L filamin A interacting protein 1-like 4.77 1.26E-07 
230551_at KSR2 kinase suppressor of ras 2 4.72 3.81E-07 
221078_s_at CCDC88A coiled-coil domain containing 88A 4.72 6.61E-14 
201525_at APOD apolipoprotein D 4.62 1.80E-07 
229552_at LOC283454 hypothetical protein LOC283454 4.62 2.12E-07 
210948_s_at LEF1 lymphoid enhancer-binding factor 1 4.59 4.28E-10 
210051_at RAPGEF3 Rap guanine nucleotide exchange factor (GEF) 3 4.58 1.11E-13 
225354_s_at SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 2 4.56 7.06E-03 
213714_at CACNB2 calcium channel, voltage-dependent, beta 2 subunit 4.55 1.95E-03 
226485_at VSIG10 V-set and immunoglobulin domain containing 10 4.52 5.13E-06 
204135_at FILIP1L filamin A interacting protein 1-like 4.51 3.45E-08 
234362_s_at CTLA4 cytotoxic T-lymphocyte-associated protein 4 4.43 1.20E-05 
204731_at TGFBR3 transforming growth factor, beta receptor III 4.36 1.95E-05 
213419_at APBB2 amyloid beta (A4) precursor protein-binding, B2 4.29 2.78E-09 
204724_s_at COL9A3 collagen, type IX, alpha 3 4.23 5.81E-07 
206865_at HRK harakiri, BCL2 interacting protein 4.20 4.38E-06 
210258_at RGS13 regulator of G-protein signaling 13 4.15 3.59E-02 
239185_at ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 4.15 2.15E-06 
205805_s_at ROR1 receptor tyrosine kinase-like orphan receptor 1 4.13 2.79E-08 
1553708_at MGC16075 hypothetical protein MGC16075 4.11 4.52E-03 
234440_at TRD@ T cell receptor delta locus 4.08 4.85E-10 
231794_at CTLA4 cytotoxic T-lymphocyte-associated protein 4 4.07 3.17E-04 
232821_at GTSF1L gametocyte specific factor 1-like 4.07 7.54E-04 
226625_at TGFBR3 transforming growth factor, beta receptor III 4.06 4.84E-05 
231472_at FBXO15 F-box protein 15 3.97 6.44E-07 
219654_at PTPLA protein tyrosine phosphatase-like, member A 3.95 2.45E-05 
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Probe ID Symbol Name 
Log2 
FC 
Adjusted 
p value 
225045_at CCDC88A coiled-coil domain containing 88A 3.94 6.14E-14 
229659_s_at PIGR polymeric immunoglobulin receptor 3.86 2.42E-11 
239233_at CCDC88A coiled-coil domain containing 88A 3.83 6.15E-12 
225998_at GAB1 GRB2-associated binding protein 1 3.77 8.05E-12 
212985_at APBB2 amyloid beta (A4) precursor protein-binding, B2 3.74 8.46E-10 
221331_x_at CTLA4 cytotoxic T-lymphocyte-associated protein 4 3.68 8.26E-05 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 3.67 6.06E-03 
206864_s_at HRK harakiri, BCL2 interacting protein 3.66 8.49E-07 
219387_at CCDC88A coiled-coil domain containing 88A 3.64 1.19E-14 
215232_at RICH2 Rho-type GTPase-activating protein RICH2 3.64 5.89E-06 
208195_at TTN titin 3.60 2.45E-05 
216748_at PYHIN1 pyrin and HIN domain family, member 1 3.57 3.33E-06 
230489_at CD5 CD5 molecule 3.55 1.31E-07 
219578_s_at CPEB1 cytoplasmic polyadenylation element binding protein 1 3.52 2.30E-04 
226002_at GAB1 GRB2-associated binding protein 1 3.50 1.46E-11 
221337_s_at ADAM29 ADAM metallopeptidase domain 29 3.49 1.42E-02 
210550_s_at RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 3.48 2.54E-11 
242344_at GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2 3.47 6.28E-03 
232060_at ROR1 receptor tyrosine kinase-like orphan receptor 1 3.45 1.94E-06 
220193_at C1orf113 chromosome 1 open reading frame 113 3.40 4.41E-11 
212135_s_at ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 3.39 6.61E-09 
242541_at ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 3.39 4.90E-05 
229234_at ZC3H12B zinc finger CCCH-type containing 12B 3.36 4.05E-10 
229114_at GAB1 GRB2-associated binding protein 1 3.34 1.53E-10 
218872_at TESC tescalcin 3.31 1.62E-08 
47553_at DFNB31 deafness, autosomal recessive 31 3.29 1.08E-07 
238462_at UBASH3B ubiquitin associated and SH3 domain containing, B 3.29 1.82E-03 
1552552_s_at CLEC4C C-type lectin domain family 4, member C 3.28 1.30E-03 
215146_s_at TTC28 tetratricopeptide repeat domain 28 3.28 1.49E-05 
212970_at APBB2 amyloid beta precursor protein-binding, B2 3.27 1.37E-09 
201508_at IGFBP4 insulin-like growth factor binding protein 4 3.26 3.65E-06 
203231_s_at ATXN1 ataxin 1 3.23 1.71E-06 
225806_at JUB jub, ajuba homolog (Xenopus laevis) 3.21 1.84E-07 
220784_s_at UTS2 urotensin 2 3.20 1.49E-02 
212838_at DNMBP dynamin binding protein 3.19 2.74E-13 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 3.18 4.55E-02 
238323_at TEAD2 TEA domain family member 2 3.18 9.34E-09 
1558345_a_at LOC439911 hypothetical gene supported by NM_194304 3.18 6.73E-10 
232820_s_at GTSF1L gametocyte specific factor 1-like 3.15 3.35E-03 
212906_at GRAMD1B GRAM domain containing 1B 3.13 2.18E-04 
228737_at TOX2 TOX high mobility group box family member 2 3.13 6.77E-06 
200998_s_at CKAP4 cytoskeleton-associated protein 4 3.12 4.88E-09 
1555687_a_at CLEC4C C-type lectin domain family 4, member C 3.12 1.03E-03 
225531_at CABLES1 Cdk5 and Abl enzyme substrate 1 3.09 9.40E-05 
206049_at SELP selectin P (CD62) 3.06 4.28E-04 
237411_at ADAMTS6 ADAM metallopeptidase with thrombospondin  motif, 6 3.05 1.34E-08 
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Log2 
FC 
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238587_at UBASH3B ubiquitin associated and SH3 domain containing, B 3.04 1.73E-03 
204011_at SPRY2 sprouty homolog 2 (Drosophila) 3.04 1.12E-04 
226884_at LRRN1 leucine rich repeat neuronal 1 3.04 7.22E-06 
232533_at METTL8 methyltransferase like 8 3.02 1.19E-06 
236496_at DEGS2 degenerative spermatocyte homolog 2, lipid desaturase  3.02 3.36E-09 
243362_s_at LOC641518 hypothetical LOC641518 3.01 3.43E-06 
205489_at CRYM crystallin, mu 3.00 1.47E-04 
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Genes that are > 8 fold down-regulated in CLL cells compared with healthy CD19
+ 
B cells 
 
Probe ID Symbol Name 
Log2 
FC 
Adjusted 
p value 
227646_at EBF1 early B-cell factor 1 7.76 4.12E-07 
207861_at CCL22 chemokine (C-C motif) ligand 22 7.48 1.60E-05 
202589_at TYMS thymidylate synthetase 6.83 5.85E-07 
210432_s_at SCN3A sodium channel, voltage-gated, type III, alpha subunit 6.78 9.49E-21 
219049_at CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 6.76 2.07E-11 
205987_at CD1C CD1c molecule 6.59 1.93E-06 
214777_at IGKV4-1 immunoglobulin kappa variable 4-1 6.53 5.97E-07 
229487_at EBF1 early B-cell factor 1 6.42 1.33E-08 
203939_at NT5E 5'-nucleotidase, ecto (CD73) 6.42 4.50E-07 
217979_at TSPAN13 tetraspanin 13 6.42 6.21E-05 
219648_at MREG melanoregulin 6.39 8.22E-08 
209773_s_at RRM2 ribonucleotide reductase M2 6.29 6.05E-08 
232204_at EBF1 early B-cell factor 1 6.27 1.66E-09 
205992_s_at IL15 interleukin 15 6.20 1.97E-07 
202503_s_at KIAA0101 KIAA0101 5.95 5.43E-07 
216491_x_at IGHM immunoglobulin heavy constant mu 5.94 9.94E-05 
222449_at PMEPA1 prostate transmembrane protein, androgen induced 1 5.93 6.61E-10 
201890_at RRM2 ribonucleotide reductase M2 5.91 8.89E-07 
239761_at GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2  5.79 6.06E-18 
204416_x_at APOC1 apolipoprotein C-I 5.79 1.47E-09 
235048_at FAM169A family with sequence similarity 169, member A 5.75 2.74E-13 
243198_at TEX9 testis expressed 9 5.72 1.76E-13 
202269_x_at GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 5.69 3.73E-07 
225626_at PAG1 phosphoprotein with glycosphingolipid microdomains 1 5.69 2.38E-08 
204115_at GNG11 guanine nucleotide binding protein (G protein), gamma 1 5.65 3.92E-08 
234764_x_at IGLV1-44 immunoglobulin lambda variable 1-44 5.65 1.55E-05 
222450_at PMEPA1 prostate transmembrane protein, androgen induced 1 5.62 3.16E-13 
225809_at PARM1 prostate androgen-regulated mucin-like protein 1 5.62 1.12E-19 
202345_s_at FABP5 fatty acid binding protein 5 (psoriasis-associated) 5.57 9.58E-06 
231577_s_at GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 5.56 2.70E-07 
224847_at CDK6 cyclin-dependent kinase 6 5.53 2.43E-15 
218546_at C1orf115 chromosome 1 open reading frame 115 5.49 6.53E-11 
226844_at MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast) 5.49 2.78E-16 
231963_at ANKRD33B ankyrin repeat domain 33B 5.48 3.32E-11 
202270_at GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 5.48 5.13E-07 
204439_at IFI44L interferon-induced protein 44-like 5.45 6.61E-04 
225655_at UHRF1 ubiquitin-like with PHD and ring finger domains 1 5.45 4.90E-08 
224851_at CDK6 cyclin-dependent kinase 6 5.42 3.05E-17 
205505_at GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2  5.41 1.09E-15 
225105_at C12orf75 chromosome 12 open reading frame 75 5.32 5.95E-08 
203029_s_at PTPRN2 
protein tyrosine phosphatase, receptor type, N 
polypeptide 2 
5.32 6.23E-12 
212813_at JAM3 junctional adhesion molecule 3 5.28 1.09E-15 
219247_s_at ZDHHC14 zinc finger, DHHC-type containing 14 5.23 1.31E-13 
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219355_at CXorf57 chromosome X open reading frame 57 5.19 9.59E-22 
213954_at FAM169A family with sequence similarity 169, member A 5.18 9.34E-15 
226702_at CMPK2 
cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial 
5.18 1.81E-04 
228988_at ZNF711 zinc finger protein 711 5.15 5.12E-11 
201417_at SOX4 SRY (sex determining region Y)-box 4 5.14 6.61E-14 
225864_at FAM84B family with sequence similarity 84, member B 5.12 5.47E-09 
205139_s_at UST uronyl-2-sulfotransferase 5.08 1.57E-08 
209101_at CTGF connective tissue growth factor 5.07 6.02E-10 
224435_at C10orf58 chromosome 10 open reading frame 58 5.05 1.18E-06 
223484_at C15orf48 chromosome 15 open reading frame 48 5.04 8.79E-06 
204963_at SSPN sarcospan (Kras oncogene-associated gene) 5.04 2.28E-09 
227354_at PAG1 phosphoprotein with glycosphingolipid microdomains 1 5.03 2.72E-09 
206385_s_at ANK3 ankyrin 3, node of Ranvier (ankyrin G) 5.03 1.15E-08 
219424_at EBI3 Epstein-Barr virus induced 3 5.03 1.22E-09 
200606_at DSP desmoplakin 5.02 1.36E-06 
225710_at GNB4 guanine nucleotide binding protein, beta polypeptide 4 5.00 2.64E-06 
201719_s_at EPB41L2 erythrocyte membrane protein band 4.1-like 2 4.99 3.04E-06 
217967_s_at FAM129A family with sequence similarity 129, member A 4.95 1.01E-06 
201830_s_at NET1 neuroepithelial cell transforming 1 4.95 2.61E-07 
203038_at PTPRK protein tyrosine phosphatase, receptor type, K 4.94 4.09E-05 
205884_at ITGA4 integrin, alpha 4 (CD49D) 4.93 2.12E-07 
203213_at CDK1 cyclin-dependent kinase 1 4.93 8.74E-10 
201324_at EMP1 epithelial membrane protein 1 4.93 2.06E-06 
201928_at PKP4 plakophilin 4 4.84 5.29E-15 
205128_x_at PTGS1 prostaglandin-endoperoxide synthase 1  4.83 6.52E-13 
212558_at SPRY1 sprouty homolog 1, antagonist of FGF signaling  4.82 1.36E-12 
205885_s_at ITGA4 integrin, alpha 4 (CD49D) 4.78 3.18E-08 
1554696_s_at TYMS thymidylate synthetase 4.77 4.28E-10 
212560_at SORL1 
sortilin-related receptor, L(DLR class) A repeats-
containing 
4.76 9.70E-04 
219493_at SHCBP1 SHC SH2-domain binding protein 1 4.75 1.01E-09 
244313_at CR1 complement component (3b/4b) receptor 1 4.72 2.05E-11 
229568_at MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast) 4.71 1.76E-18 
213416_at ITGA4 integrin, alpha 4 (CD49D) 4.71 8.56E-06 
203214_x_at CDK1 cyclin-dependent kinase 1 4.71 6.02E-10 
210559_s_at CDK1 cyclin-dependent kinase 1 4.71 8.47E-10 
208018_s_at HCK hemopoietic cell kinase 4.68 2.79E-07 
202336_s_at PAM peptidylglycine alpha-amidating monooxygenase 4.66 2.05E-11 
215813_s_at PTGS1 prostaglandin-endoperoxide synthase 1 4.65 3.06E-12 
212975_at DENND3 DENN/MADD domain containing 3 4.65 1.93E-09 
225662_at ZAK sterile alpha motif and leucine zipper containing kinase 4.64 8.43E-05 
221530_s_at BHLHE41 basic helix-loop-helix family, member e41 4.63 2.11E-04 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 4.59 7.56E-06 
209276_s_at GLRX glutaredoxin (thioltransferase) 4.59 3.24E-08 
211597_s_at HOPX HOP homeobox 4.58 2.58E-06 
224428_s_at CDCA7 cell division cycle associated 7 4.58 2.01E-09 
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204533_at CXCL10 chemokine (C-X-C motif) ligand 10 4.58 5.04E-05 
218532_s_at FAM134B family with sequence similarity 134, member B 4.57 1.75E-10 
222317_at PDE3B phosphodiesterase 3B, cGMP-inhibited 4.57 3.74E-07 
229450_at IFIT3 interferon-induced protein with tetratricopeptide repeat 3 4.56 9.66E-04 
202478_at TRIB2 tribbles homolog 2 (Drosophila) 4.55 3.35E-08 
217371_s_at IL15 interleukin 15 4.50 6.25E-07 
225330_at IGF1R insulin-like growth factor 1 receptor 4.50 4.22E-05 
204249_s_at LMO2 LIM domain only 2 (rhombotin-like 1) 4.49 8.31E-09 
215071_s_at HIST1H2AC histone cluster 1, H2ac 4.48 2.62E-07 
201739_at SGK1 serum/glucocorticoid regulated kinase 1 4.48 9.52E-07 
218854_at DSE dermatan sulfate epimerase 4.48 3.11E-08 
205775_at FAM50B family with sequence similarity 50, member B 4.44 1.93E-12 
213817_at IRAK3 interleukin-1 receptor-associated kinase 3 4.44 8.10E-09 
228155_at C10orf58 chromosome 10 open reading frame 58 4.44 7.36E-08 
226017_at CMTM7 CKLF-like MARVEL transmembrane domain contain 7 4.42 2.37E-06 
212274_at LPIN1 lipin 1 4.41 3.75E-05 
219607_s_at MS4A4A membrane-spanning 4-domains, subfamily A, member 4 4.40 9.20E-07 
228698_at SOX7 SRY (sex determining region Y)-box 7 4.39 2.08E-15 
233261_at EBF1 early B-cell factor 1 4.39 1.21E-09 
225202_at RHOBTB3 Rho-related BTB domain containing 3 4.39 5.74E-10 
204591_at CHL1 cell adhesion molecule with homology to L1CAM 4.38 4.42E-11 
201829_at NET1 neuroepithelial cell transforming 1 4.38 9.47E-07 
215017_s_at FNBP1L formin binding protein 1-like 4.37 5.86E-08 
222838_at SLAMF7 SLAM family member 7 4.36 6.09E-05 
209189_at FOS FBJ murine osteosarcoma viral oncogene homolog 4.33 1.17E-06 
234366_x_at IGL@ immunoglobulin lambda locus 4.32 5.12E-09 
211696_x_at HBB hemoglobin, beta 4.31 1.84E-03 
230509_at SNX22 sorting nexin 22 4.31 1.01E-09 
227361_at HS3ST3B1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 4.30 1.08E-08 
217966_s_at FAM129A family with sequence similarity 129, member A 4.29 4.71E-09 
235175_at GBP4 guanylate binding protein 4 4.28 3.63E-06 
1553994_at NT5E 5'-nucleotidase, ecto (CD73) 4.27 2.59E-07 
203509_at SORL1 sortilin-related receptor, L, A repeats-containing 4.26 6.27E-04 
226932_at SSPN sarcospan (Kras oncogene-associated gene) 4.25 2.72E-12 
224996_at ASPH aspartate beta-hydroxylase 4.24 5.74E-15 
242625_at RSAD2 radical S-adenosyl methionine domain containing 2 4.24 2.41E-04 
212124_at ZMIZ1 zinc finger, MIZ-type containing 1 4.23 2.25E-06 
213624_at SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A 4.22 2.44E-08 
223503_at TMEM163 transmembrane protein 163 4.22 1.09E-15 
204491_at PDE4D phosphodiesterase 4D, cAMP-specific (Drosophila) 4.22 4.54E-11 
218585_s_at DTL denticleless homolog (Drosophila) 4.21 3.35E-08 
203764_at DLGAP5 discs, large (Drosophila) homolog-associated protein 5 4.20 1.12E-07 
1555728_a_at MS4A4A membrane-spanning 4-domains, subfamily A, member 4 4.20 4.15E-07 
228372_at C10orf128 chromosome 10 open reading frame 128 4.19 5.72E-06 
202870_s_at CDC20 cell division cycle 20 homolog (S. cerevisiae) 4.19 6.71E-07 
214582_at PDE3B phosphodiesterase 3B, cGMP-inhibited 4.18 3.50E-07 
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218793_s_at SCML1 sex comb on midleg-like 1 (Drosophila) 4.18 2.81E-06 
213122_at TSPYL5 TSPY-like 5 4.17 1.79E-04 
204493_at BID BH3 interacting domain death agonist 4.16 8.93E-07 
211026_s_at MGLL monoglyceride lipase 4.14 9.06E-08 
202976_s_at RHOBTB3 Rho-related BTB domain containing 3 4.13 1.25E-09 
230422_at FPR3 formyl peptide receptor 3 4.13 2.45E-05 
214768_x_at FAM20B family with sequence similarity 20, member B 4.13 4.20E-02 
212276_at LPIN1 lipin 1 4.12 2.75E-05 
211725_s_at BID BH3 interacting domain death agonist 4.11 7.65E-07 
219313_at GRAMD1C GRAM domain containing 1C 4.11 1.86E-08 
209642_at BUB1 budding uninhibited by benzimidazoles 1 homolog  4.10 9.11E-11 
212820_at DMXL2 Dmx-like 2 4.09 1.14E-06 
225922_at FNIP2 folliculin interacting protein 2 4.09 4.83E-06 
225688_s_at PHLDB2 pleckstrin homology-like domain, family B, member 2 4.09 7.18E-08 
203915_at CXCL9 chemokine (C-X-C motif) ligand 9 4.09 1.26E-06 
202820_at AHR aryl hydrocarbon receptor 4.09 5.65E-09 
201565_s_at ID2 inhibitor of DNA binding 2 4.08 7.74E-07 
218662_s_at NCAPG non-SMC condensin I complex, subunit G 4.08 5.35E-09 
1554018_at GPNMB glycoprotein (transmembrane) nmb 4.08 3.29E-05 
235780_at PRKACB protein kinase, cAMP-dependent, catalytic, beta 4.07 1.16E-13 
218284_at SMAD3 SMAD family member 3 4.06 6.30E-05 
223700_at MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) 4.06 2.38E-08 
225665_at ZAK sterile alpha motif and leucine zipper containing kinase 4.03 5.36E-05 
209714_s_at CDKN3 cyclin-dependent kinase inhibitor 3 4.03 2.34E-09 
210644_s_at LAIR1 leukocyte-associated immunoglobulin-like receptor 1 4.03 2.00E-05 
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 4.03 4.65E-05 
234884_x_at IGL@ immunoglobulin lambda locus 4.01 4.75E-06 
209301_at CA2 carbonic anhydrase II 4.01 2.78E-12 
201718_s_at EPB41L2 erythrocyte membrane protein band 4.1-like 2 4.01 2.73E-06 
209891_at SPC25 NDC80 kinetochore complex component, homolog  4.00 1.08E-08 
204971_at CSTA cystatin A (stefin A) 4.00 1.90E-07 
209116_x_at HBB hemoglobin, beta 3.99 2.53E-03 
1555756_a_at CLEC7A C-type lectin domain family 7, member A 3.98 1.49E-05 
212845_at SAMD4A sterile alpha motif domain containing 4A 3.98 7.60E-13 
201291_s_at TOP2A topoisomerase (DNA) II alpha 170kDa 3.97 5.44E-07 
225622_at PAG1 phosphoprotein with glycosphingolipid microdomains 1 3.96 3.36E-10 
212923_s_at C6orf145 chromosome 6 open reading frame 145 3.96 9.96E-08 
223922_x_at MS4A6A membrane-spanning 4-domains, family A, member 6A 3.96 7.93E-06 
204430_s_at SLC2A5 solute carrier family 2, member 5 3.95 1.40E-05 
235310_at GCET2 germinal center expressed transcript 2 3.95 2.17E-15 
224356_x_at MS4A6A membrane-spanning 4-domains, family A, member 6A 3.95 4.80E-06 
204014_at DUSP4 dual specificity phosphatase 4 3.93 2.78E-04 
207900_at CCL17 chemokine (C-C motif) ligand 17 3.93 1.10E-07 
230550_at MS4A6A membrane-spanning 4-domains, family A, member 6A 3.93 2.81E-06 
207165_at HMMR hyaluronan-mediated motility receptor (RHAMM) 3.93 1.26E-08 
204825_at MELK maternal embryonic leucine zipper kinase 3.92 1.36E-07 
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1554519_at CD80 CD80 molecule 3.92 2.30E-05 
203922_s_at CYBB cytochrome b-245, beta polypeptide 3.91 6.47E-06 
223280_x_at MS4A6A membrane-spanning 4-domains, family A, member 6A 3.91 9.77E-06 
221636_s_at MOSC2 MOCO sulphurase C-terminal domain containing 2 3.90 1.84E-08 
229971_at GPR114 G protein-coupled receptor 114 3.88 9.33E-14 
220651_s_at MCM10 minichromosome maintenance complex component 10 3.88 8.24E-08 
220532_s_at TMEM176B transmembrane protein 176B 3.88 5.69E-05 
215049_x_at CD163 CD163 molecule 3.88 3.70E-05 
1558438_a_at IGHG1 immunoglobulin heavy constant gamma 1  3.88 9.28E-08 
202705_at CCNB2 cyclin B2 3.87 1.87E-08 
211798_x_at IGLJ3 immunoglobulin lambda joining 3 3.87 2.72E-05 
218663_at NCAPG non-SMC condensin I complex, subunit G 3.87 1.41E-09 
212592_at IGJ immunoglobulin J polypeptide 3.86 6.22E-03 
223344_s_at MS4A7 membrane-spanning 4-domains, subfamily A, member 7 3.86 2.08E-04 
226936_at C6orf173 chromosome 6 open reading frame 173 3.85 4.17E-09 
225673_at MYADM myeloid-associated differentiation marker 3.85 3.74E-06 
211881_x_at IGLJ3 immunoglobulin lambda joining 3 3.84 1.17E-05 
227006_at PPP1R14A protein phosphatase 1, regulatory (inhibitor) subunit 14A 3.83 5.20E-11 
219148_at PBK PDZ binding kinase 3.82 6.99E-09 
205098_at CCR1 chemokine (C-C motif) receptor 1 3.82 5.30E-05 
209135_at ASPH aspartate beta-hydroxylase 3.80 1.76E-12 
226456_at C16orf75 chromosome 16 open reading frame 75 3.80 5.74E-10 
204026_s_at ZWINT ZW10 interactor 3.77 3.14E-09 
203645_s_at CD163 CD163 molecule 3.77 7.74E-05 
211612_s_at IL13RA1 interleukin 13 receptor, alpha 1 3.77 1.41E-05 
232682_at MREG melanoregulin 3.77 1.56E-09 
205379_at CBR3 carbonyl reductase 3 3.76 4.06E-11 
217232_x_at HBB hemoglobin, beta 3.75 2.70E-03 
1555758_a_at CDKN3 cyclin-dependent kinase inhibitor 3 3.74 5.41E-07 
202742_s_at PRKACB protein kinase, cAMP-dependent, catalytic, beta 3.73 1.59E-10 
1553132_a_at TC2N tandem C2 domains, nuclear 3.73 1.31E-07 
219666_at MS4A6A membrane-spanning 4-domains, family A, member 6A 3.73 4.09E-05 
225897_at MARCKS myristoylated alanine-rich protein kinase C substrate 3.72 1.66E-04 
217975_at WBP5 WW domain binding protein 5 3.71 3.06E-10 
205681_at BCL2A1 BCL2-related protein A1 3.71 2.67E-04 
224848_at CDK6 cyclin-dependent kinase 6 3.71 6.61E-14 
210904_s_at IL13RA1 interleukin 13 receptor, alpha 1 3.71 2.35E-05 
224358_s_at MS4A7 membrane-spanning 4-domains, subfamily A, member 7 3.70 3.64E-05 
203968_s_at CDC6 cell division cycle 6 homolog (S. cerevisiae) 3.69 8.14E-08 
204015_s_at DUSP4 dual specificity phosphatase 4 3.69 6.42E-06 
214453_s_at IFI44 interferon-induced protein 44 3.69 3.04E-03 
242794_at MAML3 mastermind-like 3 (Drosophila) 3.66 3.23E-12 
228868_x_at CDT1 chromatin licensing and DNA replication factor 1 3.66 5.29E-09 
214039_s_at LAPTM4B lysosomal protein transmembrane 4 beta 3.65 2.94E-03 
219159_s_at SLAMF7 SLAM family member 7 3.65 1.41E-05 
220377_at FAM30A family with sequence similarity 30, member A 3.65 2.29E-02 
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201310_s_at C5orf13 chromosome 5 open reading frame 13 3.65 1.09E-06 
202087_s_at CTSL1 cathepsin L1 3.64 7.81E-06 
232231_at RUNX2 runt-related transcription factor 2 3.63 2.27E-07 
206478_at KIAA0125 KIAA0125 3.63 2.72E-02 
201292_at TOP2A topoisomerase (DNA) II alpha 170kDa 3.62 3.09E-07 
222680_s_at DTL denticleless homolog (Drosophila) 3.62 3.48E-08 
204747_at IFIT3 interferon-induced protein with tetratricopeptide repeat 3 3.62 2.61E-03 
206488_s_at CD36 CD36 molecule (thrombospondin receptor) 3.61 9.89E-05 
203418_at CCNA2 cyclin A2 3.61 1.19E-08 
202954_at UBE2C ubiquitin-conjugating enzyme E2C 3.61 6.16E-08 
227697_at SOCS3 suppressor of cytokine signaling 3 3.60 4.27E-05 
208820_at PTK2 PTK2 protein tyrosine kinase 2 3.59 4.93E-03 
206214_at PLA2G7 phospholipase A2, group VII 3.59 2.05E-05 
233969_at IGL@ immunoglobulin lambda locus 3.58 9.43E-07 
1553995_a_at NT5E 5'-nucleotidase, ecto (CD73) 3.58 3.10E-09 
201631_s_at IER3 immediate early response 3 3.58 1.71E-06 
206420_at IGSF6 immunoglobulin superfamily, member 6 3.58 7.99E-07 
204112_s_at HNMT histamine N-methyltransferase 3.57 1.02E-04 
200648_s_at GLUL glutamate-ammonia ligase (glutamine synthetase) 3.57 7.82E-04 
203923_s_at CYBB cytochrome b-245, beta polypeptide 3.57 1.87E-04 
215543_s_at LARGE like-glycosyltransferase 3.56 4.87E-16 
219386_s_at SLAMF8 SLAM family member 8 3.55 2.82E-06 
225603_s_at C8orf83 chromosome 8 open reading frame 83 3.55 1.17E-04 
204646_at DPYD dihydropyrimidine dehydrogenase 3.54 2.35E-03 
205003_at DOCK4 dedicator of cytokinesis 4 3.54 8.94E-06 
201141_at GPNMB glycoprotein (transmembrane) nmb 3.54 4.98E-06 
204639_at ADA adenosine deaminase 3.54 5.68E-06 
219918_s_at ASPM asp homolog, microcephaly associated (Drosophila) 3.54 2.26E-06 
204962_s_at CENPA centromere protein A 3.53 2.28E-06 
214595_at KCNG1 potassium voltage-gated channel, subfamily G, member 1 3.53 7.91E-11 
1555745_a_at LYZ lysozyme (renal amyloidosis) 3.52 7.03E-04 
208636_at ACTN1 actinin, alpha 1 3.52 2.72E-05 
206039_at RAB33A RAB33A, member RAS oncogene family 3.51 2.74E-13 
219527_at MOSC2 MOCO sulphurase C-terminal domain containing 2 3.51 1.80E-07 
203139_at DAPK1 death-associated protein kinase 1 3.51 2.18E-05 
201670_s_at MARCKS myristoylated alanine-rich protein kinase C substrate 3.50 6.70E-05 
234970_at TC2N tandem C2 domains, nuclear 3.49 6.22E-06 
225924_at FNIP2 folliculin interacting protein 2 3.49 6.44E-07 
235574_at GBP4 guanylate binding protein 4 3.48 3.56E-06 
208092_s_at FAM49A family with sequence similarity 49, member A 3.47 1.58E-04 
203153_at IFIT1 interferon-induced protein with tetratricopeptide repeat 1 3.47 1.34E-02 
201566_x_at ID2 inhibitor of DNA binding 2 3.47 7.89E-08 
209683_at FAM49A family with sequence similarity 49, member A 3.46 5.40E-03 
221524_s_at RRAGD Ras-related GTP binding D 3.46 1.36E-07 
226460_at FNIP2 folliculin interacting protein 2 3.46 4.90E-06 
201927_s_at PKP4 plakophilin 4 3.45 2.30E-09 
John Riches Appendices 
230 
 
Probe ID Symbol Name 
Log2 
FC 
Adjusted 
p value 
204103_at CCL4 chemokine (C-C motif) ligand 4 3.45 7.82E-04 
238669_at PTGS1 prostaglandin-endoperoxide synthase 1 3.45 1.32E-10 
223307_at CDCA3 cell division cycle associated 3 3.44 9.96E-08 
217552_x_at CR1 complement component (3b/4b) receptor 1  3.43 4.74E-13 
206632_s_at APOBEC3B 
apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B 
3.43 3.29E-07 
221704_s_at VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 3.42 6.48E-05 
223159_s_at NEK6 NIMA (never in mitosis gene a)-related kinase 6 3.42 1.01E-06 
202859_x_at IL8 interleukin 8 3.42 7.61E-03 
201325_s_at EMP1 epithelial membrane protein 1 3.42 9.21E-06 
212188_at KCTD12 potassium channel tetramerisation domain containing 12 3.41 9.08E-06 
202741_at PRKACB protein kinase, cAMP-dependent, catalytic, beta 3.41 1.80E-08 
227647_at KCNE3 
potassium voltage-gated channel, Isk-related family, 
member 3 
3.40 6.09E-06 
213241_at PLXNC1 plexin C1 3.40 1.52E-07 
226611_s_at CENPV centromere protein V 3.40 1.99E-05 
224553_s_at TNFRSF18 tumour necrosis factor receptor superfamily, member 18 3.37 1.16E-04 
227449_at EPHA4 EPH receptor A4 3.36 9.26E-08 
202796_at SYNPO synaptopodin 3.36 1.66E-09 
203030_s_at PTPRN2 
protein tyrosine phosphatase, receptor type, N 
polypeptide 2 
3.36 2.73E-09 
209884_s_at SLC4A7 solute carrier family 4, member 7 3.36 1.63E-03 
1563209_a_at MACROD2 MACRO domain containing 2 3.36 1.04E-04 
210139_s_at PMP22 peripheral myelin protein 22 3.36 4.60E-05 
240890_at LOC643733 hypothetical LOC643733 3.35 5.04E-07 
223343_at MS4A7 membrane-spanning 4-domains, subfamily A, member 7 3.35 5.96E-04 
228766_at CD36 CD36 molecule (thrombospondin receptor) 3.35 1.72E-04 
208146_s_at CPVL carboxypeptidase, vitellogenic-like 3.35 5.04E-05 
202095_s_at BIRC5 baculoviral IAP repeat-containing 5 3.35 4.05E-05 
213797_at RSAD2 radical S-adenosyl methionine domain containing 2 3.35 4.25E-04 
211429_s_at SERPINA1 serpin peptidase inhibitor, clade A, member 1 3.34 4.90E-05 
209191_at TUBB6 tubulin, beta 6 3.34 3.61E-03 
201785_at RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 3.34 8.15E-05 
1569481_s_at SNX22 sorting nexin 22 3.33 4.85E-10 
211794_at FYB FYN binding protein (FYB-120/130) 3.33 7.18E-05 
212446_s_at LASS6 LAG1 homolog, ceramide synthase 6 3.32 8.34E-03 
200862_at DHCR24 24-dehydrocholesterol reductase 3.31 1.39E-05 
213002_at MARCKS myristoylated alanine-rich protein kinase C substrate 3.31 3.73E-06 
206118_at STAT4 signal transducer and activator of transcription 4 3.31 7.31E-05 
229560_at TLR8 toll-like receptor 8 3.31 6.44E-04 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 3.31 1.15E-04 
226066_at MITF microphthalmia-associated transcription factor 3.31 1.41E-05 
205569_at LAMP3 lysosomal-associated membrane protein 3 3.30 5.56E-05 
218510_x_at FAM134B family with sequence similarity 134, member B 3.28 2.80E-12 
227143_s_at BID BH3 interacting domain death agonist 3.28 1.36E-06 
206978_at CCR2 chemokine (C-C motif) receptor 2 3.28 2.61E-05 
221210_s_at NPL N-acetylneuraminate pyruvate lyase  3.27 1.46E-05 
217875_s_at PMEPA1 prostate transmembrane protein, androgen induced 1 3.27 1.05E-12 
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208949_s_at LGALS3 lectin, galactoside-binding, soluble, 3 3.27 2.34E-06 
209684_at RIN2 Ras and Rab interactor 2 3.27 3.41E-04 
221523_s_at RRAGD Ras-related GTP binding D 3.26 2.89E-06 
212192_at KCTD12 potassium channel tetramerisation domain containing 12 3.26 2.26E-05 
205237_at FCN1 ficolin (collagen/fibrinogen domain containing) 1 3.25 2.39E-04 
205692_s_at CD38 CD38 molecule 3.25 3.92E-08 
201445_at CNN3 calponin 3, acidic 3.25 3.50E-03 
209679_s_at SMAGP small cell adhesion glycoprotein 3.23 5.01E-09 
202191_s_at GAS7 growth arrest-specific 7 3.23 1.19E-06 
202551_s_at CRIM1 cysteine rich transmembrane BMP regulator 1  3.22 2.58E-06 
206983_at CCR6 chemokine (C-C motif) receptor 6 3.22 3.28E-04 
201280_s_at DAB2 disabled homolog 2, mitogen-responsive phosphoprotein 3.22 1.14E-04 
206392_s_at RARRES1 retinoic acid receptor responder (tazarotene induced) 1 3.22 4.75E-04 
219788_at PILRA paired immunoglobin-like type 2 receptor alpha 3.22 1.83E-05 
221872_at RARRES1 retinoic acid receptor responder (tazarotene induced) 1 3.21 1.96E-04 
202479_s_at TRIB2 tribbles homolog 2 (Drosophila) 3.21 4.64E-11 
225353_s_at C1QC complement component 1, q subcomponent, C chain 3.20 6.30E-07 
218559_s_at MAFB v-maf musculoaponeurotic fibrosarcoma oncogene, B  3.19 1.92E-04 
209555_s_at CD36 CD36 molecule (thrombospondin receptor) 3.19 1.71E-03 
227486_at NT5E 5'-nucleotidase, ecto (CD73) 3.19 1.92E-08 
203474_at IQGAP2 IQ motif containing GTPase activating protein 2 3.19 3.20E-04 
227417_at MOSC2 MOCO sulphurase C-terminal domain containing 2 3.18 7.94E-06 
205099_s_at CCR1 chemokine (C-C motif) receptor 1 3.17 3.69E-05 
205394_at CHEK1 CHK1 checkpoint homolog (S. pombe) 3.17 1.16E-07 
221724_s_at CLEC4A C-type lectin domain family 4, member A 3.15 1.23E-04 
242136_x_at MGC70870 C-terminal binding protein 2 pseudogene 3.14 1.59E-06 
204232_at FCER1G Fc fragment of IgE, receptor for; gamma polypeptide 3.14 1.50E-04 
209732_at CLEC2B C-type lectin domain family 2, member B 3.14 8.69E-03 
218542_at CEP55 centrosomal protein 55kDa 3.13 2.33E-06 
224009_x_at DHRS9 dehydrogenase/reductase (SDR family) member 9 3.13 2.46E-05 
232798_at DNAJC5B DnaJ (Hsp40) homolog, subfamily C, member 5 beta 3.13 2.26E-08 
201888_s_at IL13RA1 interleukin 13 receptor, alpha 1 3.13 1.22E-05 
202599_s_at NRIP1 nuclear receptor interacting protein 1 3.13 9.14E-03 
201887_at IL13RA1 interleukin 13 receptor, alpha 1 3.12 4.86E-05 
209709_s_at HMMR hyaluronan-mediated motility receptor (RHAMM) 3.12 1.47E-07 
206115_at EGR3 early growth response 3 3.12 1.48E-02 
210448_s_at P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 3.11 3.60E-05 
238756_at GAS2L3 growth arrest-specific 2 like 3 3.11 2.77E-05 
222670_s_at MAFB v-maf musculoaponeurotic fibrosarcoma oncogene, B 3.11 2.49E-04 
219000_s_at DSCC1 defective in sister chromatid cohesion 1 homolog 3.11 3.09E-08 
204822_at TTK TTK protein kinase 3.10 1.48E-08 
219836_at ZBED2 zinc finger, BED-type containing 2 3.10 1.92E-06 
203936_s_at MMP9 matrix metallopeptidase 9  3.09 3.06E-03 
1554899_s_at FCER1G Fc fragment of IgE, receptor for; gamma polypeptide 3.09 1.46E-04 
202600_s_at NRIP1 nuclear receptor interacting protein 1 3.09 1.19E-02 
212364_at MYO1B myosin IB 3.09 1.16E-07 
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202975_s_at RHOBTB3 Rho-related BTB domain containing 3 3.07 1.70E-09 
205372_at PLAG1 pleiomorphic adenoma gene 1 3.07 1.25E-08 
202833_s_at SERPINA1 serpin peptidase inhibitor, clade A, member 1 3.07 8.61E-04 
232504_at LOC285628 hypothetical protein LOC285628 3.07 1.58E-04 
218692_at GOLSYN Golgi-localized protein 3.07 7.31E-04 
225589_at SH3RF1 SH3 domain containing ring finger 1 3.06 5.29E-10 
1555349_a_at ITGB2 integrin, beta 2 3.05 1.21E-04 
220088_at C5AR1 complement component 5a receptor 1 3.05 1.05E-04 
201669_s_at MARCKS myristoylated alanine-rich protein kinase C substrate 3.05 1.99E-04 
201743_at CD14 CD14 molecule 3.05 1.59E-03 
212526_at SPG20 spastic paraplegia 20 (Troyer syndrome) 3.05 3.41E-02 
223204_at FAM198B family with sequence similarity 198, member B 3.04 7.26E-04 
223319_at GPHN gephyrin 3.04 8.98E-05 
212022_s_at MKI67 antigen identified by monoclonal antibody Ki-67 3.03 7.22E-07 
209264_s_at TSPAN4 tetraspanin 4 3.03 3.75E-05 
205034_at CCNE2 cyclin E2 3.03 1.25E-08 
209959_at NR4A3 nuclear receptor subfamily 4, group A, member 3 3.02 2.20E-03 
226039_at MGAT4A 
mannosyl glycoprotein beta-1,4-N-
acetylglucosaminyltransferase A 
3.01 1.45E-04 
209933_s_at CD300A CD300a molecule 3.01 3.75E-05 
230276_at FAM49A family with sequence similarity 49, member A 3.01 6.74E-03 
208158_s_at OSBPL1A oxysterol binding protein-like 1A 3.00 8.55E-08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
John Riches Appendices 
233 
 
Appendix C: Genes dysregulated in CD4
+
 T cells from CLL patients 
 
Probe ID Symbol Name Log2 
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Upregulated 
    1560676_at SIAH3 seven in absentia homolog 3 (Drosophila) 2.207 0.012
225227_at NA NA 1.443 0.034 
204014_at DUSP4 dual specificity phosphatase 4 1.183 0.045 
230850_at NA NA 0.865 0.044 
235652_at NA NA 0.854 0.040 
218793_s_at SCML1 sex comb on midleg-like 1 (Drosophila) 0.753 0.025 
214180_at MAN1C1 mannosidase, alpha, class 1C, member 1 0.719 0.005 
237347_at NA NA 0.647 0.026 
     Downregulated 
   228910_at NA NA -0.589 0.040
226657_at C17orf103 chromosome 17 open reading frame 103 -0.592 0.017 
1564494_s_at P4HB prolyl 4-hydroxylase, beta polypeptide -0.600 0.012 
227089_at COG5 component of oligomeric golgi complex 5 -0.631 0.026 
208853_s_at CANX calnexin -0.680 0.012 
227114_at RNF214 ring finger protein 214 -0.691 0.034 
205321_at EIF2S3 eukaryotic translation initiation factor 2, subunit 3   -0.704 0.024 
205446_s_at ATF2 activating transcription factor 2 -0.706 0.012 
203629_s_at COG5 component of oligomeric golgi complex 5 -0.725 0.024 
203692_s_at E2F3 E2F transcription factor 3 -0.830 0.030 
229354_at AHRR aryl-hydrocarbon receptor repressor -0.909 0.044 
224480_s_at AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 -0.909 0.005 
212665_at TIPARP TCDD-inducible poly(ADP-ribose) polymerase -1.227 0.014 
203470_s_at PLEK pleckstrin -1.473 0.040 
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230137_at TMEM155 transmembrane protein 155 3.195 0.002 
232629_at PROK2 prokineticin 2 2.945 0.041 
210354_at IFNG interferon, gamma 2.527 0.004 
220030_at STYK1 serine/threonine/tyrosine kinase 1 2.516 0.002 
207229_at KLRA1 killer cell lectin-like receptor subfamily A, member 1 2.404 0.000 
210321_at GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) 2.366 0.012 
229937_x_at LILRB1 leukocyte immunoglobulin-like receptor, subfamily B, 1 2.280 0.008 
227478_at SETBP1 SET binding protein 1 2.240 0.017 
227769_at NA NA 2.213 0.038 
221696_s_at STYK1 serine/threonine/tyrosine kinase 1 2.062 0.004 
212810_s_at SLC1A4 solute carrier family , member 4 1.981 0.002 
1555579_s_at PTPRM protein tyrosine phosphatase, receptor type, M 1.924 0.001 
241394_at NA NA 1.900 0.006 
238600_at JAKMIP1 janus kinase and microtubule interacting protein 1 1.863 0.003 
227792_at ITPRIPL2 inositol-triphosphate receptor interacting protein-like 2 1.854 0.010 
203329_at PTPRM protein tyrosine phosphatase, receptor type, M 1.821 0.001 
1555465_at MCOLN2 mucolipin 2 1.771 0.005 
203603_s_at ZEB2 zinc finger E-box binding homeobox 2 1.688 0.014 
219386_s_at SLAMF8 SLAM family member 8 1.683 0.019 
227915_at ASB2 ankyrin repeat and SOCS box-containing 2 1.679 0.008 
1558102_at NA NA 1.672 0.009 
209610_s_at SLC1A4 solute carrier family 1, member 4 1.648 0.009 
205660_at OASL 2'-5'-oligoadenylate synthetase-like 1.639 0.019 
212811_x_at SLC1A4 solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
1.635 0.007 
232504_at 285628 hypothetical protein LOC285628 1.626 0.011 
228438_at 100132891 hypothetical protein LOC100132891 1.626 0.009 
240054_at NA NA 1.598 0.000 
209032_s_at CADM1 cell adhesion molecule 1 1.590 0.014 
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Genes that are > 3 fold down-regulated in CD8
+
 T cells from CLL patients 
compared with healthy CD8
+ 
T cells 
Probe ID Symbol Description Log2 
FC 
Adjusted 
P value 
202917_s_at S100A8 S100 calcium binding protein A8 8.506 0.000 
205033_s_at NA NA 7.442 0.002 
203535_at S100A9 S100 calcium binding protein A9 7.223 0.000 
202018_s_at LTF lactotransferrin 6.906 0.000 
209116_x_at HBB hemoglobin, beta 6.764 0.002 
211696_x_at HBB hemoglobin, beta 6.510 0.003 
1555745_a_at LYZ lysozyme (renal amyloidosis) 6.281 0.000 
217232_x_at HBB hemoglobin, beta 6.256 0.002 
209771_x_at CD24 CD24 molecule 6.026 0.000 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 5.966 0.000 
216379_x_at CD24 CD24 molecule 5.796 0.000 
205159_at CSF2RB colony stimulating factor 2 receptor, beta, low-affinity  5.471 0.000 
213975_s_at LYZ lysozyme (renal amyloidosis) 5.396 0.000 
212531_at LCN2 lipocalin 2 5.237 0.002 
266_s_at CD24 CD24 molecule 5.185 0.000 
214414_x_at NA NA 5.142 0.013 
217414_x_at NA NA 5.011 0.010 
201669_s_at MARCKS myristoylated alanine-rich protein kinase C substrate 5.007 0.000 
209458_x_at NA NA 4.982 0.010 
210254_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3  4.925 0.000 
207269_at DEFA4 defensin, alpha 4, corticostatin 4.909 0.002 
210244_at CAMP cathelicidin antimicrobial peptide 4.908 0.002 
204018_x_at NA NA 4.882 0.009 
203923_s_at CYBB cytochrome b-245, beta polypeptide 4.880 0.000 
211745_x_at NA NA 4.823 0.013 
205863_at S100A12 S100 calcium binding protein A12 4.823 0.015 
205119_s_at FPR1 formyl peptide receptor 1 4.715 0.000 
202391_at BASP1 brain abundant, membrane attached signal protein 1 4.679 0.000 
211699_x_at NA NA 4.654 0.010 
208650_s_at CD24 CD24 molecule 4.631 0.000 
206207_at CLC Charcot-Leyden crystal protein 4.625 0.003 
208651_x_at CD24 CD24 molecule 4.602 0.000 
207861_at CCL22 chemokine (C-C motif) ligand 22 4.521 0.000 
211657_at CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6  4.467 0.003 
207802_at CRISP3 cysteine-rich secretory protein 3 4.336 0.012 
211734_s_at FCER1A Fc fragment of IgE, high affinity I, alpha polypeptide 4.144 0.000 
204971_at CSTA cystatin A (stefin A) 4.140 0.000 
205557_at BPI bactericidal/permeability-increasing protein 4.138 0.002 
217764_s_at RAB31 RAB31, member RAS oncogene family 4.067 0.000 
1552348_at PRSS33 protease, serine, 33 3.979 0.000 
212592_at IGJ immunoglobulin J polypeptide 3.887 0.017 
205624_at CPA3 carboxypeptidase A3 (mast cell) 3.874 0.003 
212768_s_at OLFM4 olfactomedin 4 3.855 0.015 
John Riches Appendices 
236 
 
Probe ID Symbol Description Log2 
FC 
Adjusted 
P value 
223809_at RGS18 regulator of G-protein signaling 18 3.831 0.000 
208304_at CCR3 chemokine (C-C motif) receptor 3 3.761 0.000 
231688_at MMP8 matrix metallopeptidase 8 (neutrophil collagenase) 3.755 0.010 
1554892_a_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3  3.747 0.001 
214677_x_at NA NA 3.646 0.017 
217763_s_at RAB31 RAB31, member RAS oncogene family 3.633 0.000 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 3.616 0.008 
209710_at GATA2 GATA binding protein 2 3.598 0.000 
204959_at MNDA myeloid cell nuclear differentiation antigen 3.514 0.005 
217762_s_at RAB31 RAB31, member RAS oncogene family 3.473 0.000 
202589_at TYMS thymidylate synthetase 3.425 0.001 
204351_at S100P S100 calcium binding protein P 3.406 0.002 
209369_at ANXA3 annexin A3 3.371 0.011 
1552386_at GAPT GRB2-binding adaptor protein, transmembrane 3.289 0.000 
227889_at LPCAT2 lysophosphatidylcholine acyltransferase 2 3.279 0.000 
204232_at FCER1G Fc fragment of IgE, high affinity I, gamma polypeptide 3.277 0.001 
209949_at NCF2 neutrophil cytosolic factor 2 3.253 0.000 
210029_at IDO1 indoleamine 2,3-dioxygenase 1 3.251 0.000 
201163_s_at IGFBP7 insulin-like growth factor binding protein 7 3.250 0.002 
209160_at AKR1C3 aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II) 
3.249 0.003 
1553177_at SH2D1B SH2 domain containing 1B 3.229 0.007 
217022_s_at NA NA 3.179 0.024 
1554899_s_at FCER1G Fc fragment of IgE, high affinity I, gamma polypeptide 3.108 0.001 
206177_s_at ARG1 arginase, liver 3.070 0.025 
202990_at PYGL phosphorylase, glycogen, liver 3.045 0.000 
204446_s_at ALOX5 arachidonate 5-lipoxygenase 3.026 0.013 
214370_at S100A8 S100 calcium binding protein A8 3.017 0.000 
201670_s_at MARCKS myristoylated alanine-rich protein kinase C substrate 2.839 0.002 
208470_s_at NA NA 2.794 0.034 
204105_s_at NRCAM neuronal cell adhesion molecule 2.718 0.025 
226068_at SYK spleen tyrosine kinase 2.684 0.001 
206834_at HBD hemoglobin, delta 2.672 0.000 
206637_at P2RY14 purinergic receptor P2Y, G-protein coupled, 14 2.645 0.004 
220001_at PADI4 peptidyl arginine deiminase, type IV 2.623 0.006 
202859_x_at IL8 interleukin 8 2.612 0.045 
201425_at ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 2.609 0.000 
203757_s_at CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6  2.608 0.018 
201890_at RRM2 ribonucleotide reductase M2 2.595 0.005 
205513_at TCN1 transcobalamin I binding protein, R binder family 2.571 0.008 
202503_s_at KIAA0101 KIAA0101 2.541 0.005 
206157_at PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 2.522 0.000 
228170_at OLIG1 oligodendrocyte transcription factor 1 2.521 0.001 
233401_at NA NA 2.463 0.003 
203973_s_at CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.461 0.001 
244313_at CR1 complement component (3b/4b) receptor 1 2.387 0.007 
206697_s_at HP haptoglobin 2.387 0.032 
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201417_at SOX4 SRY (sex determining region Y)-box 4 2.363 0.009 
203021_at SLPI secretory leukocyte peptidase inhibitor 2.347 0.017 
201110_s_at THBS1 thrombospondin 1 2.334 0.001 
227647_at KCNE3 potassium voltage-gated channel, Isk-related family, 3 2.303 0.011 
225897_at MARCKS myristoylated alanine-rich protein kinase C substrate 2.300 0.006 
228854_at NA NA 2.286 0.005 
200696_s_at GSN gelsolin (amyloidosis, Finnish type) 2.281 0.000 
225710_at GNB4 guanine nucleotide binding protein, beta polypeptide 4 2.273 0.024 
1552398_a_at NA NA 2.256 0.037 
207540_s_at SYK spleen tyrosine kinase 2.249 0.001 
206310_at SPINK2 serine peptidase inhibitor, Kazal type 2 2.228 0.004 
229934_at NA NA 2.228 0.013 
203753_at TCF4 transcription factor 4 2.187 0.020 
227762_at NA NA 2.137 0.005 
203921_at CHST2 carbohydrate (N-acetylglucosamine-6-O sulfotransferase 2 2.132 0.001 
242509_at NA NA 2.127 0.003 
231579_s_at TIMP2 TIMP metallopeptidase inhibitor 2 2.121 0.029 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.120 0.037 
201005_at CD9 CD9 molecule 2.105 0.003 
226817_at DSC2 desmocollin 2 2.097 0.007 
208892_s_at DUSP6 dual specificity phosphatase 6 2.073 0.014 
205051_s_at KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 2.070 0.017 
206522_at MGAM maltase-glucoamylase (alpha-glucosidase) 2.051 0.036 
231771_at GJB6 gap junction protein, beta 6, 30kDa 2.036 0.018 
44790_s_at C13orf18 chromosome 13 open reading frame 18 2.016 0.034 
223553_s_at DOK3 docking protein 3 2.011 0.013 
212386_at TCF4 transcription factor 4 1.995 0.037 
205016_at TGFA transforming growth factor, alpha 1.984 0.006 
202252_at RAB13 RAB13, member RAS oncogene family 1.984 0.002 
1553043_a_at CD300LF CD300 molecule-like family member f 1.938 0.006 
201462_at SCRN1 secernin 1 1.932 0.014 
201739_at SGK1 serum/glucocorticoid regulated kinase 1 1.923 0.004 
202897_at SIRPA signal-regulatory protein alpha 1.922 0.010 
217388_s_at KYNU kynureninase (L-kynurenine hydrolase) 1.910 0.009 
244741_s_at NA NA 1.905 0.032 
212192_at KCTD12 potassium channel tetramerisation domain containing 12 1.898 0.011 
209921_at SLC7A11 solute carrier family 7,  member 11 1.888 0.006 
230793_at LRRC16A leucine rich repeat containing 16A 1.880 0.019 
208891_at DUSP6 dual specificity phosphatase 6 1.878 0.019 
242794_at MAML3 mastermind-like 3 (Drosophila) 1.865 0.002 
210845_s_at PLAUR plasminogen activator, urokinase receptor 1.853 0.008 
222833_at LPCAT2 lysophosphatidylcholine acyltransferase 2 1.811 0.006 
1560676_at SIAH3 seven in absentia homolog 3 (Drosophila) 1.810 0.005 
205147_x_at NCF4 neutrophil cytosolic factor 4, 40kDa 1.807 0.014 
204961_s_at NA NA 1.804 0.006 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 1.785 0.015 
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204798_at MYB v-myb myeloblastosis viral oncogene homolog (avian) 1.775 0.002 
239272_at MMP28 matrix metallopeptidase 28 1.771 0.032 
212188_at KCTD12 potassium channel tetramerisation domain containing 12 1.769 0.004 
207857_at LILRA2 leukocyte immunoglobulin-like receptor, subfamily A, 2 1.766 0.046 
209773_s_at RRM2 ribonucleotide reductase M2 1.757 0.045 
1552349_a_at PRSS33 protease, serine, 33 1.744 0.010 
205382_s_at CFD complement factor D (adipsin) 1.733 0.016 
207677_s_at NCF4 neutrophil cytosolic factor 4, 40kDa 1.724 0.027 
221581_s_at LAT2 linker for activation of T cells family, member 2 1.718 0.002 
209772_s_at CD24 CD24 molecule 1.708 0.037 
204863_s_at IL6ST interleukin 6 signal transducer  1.695 0.002 
223623_at C2orf40 chromosome 2 open reading frame 40 1.680 0.048 
220088_at C5AR1 complement component 5a receptor 1 1.679 0.027 
228293_at DEPDC7 DEP domain containing 7 1.678 0.024 
223028_s_at SNX9 sorting nexin 9 1.674 0.004 
1552908_at C1orf150 chromosome 1 open reading frame 150 1.671 0.033 
203139_at DAPK1 death-associated protein kinase 1 1.664 0.020 
1552691_at ARL11 ADP-ribosylation factor-like 11 1.663 0.014 
208637_x_at ACTN1 actinin, alpha 1 1.663 0.018 
204057_at IRF8 interferon regulatory factor 8 1.653 0.002 
204440_at CD83 CD83 molecule 1.645 0.001 
1562245_a_at ZNF578 zinc finger protein 578 1.638 0.014 
244125_at NA NA 1.637 0.035 
231798_at NOG noggin 1.623 0.043 
231351_at NA NA 1.622 0.002 
228582_x_at MALAT1 metastasis associated lung adenocarcinoma transcript 1  1.617 0.033 
201887_at IL13RA1 interleukin 13 receptor, alpha 1 1.617 0.043 
1558569_at UNQ6228 hypothetical LOC100131541 1.617 0.003 
223423_at GPR160 G protein-coupled receptor 160 1.615 0.014 
244414_at NA NA 1.613 0.005 
242405_at NA NA 1.612 0.006 
209191_at TUBB6 tubulin, beta 6 1.612 0.047 
226884_at LRRN1 leucine rich repeat neuronal 1 1.611 0.004 
219671_at HPCAL4 hippocalcin like 4 1.609 0.015 
236858_s_at RUNX2 runt-related transcription factor 2 1.607 0.024 
211000_s_at IL6ST interleukin 6 signal transducer  1.606 0.004 
227184_at NA NA 1.597 0.006 
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Appendix E: Genes dysregulated in CD3
-
CD56
+
 NK cells from CLL patients 
Genes that are > 3 fold up-regulated in CD3
-
CD56
+
 NK cells from CLL patients 
compared with healthy CD3
-
CD56
+
 NK cells 
Probe ID Symbol Description Log2 
FC 
Adjusted 
P value 
238018_at FAM150B family with sequence similarity 150, member B 3.229 0.022 
220004_at DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 2.886 0.010 
219871_at FLJ13197 uncharacterized FLJ13197 2.490 0.008 
220591_s_at EFHC2 EF-hand domain (C-terminal) containing 2 2.125 0.031 
229952_at NA NA 1.889 0.001 
219412_at RAB38 RAB38, member RAS oncogene family 1.742 0.007 
204916_at RAMP1 receptor (G protein-coupled) activity modifying protein 1 1.732 0.007 
229040_at ITGB2-AS1 ITGB2 antisense RNA 1 1.723 0.006 
241278_at NA NA 1.696 0.043 
229041_s_at ITGB2-AS1 ITGB2 antisense RNA 1 1.592 0.001 
 
Genes that are > 3 fold down-regulated in CD3
-
CD56
+
 NK cells from CLL patients 
compared with healthy CD3
-
CD56
+
 NK cells 
Probe ID Symbol Description Log2 
FC 
Adjusted 
P value 
204439_at IFI44L interferon-induced protein 44-like 6.529 0.000 
203153_at IFIT1 interferon-induced protein with tetratricopeptide repeats 1 4.212 0.000 
213797_at RSAD2 radical S-adenosyl methionine domain containing 2 4.018 0.000 
242625_at RSAD2 radical S-adenosyl methionine domain containing 2 3.598 0.000 
205330_at MN1 meningioma (disrupted in balanced translocation) 1 3.454 0.010 
236595_at NA NA 3.313 0.005 
214059_at IFI44 interferon-induced protein 44 3.237 0.000 
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 3.201 0.000 
205552_s_at OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 3.108 0.001 
202086_at MX1 myxovirus  resistance 1, interferon-inducible protein p78  3.061 0.004 
229450_at IFIT3 interferon-induced protein with tetratricopeptide repeats 3 2.996 0.000 
205479_s_at PLAU plasminogen activator, urokinase 2.981 0.019 
204747_at IFIT3 interferon-induced protein with tetratricopeptide repeats 3 2.935 0.001 
214453_s_at IFI44 interferon-induced protein 44 2.870 0.000 
232081_at ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 2.760 0.001 
226702_at CMPK2 cytidine monophosphate kinase 2, mitochondrial 2.663 0.000 
230250_at PTPRB protein tyrosine phosphatase, receptor type, B 2.656 0.003 
202869_at OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 2.645 0.001 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.610 0.004 
204415_at IFI6 interferon, alpha-inducible protein 6 2.540 0.001 
222449_at PMEPA1 prostate transmembrane protein, androgen induced 1 2.505 0.003 
212680_x_at PPP1R14B protein phosphatase 1, regulatory (inhibitor) subunit 14B 2.443 0.002 
219753_at STAG3 stromal antigen 3 2.413 0.005 
214247_s_at DKK3 dickkopf 3 homolog (Xenopus laevis) 2.400 0.027 
242898_at EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 2.354 0.001 
222154_s_at SPATS2L spermatogenesis associated, serine-rich 2-like 2.235 0.005 
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230913_at NA NA 2.231 0.036 
217875_s_at PMEPA1 prostate transmembrane protein, androgen induced 1 2.202 0.012 
219866_at CLIC5 chloride intracellular channel 5 2.198 0.009 
205977_s_at EPHA1 EPH receptor A1 2.182 0.036 
222450_at PMEPA1 prostate transmembrane protein, androgen induced 1 2.170 0.024 
201465_s_at JUN jun proto-oncogene 2.119 0.000 
210001_s_at SOCS1 suppressor of cytokine signaling 1 2.086 0.001 
217497_at TYMP thymidine phosphorylase 2.054 0.001 
219211_at USP18 ubiquitin specific peptidase 18 2.048 0.002 
204567_s_at ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 2.022 0.012 
235276_at EPSTI1 epithelial stromal interaction 1 (breast) 1.978 0.000 
201466_s_at JUN jun proto-oncogene 1.978 0.000 
219949_at LRRC2 leucine rich repeat containing 2 1.938 0.034 
236439_at NA NA 1.899 0.033 
235301_at KIAA1324L KIAA1324-like 1.892 0.021 
209574_s_at C18orf1 chromosome 18 open reading frame 1 1.887 0.007 
211434_s_at CCRL2 chemokine (C-C motif) receptor-like 2 1.880 0.030 
204994_at MX2 myxovirus (influenza virus) resistance 2 (mouse) 1.873 0.012 
205660_at OASL 2'-5'-oligoadenylate synthetase-like 1.870 0.000 
204285_s_at PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 1.858 0.018 
202468_s_at CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 1.827 0.018 
227609_at EPSTI1 epithelial stromal interaction 1 (breast) 1.817 0.000 
235916_at YPEL4 yippee-like 4 (Drosophila) 1.810 0.016 
210797_s_at OASL 2'-5'-oligoadenylate synthetase-like 1.796 0.000 
209573_s_at C18orf1 chromosome 18 open reading frame 1 1.777 0.014 
204286_s_at PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 1.727 0.029 
205483_s_at ISG15 ISG15 ubiquitin-like modifier 1.724 0.019 
219352_at HERC6 
HECT and RLD domain containing E3 ubiquitin protein 
ligase family member 6 1.718 0.001 
224802_at NDFIP2 Nedd4 family interacting protein 2 1.602 0.006 
201464_x_at JUN jun proto-oncogene 1.593 0.000 
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Appendix F: Impact of lenalidomide on gene expression of CLL cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Upregulated 
    
204223_at PRELP proline/arginine-rich end leucine-rich repeat protein 4.271 3.83E-09 
1557049_at BTBD19 BTB (POZ) domain containing 19 3.589 4.66E-09 
205987_at CD1C CD1c molecule 3.467 1.65E-05 
1559067_a_at NA NA 3.249 4.23E-09 
214228_x_at TNFRSF4 tumor necrosis factor receptor superfamily, 4 3.078 1.35E-09 
230966_at IL4I1 interleukin 4 induced 1 3.058 1.83E-06 
226264_at SUSD1 sushi domain containing 1 3.018 6.91E-08 
236769_at LOC158402 uncharacterized LOC158402 3.013 9.33E-09 
238365_s_at C1orf228 chromosome 1 open reading frame 228 2.961 3.79E-11 
204103_at CCL4 chemokine (C-C motif) ligand 4 2.848 2.57E-05 
202638_s_at ICAM1 intercellular adhesion molecule 1 2.785 4.62E-08 
242520_s_at C1orf228 chromosome 1 open reading frame 228 2.777 1.24E-09 
209785_s_at PLA2G4C phospholipase A2, group  2.739 1.98E-07 
223249_at CLDN12 claudin 12 2.733 2.66E-09 
212458_at SPRED2 sprouty-related, EVH1 domain containing 2 2.677 5.19E-06 
209757_s_at MYCN v-myc myelocytomatosis viral related oncogene 2.626 2.53E-06 
210056_at RND1 Rho family GTPase 1 2.597 1.11E-10 
230787_at NA NA 2.524 1.48E-11 
229450_at IFIT3 interferon-induced with tetratricopeptide repeats 3 2.445 3.51E-03 
213925_at C1orf95 chromosome 1 open reading frame 95 2.438 2.40E-05 
1559066_at NA NA 2.421 1.49E-07 
228224_at PRELP proline/arginine-rich end leucine-rich repeat protein 2.392 1.41E-04 
205114_s_at NA NA 2.356 1.02E-05 
1556281_at NA NA 2.312 1.90E-06 
229127_at JAM2 junctional adhesion molecule 2 2.301 5.29E-07 
235175_at GBP4 guanylate binding protein 4 2.280 2.40E-05 
213348_at CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 2.268 3.27E-07 
207113_s_at TNF tumor necrosis factor 2.256 8.97E-09 
202637_s_at ICAM1 intercellular adhesion molecule 1 2.256 6.02E-09 
207426_s_at TNFSF4 
tumor necrosis factor (ligand) superfamily, member 
4 2.255 2.27E-07 
200983_x_at CD59 CD59 molecule, complement regulatory protein 2.253 2.59E-16 
209959_at NR4A3 nuclear receptor subfamily 4, group A, member 3 2.222 1.25E-04 
204083_s_at TPM2 tropomyosin 2 (beta) 2.199 4.72E-05 
208370_s_at RCAN1 regulator of calcineurin 1 2.192 2.40E-08 
230939_at LOC100996457 uncharacterized LOC100996457 2.185 1.11E-10 
204026_s_at ZWINT ZW10 interactor 2.128 1.15E-09 
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 2.114 3.88E-06 
201939_at PLK2 polo-like kinase 2 2.096 4.08E-07 
209267_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 2.081 7.54E-09 
234284_at GNG8 guanine nucleotide binding protein, gamma 8 2.071 6.07E-05 
215253_s_at RCAN1 regulator of calcineurin 1 2.054 5.06E-06 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.049 1.41E-04 
200984_s_at CD59 CD59 molecule, complement regulatory protein 2.032 5.78E-16 
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200985_s_at CD59 CD59 molecule, complement regulatory protein 2.019 2.39E-16 
239691_at C12orf77 chromosome 12 open reading frame 77 2.003 3.90E-05 
209684_at RIN2 Ras and Rab interactor 2 1.967 4.74E-03 
219213_at JAM2 junctional adhesion molecule 2 1.967 6.88E-05 
206674_at FLT3 fms-related tyrosine kinase 3 1.959 3.00E-06 
201059_at CTTN cortactin 1.956 6.85E-06 
202284_s_at CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.950 9.63E-11 
223159_s_at NEK6 NIMA (never in mitosis gene a)-related kinase 6 1.947 2.68E-05 
212463_at CD59 CD59 molecule, complement regulatory protein 1.913 1.28E-18 
200951_s_at CCND2 cyclin D2 1.910 2.28E-05 
206486_at LAG3 lymphocyte-activation gene 3 1.907 2.48E-04 
206115_at EGR3 early growth response 3 1.887 1.78E-03 
204422_s_at FGF2 fibroblast growth factor 2 (basic) 1.878 1.03E-03 
219869_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 1.876 2.01E-08 
205249_at EGR2 early growth response 2 1.848 1.11E-04 
207691_x_at ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 1.845 1.75E-06 
201693_s_at EGR1 early growth response 1 1.842 3.90E-05 
226926_at DMKN dermokine 1.841 2.49E-06 
204622_x_at NR4A2 nuclear receptor subfamily 4, group A, member 2 1.839 2.81E-04 
219255_x_at IL17RB interleukin 17 receptor B 1.830 4.65E-04 
219753_at STAG3 stromal antigen 3 1.830 3.51E-08 
209129_at TRIP6 thyroid hormone receptor interactor 6 1.815 1.41E-11 
223967_at ANGPTL6 angiopoietin-like 6 1.809 8.11E-08 
202446_s_at PLSCR1 phospholipid scramblase 1 1.797 2.81E-07 
204493_at BID BH3 interacting domain death agonist 1.793 3.84E-05 
216248_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 1.775 2.57E-04 
210904_s_at IL13RA1 interleukin 13 receptor, alpha 1 1.759 1.50E-04 
209901_x_at AIF1 allograft inflammatory factor 1 1.727 1.71E-03 
209474_s_at ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 1.721 5.97E-06 
226517_at BCAT1 branched chain amino-acid transaminase 1, cytosolic 1.713 1.74E-02 
223845_at VSIG10 V-set and immunoglobulin domain containing 10 1.711 7.63E-04 
228585_at ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 1.696 1.30E-06 
211725_s_at NA NA 1.695 3.05E-05 
201887_at IL13RA1 interleukin 13 receptor, alpha 1 1.694 1.34E-05 
222746_s_at BSPRY B-box and SPRY domain containing 1.691 2.39E-06 
227404_s_at EGR1 early growth response 1 1.688 6.35E-04 
220770_s_at C5orf54 chromosome 5 open reading frame 54 1.688 1.07E-09 
202252_at RAB13 RAB13, member RAS oncogene family 1.679 6.61E-08 
227143_s_at BID BH3 interacting domain death agonist 1.675 5.66E-06 
1565817_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 1.666 1.78E-06 
1554712_a_at GLYATL2 glycine-N-acyltransferase-like 2 1.666 4.65E-04 
205204_at NMB neuromedin B 1.662 1.30E-04 
210481_s_at CLEC4M C-type lectin domain family 4, member M 1.653 3.14E-04 
204621_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 1.652 1.78E-04 
237837_at NA NA 1.641 6.19E-06 
216973_s_at HOXB7 homeobox B7 1.622 1.04E-05 
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Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
225285_at BCAT1 branched chain amino-acid transaminase 1, cytosolic 1.615 2.89E-02 
202430_s_at PLSCR1 phospholipid scramblase 1 1.611 1.11E-06 
211612_s_at IL13RA1 interleukin 13 receptor, alpha 1 1.605 2.01E-04 
224374_s_at EMILIN2 elastin microfibril interfacer 2 1.597 2.31E-09 
207399_at BFSP2 beaded filament structural protein 2, phakinin 1.596 7.05E-05 
1553991_s_at VSIG10 V-set and immunoglobulin domain containing 10 1.594 6.92E-04 
204068_at STK3 serine/threonine kinase 3 1.585 1.94E-07 
218792_s_at BSPRY B-box and SPRY domain containing 1.584 2.09E-07 
220066_at NOD2 
nucleotide-binding oligomerization domain 
containing 2 1.583 7.52E-07 
     Downregulated 
    
205489_at CRYM crystallin, mu 2.6092 1.21E-07 
219518_s_at NA NA 2.3277 7.67E-09 
206312_at GUCY2C guanylate cyclase 2C 2.0830 4.37E-05 
216598_s_at CCL2 chemokine (C-C motif) ligand 2 2.0740 2.54E-03 
206865_at HRK harakiri, BCL2 interacting protein  2.0711 7.25E-06 
229552_at LOC283454 uncharacterized LOC283454 2.0348 2.37E-05 
213906_at MYBL1 v-myb myeloblastosis oncogene homolog-like 1 1.9810 6.34E-05 
219517_at NA NA 1.9666 2.47E-08 
209598_at PNMA2 paraneoplastic Ma antigen 2 1.9469 8.69E-03 
201005_at CD9 CD9 molecule 1.9464 1.92E-04 
202917_s_at S100A8 S100 calcium binding protein A8 1.8944 6.78E-03 
237187_at NA NA 1.8227 6.52E-06 
206864_s_at HRK harakiri, BCL2 interacting protein  1.7908 5.57E-06 
209082_s_at COL18A1 collagen, type XVIII, alpha 1 1.7775 2.91E-03 
201110_s_at THBS1 thrombospondin 1 1.7702 2.16E-02 
219840_s_at TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) 1.7341 1.29E-08 
1561363_a_at NA NA 1.7336 4.51E-07 
243469_at NA NA 1.7296 9.78E-09 
233142_at NA NA 1.7043 1.57E-03 
1564154_at NA NA 1.6893 2.77E-05 
235694_at TCFL5 transcription factor-like 5 (basic helix-loop-helix) 1.6778 6.49E-09 
210036_s_at KCNH2 potassium voltage-gated channel, subfamily H, 2 1.6613 2.54E-05 
204681_s_at RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 1.6487 2.75E-02 
207087_x_at ANK1 ankyrin 1, erythrocytic 1.6439 9.16E-06 
226733_at PFKFB2 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 1.6302 5.36E-06 
233951_at NA NA 1.6237 8.74E-07 
243309_at FLJ27352 uncharacterized LOC145788 1.6116 2.82E-09 
213839_at CLMN calmin (calponin-like, transmembrane) 1.5965 5.29E-06 
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Appendix G: Impact of lenalidomide on gene expression of healthy B cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Upregulated 
    
215784_at CD1E CD1e molecule 5.516 2.67E-18 
209324_s_at RGS16 regulator of G-protein signaling 16 3.258 1.66E-05 
200665_s_at SPARC secreted protein, acidic, cysteine-rich (osteonectin) 3.073 2.55E-06 
209325_s_at RGS16 regulator of G-protein signaling 16 2.708 2.00E-07 
220066_at NOD2 nucleotide-binding oligomerization domain 2 2.381 2.03E-09 
205968_at KCNS3 potassium voltage-gated channel, subfamily S, 3 2.299 2.10E-09 
202450_s_at CTSK cathepsin K 2.240 4.81E-04 
210056_at RND1 Rho family GTPase 1 2.146 2.02E-08 
242520_s_at C1orf228 chromosome 1 open reading frame 228 2.140 6.17E-07 
234994_at TMEM200A transmembrane protein 200A 2.098 1.04E-06 
232397_at NA NA 2.092 1.47E-06 
207426_s_at TNFSF4 tumor necrosis factor superfamily, member 4 2.040 4.71E-06 
210029_at IDO1 indoleamine 2,3-dioxygenase 1 2.023 5.12E-05 
223249_at CLDN12 claudin 12 1.993 3.01E-06 
232267_at GPR133 G protein-coupled receptor 133 1.972 6.60E-09 
234284_at GNG8 guanine nucleotide binding protein, gamma 8 1.905 6.11E-04 
238365_s_at C1orf228 chromosome 1 open reading frame 228 1.829 1.60E-06 
208592_s_at CD1E CD1e molecule 1.816 2.03E-09 
202085_at TJP2 tight junction protein 2 1.782 9.78E-05 
204932_at TNFRSF11B tumor necrosis factor receptor superfamily, 11b 1.774 4.31E-04 
203915_at CXCL9 chemokine (C-X-C motif) ligand 9 1.756 2.32E-04 
224402_s_at FCRL4 Fc receptor-like 4 1.700 6.68E-03 
204430_s_at SLC2A5 solute carrier family 2, member 5 1.681 2.94E-04 
235885_at P2RY12 purinergic receptor P2Y, G-protein coupled, 12 1.667 2.22E-03 
202481_at DHRS3 dehydrogenase/reductase (SDR family) member 3 1.664 1.02E-04 
218094_s_at NA NA 1.635 8.76E-07 
212364_at MYO1B myosin IB 1.624 9.44E-06 
210643_at TNFSF11 tumor necrosis factor superfamily, member 11 1.603 2.41E-06 
212655_at ZCCHC14 zinc finger, CCHC domain containing 14 1.596 8.89E-04 
206618_at IL18R1 interleukin 18 receptor 1 1.583 3.95E-06 
     
Downregulated 
    
216598_s_at CCL2 chemokine (C-C motif) ligand 2 2.293 3.46E-03 
204614_at SERPINB2 serpin peptidase inhibitor, clade B, member 2 2.098 2.23E-02 
201108_s_at THBS1 thrombospondin 1 1.894 1.42E-02 
240633_at DOK7 docking protein 7 1.866 8.95E-06 
211429_s_at SERPINA1 serpin peptidase inhibitor, clade A, member 1 1.815 2.54E-03 
209189_at FOS FBJ murine osteosarcoma viral oncogene homolog 1.800 2.49E-03 
229656_s_at EML6 echinoderm microtubule associated protein like 6 1.760 2.32E-04 
206244_at CR1 complement component (3b/4b) receptor 1 1.752 2.75E-09 
1555756_a_at CLEC7A C-type lectin domain family 7, member A 1.733 1.59E-02 
205237_at FCN1 ficolin (collagen/fibrinogen domain containing) 1 1.730 1.84E-02 
230550_at MS4A6A membrane-spanning 4-domains, subfamily A, 6A 1.697 9.62E-03 
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FC 
Adjusted 
p value 
201109_s_at THBS1 thrombospondin 1 1.696 1.99E-02 
201131_s_at CDH1 cadherin 1, type 1, E-cadherin (epithelial) 1.674 7.43E-04 
38487_at STAB1 stabilin 1 1.630 9.52E-03 
201325_s_at EMP1 epithelial membrane protein 1 1.622 3.86E-03 
202833_s_at SERPINA1 serpin peptidase inhibitor, clade A, member 1 1.595 1.98E-02 
209875_s_at SPP1 secreted phosphoprotein 1 1.581 4.73E-02 
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Appendix H: Impact of lenalidomide on gene expression of CLL CD4
+
 T cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Upregulated 
    
204165_at WASF1 WAS protein family, member 1 4.443 1.42E-16 
223249_at CLDN12 claudin 12 3.445 2.16E-18 
244397_at NA NA 3.192 6.89E-17 
1565817_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 3.016 1.03E-16 
240581_at LOC644135 uncharacterized LOC644135 2.849 2.85E-13 
230939_at LOC100996457 uncharacterized LOC100996457 2.804 5.96E-09 
232397_at NA NA 2.761 4.40E-14 
240103_at LOC100996457 uncharacterized LOC100996457 2.666 8.18E-08 
213238_at ATP10D ATPase, class V, type 10D 2.620 4.82E-13 
213566_at RNASE6 ribonuclease, RNase A family, k6 2.612 3.39E-09 
203476_at TPBG trophoblast glycoprotein 2.606 2.20E-08 
236787_at NA NA 2.528 4.78E-09 
202893_at UNC13B unc-13 homolog B (C. elegans) 2.389 8.30E-12 
1565579_at NA NA 2.383 2.38E-08 
219179_at DACT1 dapper, antagonist of beta-catenin, homolog 1 2.371 1.05E-08 
225308_s_at TANC1 tetratricopeptide, ankyrin repeat and coiled-coil 1 2.356 9.89E-08 
235412_at ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 2.278 1.44E-09 
207113_s_at TNF tumor necrosis factor 2.174 1.74E-06 
220770_s_at C5orf54 chromosome 5 open reading frame 54 2.154 1.60E-09 
201743_at CD14 CD14 molecule 2.001 2.04E-06 
229450_at IFIT3 interferon-induced protein tetratricopeptide repeats 3 1.920 1.76E-02 
225081_s_at CDCA7L cell division cycle associated 7-like 1.870 6.47E-12 
224374_s_at EMILIN2 elastin microfibril interfacer 2 1.831 2.74E-12 
228027_at GPRASP2 G protein receptor associated sorting protein 2 1.801 8.43E-11 
238029_s_at SLC16A14 solute carrier family 16, member 14  1.774 3.38E-06 
223095_at MARVELD1 MARVEL domain containing 1 1.766 7.39E-13 
204083_s_at TPM2 tropomyosin 2 (beta) 1.739 1.52E-05 
206380_s_at CFP complement factor properdin 1.730 8.36E-11 
227522_at CMBL carboxymethylenebutenolidase homolog  1.725 6.49E-09 
217890_s_at PARVA parvin, alpha 1.718 2.81E-07 
217196_s_at CAMSAP2 calmodulin regulated spectrin-associated protein 2 1.707 5.98E-13 
212765_at CAMSAP2 calmodulin regulated spectrin-associated protein 2 1.678 8.26E-12 
220358_at BATF3 basic leucine zipper transcription factor, ATF-like 3 1.619 1.10E-05 
230301_at NA NA 1.613 3.36E-05 
209129_at TRIP6 thyroid hormone receptor interactor 6 1.595 1.40E-12 
206600_s_at SLC16A5 solute carrier family 16, member 5  1.582 1.96E-10 
Downregulated 
    
205733_at BLM Bloom syndrome, RecQ helicase-like 2.251 3.17E-08 
220131_at FXYD7 FXYD domain containing ion transport regulator 7 1.955 1.24E-06 
210448_s_at P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 1.837 2.06E-11 
222307_at LOC282997 uncharacterized LOC282997 1.772 7.74E-17 
242509_at NA NA 1.661 1.86E-07 
336_at TBXA2R thromboxane A2 receptor 1.600 4.05E-05 
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Appendix I: Impact of lenalidomide on gene expression of CLL CD8
+
 T cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Upregulated 
    
223249_at CLDN12 claudin 12 3.328 4.79E-16 
232397_at NA NA 3.265 1.60E-08 
240581_at LOC644135 uncharacterized LOC644135 3.230 2.04E-12 
225710_at GNB4 guanine nucleotide binding prot. beta polypeptide 4 3.001 3.92E-04 
204165_at WASF1 WAS protein family, member 1 2.907 1.27E-07 
229450_at IFIT3 interferon-induced protein tetratricopeptide repeats 3 2.619 4.14E-02 
219386_s_at SLAMF8 SLAM family member 8 2.600 8.72E-07 
236787_at NA NA 2.593 6.91E-06 
244397_at NA NA 2.529 2.04E-12 
213566_at RNASE6 ribonuclease, RNase A family, k6 2.427 1.63E-04 
219385_at SLAMF8 SLAM family member 8 2.345 1.93E-06 
204083_s_at TPM2 tropomyosin 2 (beta) 2.213 9.88E-08 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.192 4.51E-03 
1565817_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 2.159 5.38E-08 
235574_at GBP4 guanylate binding protein 4 2.131 1.03E-04 
213113_s_at SLC43A3 solute carrier family 43, member 3 2.128 2.31E-11 
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 2.087 1.35E-02 
200678_x_at GRN granulin 2.025 1.61E-06 
208923_at CYFIP1 cytoplasmic FMR1 interacting protein 1 2.005 4.35E-07 
220358_at BATF3 basic leucine zipper transcription factor, ATF-like 3 1.979 5.08E-03 
224374_s_at EMILIN2 elastin microfibril interfacer 2 1.965 1.50E-09 
216041_x_at GRN granulin 1.955 1.45E-06 
207111_at EMR1 egf-like module containing, mucin- receptor-like 1 1.934 7.53E-04 
235175_at GBP4 guanylate binding protein 4 1.878 8.48E-05 
211284_s_at GRN granulin 1.873 8.54E-07 
219403_s_at HPSE heparanase 1.828 2.44E-05 
1552691_at ARL11 ADP-ribosylation factor-like 11 1.815 4.40E-04 
204068_at STK3 serine/threonine kinase 3 1.772 5.08E-07 
225081_s_at CDCA7L cell division cycle associated 7-like 1.759 1.28E-05 
207113_s_at TNF tumor necrosis factor 1.748 2.04E-06 
228937_at LACC1 laccase domain containing 1 1.739 1.14E-03 
213238_at ATP10D ATPase, class V, type 10D 1.736 1.93E-05 
227438_at ALPK1 alpha-kinase 1 1.718 9.66E-04 
1565579_at NA NA 1.711 7.09E-08 
225285_at BCAT1 branched chain amino-acid transaminase 1, cytosolic 1.692 7.37E-04 
201952_at ALCAM activated leukocyte cell adhesion molecule 1.687 1.29E-08 
206637_at P2RY14 purinergic receptor P2Y, G-protein coupled, 14 1.678 1.18E-03 
230511_at CREM cAMP responsive element modulator 1.631 4.32E-04 
224097_s_at F11R F11 receptor 1.606 3.04E-07 
Downregulated 
    
336_at TBXA2R thromboxane A2 receptor 2.794 9.29E-05 
202806_at DBN1 drebrin 1 2.557 4.98E-10 
205733_at BLM Bloom syndrome, RecQ helicase-like 1.972 6.23E-12 
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Appendix J: Genes recurrently up-regulated by lenalidomide in T cells 
 
Probe ID Symbol Name 
Upregulated 
  
204567_s_at ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 
219361_s_at AEN apoptosis enhancing nuclease 
224480_s_at AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 
229354_at AHRR aryl-hydrocarbon receptor repressor; programmed cell death 6 
201951_at ALCAM activated leukocyte cell adhesion molecule 
201952_at ALCAM activated leukocyte cell adhesion molecule 
208950_s_at ALDH7A1 aldehyde dehydrogenase 7 family, member A1 
227438_at ALPK1 alpha-kinase 1 
201302_at ANXA4 annexin A4 
201301_s_at ANXA5 annexin A4 
204765_at ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 
235412_at ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 
1562270_at ARHGEF8 Rho guanine nucleotide exchange factor (GEF) 7 
1562271_x_at ARHGEF9 Rho guanine nucleotide exchange factor (GEF) 7 
202548_s_at ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 7 
1552691_at ARL11 ADP-ribosylation factor-like 11 
218694_at ARMCX1 armadillo repeat containing, X-linked 1 
225286_at ARSD arylsulfatase D 
219359_at ATHL1 ATH1, acid trehalase-like 1 (yeast) 
213238_at ATP10D ATPase, class V, type 10D 
220358_at BATF3 basic leucine zipper transcription factor, ATF-like 3 
59644_at BMP2K BMP2 inducible kinase 
219546_at BMP2K BMP2 inducible kinase 
226853_at BMP2K BMP2 inducible kinase 
209920_at BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
210214_s_at BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
228937_at C13ORF31 chromosome 13 open reading frame 31 
224574_at C17ORF49 chromosome 17 open reading frame 49 
222883_at C1ORF163 chromosome 1 open reading frame 163 
238365_s_at C1ORF228 chromosome 1 open reading frame 228 
242520_s_at C1ORF228 chromosome 1 open reading frame 228 
228067_at C2ORF55 chromosome 2 open reading frame 55 
220770_s_at C5ORF54 chromosome 5 open reading frame 54 
223276_at C5ORF62 MSTP150 
229070_at C6ORF105 chromosome 6 open reading frame 105 
230301_at C7ORF46 chromosome 7 open reading frame 46 
209726_at CA11 carbonic anhydrase XI 
209031_at CADM1 cell adhesion molecule 1 
209032_s_at CADM1 cell adhesion molecule 1 
212765_at CAMSAP1L1 calmodulin regulated spectrin-associated protein 1-like 1 
217196_s_at CAMSAP1L1 calmodulin regulated spectrin-associated protein 1-like 1 
212763_at CAMSAP1L1 calmodulin regulated spectrin-associated protein 1-like 1 
225045_at CCDC88A coiled-coil domain containing 88A 
216598_s_at CCL2 chemokine (C-C motif) ligand 2 
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201743_at CD14 CD14 molecule 
206508_at CD70 CD70 molecule 
225081_s_at CDCA7L cell division cycle associated 7-like 
202284_s_at CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
206380_s_at CFP complement factor properdin 
223249_at CLDN12 claudin 12 
208791_at CLU clusterin 
231499_s_at CLU clusterin 
227522_at CMBL carboxymethylenebutenolidase homolog (Pseudomonas) 
201438_at COL6A3 collagen, type VI, alpha 3 
64486_at CORO1B coronin, actin binding protein, 1B 
214508_x_at CREM cAMP responsive element modulator 
230511_at CREM cAMP responsive element modulator 
209967_s_at CREM cAMP responsive element modulator 
207630_s_at CREM cAMP responsive element modulator 
221541_at CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 
1555889_a_at CRTAP cartilage associated protein 
201380_at CRTAP cartilage associated protein 
1554464_a_at CRTAP cartilage associated protein 
210844_x_at CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 
200765_x_at CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 
200764_s_at CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 
200839_s_at CTSB cathepsin B 
208923_at CYFIP1 cytoplasmic FMR1 interacting protein 1 
219179_at DACT1 dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) 
218094_s_at DBNDD2 dysbindin (dystrobrevin binding protein 1) domain containing 2 
203409_at DDB2 damage-specific DNA binding protein 2, 48kDa 
239310_at DDB2 damage-specific DNA binding protein 2, 48kDa 
200862_at DHCR24 24-dehydrocholesterol reductase 
224374_s_at EMILIN2 elastin microfibril interfacer 2 
207111_at EMR1 egf-like module containing, mucin-like, hormone receptor-like 1 
201341_at ENC1 ectodermal-neural cortex (with BTB-like domain) 
201719_s_at EPB41L2 erythrocyte membrane protein band 4.1-like 2 
213365_at ERI2 exoribonuclease 2 
221664_s_at F11R F11 receptor 
224097_s_at F11R F11 receptor 
223000_s_at F11R F11 receptor 
238484_s_at FADS2 fatty acid desaturase 2 
238861_at FADS2 fatty acid desaturase 2 
213861_s_at FAM119B family with sequence similarity 119, member B 
221856_s_at FAM63A family with sequence similarity 63, member A 
219785_s_at FBXO31 F-box protein 31 
227265_at FGL2 fibrinogen-like 2 
204834_at FGL2 fibrinogen-like 2 
235574_at GBP4 guanylate binding protein 4 
235175_at GBP4 guanylate binding protein 4 
223887_at GPR132 G protein-coupled receptor 132 
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228027_at GPRASP2 G protein-coupled receptor associated sorting protein 2 
211284_s_at GRN granulin 
200678_x_at GRN granulin 
216041_x_at GRN granulin 
208886_at H1F0 H1 histone family, member 0 
232397_at HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 
210387_at HIST1H2BC histone cluster 1 
210387_at HIST1H2BE histone cluster 1 
210387_at HIST1H2BF histone cluster 1 
210387_at HIST1H2BG histone cluster 1 
210387_at HIST1H2BI histone cluster 1 
221606_s_at HMGN5 nucleosomal binding protein 1 
219403_s_at HPSE heparanase 
222881_at HPSE heparanase 
229450_at IFIT3 interferon-induced protein with tetratricopeptide repeats 3 
1565817_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 
226759_at IKZF4 IKAROS family zinc finger 4 (Eos) 
226761_at IKZF4 IKAROS family zinc finger 4 (Eos) 
229752_at IKZF4 IKAROS family zinc finger 4 (Eos) 
205992_s_at IL15 interleukin 15 
217371_s_at IL15 interleukin 15 
204562_at IRF4 interferon regulatory factor 4 
235182_at ISM1 isthmin 1 homolog (zebrafish) 
200922_at KDELR1 KDEL endoplasmic reticulum protein retention receptor 1 
244370_at KIAA2022 KIAA2022 
230636_s_at KLF9 Kruppel-like factor 9 
221221_s_at KLHL3 kelch-like 3 (Drosophila) 
206486_at LAG3 lymphocyte-activation gene 3 
202252_at LOC100131294 RAB13, member RAS oncogene family; similar to hCG24991 
201951_at LOC100133690 activated leukocyte cell adhesion molecule 
201952_at LOC100133690 activated leukocyte cell adhesion molecule 
206600_s_at LOC100133772 similar to MCT; solute carrier family 16, member 5  
213590_at LOC100133772 similar to MCT; solute carrier family 16, member 5 ( 
223095_at LOC100270710 hypothetical LOC100270710; MARVEL domain containing 1 
236124_at LOC153546 hypothetical protein LOC153546 
227415_at LOC283508 hypothetical protein LOC283508 
240581_at LOC644135 hypothetical LOC644135 
225745_at LRP6 low density lipoprotein receptor-related protein 6 
226770_at MAGI3 membrane associated guanylate kinase, WW and PDZ domain containing 3 
223095_at MARVELD1 hypothetical LOC100270710; MARVEL domain containing 1 
218773_s_at MSRB2 methionine sulfoxide reductase B2 
202944_at NAGA N-acetylgalactosaminidase, alpha- 
228073_at NANP N-acetylneuraminic acid phosphatase 
224802_at NDFIP2 Nedd4 family interacting protein 2 
224799_at NDFIP2 Nedd4 family interacting protein 2 
235759_at NECAB1 N-terminal EF-hand calcium binding protein 1 
207075_at NLRP3 NLR family, pyrin domain containing 3 
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219557_s_at NRIP3 nuclear receptor interacting protein 3 
223535_at NUDT12 nudix (nucleoside diphosphate linked moiety X)-type motif 12 
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 
209485_s_at OSBPL1A oxysterol binding protein-like 1A 
217890_s_at PARVA parvin, alpha 
1554256_a_at PCNXL2 pecanex-like 2 (Drosophila) 
229354_at PDCD6 aryl-hydrocarbon receptor repressor; programmed cell death 6 
226731_at PELO pelota homolog (Drosophila) 
220952_s_at PLEKHA5 pleckstrin homology domain containing, family A member 5 
204519_s_at PLLP plasma membrane proteolipid (plasmolipin) 
202446_s_at PLSCR1 phospholipid scramblase 1 
241916_at PLSCR1 phospholipid scramblase 1 
208890_s_at PLXNB2 plexin B2 
209826_at PPT2 palmitoyl-protein thioesterase 2 
208121_s_at PTPRO protein tyrosine phosphatase, receptor type, O 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 
202252_at RAB13 RAB13, member RAS oncogene family; similar to hCG24991 
219622_at RAB20 RAB20, member RAS oncogene family 
209568_s_at RGL1 ral guanine nucleotide dissociation stimulator-like 1 
200885_at RHOC ras homolog gene family, member C 
223168_at RHOU ras homolog gene family, member U 
227983_at RILPL2 Rab interacting lysosomal protein-like 2 
213397_x_at RNASE4 ribonuclease, RNase A family, 4 
213566_at RNASE6 ribonuclease, RNase A family, k6 
222573_s_at SAV1 salvador homolog 1 (Drosophila) 
218276_s_at SAV1 salvador homolog 1 (Drosophila) 
213716_s_at SECTM1 secreted and transmembrane 1 
1560676_at SIAH3 seven in absentia homolog 3 (Drosophila) 
219386_s_at SLAMF8 SLAM family member 8 
206600_s_at SLC16A5 similar to MCT; solute carrier family 16, member 5  
213590_at SLC16A5 similar to MCT; solute carrier family 16, member 5  
212810_s_at SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
219869_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 
213113_s_at SLC43A3 solute carrier family 43, member 3 
227620_at SLC44A1 solute carrier family 44, member 1 
228485_s_at SLC44A1 solute carrier family 44, member 1 
229898_at SNX33 sorting nexin 33 
212558_at SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 
210829_s_at SSBP2 single-stranded DNA binding protein 2 
203787_at SSBP2 single-stranded DNA binding protein 2 
1552739_s_at ST7L suppression of tumorigenicity 7 like 
204068_at STK3 serine/threonine kinase 3 (STE20 homolog, yeast) 
203069_at SV2A synaptic vesicle glycoprotein 2A 
1565579_at TATDN2 TatD DNase domain containing 2 
238067_at TBC1D8B TBC1 domain family, member 8B (with GRAM domain) 
211276_at TCEAL2 transcription elongation factor A (SII)-like 2 
201666_at TIMP1 TIMP metallopeptidase inhibitor 1 
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202085_at TJP2 tight junction protein 2 (zona occludens 2) 
206271_at TLR3 toll-like receptor 3 
1558102_at TM6SF1 transmembrane 6 superfamily member 1 
234994_at TMEM200A transmembrane protein 200A 
207113_s_at TNF tumor necrosis factor (TNF superfamily, member 2) 
214228_x_at TNFRSF4 tumor necrosis factor receptor superfamily, member 4 
207426_s_at TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 
241819_at TNFSF8 tumor necrosis factor (ligand) superfamily, member 8 
203476_at TPBG trophoblast glycoprotein 
204083_s_at TPM2 tropomyosin 2 (beta) 
209129_at TRIP6 thyroid hormone receptor interactor 6 
220775_s_at UEVLD UEV and lactate/malate dehyrogenase domains 
202893_at UNC13B unc-13 homolog B (C. elegans) 
205019_s_at VIPR1 vasoactive intestinal peptide receptor 1 
204165_at WASF1 WAS protein family, member 1 
217975_at WBP5 WW domain binding protein 5 
1558586_at ZNF33B zinc finger protein 33B 
220661_s_at ZNF692 zinc finger protein 692 
204026_s_at ZWINT ZW10 interactor 
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Appendix K: Genes recurrently down-regulated by lenalidomide in T cells 
Probe ID Symbol Name 
Downregulated 
  204671_s_at ANKRD6 ankyrin repeat domain 6 
229215_at ASCL2 achaete-scute complex homolog 2 (Drosophila) 
205733_at BLM Bloom syndrome, RecQ helicase-like 
220560_at C11ORF21 chromosome 11 open reading frame 21 
218641_at C11ORF95 hypothetical protein LOC65998 
227806_at C16ORF74 chromosome 16 open reading frame 74 
242509_at C16ORF74 chromosome 16 open reading frame 74 
235063_at C20ORF196 chromosome 20 open reading frame 196 
223623_at C2ORF40 chromosome 2 open reading frame 40 
213268_at CAMTA1 calmodulin binding transcription activator 1 
1555370_a_at CAMTA1 calmodulin binding transcription activator 1 
1553102_a_at CCDC69 coiled-coil domain containing 69 
201005_at CD9 CD9 molecule 
202806_at DBN1 drebrin 1 
235378_at FAM161B family with sequence similarity 161, member B 
219709_x_at FAM173A family with sequence similarity 173, member A 
1555974_a_at FLJ39051 hypothetical protein LOC399972 
1555973_at FLJ39051 hypothetical protein LOC399972 
220131_at FXYD7 FXYD domain containing ion transport regulator 7 
231771_at GJB6 gap junction protein, beta 6, 30kDa 
205929_at GPA33 glycoprotein A33 (transmembrane) 
212070_at GPR56 G protein-coupled receptor 56 
212143_s_at IGFBP3 insulin-like growth factor binding protein 3 
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 
227750_at KALRN kalirin, RhoGEF kinase 
244623_at KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 
242517_at KISS1R KISS1 receptor 
236043_at LOC100130175 hypothetical protein LOC100130175 
222307_at LOC282997 hypothetical protein LOC282997 
205041_s_at ORM1 orosomucoid 1 
210448_s_at P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 
201876_at PON2 paraoxonase 2 
228113_at RAB37 RAB37, member RAS oncogene family 
240690_at SGK223 homolog of rat pragma of Rnd2 
207554_x_at TBXA2R thromboxane A2 receptor 
336_at TBXA2R thromboxane A2 receptor 
214183_s_at TKTL1 transketolase-like 1 
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Appendix L: Impact of lenalidomide on the gene expression of CLL NK cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted p 
value 
Upregulated 
    
232397_at NA NA 4.092 3.59E-07 
240581_at LOC644135 uncharacterized LOC644135 3.621 1.94E-13 
213566_at RNASE6 ribonuclease, RNase A family, k6 3.133 4.84E-09 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.735 3.47E-08 
225710_at GNB4 guanine nucleotide binding protein, beta 4 2.635 6.14E-10 
223535_at NUDT12 nudix-type motif 12 2.393 2.04E-06 
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 2.306 1.94E-07 
228910_at NA NA 2.269 3.85E-06 
224374_s_at EMILIN2 elastin microfibril interfacer 2 2.260 1.01E-12 
203153_at IFIT1 interferon-induced tetratricopeptide repeats 1 2.223 6.27E-07 
207075_at NLRP3 NLR family, pyrin domain containing 3 2.183 2.34E-07 
219386_s_at SLAMF8 SLAM family member 8 2.151 9.33E-07 
228067_at KIAA1211L KIAA1211-like 2.097 4.69E-07 
220770_s_at C5orf54 chromosome 5 open reading frame 54 2.081 6.59E-12 
204439_at IFI44L interferon-induced protein 44-like 2.081 5.74E-04 
242714_at NA NA 2.075 4.69E-07 
204466_s_at SNCA synuclein, alpha  2.035 2.64E-05 
208923_at CYFIP1 cytoplasmic FMR1 interacting protein 1 2.001 5.02E-08 
230147_at F2RL2 coagulation factor II (thrombin) receptor-like 2 1.985 4.77E-03 
223484_at C15orf48 chromosome 15 open reading frame 48 1.963 7.63E-03 
211284_s_at GRN granulin 1.930 2.74E-10 
216041_x_at GRN granulin 1.929 8.94E-10 
207949_s_at ICA1 islet cell autoantigen 1, 69kDa 1.918 1.16E-08 
225532_at CABLES1 Cdk5 and Abl enzyme substrate 1 1.898 4.61E-05 
200678_x_at GRN granulin 1.843 6.14E-09 
1565817_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 1.809 1.97E-05 
212458_at SPRED2 sprouty-related, EVH1 domain containing 2 1.778 6.42E-06 
204083_s_at TPM2 tropomyosin 2 (beta) 1.778 1.32E-06 
225207_at PDK4 pyruvate dehydrogenase kinase, isozyme 4 1.771 3.40E-03 
210547_x_at ICA1 islet cell autoantigen 1, 69kDa 1.760 5.98E-09 
229450_at IFIT3 interferon-induced tetratricopeptide repeats 3 1.752 4.38E-06 
205977_s_at EPHA1 EPH receptor A1 1.738 5.85E-05 
221618_s_at TAF9B TAF9B RNA polymerase II 1.706 1.65E-06 
206978_at CCR2 chemokine (C-C motif) receptor 2 1.695 7.81E-04 
204747_at IFIT3 interferon-induced tetratricopeptide repeats 3 1.693 6.92E-06 
218694_at ARMCX1 armadillo repeat containing, X-linked 1 1.691 6.93E-06 
240115_at LOC100286925 uncharacterized LOC100286925 1.669 1.33E-04 
205552_s_at OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 1.647 4.43E-05 
202252_at RAB13 RAB13, member RAS oncogene family 1.623 2.90E-03 
204438_at MRC1 mannose receptor, C type 1 1.611 2.77E-02 
203904_x_at CD82 CD82 molecule 1.610 3.68E-06 
208636_at ACTN1 actinin, alpha 1 1.609 7.71E-04 
223249_at CLDN12 claudin 12 1.606 4.58E-06 
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FC 
Adjusted p 
value 
213056_at FRMD4B FERM domain containing 4B 1.596 9.40E-07 
     
Downregulated 
    
212187_x_at PTGDS prostaglandin D2 synthase 21kDa (brain) 2.575 4.46E-06 
211748_x_at PTGDS prostaglandin D2 synthase 21kDa (brain) 2.443 1.18E-05 
36499_at CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2  2.043 1.21E-09 
226548_at SBK1 SH3-binding domain kinase 1 1.967 1.94E-13 
211663_x_at PTGDS prostaglandin D2 synthase 21kDa (brain) 1.879 3.69E-04 
230312_at NA NA 1.793 2.20E-04 
204684_at NPTX1 neuronal pentraxin I 1.705 8.18E-09 
226549_at SBK1 SH3-binding domain kinase 1 1.643 5.48E-11 
229215_at ASCL2 achaete-scute complex homolog 2 (Drosophila) 1.640 2.95E-09 
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Appendix M: Impact of lenalidomide on the gene expression of healthy NK cells 
 
Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Upregulated 
    
232397_at NA NA 3.454 4.51E-06 
213668_s_at SOX4 SRY (sex determining region Y)-box 4 3.212 8.50E-07 
240581_at LOC644135 uncharacterized LOC644135 2.972 2.24E-11 
239764_at LOC100996539 uncharacterized LOC100996539 2.439 4.25E-10 
204466_s_at SNCA synuclein, alpha  2.401 4.35E-06 
201418_s_at SOX4 SRY (sex determining region Y)-box 4 2.400 6.73E-07 
223366_at ZNF704 zinc finger protein 704 2.385 4.50E-06 
238263_at EPHA1-AS1 EPHA1 antisense RNA 1 2.377 4.34E-07 
201417_at SOX4 SRY (sex determining region Y)-box 4 2.291 7.56E-07 
201416_at SOX4 SRY (sex determining region Y)-box 4 2.282 2.58E-06 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 2.268 6.73E-07 
228910_at NA NA 2.267 5.24E-06 
235079_at ZNF704 zinc finger protein 704 2.240 2.49E-06 
229254_at MFSD4 major facilitator superfamily domain containing 4 2.191 1.31E-08 
226213_at ERBB3 v-erb-b2 erythroblastic leukemia viral homolog 3  2.140 6.64E-10 
225710_at GNB4 guanine nucleotide binding protein, beta 4 2.120 2.34E-08 
228067_at KIAA1211L KIAA1211-like 2.072 7.60E-07 
205977_s_at EPHA1 EPH receptor A1 1.977 1.58E-05 
207949_s_at ICA1 islet cell autoantigen 1, 69kDa 1.963 1.42E-08 
202018_s_at LTF lactotransferrin 1.923 4.48E-04 
210547_x_at ICA1 islet cell autoantigen 1, 69kDa 1.866 4.93E-09 
237597_at NA NA 1.857 2.78E-04 
204099_at SMARCD3 SWI/SNF, matrix, regulator of chromatin, D3 1.817 1.20E-06 
208923_at CYFIP1 cytoplasmic FMR1 interacting protein 1 1.802 3.35E-07 
204083_s_at TPM2 tropomyosin 2 (beta) 1.795 1.67E-06 
219753_at STAG3 stromal antigen 3 1.777 6.53E-06 
222941_at USP46 ubiquitin specific peptidase 46 1.760 6.68E-07 
213566_at RNASE6 ribonuclease, RNase A family, k6 1.759 1.73E-05 
224374_s_at EMILIN2 elastin microfibril interfacer 2 1.744 2.70E-10 
203940_s_at VASH1 vasohibin 1 1.720 2.96E-06 
203904_x_at CD82 CD82 molecule 1.715 2.34E-06 
207075_at NLRP3 NLR family, pyrin domain containing 3 1.709 7.45E-06 
1556932_at NA NA 1.700 4.52E-06 
224928_at SETD7 SET domain containing (lysine methyltransferase) 7 1.692 2.02E-07 
1556423_at VASH1 vasohibin 1 1.688 3.16E-06 
210367_s_at PTGES prostaglandin E synthase 1.673 1.44E-06 
206425_s_at TRPC3 transient receptor potential cation channel, C3 1.670 2.30E-05 
204467_s_at SNCA synuclein, alpha  1.659 3.75E-05 
205479_s_at PLAU plasminogen activator, urokinase 1.651 1.20E-03 
238726_at NA NA 1.607 6.73E-07 
210814_at TRPC3 
transient receptor potential cation channel, subfamily 
C, member 3 1.590 3.08E-04 
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Probe ID Symbol Name Log2 
FC 
Adjusted 
p value 
Downregulated 
    
219371_s_at KLF2 Kruppel-like factor 2 (lung) 2.212 0.000 
1552321_a_at CCDC65 coiled-coil domain containing 65 2.147 0.000 
211748_x_at PTGDS prostaglandin D2 synthase 21kDa (brain) 2.018 0.000 
212187_x_at PTGDS prostaglandin D2 synthase 21kDa (brain) 2.013 0.000 
1552320_a_at CCDC65 coiled-coil domain containing 65 1.931 0.000 
36499_at CELSR2 
cadherin, EGF LAG seven-pass G-type receptor 2 
(flamingo homolog, Drosophila) 1.866 0.000 
230312_at NA NA 1.749 0.000 
226863_at FAM110C family with sequence similarity 110, member C 1.722 0.002 
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